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Abstract 
 
The emergence of antibiotic resistance combined with the decline in the discovery of novel 
antibiotic scaffolds has led to an urgent need for the development of effective antimicrobial 
treatments. Recently a Gram-negative genus of bacteria, Burkholderia, has been shown to be 
an untapped source of antimicrobial compounds. Two such compounds produced by 
Burkholderia are gladiolin and enacyloxin IIa (figure 1), which are active against the multi-
drug resistant pathogens Mycobacterium tuberculosis and Acinetobacter baumannii 
respectively. Both compounds are assembled by polyketide synthases, but there are parts of 
the biosynthesis of both natural products that are not well understood.  
 
                             
 
Figure 1 The structures of gladiolin and enacyloxin IIa.  
 
The installation of the E,Z-diene motif in gladiolin (red, figure 1) was investigated using an 
intact protein MS-based assay with chemically synthesized polyketide intermediate mimics. 
The diene was shown to be installed by an unprecedented double dehydration, which appears 
to be conserved for the installation of dienes in some other polyketide natural products based 
on bioinformatics analyses. The biosynthesis of the dihydroxycyclohexanecarboxylic acid 
(DHCCA) unit of enacyloxin IIa (blue, figure 1) was also investigated using in vitro 
biochemical assays. The initial hypothesis for the pathway was shown to be incorrect, and the 
elucidation of the correct pathway also led to the discovery of a new potential biocatalyst. 
 
Using multiple biosynthetic engineering strategies that rely upon a thorough understanding of 
enacyloxin IIa biosynthesis, a library of enacyloxin IIa analogues was generated. This 
provided useful structure-activity relationship (SAR) data with regards to the binding of 
enacyloxin IIa to its target, EF-Tu. Five enacyloxin IIa analogues were also generated which 
had improved biological activity. These analogues may provide a platform for the rational 
engineering of improved enacyloxin IIa analogues harboring more complex structural changes.  
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1.1 Antibiotics 	
1.1.1 Discovery of Natural Products as a Source of Antibiotics 	
Natural products, or specialized metabolites, are organic compounds produced by an organism 
which are not essential for growth, development or reproduction, but can often aid the survival 
of the organism due to antibiotic or other properties.1 Microbial natural products have long 
provided a major foundation for the development of antibiotic drugs. Over 20,000 microbial 
natural products being described over the past several decades.2  
 
One of the earliest and most famous discoveries of a natural product with antimicrobial 
activity, was the serendipitous discovery of the fungal metabolite and b-lactam antibiotic, 
penicillin G 1.3 Sir Alexander Fleming accidently discovered that a fungal contaminant 
affected the growth of bacteria in 1928, however it was not until Howard Florey assembled a 
team including Ernst Chain and Norman Heatley in 1939, that penicillin G was successfully 
purified and its activity determined.4 In 1943 Edward Abraham along with Chain proposed the 
b-lactam structure of penicillin G, which was later confirmed in 1945 by Dorothy Hodgkin 
using X-ray crystallography.5 Fleming, along with Chain and Florey, subsequently won the 
1945 Nobel prize in physiology and medicine for the discovery and clinical studies of 
penicillin, which enabled the control of infections caused by Gram-positive pathogens such as 
Staphylococcus and Streptococcus, and revolutionized drug discovery research.6  
 
Following this discovery, Selman Waksman and H. Boyd Woodruff developed a revolutionary 
screening technique for the discovery of antimicrobial natural products, often referred to as the 
‘Waksman platform’.7,8 This technique consists of the incubation of soil sample suspensions 
with susceptible test microorganisms, and based on growth inhibition zones, single colonies of 
soil microbes (largely Actinobacteria) were isolated and screened against specifically targeted 
pathogens, before the corresponding bioactive metabolite could be isolated.8,9 This technique 
propelled antimicrobial natural product discovery into the so-called ‘golden age’ and resulted 
in a boom of new discoveries between the 1940s and 1960s.2,8,10  
 
Using this technique, the clinically important aminoglycoside antibiotic, streptomycin 2, was 
discovered in the Waksman lab by Albert Schatz in 1944, which was the first effective 
antibiotic for Mycobacterium tuberculosis.11 This was followed by the discovery of 
tetracycline 3 and its derivatives which exhibit activity against both Gram-positive and Gram-
negative pathogens.12 Many other clinically important antibiotics were discovered shortly 
thereafter including the macrolide erythromycin 4 which is still commonly administered as a 
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treatment for skin and respiratory tract infections, as well as the glycopeptide vancomycin 5, 
which is used to treat multi-drug resistant (MDR) Gram-positive pathogens (figure 1.1).13,14 
 
 
 
Figure 1.1 The structures of tetracycline (3),  streptomycin (2), erythromycin (4),  
penicillin G (1) and vancomycin (5).   	
1.1.2 Emergence of Antimicrobial Resistance  
 
A consequence of the use of the antibiotics discovered in the ‘golden age’ (figure 1.1) was the 
emergence of widespread antimicrobial resistance (AMR). Bacteria have developed a variety 
of resistance mechanisms, including efflux pumps, decreased membrane permeability, target 
modification and antibiotic modifying enzymes.15 Despite b-lactam antibiotics, such as 
penicillin G 1, constituting greater than 60 % of the antimicrobials used in human medicine, 
resistance to this class of antibiotics is widespread.16 Penicillin G 1 was introduced into the 
clinic in the early 1940s, but penicillin-resistant Staphylococus aureus emerged as soon as 
1944.17 Staphylococcal resistance is mediated by b-lactamases, which inactivate the antibiotic 
by catalyzing the hydrolysis of the b-lactam core.17  
 
The emergence of penicillin-resistant Staphylococus aureus was initially combated by 
discovering new b-lactam antibiotics, such as cephalosporin C 6, which was stable to the 
staphylococcal b-lactamase.17 Another approach was the development of semi-synthetic b-
lactams such as methicillin 7, which were able to evade the lactamases via the steric protection 
of the b-lactam ring (figure 1.2).18 However methicillin-resistant Staphylococus aureus 
(MRSA), which exhibits resistance to b-lactam antibiotics via the production of a modified 
penicillin binding protein (PBP2a, the target of b-lactam antibiotics) emerged. This limits the 
accessibility of the antibiotic to the active site of the target.19 As a result, b-lactam antibiotics 
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alone are not sufficient to treat MRSA infections, but are often used in combination with other 
antibiotics that act synergistically.20 
 
In addition to resistance via the production of a modified penicillin binding protein, extended-
spectrum b-lactamases (ESBL) also emerged. This resulted in strains that were resistant to 
later-generation, semi-synthetic b-lactam antibiotics.17 To overcome this, a combination of the 
antibiotic and a b-lactamase inhibitor is administered. An example of a b-lactamase inhibitor 
is clavulanic acid 8, a b-lactam natural product that, despite showing poor antibiotic activity, is 
a potent inhibitor of b-lactamases.21 Clavulanic acid 8 is administered with the semi-synthetic 
penicillin analogue, amoxicillin 9. This treatment, marketed as Augmentin, was the best 
selling antibiotic treatment in 2001 (figure 1.2).22 Despite this success, many b-lactamases are 
not inhibited by current clinically available inhibitors.23 The emergence and evolution of AMR 
to b-lactam antibiotics is mirrored by other antibiotics discovered in the ‘golden era’ (figure 
1.1), highlighting the importance of identifying new antibiotics, or improving existing ones. 
 
 
 
Figure 1.2 The structures of b-lactams cephalosporin C 6,  methicillin 7, clavulanic acid 
8 and amoxicillin 9 discovered or developed to combat AMR.  
 
1.1.3 Strategies for Improving Antibiotics  
 
Some of the strategies used for combating resistance to b-lactam antibiotics discussed in 
section 1.1.2 have been used to overcome resistance to other antibiotics. New strategies have 
also been developed. In addition to combating resistance, structural modification of antibiotics 
can be used to improve potency, spectrum of activity, stability, oral bioavailability and 
pharmokinetic properties. 
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1.1.3.1 Semi-synthesis 	
The semi-synthetic production of antibiotics consists of the synthetic modification of naturally 
produced antibiotic scaffolds. In addition to the development of semi-synthetic b-lactam 
antibiotics such as methicillin 7 (figure 1.2), to overcome b-lactamase mediated resistance, 
many other antibiotic scaffolds have been modified by semi-synthesis to evade a range of 
resistance mechanisms. A prime example is the recent food and drug administration (FDA)-
approved semi-synthetic aminoglycoside antibiotic plazomicin 10 (figure 1.3), which evades 
the action of multiple inactivating enzymes that reduce the effectiveness of earlier 
aminoglycosides such as gentamicin and butirosin.24  
 
Semi-synthetic antibiotics can also be developed to improve pharmokinetic properties. For 
example, the semi-synthetic tetracycline derivative minocycline 11 has increased tissue 
penetration, a longer half-life and activity against a broader range of pathogens relative to 
natural tetracyclines, due to its increased lipophilicity.25 There are also examples of semi-
synthetic antibiotic derivatives with increased bioavailability and stability. First generation 
macrolide antibiotics such as erythromycin 4 have poor bioavailability and low stability at the 
acidic pH of the stomach, which due to acid-catalyzed hemiketal formation results in the 
formation of inactive spiroketal derivatives.13 However, the development of semi-synthetic 
macrolides, such as clarithromycin 12, which harbors a modification that prevents hemiketal 
formation, has resulted in more stable and bioavailable macrolide antibiotics (figure 1.3).26 
 
      
 
Figure 1.3 Structures of the semi-synthetic antibiotics plazomicin 10, minocycline 11 
and clarithromycin 12 with the synthetic modifications highlighted in red.  
 
Semi-synthetic approaches continue to be used to produce antibiotic analogues, however this 
strategy is inherently limited.27 Modifications can only be made at positions on the antibiotic 
scaffold that are amenable to functionalization, and due to the often highly functionalized and 
sensitive structures of natural products, degradation or unwanted byproducts are commonly 
observed. 
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1.1.3.2 Total Synthesis 	
The limited scope of semi-synthetic modification can in theory be combated using carefully 
designed total syntheses, which can be used generate a diverse library of analogues. An 
excellent example of this is the recently FDA-approved antibiotic eravacycline 13, which was 
developed using a synthetic library approach.28 Eravacycline 13 is an analogue of tetracycline 3, 
which harbors several structural modifications, including an N-alkyl glycylamido group at the 9-
position of the tetracycline core resulting in activity against tetracycline-resistant pathogens.29 
Synthetic analogues of b-lactam antibiotics have also been developed, including the N-
sulfonated b-lactam, carumonam 14, which displays greater potency against Gram-negative 
pathogens such as Klebsiella pneumonia and Enterobacter cloacae than previous b-lactam 
antibiotics.30 Myers and co-workers have also developed a robust synthetic route for the 
synthesis of macrolide antibiotic analogues, including FSM-100573 15, which exhibits 
enhanced activity against MDR Streptococcus pneumonia and Pseudomonas aeruginosa 
(figure 1.4).31 
 
    
 
Figure 1.4 The structures of synthetic antibiotics eravacycline 13,  carumonam 14 and 
FSM-100573 15. 
 
Despite the promise of these approaches, antibiotic scaffolds are often highly complex, 
harbouring many stereocentres and sensitive functional groups. This makes the synthesis of 
such molecules challenging and time consuming, and often only modest amounts of material 
can be produced.						
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1.1.3.3 Genetic Engineering 	
The discovery that the genes directing the biosynthesis of antimicrobial natural products are 
clustered, coupled with developments in synthetic biology and mechanistic understanding of 
biosynthetic pathways, has provided a basis for genetic engineering to produce antibiotic 
analogues.32 The biosynthesis of aminoglycoside antibiotic kanamycin A 16 was recently 
established, facilitating in vivo engineering of the pathway to produce amikacin 17, a semi-
synthetic aminoglycoside. The pathway was further manipulated to produce 1-N-AHBA-
kanamycin 18, which shows greater antibacterial activity than amikacin 17 (figure 1.5).33 The 
gene cluster that directs the biosynthesis of tetracycline antibiotic chelocardin 19 was also 
identified and engineered to produce a novel tetracycline analogue, 2-carboxamido-2-deacetyl-
chelocardin (CDCHD) 20 (figure 1.5).34 CDCHD 20 is a promising lead because it is active 
against the full panel of ESKAPE pathogens, a group of problematic, MDR Gram-negative 
pathogens comprising of Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, 
Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species.35 A library of 
glycopeptide antibiotics was also generated using a synthetic biology approach from a minimal 
teicoplanin scaffold 21. This resulted in novel analogues, which were active against 
glycopeptide resistant bacteria (figure 1.5).36  
 
  
 
Figure 1.5 The structures of kanamycin A 16, amikacin 17, 1-N-AHBA-kanamycin 18, 
chelocardin 19, CDCHD 20 and the teicoplanin scaffold 21 used to generate 
glycopeptide analogues (with differing R groups). 	
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1.1.3.4 Identifying New Antimicrobial Natural Products 	
An alternative to the modification of current antibiotic scaffolds is to isolate new antimicrobial 
natural products. Since the so-called ‘golden era’ of antimicrobial discovery, the isolation of 
new antibiotics has significantly declined, but the development of more advanced antimicrobial 
screening techniques has resulted in the isolation of new antibiotic scaffolds. For example, the 
development of a novel screening technique based upon antibiotic self-resistance by Wright and 
co-workers resulted in the isolation of a novel glycopeptide antibiotic scaffold, pekiskomycin 22 
(figure 1.6).37 In addition to screening techniques, the development of bioinformatic tools 
coupled with the decreasing cost of genome sequencing has enabled the identification of novel 
antibiotic gene clusters using genome mining, a computational technique which facilitates the 
discovery of biosynthetic gene clusters by searching genomes for conserved motifs.38,39 Using 
this approach, Challis and co-workers identified a large cryptic polyketide synthase (PKS) gene 
cluster in the genome of S. ambofaciens. The gene cluster was activated by the overexpression 
of a putative pathway-specific regulator, resulting in the production of the unique class of 
glycosylated macrolides, stambomycin A(23)-D (figure 1.6).40 
 
     
       
Figure 1.6 The structures of stambomycin A 23, pekiskomycin 22 and teixobactin 24. 
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The majority of antimicrobial natural products in the clinic have been isolated from soil 
microorganisms (often strains belonging to the Streptomyces genus). However it is estimated 
that less than one per cent of soil microorganisms are culturable using conventional 
techniques.41 This implies there is a huge untapped resource of potential antimicrobial natural 
products, which has prompted the development of methods to access the metabolites of 
“unculturable” soil microorganisms. The development of a multichannel device, the iChip, 
which allows the simultaneous isolation and growth of uncultured soil bacteria, allowed Lewis 
and co-workers to isolate teixiobactin 24 (figure 1.6).42 Teixiobactin 24 is an antibiotic that 
belongs to a novel structural class and is produced by a new species of Gram-negative, b-
proteobacteria provisionally named Eleftheria terrae.43 Although the majority of clinically used 
antimicrobial natural products originate from Gram-positive Actinobacteria, Gram-negative 
bacteria such as b-proteobacteria are becoming increasingly recognised as a valuable source of 
novel antimicrobials, particularly for the treatment of problematic Gram-negative pathogens.44 
  
1.2 Burkholderia 
 
Burkholderia is also a genus of Gram-negative b-proteobacteria that is an emerging source of 
bioactive natural products. The genus was defined in 1992 having previously been included in 
the Pseudomonas genus due to phylogenetic similarities. The genus has now expanded to 
include almost 100 species, which occupy a diverse range of ecological niches, ranging from 
the rhizosphere of plants, to humans. Several Burkholderia species have been shown to have 
agricultural benefits, including promoting plant growth and degrading pollutants. However, 
their industrial use is limited, because many species are reported to be opportunistic pathogens 
of plants and for humans.45  
 
One particular group of genetically distinct, but phenotypically similar Burkholderia species, 
known as the Burkholderia cepacia complex (Bcc), consists of opportunistic pathogens that 
can cause severe infections in cystic fibrosis (CF) sufferers and immunocompromised patients. 
Bcc species in particular have attracted interest from researchers due to their resistance to a 
range of antibiotics, their broad-spectrum of antimicrobial activity, and their ability to produce 
a variety of bioactive molecules.46 Bioactive natural products produced by Burkholderia 
species include the respiratory toxin bongkrekic acid 25, the polyene antibiotic caryoynencin 
26, the antimitotic agent rhizoxin 27, and the antifungal cyclic lipopeptide burkholdine 1215 
28 (figure 1.7).47–50 The work described in this thesis focuses on two polyketides produced by 
Burkholderia species: gladiolin 29 and enacyloxin IIa 30 (figure 1.7). 
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Figure 1.7 The structures of Burkholderia produced natural products bongkrekic acid 
25,  burkholdine 1215 28,  rhizoxin 27,  caryoynencin 26,  gladiolin 29 and enacyloxin IIa 
30. 
1.3 Polyketide Synthases 	
 
Polyketide synthases (PKSs) are remarkable biosynthetic machines that catalyze the assembly 
of complex hydrocarbon scaffolds from a series of acyl thioester building blocks.51 PKSs can 
be subdivided into three types based on their structural organization and catalytic mechanism. 
Type I PKSs consist of giant multifunctional polypeptides containing several catalytic 
domains, whereas type II PKSs consist of several discrete, iteratively-acting enzymes, and 
type III PKSs employ only a single iterative condensing enzyme.52  
 
Type I PKSs can be further categorized depending on whether the multifunctional 
polypeptides are used in an iterative or modular manner. Type I iterative PKSs harbor one of 
each of the catalytic domains required for polyketide assembly within a single multifunctional 
polypeptide. The catalytic domains are used repeatedly in multiple rounds of chain elongation, 
assembling the polyketide chain in an iterative manner.53 In contrast, type I modular PKSs 
consist of multiple modules in which each of the catalytic domains is typically used once 
during chain assembly. Each module is normally responsible for catalyzing a single round of 
O OH
O
HO
OH
O
bongkrekic acid 25
OH
OH
O
caryoynencin 26
O O
O
O
O
N
H
H
H
O
HO
O
O
rhizoxin 27
N
H
NH
O
HN
OHO
OH
OH
OHN
O
NH
O NH2
H
N
O
NH
O
O
H2N
O
HO
HO
OH
O
H2N
O OH
O
OH
HO
HO
burkholdine 1215 28
O
O
H2N
Cl
OH O
OH
OH Cl
O
O
CO2H
OH
enacyloxin IIa 30
OH O
O
OH
OHOH
OH
OH OH
O
OMe
gladiolin 29
	 11	
chain elongation. However, there are some examples of iterative module use by type I modular 
PKSs.54,55  
 
1.3.1 Type I Modular PKSs 
 
Typically, each chain extension module harbors three minimal catalytic domains: an acyl 
carrier protein (ACP) domain, an acyltransferase (AT) domain and a ketosynthase (KS) 
domain. The catalytic activity of these three domains results in the incorporation of one acyl-
coenzyme A (CoA) thioester extender unit into the nascent polyketide chain, resulting in a 
single round of chain elongation (section 1.3.1.1). Many chain extension modules also contain 
accessory domains, including ketoreductase (KR), dehydratase (DH), methyltransferase (MT) 
and enoyl reductase (ER) domains, which are responsible for processing the 3-keto thioester 
resulting from chain elongation (section 1.3.1.2). The release of the assembled polyketide 
chain is usually catalyzed via a terminal thioesterase (TE) domain, and is usually achieved via 
macrolactonization, transesterification or hydrolysis.56  
 
The polyketide scaffold of macrolide antibiotic erythromycin 4 is assembled by an archetypal 
example of a type I modular PKS, the 6-deoxyerythronolide B synthase (DEBS). DEBS 
consists of three polypeptide units (DEBS1-3), which can be split into seven modules 
responsible for the condensation of one propionyl-CoA starter unit with six methylmalonyl-
CoA extender units. The resulting heptaketide acyl chain is then offloaded via lactonization to 
afford 6-deoxyerythronolide B 31, which is then glycosylated, hydroxylated and methylated to 
produce erythromycin 4 (scheme 1.1).57  
 
It is important to note that for the purposes of this study, a module can be defined as the 
combination of domains responsible for catalyzing a single chain extension, starting from an 
elongating KS domain, and ending at the first downstream ACP domain. This “functional” 
definition of a module has consistently been used in the literature and originates from the 
domain architecture of mammalian fatty acid synthase (FAS), which exists as KS-AT-DH-ER-
KR-ACP-TE. PKS modules were defined equivalently to begin with KS and end with ACP, 
with the AT domain and optional processing domains in the middle.58 Recent work by Abe 
and co-workers indicated that throughout the evolution of PKSs, the accessory domains appear 
to migrate with the downstream KS domain, and they propose that modules should be 
redefined so that the accessory domains are grouped with the downstream KS domain.59 
However this newly proposed “evolutionary” definition of a module complicates the 
“functional” role of a module, and so will not be used for the systems studied in this thesis.  
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Scheme 1.1 The DEBS-catalyzed assembly of 6-deoxyerythronolide 31 followed by 
post-PKS tailoring steps to afford macrolide antibiotic erythromycin 4. 
 
1.3.1.1 Minimal catalytic domains 	
ACP domains are small, four-helical bundles, which tether the growing polyketide chain via a 
thioester bond, and are responsible for shuttling the biosynthetic intermediates between the 
catalytic domains of a module. They are post-translationally converted from their inactive apo-
form to their catalytically active holo-form by a phosphopantetheinyl transferase. This enzyme 
catalyzes the condensation of a conserved serine residue of the ACP domain with CoA 32, 
resulting in the addition of a flexible, phosphopantetheinyl arm bearing a terminal thiol 
(scheme 1.2).60  
 
 
 
Scheme 1.2 The post-translational conversion of apo-ACP domains to their holo form. 
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AT domains are responsible for priming downstream holo-ACP domains with either a starter 
unit (in the loading module) or an extender unit (in chain extension modules). Commonly used 
starter units include acetyl-CoA and propionyl-CoA, whereas extender units are often their 
respective carboxylated derivatives, malonyl-CoA and methylmalonyl-CoA. However, there 
are many examples of PKSs using more structurally diverse starter and extender units, and 
many systems utilize a KSQ domain in the loading module, which catalyzes the 
decarboxylation of a malonated ACP domain (loaded by an AT domain) to generate the starter 
unit in situ.61,62 The starter/extender unit is first loaded onto a catalytic serine residue of the AT 
domain, which is activated as a nucleophile by a conserved histidine residue. The resulting 
AT-tethered acyl group is then translocated onto the phosphopantetheinyl arm of the 
downstream holo-ACP domain (scheme 1.3).63 
 
                      
 
Scheme 1.3 The transacylation catalyzed by AT domains, which results in the loading 
of CoA thioesters onto holo-ACP domains. 
 
The KS domain is typically responsible for catalyzing the elongation of the polyketide chain 
via a decarboxylative Claisen condensation. Initially, the ACP-bound polyketide chain 
generated by the upstream module is translocated onto the conserved active site cysteine 
residue of the KS domain. The KS domain then catalyzes the condensation between the 
malonated downstream ACP domain (loaded by the AT domain), and the nascent polyketide 
chain tethered to the KS domain, resulting in elongation of the chain by two carbons (scheme 
1.4). The translocation and Claisen condensation reactions have been reported to be mediated 
by two conserved histidine residues by Khosla and coworkers.64 However the mechanism they 
propose (scheme 1.4) may not be correct, as non-elongating KS domains (KS0 domains, 
section 1.3.3.1) lacking one of the conserved histidine residues (His1) are still capable of 
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catalyzing translocation. The extender unit loaded by the AT domains in DEBS is (2S)-
methylmalonyl-CoA, but the condensation catalyzed by the KS domain occurs with inversion 
of stereochemistry to generate a (2R)-methylmalonyl thioester product (scheme 1.4).65 
       
 
 
Scheme 1.4 The KS domain-catalyzed translocation and elongation reactions resulting 
in chain elongation by two carbon units. 
 
1.3.1.2 Accessory catalytic domains 
 
In addition to the minimal catalytic domains described above, PKS chain extension modules 
usually contain one or more accessory domains, which modify the C-2 and/or C-3 atoms of the 
3-keto thioester intermediate produced by the KS domain. KR domains typically reduce the 3-
keto thioester to produce a stereodefined 3-hydroxy thioester. The stereochemistry of the 3-
hydroxy thioester can be predicted based upon sequence alignments. KR domains that reduce 
(2R)-2-methyl-3-keto thioesters (generated by the KS domain, scheme 1.4) to install (2R,3S)-
2-methyl-3-hydroxy thioesters are often referred to as A1-type KR domains, and those that 
install (2R,3R)-2-methyl-3-hydroxy thioesters are B1-type (scheme 1.5A).65 The B1-type KR 
domains harbor a conserved aspartate residue which is not present in A1-type KR domains.66 
The reduction is catalyzed using a nicotinamide adenine dinucleotide phosphate (NADPH) 
cofactor, which delivers a hydride nucleophile to the ketone carbonyl group, whilst the 
resulting oxyanion is protonated via a conserved tyrosine residue.67  
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KR domains are also capable of catalyzing the racemization of the C-2 methyl group, followed 
by subsequent diastereoselective reduction to form (2S,3S)-2-methyl-3-hydroxy thioesters 
(A2-type KR domain) or (2S,3R)-2-methyl-3-hydroxy thioesters (B2-type KR domain).65 The 
racemization proceeds via deprotonation at the C-2 position to form an enolate intermediate 
followed by subsequent reprotonation, the residue responsible for the proton exchange is yet to 
be determined (scheme 1.5B).68 There are also examples of KR domains that lack any catalytic 
activity (C1-type), and KR domains capable of racemization but not reduction (C2-type), all of 
which can be identified using sequence alignments.69 It is important to note that KR domains 
that reduce 3-keto thioesters (lacking the C-2 methyl group) can simply be referred to as A-
type or B-type depending on whether they produce (3S)- or (3R)-hydroxy thioesters 
respectively.  
                
 
 
Scheme 1.5 A The (B1-type) KR domain-catalyzed reduction to form a (2R,3R)-2-
methyl-3-hydroxy thioester. B The (B2-type) KR domain-catalyzed racemization and 
reduction to form a (2S,3R)-2-methyl-3-hydroxy thioester. 
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The 3-hydroxy thioester product of the KR domain can then be processed by a DH domain if 
one is present in the module. DH domains typically catalyze dehydration of the 3-hydroxy 
thioester to produce the corresponding 2-enoyl thioester via a syn-elimination mechanism, 
using a conserved histidine residue. The syn-elimination mechanism results in the dehydration 
of (R)-configured alcohols to afford (E)-configured alkenes, and (S)-configured alcohols to 
afford (Z)-configured alkenes. The dehydration is believed to proceed via an E1CB mechanism 
involving deprotonation at the C-2 carbon by the histidine residue to form an enolate 
intermediate, from which the C-3 hydroxyl group is eliminated.70 The role of a conserved 
aspartate residue has been the subject of some debate, which is discussed in detail in section 
2.1.1.2. Recent work by Cane and coworkers suggests that the histidine residue used to 
generate the enolate acts as the proton donor, and the aspartate is used to bind and orient the 
substrate (scheme 1.6).71  
 
 
 
Scheme 1.6 A The DH-catalyzed dehydration of a (3R)-hydroxy thioester intermediate 
to produce a (2E)-enoyl thioester. B The dehydration of a (3S)-hydroxy thioester 
intermediate to produce a (2Z)-enoyl thioester. 
 
The resulting 2-enoyl thioester can then be reduced by an ER domain, resulting in a saturated 
acyl thioester intermediate. The ER-catalyzed reduction of 2-methylenoyl thioesters results in 
the generation of a defined stereocenter at the 2-position. The stereoselectivity of the ER 
domain can again be predicted using conserved amino acid residues, with the presence of a 
conserved tyrosine residue usually resulting in the formation of a (2S)-configured product.72 
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The catalytic mechanism of ER domains consists of the nucleophilic attack of a hydride 
(donated by NADPH) at the 3-position of the 2-enoyl thioester. This results in an enolate 
intermediate, which is protonated at the 2-position to afford the saturated acyl thioester 
(scheme 1.7). The catalytic residue responsible for the protonation remains to be identified.73 
 
  
 
Scheme 1.7 The ER-catalyzed reduction of a 2-enoyl thioester intermediate to afford 
stereodefined saturated acyl thioesters. 
 
In addition to the accessory domains described above, some PKS modules harbor 
methyltransferase (MT) domains. These domains either methylate the 2-position of the 3-keto 
thioester intermediate (C-MTs), or O-methylate the 3-hydroxy group resulting from 
ketoreduction (O-MTs) and use a S-adenosylmethionine (SAM) cofactor.74,75 
 
1.3.1.3 Polyketide chain offloading 
 
The offloading of the fully assembled polyketide chain is usually catalyzed by a TE domain 
located at the C-terminus of the PKS. Firstly the ACP-bound polyketide chain is translocated 
onto a conserved serine residue of the TE domain, which is catalyzed by a conserved histidine 
residue. The chain is then offloaded from the megasynthase via either intramolecular 
(macrocyclization, blue) or intermolecular (hydrolysis or transesterification, red) nucleophilic 
attack, again catalyzed by the conserved histidine residue (scheme 1.8).76 Many other chain 
release mechanisms have also been reported, including thioester reduction to produce an 
aldehyde, which can be further reduced to an alcohol, and tetronate formation via 
condensation with a glyceryl thioester, mediated by a FabH-like ketosynthase.77,78 
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Scheme 1.8 The TE-catalyzed offloading of the ACP-bound polyketide chain by 
macrocyclization (blue arrows) or hydrolysis (red arrows).  
 
1.3.2 Post-PKS Tailoring Enzymes 
 
Following the assembly and offloading of the polyketide scaffold, further structural 
modifications are often introduced via post-PKS tailoring enzymes. These enzymes can 
catalyze the installation of a variety of functional groups, which often make an important 
contribution to the bioactivity of the molecule. Tailoring enzymes have commonly been the 
target of combinatorial biosynthesis approaches for the generation of natural product 
analogues (section 3.1.1.1), and have also been developed into robust in vitro biocatalysts.79,80 
They can be subdivided into several classes based upon their catalytic mechanism and the 
functionality they install. 
 
1.3.2.1 Oxidoreductases 
 
Oxidoreductases are a broad class of tailoring enzymes, incuding oxygenases, oxidases, 
peroxidases, reductases and dehydrogenases. A common class of oxygenase enzymes are 
heme-dependent cytochrome P450 monooxygenases (CYP450s), which are capable of 
catalysing hydroxylation, epoxidation and dealkylation, among other reactions.81 Two 
CYP450s are encoded by genes in the erythromycin 4 biosynthetic gene cluster (EryF and 
EryK). These are responsible for post-PKS hydroxylation at the 6- and 12-positions of the 
macrolide (figure 1.8).82 Post-PKS hydroxylation can also be catalysed by non-heme iron and 
a-ketoglutarate (aKG)-dependant dioxygenases, such as the enzyme responsible for 
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introducing the hemiketal hydroxyl group into the antitumour agent FR901464 33 (figure 
1.8).83 There are also many examples of flavin-dependent oxidoreductases, such as the flavin 
adenine dinucleotide (FAD)-dependant dehydrogenase involved in the oxidation of a 
hemiacetal to a lactone during the biosynthesis of antitumour drug gilvocarcin V 34.84 
 
 
 
Figure 1.8 The structures of natural products erythromycin 4, FR901464 33 and 
gilvocarcin 34. Post-PKS modifications in their biosynthesis are highlighted in red. 
 
1.3.2.2 Transferases 
 
Many post-PKS tailoring enzymes catalyze the transfer of functional groups onto heteroatoms 
of the polyketide scaffold, including glycosyl transferases, methyl transferases, acyl 
transferases and carbamoyl transferases.79 Two glycosyl transferase enzymes catalyze the 
transfer of L-mycarose and D-desosamine onto the erythromycin scaffold, prior to O-
methylation of the D-desosamine residue by an O-MT domain (red/blue, figure 1.9).85 Both 
methyl transferase and acyl transferase post-PKS tailoring enzymes are involved in rifamycin 
B 35 biosynthesis, catalyzing O-methylation and O-acetylation respectively.86 The 
biosynthetic gene cluster of another ansmaycin antibiotic, geldanamycin 36, contains genes 
encoding a carbamonyl transferase in addition to methyl transferases which are involved in 
methoxymalonyl precursor biosynthesis (figure 1.9).87 
 
          
 
Figure 1.9 The structures of natural products erythromycin 4, rifamycin B 35 and 
geldanamycin 36,  which have undergone post- or pre-PKS modification (red/blue). 
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1.3.2.3 Halogenases 
 
Many polyketide natural products contain halogens that contribute to their bioactivity. 
Chloride and bromide groups are most commonly observed, but there are examples of 
fluorinated and iodinated polyketides.88 The introduction of halogens at electron-rich (often 
aromatic) positions is usually catalyzed by flavin-dependent halogenases. Examples include 
post-PKS chlorination during 7-chlortetracycline 37 biosynthesis as well as the biosynthesis of 
anti-cancer agent radicicol 38 (figure 1.10).89 Halogenation at aliphatic positions is usually 
catalyzed by Fe(II) and aKG-dependent halogenases,90 which often act during polyketide 
assembly on ACP-tethered intermediates. A well-studied example is the introduction of the 
vinyl chloride group in the biosynthesis of jamaicamide A 39 (figure 1.10).91 
  
 
 
Figure 1.10 The structures of halogenated polyketide natural products chlortetracycline 
37,  radicicol 38 and jamaicamide A 39. Halogens introduced by tailoring enzymes are 
highlighted in red. 
 
1.3.3 trans-AT PKSs 
 
Type I modular PKSs can be subdivided into cis- and trans-AT types on the basis of 
phylogenetic analyses. cis-AT PKSs such as DEBS (scheme 1.1) have AT domains embedded 
within each module, which are responsible for priming the adjacent ACP domain with a starter 
or extender unit. trans-AT PKSs have separately encoded AT domains that act in trans to 
prime ACP domains in the assembly line with extender units (figure 1.11).92 Recent work has 
suggested that some ACP domains in trans-AT PKSs, particularly those directly downstream 
of KS0 domains (section 1.3.3.1) avoid malonylation.93 trans-AT PKSs also frequently have 
trans-acting ER domains which catalyse enoyl reduction of unsaturated thioester intermediates 
in trans. 
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Figure 1.11 The comparison of a typical cis-AT PKS module harboring embedded AT  
and ER domains, with a trans-AT PKS module which has a separately encoded AT and 
ER domains. 
 
cis-AT PKSs typically obey the co-linearity principle, in that the order and function of 
catalytic modules and domains in the megasynthase generally correlates to the structure of the 
polyketide product. This makes it possible to predict the structure of putative polyketide 
products based upon domain architecture alone.94 Many of the domains discussed in sections 
1.3.1.1 and 1.3.1.2 are still present in trans-AT PKS systems, however they are often miss-
assigned and can have variants that catalyze different reactions to those discussed in the 
previous sections.94 trans-AT PKS systems can also have great architectural diversity 
including modules with unusual domain orders and modules split across polypeptide subunits, 
which often makes the structures of putative polyketide products from trans-AT PKSs difficult 
to predict based on domain and module architecture alone. Some common features of trans-
AT PKSs are discussed in the following sections (1.3.3.1-1.3.3.4). 
 
1.3.3.1 KS0 Domains 
 
A unique feature of trans-AT PKSs is KS0 domains, which are non-elongating variants of KS 
domains. These domains are structurally similar to KS domains (section 1.3.1.1), but lack a 
conserved histidine residue required for the decarboxylative Claisen condensation, and so are 
not able to catalyse chain elongation. Despite this, KS0 domains still harbour the conserved 
cysteine residue required for translocation, and so are capable of facilitating transfer of the 
acyl chain onto downstream carrier proteins, this is exemplified in the chain release 
mechanism of enacyloxin biosynthesis (section 1.5).93,95 
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1.3.3.2 Pyran Synthase Domains 
 
Pyran synthase (PS) domains are variants of DH domains that are exclusive to trans-AT PKSs. 
They catalyse the formation of 5- or 6-membered ether rings via an oxa-Michael addition 
(scheme 1.9). PS domains resemble DH domains, but contain a deletion within the 
HxxxGxxxxP active-site motif that is found in canonical DH domains.94 The mechanism of 
oxacycle formation is not fully understood, but it is thought that a conserved active site 
histidine residue catalyzes proton transfer during the Michael addition (scheme 1.9).96 
 
          	
Scheme 1.9 The PS-catalyzed cycloether ring formation observed in trans-AT PKSs. 	
1.3.3.3 b-Branching Cassette 
 
trans-AT PKS gene clusters often encode trans-acting b-branching cassettes that are 
responsible for the introduction of b-branches into the polyketide chain. b-Methyl branching is 
typically catalyzed by a series of enzymes known as the 3-hydroxy-3-methylglutaryl synthase 
(HMGS) cassette.94 This includes a KSQ domain, which is responsible for the decarboxylation 
of a separate malonyl-ACP to form the corresponding-acetyl ACP. The KSQ domain cannot 
catalyse chain elongation because its active site cysteine residue is mutated to a glutamine. A 
HMGS enzyme catalyzes the aldol addition of the acetyl unit onto the 3-keto thioester bound 
to an ACP domain of the megasynthase, followed by hydrolysis. The aldol product is then 
dehydrated and decarboxylated by two enoyl-CoA hydratase-like enzymes (ECH), resulting in 
the installation of the b-methyl group (scheme 1.10).97 Variants of b-branching cassettes are 
also employed for the installation of other functional groups such as cyclopropanes.98 
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Scheme 1.10 The HMGS cassette responsible for the installation of a b-methyl group. 
§ denotes a separately encoded ACP domain, * denotes a megasynthase ACP domain.  
 
1.3.3.4 Split Modules 
 
Split modules are a good example of the unusual domain architecture that can be found in 
trans-AT PKSs. They are modules that span across polypeptide subunits and harbour an inter-
subunit gap (figure 1.12). Split modules harboring a DH domain at the N-terminus of the 
downstream subunit are often referred to as “dehydrating bimodules” of which there are two 
types, type A and type B.94 Type A harbour a KS0 domain at the C-terminus of the upstream 
subunit and are proposed to install an alkene, whereas type B harbour a KS domain at the C-
terminus of the upstream subunit and are proposed to install a diene. However, there is no 
biochemical evidence for this.99 The subunits are brought together during chain assembly by a 
disordered DH-docking (DHD) domain appended to the C-terminus of the upstream subunit, 
which docks to the surface of the DH domain at the N-terminus of the downstream subunit 
(figure 1.12).100 Split modules are discussed in more detail in section 2.1.2. 
 
          
 
Figure 1.12 Organisation of type A and type B split modules also known as 
‘dehydrating bimodules’ in trans-AT PKSs.  	
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1.4 Gladiolin 
 
Gladiolin 29 is a macrolide antibiotic, which has been isolated from Burkholderia gladioli 
BCC0238, a clinical isolate from a CF patient. It shows potent activity against Mycobacterium 
tuberculosis, with a minimum inhibitory concentration (MIC) of 0.4 µg/mL against the H37Rv 
strain, and has been shown to be active against several antibiotic resistant clinical isolates.101 
The target of gladiolin is RNA polymerase, which is also inhibited by several other antibiotics 
used to treat tuberculosis, such as rifampicin.102  
 
Gladiolin 29 is assembled by a trans-AT PKS consisting of 17 modules that is encoded by six 
genes (GbnD1-GbnD6). Three upstream genes encode two trans-acting AT domains (GbnB 
and GbnL), and an acyl hydrolase (AH) domain (GbnT), which hydrolyzes acylated ACP 
domains that block polyketide assembly (scheme 1.11).101,103 Polyketide assembly is initiated 
by the GbnB-catalyzed transacylation of a succinyl-CoA starter unit onto a standalone ACP 
domain (GbnA). The succinyl group is then converted to a succinamide group via an 
asparagine synthetase (GbnC), before the acyl chain is transferred onto the N-terminal KS 
domain (KS1) of the PKS, which then catalyzes elongation with the malonated downstream 
ACP domain (scheme 1.11).  
 
The resulting ACP-bound keto-ester is then converted to a 3-methyl-2-enoyl thioester, 
catalyzed by the HMGS cassette described in section 1.3.3.3, which includes a KSQ (GbnG), 
HMGS (GbnH) and two enoyl-CoA hydratase-like enzymes (GbnI and GnbJ, scheme 1.11). A 
b-methyl branch is also installed by module 6. In addition, a trans-acting ER domain (GbnE) 
is encoded by the gene cluster. This catalyzes reduction of enoyl thioester intermediates 
attached to the ACP domains of modules 5 and 10, accounting for the saturation of C-17 and 
C-27 of gladiolin.97,101 Once off-loaded from the PKS, the amide variant of gladiolin (40) then 
undergoes hydrolysis catalyzed by an amide hydrolase (GbnM) to produce gladiolin 29. 
 
The assembly of gladiolin 29 requires 17 chain elongation reactions. However, there appears 
to be 20 KS domains, each capable of catalyzing chain elongation, embedded within the PKS. 
This suggests that three KS domains may function as transacylase domains, facilitating the 
transfer of the growing polyketide chain to a downstream ACP domain without catalyzing 
elongation. However, it is difficult to identify which three KS domains do not elongate the 
polyketide chain without experimental data. In addition, there appears to be six functional DH 
domains within the PKS, yet seven dehydrations are required for the assembly of gladiolin 29. 
This suggests that one of the DH domains may catalyze two successive dehydrations. 
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Scheme 1.11 Domain and module organization of the gladiolin 29 trans-AT PKS, along with putative ACP-bound intermediates resulting from the 
reactions catalyzed by each module. The b-methyl 2-enoyl thioesters assembled by modules 1 and 6 (*) are installed by the HMGS cassette.
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Module 13 of the gladiolin PKS harbors a type B split module (section 1.3.3.4) which is 
proposed to result in the installation of the (E,Z)-configured diene of gladiolin 29 (scheme 1.12). 
Given that there is only one DH domain present within the module, this DH domain may 
catalyze a previously uncharacterized double dehydration.  
 
 
 
Scheme 1.12 The type B split module present in the gladiolin PKS thought to be 
responsible for the installation of the (E,Z)-diene motif (red). 	
1.5 Enacyloxin 
 
Another polyketide that exhibits antimicrobial activity is enacyloxin IIa 30 (figure 1.13), which 
is produced by Burkholderia ambifaria AMMD. This metabolite was identified by screening 
Bcc isolates against pathogenic bacteria leading to the identification of activity of the B. 
ambifaria strain against B. multivorans, a pathogen which commonly causes infections in CF 
patients.104,105 Enacyloxin IIa 30 and several congeners were originally isolated from the g-
proteo-bacterium, Frateuria sp. W-315 by Watanabe and co-workers (figure 1.13). However the 
enacyloxin biosynthetic gene cluster has only been identified in B. ambifaria.106–108  
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Figure 1.13 The enacyloxin congeners isolated by Watanabe and co-workers. The 
stereocenter marked (S) is now believed to be (R)-configured.  
 
In addition to being active against cystic fibrosis pathogens, enacyloxin IIa 30 shows potent 
(MIC of 2 µg/mL), narrow-spectrum activity against Acinetobacter baumannii.104 A. baumannii 
is a Gram-negative MDR pathogen that causes hospital-acquired infections, and is high on the 
world health organizations (WHOs) priority list of dangerous pathogens.109 The antibiotic acts 
by targeting ribosomal elongation factor thermo unstable (EF-Tu). Guanosine 5’-triphosphate 
(GTP)-bound EF-Tu carries aminoacyl-tRNA to the mRNA-programmed ribosome during 
bacterial protein synthesis. The codon-anticodon interaction at the ribosome promotes the 
hydrolysis of the bound GTP, which triggers the release of the EF-Tu-Guanosine 5’-diphosphate 
(GDP) complex, as well as peptide bond formation during protein synthesis. The binding of 
enacyloxin IIa hinders the release of the EF-Tu-GDP complex from the ribosome, which 
inhibits recycling of EF-Tu, peptide bond formation and hence bacterial protein synthesis.  
 
The structure of enacyloxin IIa 30 co-crystallized with the EF-Tu-GDP complex from E.coli 
solved by Parmeggiani and co-workers is shown in figure 1.14.110 The dissociation constant (Kd) 
for the EF-Tu-enacyloxin complex could not be determined however due to the poor water 
solubility of enacyloxin IIa, and so little is known about the affinity of enacyloxin IIa for EF-Tu 
compared to the derivatives isolated by Watanabe and co-workers (figure 1.13).110 
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Figure 1.14 The crystal structure of enacyloxin IIa 30 bound to the EF-Tu-GDP complex. 
 
Based on the binding of enacyloxin IIa 30 to the EF-Tu-GDP complex shown in figure 1.14, the 
structure of enacyloxin IIa can be split into three sections (figure 1.15). Firstly the 
dihydroxycyclohexane carboxylic acid (DHCCA) unit (green), which appears to be involved in 
polar contacts with a lysine (313) and a tyrosine (160) residue in the binding pocket. The polyol 
region (blue), which appears to make polar contacts with two arginine residues (123 and 373), 
two ordered water molecules as well as a backbone alanine residue (96). Finally the polyene 
region (red), which acts as a rigid linker region. In order to determine whether these polar 
contacts are key to activity, it would be useful to generate a library of enacyloxin analogues 
harbouring structural changes in both the DHCCA and polyol regions. This would provide 
useful structure-activity relationship (SAR) data, and potentially more potent analogues.  
 
                         
 
Figure 1.15 The key polar contacts between enacyloxin and the binding site in EF-Tu. 
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The enacyloxin biosynthetic gene cluster contains seven PKS genes, encoding a hybrid cis-
AT/trans-AT PKS consisting of ten chain extension modules and a loading module (scheme 
1.13). Curiously, no standalone AT domains are encoded within the cluster, suggesting that 
either the AT domains of modules 1 and 6 may act in trans in order to malonate ACP domains 
of other modules, or there may be a trans-acting AT encoded outside of the cluster. Polyketide 
assembly is initiated by the GCN5-related N-acetyltransferase (GNAT) domain which catalyzes 
the decarboxylation of methylmalonyl-ACP (generated by the MT domain of the loading 
module from malonyl-ACP) to generate propionyl-ACP. The subsequent domain architecture 
shows perfect co-linearity with the proposed biosynthetic intermediates, with the exception of a 
DH domain missing from module 6 and a KR domain from module 9. The functions of these 
missing domains may be catalysed by trans-acting enzymes, or neighbouring modules.104 
 
	
		
Scheme 1.13 The enacyloxin gene cluster and proposed biosynthetic pathway. Note that 
the domain marked ‘?’ in Bamb_5917 is of unknown function. The putative functions of 
all the genes involved in enacyloxin biosynthesis can be found in appendix 8.6. 
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The PKS chain release mechanism is particularly unusual (scheme 1.14). A KS0 domain is 
present at the C-terminus of the final PKS subunit (Bamb_5919), rather than the TE domain 
usually responsible for chain release during polyketide assembly. The KS0 domain catalyses the 
transfer of the ACP-bound intermediate of module 10 onto a peptidyl carrier protein (PCP) 
domain (Bamb_5917).93 The PCP-bound polyketide chain is then offloaded by a condensation 
domain (Bamb_5915) with DHCCA 48. Condensation reactions of PCP-bound thioesters 
catalysed by condensation domains are frequently observed in nonribosomal peptide synthetases 
(NRPSs). However the thioester is typically condensed with an amine to form an amide rather 
than an alcohol to form an ester.111  
 
                           
 
Scheme 1.14 The off-loading mechanism from the enacyloxin PKS. 
 
DHCCA 48 is proposed to be derived from shikimate 47, with five enzymes (Bamb_5912, 
5913, 5914, 5916 and 5918) hypothesized to be involved in the pathway (scheme 1.15). The 
pathway consists of the reduction of 3-dehydroshikimate 49 to shikimate 47 by a shikimate 
dehydrogenase (Bamb_5913), followed by reduction to a trihydroxycyclohexanecarboxylic acid 
(THCCA) intermediate 50 by one of two enoyl reductases (Bamb_5914 or 5918). This 
intermediate is then proposed to be dehydrated by Bamb_5912 and isomerized by Bamb_5916 
to form unsaturated DHCCA analogue 51. The final step to form DHCCA 48 is catalyzed by the 
remaining enoyl reductase (Bamb_5914 or 5918). However, none of these steps have been 
confirmed experimentally. 
 
 
 
Scheme 1.15 The proposed pathway for DHCCA (48) biosynthesis. 
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The condensation product, pre-enacyloxin 46, is then proposed to be elaborated by five tailoring 
enzymes (Bamb_5927, 5928, 5930, 5931 and 5932) to form enacyloxin IIa 30 (scheme 1.16). 
Pyrroloquinoline quinone (PQQ)-dependent dehydrogenase (Bamb_5932) has been 
characterized as an extracellular enzyme responsible for the oxidation of enacyloxin IVa 43 to 
enacyloxin IIa 30.112 Enacyloxin IVa 43 was isolated from Frateuria sp. W-315 (figure 1.13). 
However, Watanabe and co-workers assigned the C-15 stereocentre as (S)-configured, which is 
not in agreement with the predicted stereoselectivity of the module 4 KR domain encoded by 
the gene cluster from B. ambifaria.107  
 
The four remaining tailoring enzymes are putative carbamoyl transferase Bamb_5930, Fe(II) 
and a-KG-dependant dioxygenase Bamb_5927, FAD-dependant halogenase Bamb_5928 and 
Fe(II) and a-ketoglutarate-dependant halogenase Bamb_5931. These are proposed to 
carbamoylate, hydroxylate and halogenate pre-enacyloxin 46, to form enacyloxin IVa 43. 
However the order of these steps, or whether in fact they act on ACP-bound polyketide 
intermediates rather than pre-enacyloxin 46 post-PKS assembly, is yet to be established.  
 
 
 
Scheme 1.16 The proposed tailoring steps of the enacyloxin biosynthetic pathway 
leading to the production of enacyloxin IIa 30 from pre-enacyloxin 46. 
 
1.6 Aims of the Project 
 
The overall aim of this project was to develop a better understanding of the gladiolin and 
enacyloxin biosynthetic pathways with a view to engineered biosynthesis of antibiotic 
analogues. More specifically, the first aim was to establish the role of the module 13 DH 
domain in generating the E,Z-diene motif of gladiolin 29. This would provide greater insight 
into how DH domains function in type B split modules, which are commonly found in trans-AT 
PKS systems but are largely uncharacterized. The second aim was to generate a structurally 
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diverse library of enacyloxin analogues using established and newly developed strategies, which 
could provide useful SAR data in addition to analogues with increased potency. The final aim 
was to confirm the biosynthetic pathway for the DHCCA 48 unit of enacyloxin IIa 30. This 
could be achieved using a combination of in vitro assays of recombinant proteins putatively 
involved in the pathway with chemically synthesized substrates, in addition to gene deletion 
studies. 
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2. Results and Discussion I: Diene-Forming DH Domains 
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2.1 Introduction 
2.1.1 Dehydratase (DH) Domains 
2.1.1.1 Structure of DH Domains 	
The structures of many DH domains have been solved, with much of the initial structural work 
being based upon bacterial (type II) FAS DHs. These discrete proteins (FabA and FabZ) exist as 
dimers consisting of a structure known as the “hotdog fold” whereby an antiparallel b-sheet 
“bun” encases a hydrophobic a-helical “sausage” (figure 2.1A). Each pair of dimers harbors 
two inter-subunit active sites, which contain a histidine from one monomer and either an 
aspartate (FabA) or a glutamate (FabZ) from the other monomer (figure 2.1B).113–116 This 
culminates in a catalytic dyad that is observed in the active sites of all DH domains and has been 
shown to be essential to catalytic activity via site-directed mutagenesis experiments.115 
  
 
 
Figure 2.1 The crystal structure of FabA (PDB: 4B0C) from Pseudomonas aeruginosa.  
(A): The two monomers are shown in blue and green respectively, with the a-helix of 
each monomer shown in grey illustrating the “hotdog fold”. (B): The two active sites 
encompassed by the dimer with aspartate and histidine residues being provided by each 
monomer (D,H and D’, H’ respectively).11 4 
 
DH domains from mammalian (type I) FAS and PKSs retain many of the structural features 
found in bacterial FAS DHs. However, they are no longer standalone enzymes but are 
incorporated into megasynthases. They still exist as dimers, however one key structural 
difference is that rather than having inter-subunit active sites, each monomer exists as a “double 
hotdog fold” in which the catalytic dyad is found (figure 2.2).99,117–120  	
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C	
N’	
C’	
H	
H’	
D’	
D	
(A)	 (B)	
	 35	
		
Figure 2.2 The crystal structure of EryDH4 (PDB: 3EL6). (A): The “double hotdog fold” 
with the antiparallel b-sheets shown in green and the two a-helices shown in grey. (B): 
The active site aspartate and histidine residues (D and H).1 18 	
2.1.1.2 Mechanism of DH Domains 	
DH domains have been shown to reversibly catalyze the dehydration of 3-hydroxyacyl thioester 
intermediates (in both FAS and PKS systems), as well as 2-methyl-3-hydroxyacyl thioester 
intermediates (in PKS systems), all via a stereoselective syn elimination mechanism (section 
1.3.1.2).70,121,122 The stereochemistry of a 3-hydroxyacyl thioester substrate dehydrated by the 
DH domain can be predicted based upon the amino acid sequence of the upstream KR domain 
(A-type (KRA) installs (S)- and B-type (KRB) installs (R)-configured hydroxyl groups, scheme 
2.1).65,123 The syn elimination results in the dehydration of (3R)-hydroxyacyl thioesters to form 
(2E)-enoyl thioesters and dehydration (3S)-hydroxyacyl thioesters to form (2Z)-enoyl thioesters 
(scheme 2.1).124–129 
       
 
 
Scheme 2.1 Biochemically characterized examples of DH domain-catalyzed syn 
eliminations: Dehydration to afford a (2E)-enoyl thioester in borrelidin biosynthesis and 
dehydration to afford a (2Z)-enoyl thioester in fostriecin biosynthesis.12 5 ,13 0 
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The syn elimination mechanism is believed to proceed via deprotonation at the C-2 position by 
the catalytic histidine residue to form an enolate intermediate, before the elimination of the C-3 
hydroxyl group in order to form the resulting alkene. The role of the catalytically important 
aspartate residue has been the subject of some debate. Many reports suggest that its role is to 
reprotonate the leaving hydroxyl group, facilitating the required cleavage of the C-O bond in a 
“two-base” or “base-acid” mechanism (scheme 2.2).70,99,113–116 The main rational behind this 
mechanism is the spatial relationship between the thioester substrate and the catalytic aspartate 
and histidine dyad.  
 
 
 
Scheme 2.2 The “base-acid” mechanism whereby the histidine deprotonates at the C-2-
position and the aspartate reprotonates the C-3 hydroxyl group to form (E)- and (Z)-
configured alkenes. 
 
This mechanism would require the pKa of the acidic aspartate residue (pKa ~ 4) to exceed that of 
the histidine imidazolium (pKa ~ 6) for the aspartate to be protonated whilst the imidazolium is 
deprotonated at physiological pH. Although the observed pKa of an active site amino acid 
residue can differ from those of the free amino acids,131 as yet there has been no reported 
experimental evidence confirming the pKa differences required for the “base-acid” mechanism. 
In fact, one of the only reported studies of the pH dependence of PKS DH domains actually 
indicated that the active site histidine had a pKa of ~ 7, meaning it is even less likely that the pKa 
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of the active site aspartate exceeds that of the histidine, which suggests that the “base-acid” 
mechanism is not correct.132 A recent kinetic study by Cane and co-workers provides 
experimental evidence for a “single-base” mechanism.71 They propose the histidine residue both 
deprotonates at the C-2-position and reprotonates the C-3 hydroxyl group on the same face, 
whilst the aspartate residue is proposed to bind and orient the substrate (scheme 2.3). This 
provides rationale for the syn elimination observed whilst avoiding the pKa-associated problems 
of the “base-acid” mechanism. 
 
 
 
Scheme 2.3 The “single-base” mechanism whereby the histidine both deprotonates at the 
a-position and reprotonates the leaving hydroxyl group to form (E) and (Z)-configured 
alkenes. 
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2.1.2 Split Modules 
2.1.2.1 Split Modules in trans-AT PKSs 
 
DH domains from trans-AT PKS systems have been shown to have variants that catalyze 
reactions other than dehydration such as enoyl isomerization (enoyl isomerases (EIs)) and pyran 
formation (PSs, section 1.3.3.2).133,134 They can also occur in split modules, which are a 
common feature of trans-AT PKSs (section 1.3.3.4).94,135 Split modules harboring a DH domain 
at the interface are often referred to as “dehydrating bimodules” and have of a KS-KR-ACP-KS 
domain architecture at the C-terminus of an upstream PKS subunit, and a DH-ACP didomain 
motif at the N-terminus of the downstream subunit (figure 2.3). The subunits interact with one 
another via a DHD domain at the C-terminus of the KS domain and the surface of the 
downstream DH domain.100  
 
These split modules can be categorized into either type A or type B varieties.136 Type A split 
modules result in the formation of either a (2E)- or (2Z)-configured enoyl thioester intermediate 
and harbor a KS0 domain (section 1.3.3.1) at the C-terminus of the upstream subunit (figure 
2.3). In contrast, type B split modules have a catalytically active KS domain at the interface, as 
well as an additional KR domain downstream of the DH domain, and are proposed to result in 
the formation of a 2,4-dienoyl thioester intermediate with either an (E,E)- or an (E,Z)-
configuration (figure 2.3).94,99,136,137 The structure of a DH domain from a type B split module 
(module 10 of the difficidin PKS) was recently solved by Keating-Clay and co-workers.99  
 
              
 
Figure 2.3 The domain architecture of type A and type B split modules. The KS0 domain 
in type A facilitates chain transfer whereas the KS domain in type B is proposed to result 
in an additional chain elongation. 	
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2.1.2.2 Split Module in the Gladiolin PKS 	
Module 13 of the gladiolin PKS (scheme 2.4) appears to be a split module, which is responsible 
for the installation of the (E,Z)-diene in the macrolide ring of gladiolin 29. The module has a 
type B split module architecture, as the KS domain is capable of catalyzing chain elongation 
provided the relevant ACP domain is malonated. In addition, there are six DH domains in the 
gladiolin PKS, yet seven dehydrations are required to assemble gladiolin, suggesting at least one 
DH domain must catalyze more than a single dehydration. It is also important to note that the 
KR domain upstream of the DH domain is A-type (predicted to install a (3S)-configured 
hydroxyl group), whereas the KR domain downstream of the DH domain is B-type (predicted to 
install a (3R)-configured hydroxyl group). 
 
 
 
Scheme 2.4 The type B split module present in the gladiolin PKS thought to be 
responsible for the installation of the (E,Z)-diene motif (red). 
 
2.1.3 Aims  	
We aimed to biochemically characterize the GbnD5 DH domain found in module 13 of the 
gladiolin PKS (scheme 2.4). More specifically, using in vitro biochemical assays, the role of the 
DH domain in forming the (E,Z)-diene motif found in gladiolin was investigated. A variety of 
chemically synthesized substrates were used to probe the mechanism and stereospecificity of the 
domain. 
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2.1.4 in vitro Assay used to Probe the DH Domain 	
Diffusible small molecule probes such as acyl-N-acetylcysteamine (SNAC) or acyl-pantetheine 
substrates have previously been used to investigate the function of individual PKS domains in 
vitro.71,73,138–143 However this approach has been somewhat less successful when investigating 
the function of DH domains, potentially due to the slow kinetics of excised DH domains 
coupled with the reversibility of the reaction.144 A study by Cane and co-workers even reported 
an SNAC substrate binding incorrectly in the active site of a DH domain, resulting in reversal of 
stereospecificity.127 An alternative approach utilizes ACP-bound substrates.70,125,127,145 
 
To probe the catalytic activity of the DH domain from module 13 of the gladiolin PKS, an intact 
protein mass spectrometry (MS)-based assay was used to detect DH-catalysed dehydration and 
rehydration. Firstly, the GbnD5 DH-ACP didomain was overproduced (Dr. Matt Jenner) and 
loaded with chemically synthesized pantetheine thioester substrates.100 The loading reaction 
(conditions described in section 6.7.1) consisted of the conversion of the pantetheine thioester to 
the corresponding acyl-coenzyme A using a cassette of accessory enzymes from E. coli 
(constructs obtained from the group of Dr. Manuela Tosin). This enzymatic approach was used 
because CoA thioesters can often be challenging to synthesize directly. This is followed by 
loading onto the ACP domain of the apo-DH-ACP didomain using the non-specific 4’-
phosphopantethenyl transferase, Sfp (scheme 2.5).146–148  
 
 
 
Scheme 2.5 The intact protein MS-based assay used to probe the activity of the GbnD5 
DH domain using a representative synthetic pantetheine substrate. 
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DH-catalysed dehydration or rehydration of loaded substrates could be detected by intact 
protein MS (section 6.1), as indicated by +/− 18 Da mass shifts (scheme 2.5). It is worth noting 
that during preliminary experiments the standalone GbnD5 DH domain (overproduced by Dr. 
Matt Jenner) was found to be unable to dehydrate pantetheine thioesters.  
 
2.2 Results and Discussion 
2.2.1 Catalytic Activity of the GbnD5 DH Domain 
2.2.1.1 Dehydration of 3-Hydroxyacyl Thioesters 
 
Firstly, the activity and stereospecificity of the GbnD5 DH domain towards 3-hydroxyacyl 
thioesters was examined. To do this, both (3R)- and (3S)-3-hydroxyacyl pantetheine thioesters 
53 and 54 were synthesized (scheme 2.6). Commercially available hexanoic acid 55 was 
converted to β-keto ester 56 via formation of the Meldrum’s acid adduct and subsequent 
thermolysis in methanol. Following this, both (R)- and (S)-configured 3-hydroxy esters 57 and 
58 were prepared via asymmetric reduction under a H2 atmosphere (50 bar). This was achieved 
using Noyori’s (R)- or (S)-BINAP ruthenium catalysts, respectively, and afforded the desired 
alcohols in excellent yield and enantiomeric excess (e.e.).149,150 The stereochemistry of the 
alcohols were confirmed via comparison of optical rotation values to those in the literature, and 
the e.e. was calculated from NMR shifts after conversion to the Mosher’s esters 59 and 60.151 
Saponification followed by coupling with protected pantetheine 61 using 1’-
carbonyldiimidazole (CDI) and removal of the acetonide protecting group using acidic 
conditions afforded 53 and 54.152 
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Scheme 2.6 The synthetic route used to prepare (3R)-3-hydroxyacyl pantetheine thioester 
53. 54 was generated in similar yields, using an analogous procedure. 
 
The (3R)- and (3S)-3-hydroxyacyl pantetheine thioesters, 53 and 54, were separately loaded 
onto the GbnD5 DH-ACP didomain using the method described in section 6.7.1 and incubated 
for 3 h. The deconvoluted spectra from intact protein MS analyses showed that the DH domain 
can dehydrate the (3R)-3-hydroxyacyl thioester (figure 2.4). In contrast, the (3S)-3-hydroxyacyl 
thioester was not significantly dehydrated. The apo-DH-ACP didomain was also subjected to 
intact protein MS analysis without the loaded pantetheine substrate as a negative control 
(appendix 8.4). No dehydration was observed confirming that the dehydration is occurring at the 
loaded acyl chain.  
 
To determine the geometry of the unsaturated product resulting from the DH-catalyzed 
dehydration of the (3R)-3-hydroxyacyl thioester, attempts were made to cleave the product from 
the DH-ACP didomain. However, attempts at both enzymatic and chemical cleavage of the DH-
ACP-bound 2-enoyl thioester were unsuccessful. It was thought that this may be due to the DH 
domain blocking the cleavage of the ACP-bound pantetheine thioester. 
 
 
 
 
 
 
 
6263
53 54
55
OH
O O
O
O OH
O
O
HS
H
N
O
H
N
O
OO
OH
OH
O
S
H
N
O
H
N
O
OOOOH
S
H
N
O
H
N
O
OHOHOOH
S
H
N
O
H
N
O
OHOHOOH
61
5756
1) Meldrum's Acid
EDC, DMAP, THF
2) Δ, MeOH
86 % (2 steps)
[(R)-Ru(OAc)2(BINAP)]
HCl, H2 (50 bar)
MeOH, 90 %
>95 % e.e.
LiOH
THF/H2O
81 %
CDI, CH2Cl2, 75 %
AcOH
H2O
83 %
	 43	
           
 
                     
 
Figure 2.4 Deconvoluted spectra from intact protein MS analyses of the GbnD5 DH-ACP 
didomain onto which thioesters 53 and 54 were loaded. The corresponding masses of the 
dehydrated and rehydrated species can be found in appendix 8.5. 
 
2.2.1.2 Rehydration of E- and Z-configured 2-Enoyl Thioesters 
 
If dehydration of the (3R)-3-hydroxyacyl thioester proceeds via a syn-elimination mechanism, 
the (2E)-2-enoyl thioester should be produced.125,127 Because it was not possible to determine 
the geometry of the dehydration product directly, the ability of the DH domain to catalyze 
rehydration of (2E)- and (2Z)-2-enoyl thioesters was examined. Both (2E)- and (2Z)-2-enoyl 
pantetheine thioesters, 64 and 65, were synthesized according to the route shown in scheme 2.7. 
The (2E)-2-enoyl pantetheine thioester 64 (synthesized by Dr. Doug Roberts) was prepared via 
the coupling of commercially available (2E)-2-hexenoic acid 66 with protected pantetheine 61, 
and subsequent deprotection using an acidic resin.73 The (2Z)-2-enoyl pantetheine thioester 65 
was synthesized by coupling of commercially available hexynoic acid 67 to protected 
pantetheine 61, acidic deprotection to afford alkyne 68, and hydrogenation over Lindlar’s 
catalyst. This reaction was slow, presumably because the thioester poisons the palladium 
catalyst, and additional catalyst had to be added at regular intervals. However after ten days and 
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addition of almost a stoichiometric amount of catalyst, (2Z)-2-enoyl pantetheine thioester 65 
was produced. It was necessary for the (Z)-configured alkene to be installed in the last step, 
because the acidic conditions used for removal of the acetonide group promoted the 
isomerization of the (Z)-configured alkene to the (E)-configured isomer. 
 
 
 
Scheme 2.7 Synthesis of (2E)- and (2Z)-2-enoyl pantetheine thioesters, 64 (Dr. Douglas 
Roberts) and 65. 
 
The (2E)- and (2Z)-2-enoyl pantetheine substrates, 64 and 65 were separately loaded onto the 
GbnD5 DH-ACP didomain (figure 2.5). The deconvoluted spectra from intact protein MS 
analyses showed that the DH domain rehydrates the (2E)-2-enoyl thioester (figure 2.5). In 
contrast, no rehydration of the (2Z)-2-enoyl thioester was observed.  
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Figure 2.5 Deconvoluted spectra from intact protein MS analyses of the GbnD5 DH-ACP 
didomain onto which thioesters 64 and 65 were loaded. 
 
These data indicate that the DH domain catalyzes the interconversion of (3R)-3-hydroxyacyl 
and (2E)-2-enoyl thioesters, but cannot interconvert (3S)-3-hydroxyacyl and (2Z)-2-enoyl 
thioesters (scheme 2.8). This behaviour is consistent with the syn-elimination of water from 
(3R)-3-hydroxyacyl thioesters observed for other DH domains. 
 
           
 
Scheme 2.8 The GbnD5 DH domain catalyzes the interconversion of  (3R)-3-hydroxyacyl 
and (2E)-2-enoyl thioesters, but cannot interconvert (3S)-3-hydroxyacyl and (2Z)-2-enoyl 
thioesters.  
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2.2.1.3 Dehydration of a (3R,5S)-3,5-Dihydroxyacyl Thioester Intermediate  	
In section 2.2.1.1, it was shown that the DH domain is able to dehydrate a (3R)-3-hydroxyacyl 
thioester. The KR domain predicted to produce a (3R)-3-hydroxyacyl thioester (KRB domain) is 
downstream of the DH domain (scheme 2.9). Thus, the role of the KR domain upstream of the 
DH domain (in module 12) is unclear. Given that this domain is predicted to produce a (3S)-3-
hydroxyacyl thioester (KRA domain), it was proposed that the DH domain converts a (3R,5S)-
3,5-dihydroxyacyl thioester (generated via the steps shown in scheme 2.9) to an (E,Z)-diene via 
an unprecedented double dehydration. 
 
 
 
Scheme 2.9 The biosynthetic steps involved in generating the (3R ,5S)-3,5-dihydroxyacyl 
thioester intermediate proposed to be the substrate for the GbnD5 DH domain. * Denotes 
the PKS domain involved in catalyzing each step.  
 
To examine whether the DH domain is able to catalyze double dehydration of a (3R,5S)-3,5-
dihydroxyacyl thioester to an (E,Z)-diene, the (3R,5S)-3,5-dihydroxyacyl and (2E,4Z)-dienoyl 
pantetheine thioesters, 71 and 72, were synthesized and loaded onto the GbnD5 DH-ACP 
didomain to investigate the dehydration and rehydration reactions, respectively.  
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The (3R,5S)-3,5-dihydroxyacyl pantetheine thioester, 71, was synthesized from commercially 
available methyl (3S)-3-hydroxybutanoate 73. The alcohol was tert-butyldimethylsilyl (TBS) 
protected, followed by reduction of the ester to the corresponding aldehyde 74 using 
diisobutylaluminium hydride (DIBAL-H). Following the procedure of Vederas et. al., the 
aldehyde 74 was used in a TiCl4-catalyzed, non-selective aldol reaction with 75, this led to the 
formation of the syn- and anti-diastereomers, 76 and  77, which were separable by silica 
chromatography.153 The chiral auxiliary was then displaced using protected pantetheine 61 
under basic conditions, and both the TBS and acetonide protecting groups were removed under 
acidic conditions to afford the (3R,5S)-3,5-dihydroxyacyl pantetheine thioester, 71 (scheme 
2.10). (3S,5S)-3,5-Dihydroxyacyl pantetheine thioester, 78 was also synthesized via this route 
from the syn-diastereomer 76 (section 2.2.3.1). 
 
 
 
Scheme 2.10 Synthesis of the (3R,5S)-3,5-dihydroxyacyl pantetheine thioester, 71.  The 
(3S,5S)-3,5-dihydroxyacyl pantetheine thioester, 78,  was made via the same route. 
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The relative stereochemistry of the syn- and anti-diastereomers, 76 and 77, was confirmed by 
comparing chemical shift values in the 1H NMR spectrum with those reported by Vederas et. 
al., as well as comparing coupling constants with those reported for similar compounds in the 
literature (figure 2.6).153,154 
 
 
 
Figure 2.6 Regions of 1H NMR spectra for 76 and 77.  According to a study by Hodge et. 
al. , the α-protons (red) of syn- and anti-Evans’ aldol products have diagnostic coupling 
constants, allowing assignment of relative stereochemistry. The upfield α-proton of the 
syn-product is predicted to have coupling constants of around 17.6 and 2.7 Hz, and the 
downfield α-proton 17.6 and 9.5 Hz. The upfield α-proton of the anti-product is 
predicted to have coupling constants of around 17.5 and 9.5Hz, and the downfield α-
proton 17.5 and 3.1Hz. The coupling constants for the α-protons of both 76 and 77 
appear to be in agreement with this study.1 5 4 
 
(2E,4Z)-Dienoyl pantetheine thioester, 72, was synthesized from commercially available tert-
butyl acrylate 81. Following a procedure reported by Davies et. al., tert-butyl acrylate 81 was 
coupled with (Z)-bromopropene via a Heck-type coupling reaction, and the tert-butyl protecting 
group was removed under acidic conditions to afford (2E,4Z)-2,4-hexadienoic acid 82.155 
Initially, acid 82 was coupled to protected pantetheine 61 and deprotected using acidic 
conditions as conducted previously. However, the acidic deprotection conditions caused 
isomerization of the (E,Z)-diene to an (E,E)-diene. To overcome this, the acid 82 was converted 
to the corresponding acid chloride 83 and condensed with pantetheine 84 in a one-pot procedure 
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to afford the (2E,4Z)-dienoyl pantetheine thioester, 72, in a poor yield but with the desired 
(E,Z)-diene geometry (scheme 2.11). 
 
 
       
 
Scheme 2.11 Synthesis of (2E ,4Z)-dienoyl pantetheine thioester, 72. 
 
The (3R,5S)-3,5-dihydroxyacyl and (2E,4Z)-dienoyl pantetheine thioesters, 71 and 72, were 
separately loaded onto the GbnD5 DH-ACP didomain and intact protein MS analysis was 
conducted (figure 2.7). A cluster of three peaks, each separated by 18 Da, was observed for the 
(3R,5S)-3,5-dihydroxyacyl pantetheine thioester, 71. The peak with the greatest mass 
corresponds to the loaded diol. The central peak is consistent with a (2E,5S)-5-hydroxy-2-enoyl 
thioester resulting from elimination of the (3R)-configured hydroxyl group, as observed in 
earlier assays (section 2.2.1.1), however this species could also correspond to a species resulting 
from elimination of the C-5 hydroxyl group. The remaining peak is consistent with a (2E,4Z)-
2,4-dienoyl thioester, and indicates that the GbnD5 DH domain is able to catalyze a double 
dehydration. Loading of the (2E,4Z)-dienoyl pantetheine thioester, 72, results in the same 
cluster of three peaks, indicating that the E,Z-diene can be fully rehydrated back to the diol via a 
mono-rehydrated intermediate (figure 2.7). These results indicate that the GbnD5 DH domain 
can reversibly dehydrate a (3R,5S)-3,5-dihydroxyacyl thioester, to form a (2E,4Z)-dienoyl 
thioester, which is predicted to correspond to the E,Z-diene motif in gladiolin 29. 
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Figure 2.7 Deconvoluted spectra from intact protein MS analyses of the GbnD5 DH-ACP 
didomain onto which thioesters 71 and 72 were loaded. Note the presence of a peak in 
both spectra corresponding to the holo-DH-ACP didomain, This presumably arises from 
spontaneous δ-lactonization of the diols. 
 
This is the first biochemical evidence for double dehydration catalyzed by a DH domain. The 
data obtained are consistent with a syn-elimination mechanism in which the (R)-configured 
alcohol is eliminated to form an (E)-configured alkene and the (S)-configured alcohol yields a 
(Z)-configured alkene. However, the mechanistic details and structural features of the GbnD5 
DH domain which enable it to catalyze a double dehydration required further investigation. 
 
2.2.2 Catalytic Mechansim of the GbnD5 DH Domain 
2.2.2.1 Identification of an Additional Active Site Histidine Residue 
 
To better understand the mechanism of the double dehydration reaction catalyzed by the GbnD5 
DH domain, the sequences of DH domains from type B split modules (including the GbnD5 DH 
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domain) were aligned with sequences of well-characterized, cis-AT PKS DH domains. (Dr. 
Matt Jenner, figure 2.8).  
 
 
Figure 2.8 Sequence alignment of DH domains predicted to catalyze double dehydrations 
with canonical DH domains from cis-AT PKSs. 
 
The alignment shows that DH domains from type B split modules contain a histidine residue 
(His2) in place of a conserved tyrosine residue in cis-AT PKS DH domains. In light of this, a 
homology model of the GbnD5 DH domain, based on the crystal structure of a DH domain from 
a type B split module in the difficidin PKS, was generated (Dr. Matt Jenner, figure 2.9).99 
 
 
 
Figure 2.9 The homology model of the GbnD5 DH domain indicating that it contains an 
additional active site histidine residue (His15 8) compared with the EryAII DH domain 
active site. 
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The additional histidine residue appears to be ideally positioned to catalyze dehydration of a 
(2E,5S)-5-hydroxy-2-enoyl thioester (scheme 2.12). Keatinge-Clay and co-workers noticed the 
presence of this additional active site histidine residue in the DH domain from module 10 of the 
difficidin PKS. However, they suggested it is unlikely to be involved in catalysis due to the 
proximity of the residue with respect to the pantetheine-bound acyl chain.99  
 
                            
 
Scheme 2.12 Proposed roles of His2 3 and His1 58 in the double dehydration reaction 
catalyzed by the GbnD5 DH domain.  
 
2.2.2.2 The Additional Histidine is Required for a Vinylogous Dehydration 
 
To investigate the role played by the additional histidine residue,  (2E,5S)-5-hydroxy-2-enoyl 
pantetheine thioester, 86, was synthesized (scheme 2.13). The (E)-configured double bond was 
introduced via a Wittig reaction between aldehyde 74 (scheme 2.10) and stabilized phosphorane 
87. Hydrolysis of the ester, followed by coupling with protected pantetheine 61 and removal of 
both the TBS and acetonide protecting groups under acidic conditions culminated in the 
formation of (2E,5S)-5-hydroxy-2-enoyl pantetheine thioester, 86. 
 
   
 
Scheme 2.13 Synthesis of (2E ,5S)-5-hydroxy-2-enoyl pantetheine thioester, 86. 
DH
S
(R)
O
HO
(S)HO
His23
DH
S
(E)
O
(S)HO
His158
DH
S
(E)
O
(Z)
O
Si
89
OH
O
OO
Si
S
H
N
O
H
N
O
OO
90
OOH
S
H
N
O
H
N
O
OHOH
AcOH
H2O
88 %
EDC
DMAP
CH2Cl2
80 %
O
Si
O
H
O
Si
O
O
86
8874
LiOH
H2O/THF
81 %
PPh3
H
O
OEt
87
Toluene
94 %
HS
H
N
O
H
N
O
OO
61
	 53	
The (2E,5S)-5-hydroxy-2-enoyl pantetheine thioester, 86, was loaded onto the DH-ACP 
didomain (figure 2.10). The same cluster of three peaks was observed in the intact protein MS 
analysis as for both the diol and diene substrates, 71 and 72, indicating that the (2E,5S)-5-
hydroxy-2-enoyl thioester is an intermediate in diene formation. When the (2E,5S)-5-hydroxy-
2-enoyl pantetheine thioester, 86, is loaded onto a H158Y mutant (generated by Dr. Matt 
Jenner) of the DH-ACP didomain, only peaks corresponding to the loaded thioester and the diol 
resulting from addition of water to the C=C double bond were observed. This confirms that 
His158 is involved in diene formation. 
                 
 
 
 
Figure 2.10 The deconvoluted intact protein MS of the GbnD5 DH-ACP didomain (left) 
and the H158Y mutant (right) after the loading of pantetheine thioester 86.  
 
It is proposed that His158 deprotonates the (2E,5S)-5-hydroxy-2-enoyl thioester intermediate at 
the C-4 position, affording a vinylogous enolate intermediate that eliminates the C-5 hydroxyl 
group with concomitant proton transfer from the His158 residue. The aspartate residue is 
proposed to position the substrate appropriately via hydrogen bonding interactions (scheme 
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2.14). This is analogous to a vinylogous dehydration recently observed in curacin biosynthesis, 
and is consistent with the “single base” mechanism proposed by Cane and co-workers.71,132 
 
                 
 
Scheme 2.14 The proposed mechanism of the double dehydration reaction catalyzed by 
the GbnD5 DH domain. 
 
2.2.3 Substrate Tolerance of the GbnD5 DH Domain 
2.2.3.1 Dehydration of Stereoisomeric 3,5-Dihydroxyacyl Thioesters 	
To more fully evaluate the substrate tolerance of the GbnD5 DH domain, the three 
diastereomers of (3R,5S)-3,5-dihydroxyacyl pantetheine thioester, 71, were also synthesized and 
loaded onto the GbnD5 DH-ACP didomain. (3S,5S)-3,5-Dihydroxyacyl pantetheine thioester, 
78, was synthesized via the route shown in scheme 2.10. The (3S,5R)- and (3R,5R)-3,5-
dihydroxyacyl pantetheine thioesters, 91 and 92 respectively, were synthesized using the route 
shown in scheme 2.15. Aldehyde 93 was synthesized via the same route and with similar yields 
to aldehyde 74 (scheme 2.10) from commercially available methyl (3R)-3-hydroxybutanoate. 
The aldehyde was then subjected to the same TiCl4-catalyzed aldol reaction as used previously, 
yielding a separable mixture of aldol products. The relative stereochemistry of the products, 94 
and 95, was again confirmed by the analysis of diagnostic coupling constants in the 1H NMR 
spectrum, as was conducted for diastereomers 76 and 77 (figure 2.6). The auxiliary was 
displaced using protected pantetheine 61, and acid catalyzed deprotection afforded the desired 
thioesters. 
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Scheme 2.15 Synthesis of 3,5-dihydroxyacyl pantetheine thioesters, 91 and 92.   
 
Pantetheine thioesters 78, 91 and 92 were loaded onto GbnD5 DH-ACP didomain and DH-
catalyzed activity was examined using intact protein MS analysis (figure 2.11). As expected, 
negligible dehydration was observed for thioesters 78 and 91. This was unsurprising because it 
had already been shown that the DH domain is not capable of processing (3S)-configured 
substrates (section 2.2.1.1). Interestingly, peaks corresponding to a mono-dehydrated and a 
doubly dehydrated species were observed for thioester 92. The single dehydration was expected 
because it had already been shown that the DH domain is capable of processing (3R-configured 
substrates (section 2.2.1.1). However, the additional dehydration, which is thought to result in 
the formation of an (E,E)-configured diene, suggests that the DH domain may be promiscuous 
with respect to the stereochemistry of the C-5 hydroxyl group. 
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Figure 2.11 The deconvoluted intact protein MS of the GbnD5 DH-ACP didomain loaded 
with substrates 78, 91 and 92. 
 
2.2.3.2 Rehydration of an (E,E)-Configured Dienoyl Thioester 
 
To investigate GbnD5 DH-catalysed, (E,E)-configured diene formation, (2E,5R)-5-hydroxy-2-
enoyl and (2E,4E)-dienoyl pantetheine thioesters, 98 and 99, were synthesized using the routes 
shown in scheme 2.16. (2E,5R)-5-Hydroxy-2-enoyl pantetheine thioester, 98, was synthesized 
in the same way as the (2E,5S)-5-hydroxy-2-enoyl pantetheine thioester, 86, using aldehyde 93 
as the starting material. The (2E,4E)-dienoyl pantetheine thioester, 99, was synthesized via the 
coupling of commercially available sorbic acid 100, to protected pantetheine 61, followed by 
acid-catalyzed deprotection. The product, 99, was isolated in a poor yield. This may be due to 
polymerization which appears to be promoted by the acidic conditions. 
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Scheme 2.16 Syntheses of (2E ,5R)-5-hydroxy-2-enoyl and (2E,4E)-dienoyl pantetheine 
substrates, 98 and 99, respectively. 
 
Both thioester substrates, 98 and 99, were loaded onto GbnD5 DH-ACP didomain (figure 2.12). 
Intact protein MS analysis showed that the (2E,5R)-5-hydroxy-2-enoyl thioester is converted to 
a diene, confirming that the DH domain is capable of eliminating a (5R)-configured hydroxyl 
group. However, no significant peak corresponding to rehydration to the diol is observed. A 
peak corresponding to a mono-rehydrated species is observed for the (2E,4E)-dienoyl thioester, 
but there is again no significant peak corresponding to a diol present. This suggests that the 
GbnD5 DH domain is capable of dehydrating a (3R,5R)-3,5-dihydroxyacyl thioester to a 
(2E,4E)-dienoyl thioester. However, it cannot rehydrate the diene to a diol, perhaps because it is 
not the native substrate of the DH domain. This is further confirmation that the diene installed 
by the DH domain has an E,Z-geometry, as the (2E,4Z)-dienoyl thioester was fully rehydrated 
back to the diol (section 2.2.1.3), indicating that this is the native geometry installed by the 
domain. 
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Figure 2.12 The deconvoluted intact protein MS of the GbnD5 DH-ACP didomain loaded 
with substrates 98 and 99. 
 
2.3 Conclusions 
2.3.1 Summary 
 
In this study, the first example of a DH domain capable of catalyzing a double dehydration was 
discovered. The GbnD5 DH domain has been shown to reversibly dehydrate a (3R,5S)-3,5-
dihydroxyacyl thioester to form a (2E,4Z)-2,4-dienoyl thioester corresponding to the E,Z-diene 
observed in gladiolin. An additional histidine residue in the active site of the DH domain was 
identified, and was shown to catalyze dehydration of a (2E,5S)-5-hydroxy-2-enoyl thioester 
intermediate. The substrate tolerance of the domain was investigated using a variety of 
pantetheine thioesters, and it was shown to also be capable of producing an (E,E)-diene from a 
(3R,5R)-3,5-dihydroxyacyl thioester.  
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2.3.2 Diene Synthase Domains in Other Systems 
 
A phylogenetic analysis (conducted by Dr. Matt Jenner, appendix 8.1) identified several other 
DH domains that are predicted to install dienes into their respective polyketide products. Most 
of these are part of dehydrating bimodules, but some are incorporated into conventional 
modules and some are present in cis-AT PKS systems. In most cases they appear to be 
responsible for (E,Z)-diene formation. However, one example (tartrolon) is predicted to form an 
(E,E)-diene, consistent with the observation that the GbnD5 DH domain can convert a (3R,5R)-
3,5-dihydroxyacyl thioester to a diene (section 2.2.3.2). Two examples of systems predicted to 
harbor DH domains that install dienes (leinamycin 105 and macrolactin A 106 biosynthesis) are 
shown in figure 2.13, and the domain architectures of more systems with these DH domains can 
be found in section 5.1.1. 
 
 
 
Figure 2.13 Putative diene-forming DH domains present in leinamycin 105 and 
macrolactin A 106 biosynthesis. 	
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The presence of previously unrecognized diene-forming DH domains in many systems 
reinforces the importance of characterizing PKS catalytic domains. The understanding gained 
from this study has not only shed light upon the biosynthetic mechanism for formation of (E,Z)-
dienes motifs in many polyketide natural products, but has also led to the discovery of a novel 
and highly conserved enzyme which could potentially be exploited as a biocatalyst, or for 
biosynthetic engineering to create novel natural product analogues. 
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3. Results and Discussion II: Enacyloxin IIa Analogues 
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3.1 Introduction 
3.1.1 Approaches used for the Generation of Natural Product Analogues 	
As discussed in section 1.1.3, traditional strategies for the generation of natural product 
analogues have relied upon synthetic and semi-synthetic approaches. However, these strategies 
can often be challenging as well as time-consuming, particularly for natural products that are 
highly functionalized and contain multiple stereocentres such as enacyloxin IIa 30 (section 1.5). 
Despite several reports detailing the synthesis of enacyloxin IIa 30 fragments, there have been 
no successful reports of the total synthesis.156–158  	
3.1.1.1 Gene Disruption to Generate Natural Product Analogues 
 
An alternative approach is to use genetic engineering to manipulate the associated gene cluster 
in order to generate structural analogues. This can be achieved in the native host providing it is 
genetically tractable, or with the development of cloning and DNA synthesis, the gene cluster 
can be cloned and expressed into fast growing, genetically tractable heterologous hosts, 
optimized for genetic engineering. One approach used to generate structural changes in natural 
products is the disruption of genes that act downstream in a biosynthetic pathway. Tailoring 
genes are often good candidates for engineering as their role is often to install late stage 
functionality without being directly involved in the biosynthesis of the core of the molecule. 
This strategy has been used successfully to generate analogues via the deletion of cytochrome 
P450 enzymes such as hydroxylases and epoxidases, as well as halogenases, dehydrogenases, 
carbamoyl transferases and many other tailoring genes.79,159–164  
 
This approach was used to generate an analogue of anti-cancer drug macbecin I 107 (scheme 
3.1) which had improved activity. The deletion of the gene encoding monooxygenase tailoring 
enzyme (mbcM), resulted in the production of analogue 108, which has an improved binding 
affinity for its target, Hsp90, compared with macbecin I (Kd 3 nM vs 240 nM), as well as 
reduced toxicity.164 An example of the generation of a library of structural variants using this 
strategy is the investigation of ansamitocin P-3 (109) biosynthesis by Floss and co-workers. 
They deleted genes encoding various tailoring enzymes in order to determine their function, but 
in the process generated a library of ansamitocin analogues which lack the groups highlighted in 
red (scheme 3.1).163    
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 Scheme 3.1 The deletion of tailoring enzymes to generate analogues of macbecin I (107) 
and ansamitocin P-3 (109).   
 
As well as the inactivation of tailoring enzymes, the inactivation of individual domains within 
megasynthases has also been used to generate analogues. This is achieved via site-directed 
mutagenesis to avoid complete disruption of the megasynthase. Inactivation of KR, DH and ER 
domains have all been used to generate analogues.165–171 A good example of this is the 
antifungal agent amphotericin B 110. Caffrey and co-workers inactivated a KR domain (KR16) 
in the PKS, which resulted in the production of oxo-derivative 111, this analogue had reduced 
antifungal activity, but showed a decrease in undesirable hemolytic activity (scheme 3.2).170 
 
 
 
Scheme 3.2 The inactivation of a KR domain from module 16 of amphotericin 
biosynthesis resulting in an analogue with an additional ketone group (red).1 7 0 
 
3.1.1.2 Mutasynthesis to Generate Natural Product Analogues 
 
The strategy of inactivating genes can be coupled with the feeding of precursors to generate 
novel structural analogues in an approach commonly known as mutasynthesis. This often 
involves the deletion of genes responsible for the biosynthesis of a precursor, followed by the 
feeding and incorporation of precursor analogues. This exploits the promiscuity of downstream 
enzymes, and has been used to generate a diverse array of analogues of many classes of natural 
products including macrolides, aminoglycosides and glycopeptides.172–177 Starter units are often 
a common target of this strategy, as highlighted by the engineered biosynthesis of rapamycin 
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(112) analogues (scheme 3.3). A mutant strain lacking the genes responsible for the biosynthesis 
of the 4,5-dihydroxy-1-cyclohexenecarboxylic acid (DHCHC) starter unit 113, was fed with 
DHCHC analogues 114-119 to afford rapamycin analogues with the unnatural starter units 
incorporated.173 
 
 
 
Scheme 3.3 A mutasynthetic approach to generating rapamycin analogues. Starter unit 
mimics 114-119 were incorporated using a mutant lacking the genes required for the 
assembly of the DHCHC starter unit (red).1 73 
 
Another common target for the generation of analogues via mutasynthesis is early stage PKS-
bound intermediates. Small molecule PKS intermediate mimics can be fed into KS domain-
inactivated mutants in order to generate a range of polyketide natural product analogues. This 
technique has been used extensively to exploit the erythromycin biosynthetic pathway.178–183 
The KS domain of module 1 was inactivated, and the producing strain fed with acyl-N-
acetylcysteamine thioester (acyl-SNAC) substrates 120-123. This resulted in the production of 
erythromycin analogues 124-127 as the inactivated KS domain uses the acyl-SNAC as a starter 
unit (scheme 3.4).178  
 
        
 
Scheme 3.4 A mutasynthesis approach to generate erythromycin analogues 124-127.17 8 
Note that the feeding of SNAC 123 resulted in ring-expanded product 127. 
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These strategies rely on the ability of downstream enzymes to accept non-native substrates. In 
some pathways, these enzymes are so promiscuous that simply feeding a precursor at a 
sufficient concentration is enough to generate analogues without the need for any genetic 
manipulation. This simple technique is often referred to as ‘precursor directed biosynthesis’ and 
has been used for many pathways, a prime example being the incorporation of non-
proteinogenic amino acid units in the NRPS-generated immunosuppressant cyclosporine 128 
(figure 3.1).184–186 The adenylation domains from the cyclosporine NRPS are sufficiently 
promiscuous to accept non-proteinogenic amino acid analogues, resulting in the production of 
cyclosporine analogues 129-132.186 However, a common problem with this technique is that a 
mixture of the desired analogue and the natural product may be produced, making purification 
of the analogue difficult. 
 
        
 
Figure 3.1 Feeding of non-proteinogenic amino acids into the cyclosporine (128) 
producing strain results in the production of analogues 129-132.1 8 6  
 
A combination of the deletion of tailoring genes with precursor directed biosynthesis was used 
by Liu and co-workers to generate a remarkable 380 antimycin (133) analogues. The 
NRPS/PKS-catalyzed assembly uses a tryptophan-derived starter unit, which could be 
complimented with 5-fluoro-tryptophan in order to generate a fluorinated starter unit. The AT 
domain in the PKS module primes an alkylmalonyl-CoA extender unit, but also has sufficient 
promiscuity to prime a range of synthetic, non-natural extender units, providing diversity at the 
C-7 position. Once the core structure is assembled, an acyl transferase tailoring enzyme acylates 
at the C-8 position using CoA acyl donors. This enzyme is also promiscuous in that it can 
catalyze acylation with a range of alternative CoAs, generating diversity at the C-8 position. 
This tailoring gene was also deleted in order to generate analogues lacking the acyl group at the 
C-8 position (scheme 3.5).187 
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Scheme 3.5 The generation of 380 antimycin (133) analogues via multiple strategies. 
 
 
One of the major problems with the mutasynthesis and precursor directed biosynthesis strategies 
is that the downstream enzymes may not always have the desired promiscuity. In order to 
address this, approaches have been used whereby domains have been engineered to accept non-
native substrates.185,188–191 This strategy was used successfully when a single mutation in an 
adenylation domain altered its amino acid specificity, resulting in the isolation of a novel 
NRPS-generated calcium-dependant antibiotic (CDA) 134. The adenylation domain of module 
10 of the NRPS was engineered to accept methyl glutamine as a substrate, and after the feeding 
of methyl glutamine derivative 135, the corresponding methyl glutamine analogue of the 
antibiotic 136 was isolated (scheme 3.6). 192 
 
          
 
Scheme 3.6 An A-domain from a NRPS-generated CDA (134) was engineered to accept 
methyl glutamine derivative 135.19 2 
 
Another example of the use of this strategy is a mutant variant of malonyl-CoA synthetase, 
MatB. The role of this enzyme is to generate malonyl-CoA, the commonly used extender unit of 
PKSs, however the mutant variant is capable of generating an array of alternative extender units 
after feeding of the appropriate acid. The combination of this enzyme with promiscuous AT 
domains, has resulted in a diverse array of analogues from several systems.193–196 An example of 
this is the trans-AT PKS kirromycin 137 system (scheme 3.7). The promiscuous KirCII AT 
domain which acts in trans, is capable of priming an ACP domain with unnatural extender units 
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generated by the MatB mutant to afford kirromycin analogues.193 One of the analogues harbors 
an alkyne group, which can act as a synthetic handle for click chemistry. 
 
                 
 
Scheme 3.7 The use of an engineered malonyl-CoA synthetase, MatB, to generate 
unnatural extender units.  The promiscuous KirCII AT domain primes the extender units 
onto the relevant ACP domain before incorporation into kirromycin (137).1 9 3 
 
There have been many more complex strategies developed in recent years, including domain 
swapping, module swapping and the generation of hybrid systems consisting of genes from 
different pathways.188,197,198 However, these approaches are beyond the scope of this chapter. 
Further to this, despite the engineering of megasynthases being used successfully in many cases, 
it can result in low product yields or completely abolished production, possibly due to the 
downstream domains in the megasynthase not being able to accept the modified acyl chain. A 
greater understanding of the molecular architecture, inter-subunit interactions and specificity of 
natural product assembly lines is required before the engineering of megasynthases can be 
utilized to its full potential.59,198–201  	
3.1.2 Previous Work in the Challis Group 	
All enacyloxin analogues in this section were generated by Dr. Joleen Masschelein. 	
3.1.2.1 Enacyloxin as a Target for Genetic Engineering 
 
Recently, the Bamb_5915 condensation domain responsible for the off-loading of the chain with 
the DHCCA (48) unit has been shown to catalyze the condensation of an acyl chain mimic 
(acetyl-PCP domain) with a variety of DHCCA analogues in vitro.93 The overproduced 
Bamb_5917 PCP domain was loaded with acetyl CoA, before the addition of the Bamb_5915 
condensation domain along with a DHCCA analogue (138-144), the production of the 
condensed acetyl-DHCCA analogue 145 was detected using LC-MS (scheme 3.8).  
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Scheme 3.8 DHCCA (48) analogues 138-144 accepted by the Bamb_5915 condensation 
domain during in vitro assays.93 A detailed procedure for the condensation assay is 
described in section 6.7.2. 
 
As well as the promiscuous condensation domain, the enacyloxin biosynthetic gene cluster 
encodes tailoring enzymes including two halogenases (Bamb_5928 and 5931), a dioxygenase 
(Bamb_5927), a dehydrogenase (Bamb_5932) and a carbamoyl transferase (Bamb_5930) as 
shown in figure 3.2. Given the presence of these features, it was thought that both the gene 
disruption and mutasynthesis strategies (sections 3.1.1.1 and 3.1.1.2) could be used to generate a 
library of enacyloxin IIa (30) derivatives. This would lead to analogues harboring structural 
changes in both the polyol region and the DHCCA unit, providing useful SAR data associated 
with the polar contacts observed in the crystal structure (figure 1.14) and potentially analogues 
with increased potency. More potent analogues may then serve as a platform for making more 
complex changes to the structure, such as engineering the megasynthase,  
 
 
                              
 
Figure 3.2 The enacyloxin gene cluster. The groups installed by the tailoring enzymes 
(blue) as well as the DHCCA unit (green) serve as handles for genetic engineering. 
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The original producing B.ambifaria AMMD strain was found to be intractable, however another 
producing strain (B.ambifaria BCC0203) was identified which is genetically tractable, meaning 
genetic manipulation can be carried out in a native producer rather than having to 
heterologously express the gene cluster. The strain is also fast-growing, and produces 
enacyloxin in a good titre (>10 mg/L), all of which will facilitate the engineering of analogues. 	
3.1.2.2 Targeting the Tailoring Enzymes 	
Using an in-frame gene deletion approach (section 6.4.1), initial inroads were made into 
deleting the tailoring genes in order to generate analogues. Vectors for the deletion of genes 
encoding the Fe(II) α-KG-dependent dioxygenase (Bamb_5927), the Fe(II) α-KG-dependent 
chlorinase (Bamb_5931) and the carbamoyl transferase (Bamb_5930) were constructed and 
used to make the respective gene deletions in the B.ambifaria BCC0203 wild-type strain. The 
corresponding analogues were isolated and characterized, and their activity against A. 
baumannii was determined (figure 3.3). The deletion of the gene encoding carbomyl transferase 
(Bamb_5930) resulted in cyclic ether analogue 44, this results from hemiketal formation 
between the de-carbamoylated hydroxyl group and the keto group. Both cyclic ether and des-
chloro analogues 44 and 41 were isolated from Frateuria sp. W-315 by Watanabe and co-
workers as before the biosynthetic gene cluster was identified in B. ambifaria (section 1.5).158 
 
                 
 
Figure 3.3 The enacyloxin analogues isolated from B.ambifaria BCC0203 Δ5927, Δ5931 
and Δ5930 mutant strains along with their respective activities (Dr. Joleen Masschelein). 
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As well as deleting the tailoring genes individually, mutants were generated in which multiple 
genes were deleted to produce a more diverse array of analogues. Two double knock-out 
mutants were generated, one lacking the dioxygenase and halogenase enzymes (Δ5927 + 5931 
mutant strain), and the other lacking the dioxygenase and carbomyl transferase (Δ5927 + 5930 
mutant strain). The resulting analogues are shown in figure 3.4. 
 
                
 
Figure 3.4 The enacyloxin analogues isolated from B.ambifaria BCC0203 Δ5927 + 5931 
and Δ5927 + 5930 double knock-out mutant strains along with their respective activities 
(Dr. Joleen Masschelein). 	
3.1.2.3 Generating Enacyloxin Analogues via a Mutasynthesis Approach 
 
To utilize the aforementioned promiscuity of the condensation domain demonstrated in vitro 
(section 3.1.2.1), a mutant was generated in which some of the genes involved in DHCCA 
biosynthesis (bamb_5912-bamb_5914) were deleted. This abolished the production of the 
DHCCA unit, and hence enacyloxin IIa. This mutant was then fed with synthetic and 
commercially available DHCCA analogues (138, 140 and 143) to generate enacyloxin 
derivatives 148-150 (figure 3.5). 
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Figure 3.5 The enacyloxin analogues isolated from feeding the B.ambifaria BCC0203 
Δ5912-14 mutant strain with DHCCA analogues 138.  140 and 143, along with their 
activity (Dr. Joleen Masschelein).  
 
One potential limitation of enacyloxin IIa as a viable drug candidate is that the ester linkage 
from the DHCCA unit to the linear acyl chain may be susceptible to in vivo hydrolysis. 
However, it appears that the mutasynthesis strategy can be used to generate analogues that 
harbor a more stable amide group in place of the ester (149 and 150). Despite the increased 
stability, both of these analogues have lost potency relative to enacyloxin IIa, and so further 
structural modifications may need to be made to restore the activity. It is also clear that the 
DHCCA unit is very important with regards to the activity of the compound, as when it is 
replaced with an acyclic unit (143) the activity is lost. 	
3.1.2.4 Discovery of Vibroxin 
 
A gene cluster homologous to the enacyloxin biosynthetic gene cluster was identified in the 
genome of a Vibrio rhizosphaerae strain using genome mining. V. rhizosphaerae was grown on 
the enacyloxin-producing basal salts medium (BSM), and the metabolite associated with the 
newly identified gene cluster was isolated and characterized as vibroxin 151 (figure 3.6). 
Vibroxin retains many of the structural features of enacyloxin IIa 30, but has an alternative 
starter unit, an additional alkene (installed by an additional DH domain in the PKS) and lacks 
some of the functional groups introduced by tailoring enzymes, all changes that occur in the 
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polyol region of the molecule. Vibroxin 151 is more potent than enacyloxin IIa 30, which 
validates the strategy of generating enacyloxin analogues harboring structural changes in the 
polyol region of the molecule. It would also be useful to generate analogues of vibroxin using 
the previously described strategies, however the V. rhizosphaerae producing strain is not 
genetically tractable, and so the heterologous expression of this gene cluster to enable genetic 
engineering is required. 
 
                  
 
Figure 3.6 The structure of vibroxin 151 compared to enacyloxin IIa 30. 	
3.1.3 Aims  	
The overall aim of this project was to generate a more complete library of enacyloxin IIa 
analogues using multiple strategies. This would include deleting the genes encoding the 
remaining tailoring enzymes, as well as making various combinations of these knock-out 
mutants. In addition to this, the mutasynthesis strategy would be used alongside chemically 
synthesized DHCCA mimics in order to generate a more diverse array of analogues. It was 
hoped that this would lead to derivatives harboring structural changes in both the polyol region 
and the DHCCA unit in order to determine the importance of the polar contacts between 
enacyloxin IIa and EF-Tu (see section 1.5). This would provide useful SAR data and potentially 
deliver analogues with increased potency, which may then provide a platform for the rational 
design of improved analogues and eventually making more complex changes to the structure.  
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3.2 Results and Discussion 
3.2.1 Generation of Analogues via Deletion of Genes Encoding Tailoring 
Enzymes 	
The analogues in this section were generated in collaboration with Dr. Xinyun Jian. 
3.2.1.1 Producing the Mutant Strains 
 
Gene deletions were generated using a double homologous recombination approach (section 
6.4.1).202 This involved the cloning of the two flanking regions (500-1000 base pairs) of the 
gene to be deleted, into a suicide plasmid (pGPI). This plasmid has two important features 
required for the gene deletion: a trimethoprim resistance marker, as well as a SceI endonuclease 
restriction site.  
 
The plasmid was introduced into E. coli SY327 by electroporation, after the ligation of the two 
flanking arms into the plasmid. The transformants were selected on LB agar plates 
supplemented with trimethoprim before the construct was verified by sequencing. The plasmid 
could then be introduced into the B .ambifaria BCC0203 wild-type strain via triparental 
conjugation using the E. coli SY327 (pGPI) donor strain along with an E. coli HB101 
(pRK2013) helper strain. Transconjugants were then selected for using trimethoprim and 
gentamicin. The trimethoprim forces the first recombination event to occur; the wild-type 
B.ambifaria strain is not resistant to trimethoprim, and so needs to integrate the pGPI plasimid 
into its genomic DNA in order to survive. Gentamicin is used to select against E. coli strains, 
leaving only the gentamicin and trimethoprim resistant single crossover B. ambifaria strain. The 
single crossover event was confirmed using colony PCR. 
 
Another plasmid (pDAI) was then introduced into the mutant; this plasmid has the gene 
encoding the SceI endonuclease as well as tetracycline resistance.  Using E. coli SY327 (pDAI) 
as the donor strain, the plasmid was introduced into the B. ambifaria BCC0203 single crossover 
mutant via the same triparental conjugation, using the E. coli HB101 (pRK2013) helper strain. 
Transconjugants were then selected for using tetracycline and gentamicin. The introduction of 
the pDAI plasmid forces the second recombination event to occur; the SceI endonuclease 
encoded by the pDAI plasmid makes a clean cut at the SceI restriction site, which is now 
incorporated into the genomic DNA. To repair this cut, a second homologous recombination 
event occurs to eliminate the pGPI plasmid, resulting in a mixture of wild-type and deletion 
strains, which were discriminated using colony PCR (figure 3.7). 
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Figure 3.7 The construction of in-frame gene deletions in B. ambifaria BCC0203.  
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The PCR used to confirm the gene deletion was conducted using either the forward primer of 
the 5’ flanking arm and the reverse primer of the 3’ flanking arm, or a newly designed set of 
primers if the melting temperature or GC content of the primers were not compatible. The 
mutant is clearly distinguishable from the wild-type as the region amplified is significantly 
shorter in the mutant because the gene is no longer present between the flanking arms (figure 
3.8). The genetic evidence confirming the mutants constructed in this chapter can be found in 
section 6.4.2. 
 
 
 
Figure 3.8 PCR screening to identify in-frame deletion mutants. The agarose gel 
corresponds to the deletion of the gene encoding PQQ-dependent dehydrogenase 
Bamb_5932. The lanes correspond to the PCR of wild-type B.ambifaria BCC0203 
genomic DNA (gDNA), wild-type B.ambifaria BCC0203 (WT), pGPI plasmid (plasmid), 
single crossover mutant (s.c.) and double crossover mutant (d.c.) respectively. 
 
To detect the production of enacyloxin analogues by the mutant strains, they were grown on a 
single plate of BSM before extraction and UHPLC-ESI-Q-TOF-MS analysis (section 6.1). After 
production of the desired analogue was confirmed, the strain was grown on a larger scale (1 L of 
BSM) before extraction and preparative HPLC purification (section 6.1). The analogue was then 
characterized using NMR spectroscopy before its activity against A.baumannii determined using 
whole cell (MIC) assays (section 6.5.4).  
 
All of the enacyloxin analogues generated during this project were tested against two strains of 
A. baumannii in order to validate the observed activity. The analogues were tested against both 
A. baumannii ATCC17978 – a genome sequenced strain isolated in 1951, and A. baumannii 
DSM25645 – a recent clinical isolate from a soldier injured in the 2008 Georgian-Russian war 
that is resistant to many classes of antibiotics.104 All of the analogues showed the same activity 
against both strains and, so only a single MIC value is shown for each compound. 
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3.2.1.2 Deletion of the Genes Encoding the Remaining Tailoring Enzymes 
 
Among the genes encoding tailoring enzymes, those encoding the PQQ-dependent 
dehydrogenase (Bamb_5932), responsible for the installation of the ketone, and flavin-
dependent halogenase (Bamb_5928), responsible for the chlorination of the polyene, had yet to 
be deleted (figure 3.9).  
 
 
 
                              
 
Figure 3.9 Genes encoding the PQQ-dependent dehydrogenase (Bamb_5932), responsible 
for the installation of the ketone, and flavin-dependent halogenase (Bamb_5928), 
responsible for the chlorination of the polyene. 
 
The deletion of bamb_5932 resulted in the production of expected enacyloxin analogue 43 
(figure 3.10). The structure of 43 was confirmed by the addition of 2 Da in the HRMS relative 
to enacyloxin IIa, as well as the disappearance of the diagnostic ketone carbon shift in the 13C-
NMR spectrum. This analogue was also isolated from Frateuria sp. W-315 by Watanabe and 
co-workers and was named enacyloxin IVa, however the configuration of the additional 
stereocenter was assigned incorrectly (section 1.5).104,112 The correct configuration of the 
additional stereocenter generated by the gene deletion was confirmed using Kishi’s NMR 
database for contiguous polyols (section 3.2.1.4).203  
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Figure 3.10 A UV chromatograms (360 nm) from LC-MS analyses of B.  ambifaria  wild-
type and Δ5930 mutant extracts. B The HRMS for the species eluting at 14.15 min from 
the Δ5930 mutant extract. C The structure assigned by NMR spectroscopy and the 
activity of the analogue against A.  baumannii. 
 
The deletion of bamb_5928 resulted in the production of expected enacyloxin analogue 152 
(figure 3.11). The structure of 152 was confirmed by the loss of 34 Da in the HRMS relative to 
enacyloxin IIa as well as the change in isotope distribution. The appearance of an additional 
proton in the vinyl region of the 1H NMR spectrum (5.86 ppm) also confirmed that the vinyl 
chloride group was no longer present.  
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Figure 3.11 A UV chromatogram (360 nm) from LC-MS analyses of B.  ambifaria 
(Δ5928) extracts. B The HRMS for the species eluting at 14.1 min. C The structure 
assigned by NMR spectroscopy and the activity of the analogue against A . baumannii. 	
3.2.1.3 Generation of Multiple Knock-out Mutants 
 
In order to produce a greater diversity of analogues, mutant strains with multiple gene deletions 
were generated. This was accomplished via two routes: either new deletion constructs were 
designed to eliminate multiple genes that were adjacent in the gene cluster, or the deletion 
constructs were used in combination to delete genes not adjacent in the cluster. To do this, the 
single knock-out mutant strains were cured on M9 minimal medium (section 6.2.2) to remove 
the pDAI plasmid. The same procedure was then employed using the appropriate mutant strain 
in place of the wild-type B. ambifaria BCC0203 strain. 
 
Firstly, a double knock-out mutant strain was generated in which the genes encoding both the 
carbamoyl transferase (Bamb_5930) and the PQQ-dependent dehydrogenase (Bamb_5932) 
were deleted in order to generate a linear de-carbamoylated analogue. As these genes are not 
adjacent in the cluster, the B.ambifaria BCC0203 Δ5930 mutant was cured and treated with the 
bamb_5932 deletion construct to generate the double knock-out mutant. This resulted in the 
production of the expected linear enacyloxin analogue 45 (figure 3.12). The structure of 45 was 
confirmed by the loss of 41 Da in the HRMS relative to enacyloxin IIa, as well as the 
disappearance of both the carbamoyl and ketone carbons in the 13C-NMR spectrum. This 
analogue was also isolated by Watanabe and co-workers as decarbomyl enacyloxin IVa (section 
1.5). 
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Figure 3.12 A UV chromatogram (360 nm) from LC-MS analyses of B.  ambifaria (Δ5930 
+ 32) extracts. B The HRMS for the species eluting at 14.0 min. C The structure assigned 
by NMR spectroscopy and the activity of the analogue against A . baumannii. 
 
Next, a double knock-out mutant strain was generated in which the genes encoding both 
carbamoyl transferase (Bamb_5930) and the Fe(II) α-KG-dependent halogenase (Bamb_5931) 
were deleted. As these genes are adjacent in the cluster, a pGPI construct could be generated in 
which the flanking regions used encompass both genes. This resulted in the production of 
unexpected enacyloxin analogue 153 (figure 3.13). Both the carbamoyl group and the C-18 
chloride group are not present as expected. However, an additional keto group is also present at 
.C-19 This is thought to be due to the PQQ-dependent dehydrogenase (Bamb_5932) being able 
to oxidize the de-carbamoylated hydroxyl group now that the sterically hindering adjacent 
chloride group is no longer present. The structure of 153 was confirmed by the loss of 74 Da in 
the HRMS relative to enacyloxin IIa as well as the change in the isotope distribution. The 
appearance of an additional ketone carbon in the 13C-NMR spectrum (201.3 ppm) as well as the 
change in the chemical shifts of the adjacent protons in the 1H NMR spectrum (proton bonded to 
C-20 shifts from 5.57 ppm to 6.14 ppm) further confirmed the structure.  
 
 
 
683.2367
685.2348
593032	1_RA4_01_15427.d:	+MS,	14.7-14.7min	#880-883
0.00
0.25
0.50
0.75
4x10
Intens.
682.5 685.0 687.5 690.0 m/z
Exact	Mass	[C32H46Cl2O10Na]+:	6 3.2366	 Δ5930 + 32 UV Chromatogram, 360 nm A	 B	
Δ5932 + 30 (45), MIC = 1 µg/mL
C
O
OH
Cl
OH OH OH Cl O
OH
CO2H
OH
	 80	
 
                             
 
Figure 3.13 A UV chromatogram (360 nm) from LC-MS analyses of B.  ambifaria (Δ5930 
+ 31) extracts. B The HRMS for the species eluting at 14.0 min. C The structure assigned 
by NMR spectroscopy and the activity of the analogue against A . baumannii. 
 
A triple knock-out mutant was also constructed in which the genes encoding the carbamoyl 
transferase (Bamb_5930), the Fe(II) α-KG-dependent halogenase (Bamb_5931) and the PQQ-
dependent dehydrogenase (Bamb_5932) were all deleted. This was achieved using both the 
Bamb_5932 and Bamb_5930 + 5931 deletion constructs. The mutant strain produced the 
expected enacyloxin analogue 154 (figure 3.14). The structure of 154 was confirmed by the loss 
of 70 Da in the HRMS as well as the change in the isotope distribution. The disappearance of 
the C-15 ketone carbon in the 13C NMR spectrum (no longer present at 211.7 ppm) as well as 
the appearance of additional aliphatic protons bonded to C-18 in the 1H NMR spectrum (1.62 
ppm) further confirmed the structure.  
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Figure 3.14 A UV chromatogram (360 nm) from LC-MS analyses of B.  ambifaria 
(Δ5930-32) extracts. B The HRMS for the species eluting at 13.0 min. C The structure 
assigned by NMR spectroscopy and the activity of the analogue against A . baumannii 
 
Finally, a mutant was generated where all five tailoring genes were deleted. This was achieved 
using a pGPI construct in which the flanking regions used encompassed all of the tailoring 
genes (bamb_5927-32). This also included the gene encoding a hypothetical protein 
(bamb_5929), the role of which is unclear. The mutant strain produced expected analogue 155, 
albeit in a reduced yield compared with previous analogues. The structure of 155 was confirmed 
by the loss of 125 Da in the HRMS relative to enacyloxin IIa as well as the change in the 
isotope distribution (figure 3.15). The loss of all functional groups introduced by the tailoring 
enzymes could be accounted for in the NMR spectra, in particular the loss of the carbamoyl and 
ketone carbons in the 13C NMR spectrum (158.7 and 211.7 ppm respectively) and the presence 
of additional aliphatic and vinyl protons in the 1H NMR spectrum (1.57, 1.48 and 5.83 ppm 
respectively). 
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Figure 3.15 A UV chromatogram (360 nm) from LC-MS analyses of B.  ambifaria 
(Δ5927-32) extracts. B The HRMS for the species eluting at 14.0 min. C The structure 
assigned by NMR spectroscopy and the activity of the analogue against A . baumannii 
 
When more significant changes are made to the structure of the molecule, a greater variation in 
activity is observed. When all the functional groups introduced by the tailoring enzymes are 
removed the activity decreases significantly, confirming the importance of these groups for 
biological activity. Analogue 45 has improved activity compared with enacyloxin IIa, 
confirming that this strategy can be used to generate analogues with increased potency. 
 
3.2.1.4 Confirmation of the Stereochemistry of the Additional Stereocentre 
 
The deletion of the gene encoding the PQQ-dependent dehydrogenase (Bamb_5932) results in 
an additional stereocentre, which is present in analogues 43, 45, 154 and 155. The configuration 
of this stereocenter was confirmed using Kishi’s NMR database for contiguous polyols.203 The 
13C-NMR chemical shifts of enacyloxin analogue 155 appear to be consistent with those 
predicted by the database. The shifts are consistent with that of linearmycin A 156, a natural 
product harboring the same polyol region, the stereochemistry of which was also solved using 
the database (figure 3.16).204 Furthermore, the predicted configuration of the stereocentre is 
consistent with that predicted using KR domain sequence alignments.123  
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Figure 3.16 The assignment of the relative stereochemistry of linearmycin A 156 using 
Kishi’s NMR database.2 0 3 The 1 3C chemical shifts of enacyloxin analogue 155 appear to 
be consistent with those of linearmycin A 156 as well as those in the NMR database. 
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3.2.1.5 Generation of Analogues using Mutasynthesis 
 
Using the B. ambifaria BCC0203 Δ5912-14 mutant strain generated previously (section 
3.1.2.3), the production medium was supplemented with synthetic DHCCA analogues. A 
DHCCA analogue harboring alternative stereochemistry (157) to that observed in enacyloxin IIa 
was synthesized in order to examine what affect this change would have on activity. DHCCA 
analogue 157 was synthesized according to the route shown in scheme 3.9. Commercially 
available 5-hexenoic acid 158 was condensed with (R)-4-(phenylmethyl)-2-oxazolidinone 159, 
and asymmetric alkylation with allyl bromide afforded compound 160. Ring closing metathesis 
(RCM) using Grubbs’ 2nd generation catalyst, followed by removal of the auxiliary in basic 
conditions gave chiral cyclohexenoic acid 161. The configuration of acid 161 was confirmed by 
the comparison of optical rotation values to those in the literature. The enantiomeric purity of 
the acid was confirmed by 13C NMR analyses of the precursor 162 (figure 3.17). The treatment 
of acid 161 with mCPBA under basic conditions resulted in the formation of lactone 163. 
Hydrolysis of the lactone resulted in the formation of the desired DHCCA analogue 157. 
 
         
 
Scheme 3.9 The route used for the synthesis of DHCCA analogue 157.  
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The enantiopurity of cyclohexenoic acid 161 was determined by calculating the d.e. of 
auxiliary-bound precursor 162. The d.e. could be calculated by the comparison of  13C NMR 
shifts of compound 162 with those of diastereomeric mixture 165 which was generated via the 
acylation of auxiliary 159 with commercially available racemic 3-cyclohexene carboxylic acid. 
The d.e. of compound 162 is greater than 95 % as determined by NMR, confirming the 
enantiopurity of cyclohexene carboxylic acid 161 (figure 3.17). 
 
 
 
Figure 3.17 The 13C NMR shifts of 162 compared with a mixture of diastereomers 165. 
 
Supplementing the production medium with DHCCA analogue 157 resulted in the Δ5912-14 
mutant strain producing the expected enacyloxin analogue 166 (figure 3.18). The structure of 
166 was confirmed by the chemical shift in the 1H NMR spectrum of the proton highlighted in 
structure 166 (4.68 ppm), which is attached to a carbon atom with the opposite absolute 
stereochemistry to the natural product. The activity of the analogue against A. baumannii is the 
same as enacyloxin IIa (MIC 2 µg/mL). 
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Figure 3.18 A UV chromatogram (360 nm) from LC-MS analyses of extracts of 
B.  ambifaria (Δ5912-14) supplemented with DHCCA analogue 157.  B The HRMS for the 
species eluting at 14.4 min. C The structure assigned by NMR spectroscopy and the 
activity of the analogue against A.  baumannii.  
 
As well as altering the stereochemistry of the DHCCA unit, the activity of an analogue with an 
additional substituent on the ring was also tested. DHCCA analogue 167 harboring an additional 
hydroxyl group was synthesized (scheme 3.10) to investigate this. (S)-Configured cyclohexene 
carboxylic acid 168 was synthesized via the same route as 161, using (S)-4-(phenylmethyl)-2-
oxazolidinone (scheme 3.9). Cyclohexene carboxylic acid 168 was converted to iodolactone 169 
via treatment with iodine and potassium iodide under basic conditions. Iodolactone 169 was 
then treated with DBU to afford alkene 170, which was dihydroxylated to form the anti-
diastereomer of lactone 171 selectively, as reported by Fukuyama and co-workers.205 Hydrolysis 
of the lactone afforded DHCCA analogue 167 (scheme 3.10).  
 
                
 
Scheme 3.10 The synthetic route to DHCCA analogue 167.  
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Supplementing the production medium with DHCCA analogue 167 resulted in the Δ5912-14 
mutant strain producing enacyloxin derivative 172 (figure 3.19). The structure of 172 was 
confirmed by the increase of 16 Da in the HRMS relative to enacyloxin as well as the 
disappearance of a proton from the DHCCA unit in the 1H NMR spectrum. The analogue is 
significantly less potent than enacyloxin IIa, suggesting that additional substituents on the 
DHCCA unit adversely effect activity of the molecule. 
 
 
                                
 
Figure 3.19 A UV chromatogram (360 nm) from LC-MS analyses of extracts of 
B.  ambifaria (Δ5912-14) supplemented with DHCCA analogue 167.  B The HRMS for the 
species eluting at 13.4 min. C The structure assigned by NMR spectroscopy and the 
activity of the analogue against A.  baumannii   
 
As well as investigating the effect of substituents on the DHCCA ring, the effect of ring size on 
the activity of the compound was also tested. DHCCA analogue 173 harboring a cyclopentane 
ring was synthesized (scheme 3.11) to investigate this. Commercially available ester 174 was 
dihydroxylated and acetonide protected to allow the separation of the resulting syn- and anti-
diastereomers, 175 and 176.206 The anti-diastereomer 176 was deprotected and hydrolysed to 
afford DHCCA analogue 173. 
 
                 
 
Scheme 3.11 The synthetic route used to DHCCA analogue 173.  
 Δ5912-14 + 167 UV Chromatogram, 360 nm 
740.2205
742.2178
9_RB2_01_20161.d:	+MS,	14.0min	#841
0.00
0.25
0.50
0.75
1.00
5x10
Intens.
738 740 742 744 746 m/z
Exact	Mass	[C33H45Cl2NO12Na]+:	740.2217	
A	 B	
O OH OH O
O
OH
CO2H
Δ5912-14 + 167 (172), MIC = 16 µg/mL
C
OH2N
O
Cl
Cl
OH
OH
2) LiOH, THF/H2O
78 % (2 steps)
1) TsOH, MeOH
1) K2[OsO2(OH)4], NMO
Acetone/H2O
2) Dimethoxypropane
TsOH, CH2Cl2
O
O
O
O
O
O
O
O
O
O
O
OH
OH
HO
174
175
34 %
176
53 %
173
	 88	
Supplementing the production medium with DHCCA analogue 173 resulted in the Δ5912-14 
mutant strain producing a mixture of diastereomers, 177 and 178 (figure 3.20). The production 
of this mixture is unavoidable, because although DHCCA analogue 173 is a meso-compound 
(achiral), the condensation domain is able to acylate both hydroxyl groups, producing a mixture 
of analogues where the DHCCA unit is no longer achiral. The analogues were separated using 
preparative HPLC. However, it was not possible to distinguish between the analogues using 
NMR spectroscopy. Interestingly, one analogue was slightly more potent (MIC 2 µg/mL vs 
4 µg/mL), although both had very similar activity to enacyloxin IIa. 
 
 
                            
 
Figure 3.20 A UV chromatogram (360 nm) from LC-MS analyses of extracts of 
B.  ambifaria (Δ5912-14) supplemented with DHCCA analogue 173.  B The HRMS for the 
species eluting at 14.9 and 15.0 min. C The structures assigned by NMR spectroscopy 
and the activity of the analogues against A.  baumannii. Note it was not possible to 
distinguish between 177 and 178. 
 
Finally, the affect on activity of introducing a double bond into the ring was investigated using 
DHCCA analogue 51 (scheme 3.12). Commercially available quinic acid 180 was acetonide 
protected and esterified to afford lactone 181, which was converted to methyl ester 182 using 
sodium methoxide. Ketone 183 was generated using an oxidation-elimination reaction followed 
by reduction to alcohol 184. The alcohol was mesylated, then subjected to palladium-catalyzed 
elimination to afford ester 185. The acetonide group was removed and the ester was hydrolyzed 
to produce DHCCA analogue 51. 
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Scheme 3.12 The synthetic route to DHCCA analogue 51.  
 
Supplementing the production medium with DHCCA analogue 51 resulted in the production of 
expected enacyloxin analogue 187 (figure 3.21). The structure of 187 was confirmed by the loss 
of 2 Da in the HRMS relative to enacyloxin IIa as well as the appearance of an additional vinyl 
proton from the DHCCA unit in the 1H NMR spectrum. The analogue is more potent than 
enacyloxin IIa, and more potent than any other analogue produced, confirming that the 
mutasynthesis strategy can be used to create analogues with increased potency. 
 
 
                                    
 
Figure 3.21 A UV chromatogram (360 nm) from LC-MS analyses of extracts of 
B.  ambifaria (Δ5912-14) supplemented with DHCCA analogue 51.  B The HRMS for the 
species eluting at 15.0 min. C The structure assigned by NMR spectroscopy and the 
activity of the analogue against A.  baumannii 
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It had already been shown that the mutasynthesis strategy could be used to produce an 
enacyloxin analogue 149, with an amide in place of the ester (section 3.1.2.3). Although this 
analogue 149 is less potent than enacyloxin IIa 30 (MIC 8 µg/mL), the amide group is likely to 
be more stable than the ester linkage in enacyloxin IIa 30. In an effort to produce a more potent 
amide derivative, a 3-amino analogue of DHCCA, aminohydroxy-cyclohexanecarboxylic acid 
(AHCCA, 192) was synthesized (scheme 3.13). Iodolactone 188 was prepared via the same 
route used for iodolactone 169, from (R)-cyclohexene carboxylic acid 161. The iodolactone was 
treated with hydroxide in ethanol to from epoxide 189, which was selectively ring-opened using 
aqueous ammonia and the resulting amine was benzoylated to afford amide 190. Using thionyl 
chloride, the hydroxyl group of 190 was activated and displaced to form oxazoline 191, which 
was hydrolysed in acidic conditions to afford AHCCA 192. 
  
                       
 
 
 
 
Scheme 3.13 The synthetic route to DHCCA analogue 192. 
 
Using the same feeding procedure as for previous DHCCA analogues, the enacyloxin derivative 
could not be detected. It was unclear if this was because AHCCA 192 is not a substrate for the 
Bamb_5915 condensation domain, or due to a problem with the uptake of the derivative. The 
ability of the condensation domain to accept AHCCA 192 as a substrate was tested in vitro 
(figure 3.22). The acetylated Bamb_5917 PCP domain was incubated with Bamb_5915 (both 
overproduced and purified by Dr. Joleen Masschelein), and AHCCA 192. The production of the 
corresponding amide 193 was detected by LC-MS, by comparison with a synthetic standard 193 
which was prepared by acetylation of AHCCA 192.93 From the results of the assay, it is clear 
that Bamb_5915 is able to use AHCCA analogue 192 as a substrate, suggesting that the lack of 
production of the corresponding enacyloxin derivative may be due to poor cell uptake, 
potentially due to it’s high polarity. 
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Figure 3.22 The results of the in vitro assay confirming that AHCCA 192 is a substrate 
for the condensation domain. A detailed procedure for this assay can be found in section 
6.7.2. 
 
3.2.1.6 Production of Brominated Analogues 
 
Analogues in this section were purified in collaboration with Jake Sergeant. 
 
There are many examples of halogenase enzymes catalyzing bromination as well 
chlorination.207,208 Given the presence of genes encoding the flavin-dependent halogenase 
(Bamb_5928) and the Fe(II) a-KG-dependant halogenase (Bamb_5931) in the enacyloxin gene 
cluster, it was hoped that these enzymes could be utilized in order to generate brominated 
derivatives of enacyloxin (figure 3.23). A bromide analogue of enacyloxin was generated by 
Watanabe and co-workers by adding a source of bromide into the production medium, a similar 
strategy was employed here.209 
 
 
                                 
 
Figure 3.23 The halogenase enzymes in the enacyloxin cluster (Bamb_5928 and 5931). 
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To generate brominated enacyloxin derivatives, the source of chloride in the BSM production 
media (ammonium chloride) was replaced by a source of bromide (ammonium bromide). The 
wild-type B.ambifaria BCC0203 strain was then grown on the brominated media and any 
brominated analogues were detected using LC-MS (appendix 8.2), before being purified by 
HPLC. This resulted in the production of mono-brominated, chloro-brominated and di-
brominated analogues. This procedure was repeated using several of the mutant strains created 
in section 3.2.1.2 to generate a library of brominated analogues (table 3.1).  
 
Table 3.1: Brominated Enacyloxin Derivatives 
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B.ambifaria 
BCC0203 
Δ5927 
 
 
 
 
8 
 
 
 
32 
 
 
Using this strategy, a variety of brominated analogues could be generated, some with increased 
potency relative to the corresponding chlorinated enacyloxin derivatives. All of these analogues 
harbor a vinyl bromide functional group, which can serve as a handle for synthetic modification 
via metal catalyzed coupling reactions.210,211 These reactions typically result in the formation of 
new carbon-carbon bonds, and so the generation of brominated analogues provides scope for 
semi-synthetic derivatives of enacyloxin harboring an additional carbon skeleton at the C-11 
position. This represents a more facile method for the modification of the carbon skeleton of 
enacyloxin, compared with engineering of the megasynthase (section 3.1.1). 
 
3.2.1.7 Rational Design of a Potent Enacyloxin Derivative 
 
The SAR data resulting from the library of enacyloxin analogues were exploited to try to 
rationally design an analogue with even greater potency. The structures of analogues with 
increased potency relative to enacyloxin IIa were compared to identify changes likely to be 
responsible (figure 3.24). Analogue 187, harboring the unsaturated DHCCA unit, and analogues 
45 and 199, lacking both the ketone and carbamoyl functional groups, are both more potent than 
enacyloxin IIa. Thus, a mutant lacking the genes encoding the carbamoyl transferase 
(Bamb_5930), the PQQ dependent dehydrogenase (Bamb_5932) and the DHCCA biosynthesis 
enzymes (Bamb_5912-14) was constructed. This mutant was made by introducing the Δ5912-14 
deletion construct (provided by Dr. Joleen Masschelein) into the cured Δ5930 + 32 deletion 
mutant. The resulting strain was then grown on production medium supplemented with DHCCA 
analogue 51, and analogue 204 was purified and characterized by NMR spectroscopy (figure 
3.25). 
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Figure 3.24 The enacyloxin analogues with increased potency relative to enacyloxin IIa, 
the features identified as influencing the activity are highlighted in red.  
 
 
                              
 
Figure 3.25 A UV chromatogram (360 nm) from LC-MS analyses of extracts of 
B.  ambifaria (Δ5912-14+30+32) supplemented with DHCCA analogue 51. B The HRMS 
for the species eluting at 14.3 min. C The structure assigned by NMR spectroscopy and 
the activity of the analogue against A .  baumannii 
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Surprisingly, analogue 204 had the same potency as analogue 45. The reason for this is unclear. 
However, this result suggests that changes made to the structure of enacyloxin IIa may affect the 
activity of analogues against A. baumannii in ways other than target binding. The changes in 
polarity of the analogues may result in changes in the ability of the derivatives to cross cell 
membranes, which may influence the changes in MIC observed. The derivatives may also be 
more susceptible to efflux and degradation, making the rational design of derivatives based on 
MIC values alone more challenging.  
 
3.3 Conclusions 
3.3.1 Summary  
 
Three biosynthetic engineering strategies have been used to generate a library of enacyloxin IIa 
analogues, which harbor structural changes in both the DHCCA unit and the polyol region 
(green and blue regions respectively, figure 3.26). This has resulted in the production of five 
enacyloxin analogues that are more potent than enacyloxin IIa 30 (figure 3.26). These five 
analogues may provide a starting point for more complex changes to the structure, which may 
be necessary to further improve the activity and the stability of the molecule.  
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Figure 3.26 The five enacyloxin analogue with increased potency relative to enacyloxin 
IIa 30. 	
3.3.2 Rationalizing Changes in Activity  
 
One of the aims of this project was to probe the importance of the polar contacts between 
enacyloxin IIa 30 and EF-Tu, highlighted in the crystal structure (figure 3.27).110 Many 
analogues were generated that harbor structural changes predicted to influence the polar 
contacts. The changes in activity of the analogues were rationalized in relation to the structure.  
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Figure 3.27 The crystal structure of enacyloxin IIa bound to E. coli  EF-Tu. The polar 
contacts between the protein and the antibiotic are highlighted.  
 
Based on the key polar interactions identified in the structure (figure 3.27), the activity of some 
of the analogues produced in this chapter, as well as some of those created previously could be 
explained (figure 3.28). When the C-14 hydroxyl group (installed by the Fe(II) α-KG-dependent 
dioxygenase (Bamb_5927)) is removed, the activity does not change. This is in accordance with 
the observation that this hydroxyl group does not make any polar contacts with the protein. 
Removal of the carbamoyl group results in reduced activity. This could be due to the formation 
of the cyclic hemiacetal at the C-15 postion, but the analogue is likely to be in equilibrium with 
the acyclic ketone form. Given that the carbamoyl group appears to make several polar contacts 
with the protein, the decrease in activity is more likely due to reduced binding affinity of the 
acyclic form. When the C-15 keto group was converted to a hydroxyl group, the activity was 
significantly reduced. The keto also makes contacts with EF-Tu and the change in hybridization 
of the C-15 carbon may weaken these interactions.   
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Figure 3.28 The activity of three enacyloxin analogues relative to enacyloxin IIa 30,  
which can be explained on the basis of polar contacts observed in the crystal structure. 
 
However, when both the carbamoyl and keto groups are missing (analogue 45), the activity 
increases relative to enacyloxin IIa. This cannot be explained on the basis of the crystal 
structure, because both of these groups make polar contacts (figure 3.29). In addition, when both 
of these groups are removed individually (analogues 43 and 44), the activity is reduced. The 
increase in potency may be due to the chain binding in a different orientation, or changes in cell 
permeability. The most potent analogue generated (analogue 187) harbors an unsaturated 
DHCCA unit. Based on the crystal structure, there are no obvious interactions that could explain 
the increase in activity. The increase may again be due to changes in cell permeability, or due to 
the reduced entropic cost of binding the more rigid unsaturated DHCCA moiety in analogue 
187, relative to the more flexible DHCCA unit of enacyloxin IIa. This indicates that not all of 
the changes in activity observed for the analogues can be rationalized solely on the basis the 
polar contacts, and other factors such as changes in conformation, entropic costs and cell 
permeability need to be considered.  
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Figure 3.29 The activity of two enacyloxin analogues relative to enacyloxin IIa 30,  
which cannot be explained solely on the basis of polar contacts observed in the crystal 
structure 
  
This makes it difficult to determine the importance of the polar contacts based on the results of 
whole cell assays alone. To eliminate factors such as cell permeability, the interaction between 
EF-Tu and the analogues needs to be investigated in vitro. This could be achieved using 
isothermal titration calorimetry (ITC), which allows the determination of the dissociation 
constant (Kd) for the interaction.  
 
3.3.3 Future Work  
 
Another limitation of enacyloxin IIa as a viable drug candidate is light-induced isomerization. 
The presence of the C-6 methyl group in the polyene region, coupled with the extent of 
conjugation, promotes light-induced isomerization to a less active analogue due to steric 
clashing (figure 3.30). This stability problem cannot be addressed directly using the library of 
analogues generated in this study. 
 
                                 
 
Figure 3.30 The light-induced isomerization promoted by the C-6 methyl group. 
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In an effort to address this problem, a mutant was generated by Helen Smith, another PhD 
student in the group, in which the MT domain responsible for the installation of the methyl 
group in the polyene region was inactivated using site-directed mutagenesis. This resulted in the 
production of an enacyloxin analogue 205 lacking the C-6 methyl group thought to promote 
isomerization (figure 3.31). 
 
                                  
 
Figure 3.31 The enacyloxin analogue lacking the methyl group thought to promote 
isomerization. 
 
The activity of this analogue is reduced compared to that of enacyloxin IIa 30. This is where the 
platform of potent enacyloxin analogues generated in this chapter could be used. The features 
identified in this chapter that increase potency, could be combined with the deletion of the 
methyl group, to produce more stable enacyloxin analogues, with similar potency to the natural 
product (figure 3.32).  
 
                                
 
Figure 3.32 Potential enacyloxin analogues that may have increased stability whilst 
retaining potency. 
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Another way in which the platform of potent analogues generated in this chapter could be used, 
is to address the instability of the labile ester linkage in enacyloxin IIa. It has already been 
shown that a simplified amide derivative can be generated using the mutasynthesis strategy 
(section 3.1.2.3). This is likely to be more stable to hydrolysis, but the activity of this analogue 
was reduced (MIC of 4 µg/mL) compared with enacyloxin IIa. The features identified in this 
chapter that increase potency, could be combined with an amide linkage, to produce more 
hydrolytically resistant enacyloxin analogues that retain potency (figure 3.33).  
 
                               
 
Figure 3.33 The simplified amide analogue (149) generated in section 3.1.2.3,  along with 
potential additional amide enacyloxin analogues (209-211),  which are likely to have 
enhanced potency. 
 
As well as using the library generated in this chapter as a platform for more stable analogues, 
the brominated derivatives could be used to generate analogues with more diverse structures. 
This could be achieved using Suzuki coupling reactions (scheme 3.14).210,211 
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Scheme 3.14 The use of a palladium-catalyzed coupling reaction to derivatize 
brominated enacyloxin analogue 196. 
 
Overall, the library of enacyloxin analogues created in this chapter can be used both as a 
platform for the generation of more stable enacyloxin analogues, as well as a basis for a more 
diverse library of derivatives harboring more complex structural changes. The analogues 
produced could also be tested in animal infection models to establish whether they are viable 
drug candidates.  
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4. Results and Discussion III: DHCCA Biosynthesis 
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4.1 Introduction 
4.1.1 Shikimate Derived Natural Products 
 
The shikimate pathway is a primary metabolic route used by plants and microorganisms for the 
biosynthesis of aromatic amino acids tryptophan, tyrosine and phenylalanine, as well as other 
aromatic primary metabolites essential for survival of the organism. The pathway starts with the 
condensation of phosphoenolpyruvate 213 and erythrose-4-phosphate 214 and leads to the 
formation of chorismic acid 215 via shikimic acid 47, with various branch points along the 
pathway leading to the formation of essential primary metabolites (scheme 4.1).212,213 
 
 
 
Scheme 4.1 The shikimate pathway in plants and microorganisms. Dotted arrows 
indicated branch points where essential primary metabolites are formed. 
 
As well as being important for the production of essential primary amino acids, the shikimate 
pathway is also utilized for the biosynthesis of many secondary metabolites.214 Often these 
metabolites are comprised of the end products of the shikimate pathway, for example aromatic 
amino acids are found in many NRPS assembled natural products, and there are many 
phenylalanine-derived phenylpropanoid natural products found in plants.215 In bacteria, there are 
many examples of shikimate-derived natural products that utilize variants of the shikimate 
pathway by branching off at earlier steps.214 Examples include ansatrienin A (220), rapamycin 
(112) and ansamitocin P-3 (109) (figure 4.1).57,216,217 
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Figure 4.1 Shikimate-derived natural products, the unit incorporated from the shikimate 
pathway is highlighted in red.57 ,2 16 ,2 17  
 
4.1.2 Proposal for DHCCA Biosynthesis 
 
The DHCCA unit of enacyloxin IIa was shown to be essential to biological activity in section 
3.1.2.3. DHCCA 48 is proposed to be derived from shikimate 47, with five enzymes 
(Bamb_5912, 5913, 5914, 5916 and 5918) hypothesized to be involved in the biosynthetic 
pathway (scheme 4.2).104 The pathway consists of the reduction of 3-dehydroshikimate 49 to 
shikimate 47 by a shikimate dehydrogenase (Bamb_5913). This is followed by reduction to a 
trihydroxycyclohexanecarboxylic acid (THCCA) intermediate 50 by one of two enoyl 
reductases (Bamb_5914 or 5918). This intermediate is then dehydrated via a dehydratase 
(Bamb_5912), which is followed by isomerization via an enoyl isomerase (Bamb_5916) to form 
unsaturated DHCCA analogue 51. The final step to form DHCCA 48 is catalyzed by the 
remaining enoyl reductase enzyme (Bamb_5914 or 5918). The reduction of shikimate 47 is a 
key step in the pathway as this is the branch point away from the shikimate pathway (scheme 
4.1).  
 
 
 
 
Scheme 4.2 The proposed pathway for the biosynthesis of DHCCA 48.1 04 The putative 
functions of all the genes involved in enacyloxin biosynthesis can be found in appendix 
8.6. 
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4.1.3 Aims  
 
The aim of this project was to confirm the biosynthetic pathway of the DHCCA unit of 
enacyloxin IIa using both in vivo gene deletions and in vitro biochemical assays. As well as 
providing insight into biosynthesis of this key unit of enacyloxin IIa, it was hoped that this 
investigation would lead to the identification more genes that could be targeted for further 
engineering of enacyloxin IIa analogues.  
  
4.2 Results and Discussion 
4.2.1 Investigation of the Proposed Pathway using Gene Deletions 
 
The five genes proposed to be involved in DHCCA biosynthesis (scheme 4.2) were deleted 
using the same gene deletion methodology described in section 3.2.1.1 to try to confirm their 
respective roles in the pathway (figure 4.2). The deletion of bamb_5912 (performed by Dr. 
Joleen Masschelein) resulted in the production of enacyloxin analogue 172. This is in agreement 
with the proposed pathway, as the Bamb_5912-catalyzed dehydration of 50 cannot take place, 
resulting in the incorporation of 50 (scheme 4.2). The deletion of bamb_5913 resulted in wild-
type levels of enacyloxin IIa 30 production as well as a small amount of analogue 172. The 
production of enacyloxin IIa 30 can be explained, as despite Bamb_5913 no longer being 
present to reduce 3-dehydroshikimate 49, there may still be enough shikimic acid 47 present in 
the cell from primary metabolism in order for DHCCA biosynthesis to still proceed. The 
presence of analogue 172 cannot be explained based on the proposed pathway.  
 
The deletion of bamb_5914 abolished the production of enacyloxin IIa 30. This can be 
rationalized based on the proposed pathway if this enzyme is responsible for the reduction of 
shikimate 47. The deletion of bamb_5916 also abolished production. If the pathway is correct, 
this suggests that alkene intermediate 52 is not a substrate for the Bamb_5915 condensation 
domain. Finally, the deletion of bamb_5918 resulted in wild-type levels of enacyloxin IIa 30 
production as well as a small amount of analogue 172. This cannot be explained based on the 
proposed pathway, as if Bamb_5918 catalyzes the final reduction step, the incorporation of 
unsaturated intermediate 51 into the structure of enacyloxin should be observed, as chemically 
synthesized 51 has already been shown to be incorporated (section 3.2.1.5). Alternatively, if 
Bamb_5918 catalyzed the reduction of shikimate 47, enacyloxin IIa 30 production would be 
abolished, as the reduction of shikimate 30 would not take place. Overall, the results of these 
deletions are not congruent with the proposed pathway. 
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Figure 4.2 The UV chromatograms corresponding to the deletion of the five genes 
involved in DHCCA biosynthesis. The presence of the proposed compounds was 
confirmed by HRMS and analogue 172 was characterized by NMR.  
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4.2.2 Investigation of the Proposed Pathway using in vitro Biochemistry 
 
To investigate the proposed pathway in vitro, the five proposed DHCCA biosynthesis genes 
were cloned into an appropriate expression vector, before overproduction and purification of the 
corresponding proteins for in vitro biochemical assays. The five genes were amplified using 
primers designed with a CACC overhang on the forward primer in order to facilitate TOPO 
cloning into the pET151 expression vector (section 6.3.6.3). This vector has an IPTG-inducible 
T7 promoter and encodes a N-terminal His6-tag allowing for IPTG-induced expression and 
purification by metal-affinity chromatography (section 6.6.3). Both the bamb_5914 and 
bamb_5916 genes were cloned into pET151 as verified by sequencing. However neither of the 
corresponding proteins were successfully overproduced in either E.coli BL21(DE3) or E.coli 
C43(DE3) expression cell lines (figure 4.3). It was thought that this could be due to the high GC 
content (73 %) of the genes from the enacyloxin gene cluster not being compatible with the low 
GC content of the DNA of E.coli expression strains. 
 
             
 
Figure 4.3 The 10 % SDS-PAGE gel corresponding to the unsuccessful overproduction 
and purification of Bamb_5914 (38.4 KDa) in E.coli  BL21(DE3) cells.  The bands 
observed from the elution fractions (red) correspond to background E.coli  proteins 
binding non-specifically to the metal-affinity column.  
 
The DHCCA unit and homologues of the same five enzymes thought to be responsible for its 
biosynthesis are also found in the vibroxin (151) gene cluster (figure 4.4). The vibroxin gene 
cluster has a much lower GC content than the enacyloxin cluster, and so it was thought that 
these genes would be more compatible with the E.coli expression strains. 
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Figure 4.4 The DHCCA biosynthesis genes present in both the enacyloxin and vibroxin 
gene clusters. bamb_5912,  5913,  5914,  5916 and 5918 are equivalent to VbxL, VbxM, 
VbxN, VbxP and VbxK respectively.  
 
The five DHCCA biosynthesis genes from the vibroxin cluster were cloned into pET151 (TOPO 
cloning, ampicillin marker) as confirmed by sequencing. Only VbxM and VbxL were 
successfully overproduced and purified from E.coli BL21(DE3) cells (figure 4.5). Switching 
cell line to E.coli C43(DE3) resulted in the overproduction and purification of VbxL and VbxP 
(figure 4.5), however no expression of VbxN was observed. The VbxN gene was cloned into an 
alternative expression vector, pET28a (restriction cloning, kanamycin marker). After 
confirmation by sequencing, the protein was overproduced and purified from E.coli BL21(DE3) 
cells (figure 4.5). The production of each protein was confirmed by protein HRMS (appendix 
8.3). 
 
 
 
Figure 4.5 The 10 % SDS-PAGE gels corresponding to the production of VbxK, VbxN, 
VbxL, VbxP and VbxM from the vibroxin gene cluster.  
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Now that all five enzymes had been successfully overproduced, the proposed pathway (scheme 
4.2) could be probed using in vitro assays. Firstly, the reduction of shikimic acid 47 to THCCA 
intermediate 50 was tested using both proposed enoyl reductase enzymes (VbxN and VbxK). 
Commercially available shikimic acid 47 was incubated with either VbxN or VbxK and NADH 
or NADPH in storage buffer (section 6.7.6/6.7.9). The production of the THCCA intermediate 
50 was monitored by LCMS along with a boiled enzyme negative control reaction and the 
previously synthesized THCCA standard (scheme 3.10). The THCCA reduction product 50 
could not be detected using any combination of enzyme or cofactor (scheme 4.3). 
 
                                              
 
Scheme 4.3 The unsuccessful reduction of shikimic acid 47 using both enoyl reductases, 
VbxN and VbxK, as well as NADPH and NADH cofactors. 
 
The second enoyl reduction step in the pathway (scheme 4.2) was also investigated. The 
unsaturated intermediate 51 was synthesized previously (section 3.2.1.5), but the DHCCA 
product 48 needed to be synthesized as an LCMS standard (scheme 4.4). Cyclohexene 
carboxylic acid 161 was esterified before being dihydroxylated and acetonide protected to 
facilitate the separation of the resulting syn- and anti-diastereomers, 221 and 222. Diastereomers 
221 and 222 had been synthesized and separated previously in the literature, and so the 
comparison of diagnostic 1H NMR shifts were used in order to confirm their respective 
stereochemistry.218 The anti-diastereomer 222 was then deprotected and hydrolysed to afford 
DHCCA 48.  
 
            
 
Scheme 4.4 The route used for the synthesis of the DHCCA standard 48. 
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Unsaturated acid 51 was incubated with either VbxN or VbxK and NADH or NADPH in 
storage buffer (section 6.7.6/6.7.9). The production of DHCCA 48 was monitored by LCMS 
along with a boiled enzyme negative control reaction and the DHCCA standard. The DHCCA 
product 48 could again not be detected using any combination of enzyme or cofactor (scheme 
4.5). 
 
                                                 
 
Scheme 4.5 The unsuccessful reduction of unsaturated acid 51 using both enoyl 
reductases, VbxN and VbxK, as well as NADPH and NADH cofactors. 
 
These results, combined with the results from the gene deletions, strongly suggest that the 
initially proposed pathway (scheme 4.2) is not correct. In light of this, the sequences of the five 
proteins were subjected to basic local alignment search tool (BLAST) analyses. This tool uses 
sequence alignments and generates a conserved domain search, which allows prediction of the 
function of a protein by comparison to homologues.219 It was hoped that this would provide an 
insight into the true function of the five enzymes (VbxP, VbxN, VbxM, VbxL and VbxK). 
 
4.2.2.1 Shikimate CoA Formation Catalyzed by VbxP  
 
From the conserved domain search generated by the protein BLAST of VbxP, it appears that the 
enzyme may function as a type III CoA transferase (figure 4.6). CoA transferases catalyze the 
reversible transfer of CoA between carboxylic acids, and can be classified into three subgroups 
(types I–III) based on differences in their protein sequences and reaction mechanisms.220  
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Figure 4.6 The conserved domain search generated from protein BLAST analysis of 
VbxP, and the reaction catalyzed by CoA transferase domains. 
 
The protein is homologous to CaiB (59.9 % sequence similarity), a type III CoA transferase 
involved in carnitine metabolism, as well as a formyl-CoA transferase involved in oxalate 
degradation (scheme 4.6).221,222 These enzymes are commonly used in primary metabolic 
processes, and have recently been shown to be involved in the biosynthesis of thiocarboxylic 
acid-containing natural products.223 
 
    
 
Scheme 4.6 The reactions catalyzed by VbxK homologues, CaiB and formyl CoA 
transferase respectively. 
 
Based on the results of the BLAST analysis, it was hypothesized that VbxP may be responsible 
for the formation of shikimate CoA 223 from shikimic acid 47 (scheme 4.7). This would then 
facilitate downstream reduction of the shikimate unit, which was unsuccessful for the free acid 
47 (section 4.2.2). The reduction of an enoyl thioester is energetically more favourable than the 
enoyl acid due to the enoyl thioester being significantly more electrophilic.  
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Scheme 4.7 The proposed role of VbxP followed by downstream reduction. 
 
To investigate this hypothesis, an assay was conducted whereby shikimic acid 47 was incubated 
with VbxP and acetyl CoA 225 as a CoA donor. The production of shikimate CoA 223 was then 
detected using LC-MS analysis. A shikimate CoA standard 223 was synthesized to confirm its 
formation (scheme 4.8). Commercially available methyl shikimate 226 was acetonide protected, 
before hydrolysis to form acid 227. Acid 227 was then coupled to protected pantetheine 61 
before removal of both acetonide protecting groups afforded shikimate pantetheine 228. This 
was then used in order to generate shikimate CoA 223 in situ using the cassette of accessory 
enzymes described in section 2.1.4. 
 
                       
 
Scheme 4.8 The synthesis of shikimate pantetheine 228 followed by the formation of 
shikimate CoA 223 in situ. 
 
The results of the incubation of shikimic acid 47 with VbxP and acetyl CoA for 16 h are shown 
in figure 4.7. The chromatograms indicate that VbxP catalyzes the formation of shikimate CoA 
223, as a peak with the correct mass and same retention time as the shikimate CoA standard is 
observed from the assay, but not from the boiled enzyme control. The assay was initially 
conducted using a 1 : 1 ratio of acetyl CoA to shikimate 47, this resulted in a 1 : 1 ratio of 
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shikimate CoA 223 to acetyl CoA due to the reversibility of the reaction. In order to achieve full 
conversion to shikimate CoA 223, 10 equivalents of shikimic acid 47 relative to acetyl CoA 
were used. 
 
                                                  
 
 
Figure 4.7 The extracted ion chromatograms and HRMS corresponding to the VbxP 
catalyzed formation of shikimate CoA 223 from shikimate 47 and acetyl CoA. 
 
Type III CoA transferases are proposed to harbor a conserved aspartate residue which forms a 
mixed anhydride intermediate with the acyl group of the acyl CoA donor (acetyl CoA 225 in 
this case). The resulting CoA thiolate is then proposed to attack the anhydride to form a 
covalent CoA thioester with the aspartate residue. The acceptor acid (shikimic acid 47 in this 
case) is proposed to attack the thioester and form another mixed anhydride with the aspartate 
residue. The CoA thiolate can the attack the anhydride to form the new acyl CoA species 
(shikimate CoA 223 in this case) and regenerate the aspartate residue (scheme 4.9).220,224 
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Scheme 4.9 The mechanism used by type III CoA transferases. 
 
After aligning the amino acid sequence of VbxP with the sequences of homologues, CaiB and 
formyl CoA transferase, the conserved catalytic aspartate residue was identified (figure 4.8). To 
confirm that this aspartate residue was involved in the VbxP catalyzed formation of shikimate 
CoA 223, the aspartate was mutated to a serine residue (D171S) using site-directed mutagenesis 
which was confirmed by sequencing (section 6.6.2). 
 
 
 
Figure 4.8 The alignment of VbxP with homologues CaiB and formyl CoA transferase, 
and the SDS-PAGE gel corresponding to the D171S mutant. 
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The VbxP assay used to generate shikimate CoA 223 was repeated using the D171S mutant. 
From the chromatogram shown in figure 4.9, it’s clear that the aspartate residue plays a key role 
in catalysis as shikimate CoA 223 is no longer produced.  
 
 
 
Figure 4.9 The extracted ion chromatograms corresponding to the VbxP catalyzed 
formation of shikimate CoA 223 with wild-type VbxP and the D171S mutant. 
 
To confirm the exact role of the aspartate residue during catalysis, the assay was probed using 
intact protein MS. VbxP was incubated with acetyl CoA for 1 h, and intact protein MS was used 
to detect the formation of either of the proposed covalent anhydride or CoA thioester 
intermediates (scheme 4.9). Acetyl CoA was omitted as a negative control assay, and the assay 
was repeated with the D171S mutant to confirm any observed intermediates are due to the 
aspartate residue. From the deconvoluted spectra shown in figure 4.10, it’s clear that the 
aspartate residue of VbxP forms a covalent adduct with acetyl CoA, as the adduct is not 
observed with the D171S mutant. When the assay is left for 4 h, the protein fully converts to the 
covalent adduct. The adduct is 745 Da larger than the wild-type VbxP protein, and corresponds 
to the covalent CoA thioester adduct (scheme 4.9), indicating that VbxP catalysis does proceed 
via the proposed mechanism. 
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Figure 4.10 The deconvoluted spectra corresponding to the incubation of VbxP with 
acetyl CoA for 1 h. The CoA adduct (49060 Da) is not observed for the D171S mutant. 
 
CoA thioesters can be used as probes for the in vitro investigation of biosynthetic mechanism, 
but can often be challenging to synthesize and only a limited range are commercially available. 
As an alternative, VbxP could be used as a biocatalyst for the production of CoA thioesters in 
situ. The substrate tolerance of VbxP was explored and the enzyme was shown to catalyze the 
formation of CoA thioesters of a variety of organic acid substrates. Organic acids harboring 
heteroatoms at the C-2 position appear to be poor substrates for the CoA transferase however 
(figure 4.11).  
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Figure 4.11 The organic acid substrate tolerance of the VbxP CoA transferase. MS data 
for the corresponding CoAs generated can be found in appendix 8.7.   
 
One way in which CoA thioesters can be used for in vitro assays is for the loading of carrier 
proteins. It was thought that as an alternative to chemically synthesizing a pantetheine substrate 
and using a cassette of accessory enzymes, VbxP could be used in order to generate the CoA 
from a CoA donor and appropriate organic acid in situ. In order to test this, VbxP was incubated 
with acetyl CoA and 10 equivalents of shikimate in order to generate shikimate CoA 223. An 
apo-ACP domain (GbnD5-ACP from module 13 of gladiolin biosynthesis, section 6.6.1), Sfp 
and magnesium chloride were then added, and the loading of generated CoA was detected using 
intact protein MS (figure 4.12). From the deconvoluted spectra, it appears that the apo-ACP 
domain has been successfully loaded with the shikimate CoA 223 generated by VbxP. However 
peaks corresponding to the holo-ACP domain as well as loaded acetyl CoA are also present, 
indicating a small amount of hydrolysis has taken place, and the acetyl CoA hasn’t fully 
converted to shikimate CoA 223. Despite this, the results are promising and suggest that with 
optimization, VbxP can be used as a biocatalyst in order to generate acyl CoAs for in vitro 
assays. 
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Figure 4.12 The spectra corresponding to the loading of VbxP generated shikimate CoA 
223 onto gladiolin module 13 apo-ACP domain. 
 
4.2.2.2 Enoyl Reduction catalyzed by VbxN  
 
Having established the role of VbxP as generating shikimate CoA 223, the next step in the 
biosynthetic pathway was investigated. It was thought that the formation of the thioester would 
facilitate downstream enoyl reduction (scheme 4.7), but the corresponding enoyl reductase had 
not yet been identified. The protein BLAST results of VbxN suggested that the protein has a 
conserved NAD(P)H binding site, and is similar to both quinone oxidoreductase and PKS ER 
domains (figure 4.13). These results suggest that VbxN is a good candidate for the enzyme that 
the enoyl reduction of shikimate CoA 223. 
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Figure 4.13 The conserved domain search generated from protein BLAST analysis of 
VbxN and the reactions catalyzed by quinone oxidoreductase and PKS ER domains. 
 
To test if VbxN was capable of the reduction, an in vitro assay was conducted whereby 
shikimate CoA 223 was generated in situ using VbxP. VbxN and NADPH were then added and 
the presence of the reduced shikimate CoA product 224 was detected using LCMS analysis. 
This was conducted alongside a boiled VbxN control and a standard generated by the incubation 
of previously synthesized THCCA 167 (section 3.2.1.5) with VbxP and acetyl CoA. The 
chromatograms shown in figure 4.14 indicate that VbxN is catalyzing the reduction of shikimate 
CoA 223, as the peak corresponding to the reduced product is not present in the boiled enzyme 
control, and has the same retention time as the reduced shikimate CoA product standard 224. 
The assay was conducted with both NADPH and NADH cofactors, the reaction only proceeded 
when NADPH was used. 
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Figure 4.14 The extracted ion chromatograms and HRMS corresponding to the VbxN 
catalyzed reduction of shikimate CoA 223 to form reduced shikimate CoA 224. 
 
Having established that VbxN can catalyze the reduction of shikimate CoA 223, it was thought 
that VbxP may then catalyze the production of the THCCA 50. This may occur by VbxP using 
the reduced shikimate CoA 224 as a donor CoA, to generate another molecule of shikimate CoA 
223 and form the THCCA intermediate 50 in the process (scheme 4.10).  
 
     
 
Scheme 4.10 The proposed sequence of events leading to the formation of THCCA 
intermediate 50. 
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To test if VbxP catalyzes the production of the THCCA intermediate 50, the same VbxN 
catalyzed reduction assay can be used, as because VbxP is present in the reaction, THCCA 50 
should be formed and can be detected. This also presents an opportunity to investigate the 
stereoselectivity of the VbxN catalyzed reduction. The retention time of the THCCA formed in 
the reaction can be compared with that of synthetic, enantiomerically pure THCCA 167, as well 
as a mixture of diastereomers generated via hydrogenation (figure 4.15). 
 
       
 
 
Figure 4.15 The extracted ion chromatograms and HRMS corresponding to the VbxN 
catalyzed reduction and VbxP catalyzed formation of THCCA intermediate 50. 
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The chromatograms shown in figure 4.15 indicate that VbxP catalyzes the formation of the 
THCCA intermediate 167 due to the peak observed corresponding to the correct mass from the 
reaction but not the boiled enzyme control. The peak has the same retention time as 
enantiomerically pure THCCA standard 167, confirming the stereoselectivity of the VbxN 
catalyzed reduction. Furthermore, the stereochemistry of the resulting THCCA intermediate 
167, is the same stereochemistry observed in the enacyloxin analogue 172 isolated from the 
bamb_5912 gene deletion (section 4.2.1). To further confirm this, analogue 172 was hydrolyzed 
and the retention time of the resulting THCCA compared with that of the synthetic standards. 
The chromatograms shown in figure 4.16 confirm that the stereochemistry of the THCCA 
reduction product 167 is the same as the stereochemistry of the THCCA unit observed in 
enacyloxin analogue 172. 
 
 
 
 Figure 4.16 The extracted ion chromatograms corresponding to the hydrolysis of 
enacyloxin analogue 172 and synthetic THCCA standards. 
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Overall, the first three steps of the pathway have been characterized in vitro. The pathway 
consists of formation of a transient CoA thioester of shikimic acid by VbxP, followed a 
stereoselective enoyl reduction catalyzed by VbxN. The resulting reduced shikimate CoA 
product 224 is then used as a CoA donor by VbxP, resulting in the production of THCCA 
intermediate 167 (scheme 4.11). 
 
         
 
Scheme 4.11 The first three steps of DHCCA biosynthesis resulting in THCCA 
intermediate 167. 
 
4.2.2.3 Oxidation Catalyzed by VbxM  
 
Now that THCCA 167 had been established as an intermediate in the pathway, the biosynthetic 
steps from THCCA 167 to DHCCA 48 could be investigated. Coggins and co-workers 
previously isolated DHCCA 48 during the early 1970s, as a quinate metabolite of Lactobacillus 
plantarum.225 They proposed a pathway for the biosynthesis of DHCCA 48 from quinic acid 
227 via THCCA intermediate 167 based upon lysate assays (scheme 4.12).226 They proposed 
that a single quinate dehydrogenase enzyme catalyzes five steps in the pathway, including the 
oxidation of THCCA intermediate 167 to form ketone 228, before dehydration. Cain and co-
workers have since confirmed that a quinate dehydrogenase is capable of oxidizing THCCA 
intermediate 167 as well as some of the other intermediates in the proposed pathway.227 
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Scheme 4.12 The proposed biosynthetic pathway from quinic acid 227 to DHCCA 48. 
 
The results of the protein BLAST search for VbxM suggested that the protein functions as a 
shikimate dehydrogenase. It was thought that this enzyme may catalyze the same oxidation of 
the THCCA intermediate 167 as proposed by Coggins and co-workers (figure 4.17). 
                                                                      
                   
 
 
Figure 4.17 The conserved domain search generated from protein BLAST analysis of 
VbxM, the reaction catalyzed by shikimate dehydrogenase and the proposed oxidation 
catalyzed by VbxM. 
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To determine if VbxM was capable of catalyzing the oxidation of THCCA 167, an in vitro assay 
was conducted whereby synthetic THCCA 167 was incubated with VbxM, along with NADP+ 
or NAD+ for 16 h, and the production of ketone 228 monitored by LC-MS. The ketone product 
228 could not be detected by LC-MS from assays using either cofactor. It was thought that this 
could be due to the poor ionization of ketone product 228, or instability. Another way to 
monitor the reaction was to use UV-Vis spectroscopy, NAD(P)H has a characteristic absorption 
at 340 nm, and so by monitoring absorption at this wavelength the conversion of NAD(P)+ to 
NAD(P)H can be detected (figure 4.18). When THCCA 167 was incubated with VbxM and 
NAD+, the absorption at 340 nm increases, indicating that the oxidation of THCCA 167 is 
taking place. No change in absorbance was observed when NADP+ was used. 
    
 
Figure 4.18 The absorption at 340 nm for the VbxM catalyzed oxidation of THCCA 167 
with and without the THCCA substrate. 
 
In order to confirm that the ketone product 228 is being produced in the reaction, 
pentafluorobenzylhydroxylamine derivatizing agent 234 was used to generate a product that 
could be detected by LCMS. This derivatizing agent reacts with ketones and aldehydes to 
rapidly form ionizable oxime products (scheme 4.13). 
 
                                     
 
Scheme 4.13 The formation of ionizable oxime products from ketones using derivatizing 
agent 234. 
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The VbxM catalyzed oxidation of THCCA 167 was repeated with addition of derivatizing agent 
234 for 1 h at the end of the reaction. A standard 237 was generated for the derivatized product 
via the hydrogenation of commercially available 3-dehydroshikimate 49 to form ketone 236, 
before the addition of the derivatizing agent 234. From the chromatograms shown in figure 
4.19, a peak corresponding to the mass of the derivatized product 235 is observed from the 
reaction, which has the same retention time as the standard 237 and is not present in the boiled 
enzyme control. This is strong evidence to suggest that VbxM catalyzes the oxidation of 
THCCA 167 to form ketone product 228. 
 
               
 
 
Figure 4.19 The extracted ion chromatograms and HRMS corresponding to the VbxM 
catalyzed oxidation and derivatization of THCCA intermediate 167. 
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4.2.2.4 Dehydration catalyzed by VbxL  
 
According to the pathway proposed by Coggins and co-workers, the step following the 
oxidation of THCCA 167 is dehydration to form unsaturated ketone 229 (scheme 4.12). From 
the gene deletions in section 4.2.1, the deletion of bamb_5912 (homologue of VbxL) resulted in 
enacyloxin analogue 172, which harbors the THCCA unit. This suggests that VbxL may be 
responsible for the elimination of the hydroxyl group on the THCCA unit, and may act as a 
dehydratase responsible for the dehydration of ketone 228 (figure 4.20). The results of the 
protein BLAST analysis of VbxL suggest that the protein functions as a sugar phosphate 
isomerase (figure 4.20). The isomerization reaction requires the deprotonation of an a-
hydroxycarbonyl species, similar to what is required in an E1CB-type dehydration, indicating that 
VbxL may well catalyze a dehydration. 
                                                      
               
 
. 
 
Figure 4.20 The conserved domain search generated from protein BLAST analysis of 
VbxL, the reaction catalyzed by a sugar phosphate isomerase and the proposed 
dehydration catalyzed by VbxL. 
 
In order to test if VbxL is capable of the dehydration of ketone 228, the ketone substrate 236 
that is generated by hydrogenation of 3-dehydroshikimate 49, was incubated with VbxL, before 
the addition of derivatizing agent 234. The dehydrated product 240 can tautomerize to diketone 
241, and so the expected derivatized product should be dioxime 242. From the chromatograms 
shown in figure 4.21, a peak corresponding to the correct mass of the dioxime product 242 is 
observed from the reaction but not in the boiled enzyme control. This suggests that VbxL 
catalyzes the dehydration of ketone 228 as the next step in the pathway to afford unsaturated 
ketone 229. 
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Figure 4.21 The extracted ion chromatograms and HRMS corresponding to the VbxL 
catalyzed dehydration and derivatization of ketone 236. 
 
4.2.2.5 Enone Reduction Catalyzed by VbxK  
 
The remaining enzyme proposed to be involved in the biosynthesis of the DHCCA is VbxK. 
The results from the protein BLAST analysis of VbxK (figure 4.22) suggest that the protein 
functions as a flavin mononucleotide (FMN)-dependent enone reductase. The protein is a 
closely related homologue of YqjM, a well-characterized FMN-dependent enone reductase 
which has been shown to reduce a variety of α,β-unsaturated ketones.228 Given the function of 
YqjM, it was thought that VbxK may be capable of the enoyl reduction of unsaturated ketone 
229 (figure 4.22). 
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Figure 4.22 The conserved domain search generated from protein BLAST analysis of 
VbxK, a reduction catalyzed by YqjM and the proposed reduction catalyzed by VbxK. 
 
Unsaturated ketone 229 is a difficult substrate to synthesize and is also prone to aromatization, 
making a direct reduction assay with this intermediate difficult. In light of this, substrate mimic 
245 was synthesized (scheme 4.14) in order to probe the activity of VbxK. Lactone 246 was 
generated from iodolactone 188 (section 3.2.1.5) using DBU, before being ring-opened with 
methanol in basic conditions to afford alcohol 247. Oxidation using manganese dioxide then 
afforded unsaturated ketone substrate mimic 245. To generate saturated ketone standard 248, 
alcohol 247 was hydrogenated before oxidation using Jones’ reagent. 
 
                      
 
Scheme 4.14 The route used for the sysnthesis of the unsaturated ketone mimic 245 as 
well as saturated ketone standard 248. 
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In order to probe the activity of VbxK, substrate mimic 245 was incubated with VbxK and 
NADPH, and the presence of reduced product 248 detected by LC-MS analysis (figure 4.23). 
The presence of the peak corresponding to the correct mass of product 248 from the reaction, 
with the same retention time as standard 248, but not present in the boiled enzyme control 
confirms that VbxK is capable of reducing the substrate mimic 245. The reaction also proceeded 
when NADH was used as cofactor. 
 
                                                       
 
 
Figure 4.23 The extracted ion chromatograms and HRMS corresponding to the VbxK 
catalyzed reduction of substrate mimic 245. 
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synthesized from commercially available diol 251 via a Swern oxidation, and was incubated 
with VbxK and NADPH, before derivatization with 234. The presence of derivatized product 
252 was detected by LC-MS analysis along with derivatized standard 252 (formed from 
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standard 252, but not present in the boiled enzyme control, confirms that VbxK is capable of 
reducing keto-enol substrate 250. 
        
 
 
Figure 4.24 The extracted ion chromatograms and HRMS corresponding to the VbxK 
catalyzed reduction of keto-enol substrate 250. 
 
In order to further confirm that the role of VbxK is to reduce unsaturated ketone intermediate 
229, a coupled assay was used. VbxL was used to generate substrate 240 in situ via the 
dehydration of ketone 239, VbxK and NADPH were then added followed by derivatizing agent 
234. The production of derivatized product 254 was monitored by LC-MS (figure 4.25). The 
presence of the peak corresponding to the correct mass of the derivatized product 254 from the 
reaction, but not present in either of the boiled enzyme controls is further confirmation that the 
role of VbxK is to reduce unsaturated ketone substrate 229. 
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Figure 4.25 The extracted ion chromatograms and HRMS corresponding to the VbxK 
catalyzed reduction of VbxL-generated unsaturated ketone 240. 
 
4.2.2.6 Reduction Catalyzed by VbxM  
 
Now that the enone reduction step catalyzed by VbxK had been confirmed, it was proposed that 
a single reduction step remained in order to generate DHCCA 48 from ketone 233 (scheme 
4.15). From the pathway proposed by Coggins and co-workers, the proposed final reduction step 
is also catalyzed by the quinate dehydrogenase.226 These enzymes are well known to catalyze 
reversible reductions, and so it was thought that VbxM may catalyze the final reduction step in 
the DHCCA biosynthetic pathway in addition to its previous role of oxidizing THCCA 167.227 
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Scheme 4.15 The steps confirmed from THCCA 167 to form ketone 233,  and the final 
reduction step to form DHCCA 48 predicted to be catalyzed by VbxM. 
 
Ketone 233 is a difficult substrate to synthesize, however DHCCA 48 had been synthesized 
previously (scheme 4.4). As this reaction is predicted to be reversible, the reverse reaction 
which consists of the oxidation of DHCCA 48 to generated ketone 233 could be probed.227,229 
DHCCA 48 was incubated with VbxM and NAD+, followed by the addition of derivatizing 
agent 234 and the presence of the derivatized ketone product 256 detected by LC-MS. The 
derivatized product of the enone reduction catalyzed by VbxK (section 4.2.2.5) was used as a 
product standard (254). From the chromatograms shown in figure 4.26, the presence of the peak 
corresponding to the correct mass of derivatized product 256, with the same retention time as 
the enzymatically generated standard 254, but not present in the boiled enzyme control reaction, 
indicates that VbxM is catalyzing the oxidation. Due to the reversibility of these enzymes, this 
is evidence to suggest that VbxM can catalyze the final reduction step of the pathway 
(scheme 4.15).  
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Figure 4.26 The extracted ion chromatograms and HRMS corresponding to the VbxM 
catalyzed oxidation of DHCCA 48. 
 
The results of the oxidation assay with VbxM indicate that the oxidation is taking place, 
however the assay does not confirm which of the two hydroxyl groups from DHCCA 48 
undergoes oxidation. In order to probe this, alcohol 257 and ketone standard 258 were 
synthesized (scheme 4.16) via asymmetric reduction and hydrolysis of chiral keto-ester 248. 
 
            
 
Scheme 4.16 The route used for the synthesis of alcohol 257 and ketone 258. 
MeOH, 1 hRT, 16 h
 pH 7.4
48 233
234
256
O OH
HO
OH
VbxM
O OH
O
OH
O OH
N
OH
O
H2N
F
F
F
F
F
O
F
FF
F
F
NAD+
354.0752
16_GC2_01_19371.d:	+MS,	17.2-17.3min	#1032-1037
0.0
0.2
0.4
0.6
4x10
Intens.
354 356 358 360 m/z
Boiled Enzyme Control EIC 354.0765 ±0.005 
Reaction EIC 354.0765 ±0.005 
VbxK Generated Standard EIC 354.0765 ±0.005 
X
O OH
N
OHO
F
FF
F
F
Exact Mass (M + H): 354.0765 
X
X
O OH
N
OH
O
H2N
F
F
F
F
F
O
F
FF
F
F
OH
O OH
O OH
X
O OH
O
OH
X
2) VbxK
NADPH
1) VbxL
254		
234		
256		
239		 255		
248
OO
O
LiOH
THF/H2O
96 %
258
OHO
O
L-selectride
THF, 28 %
259
OO
HO
LiOH
THF/H2O
96 %
257
OHO
HO
	 136	
Alcohol 257 was incubated with VbxM and NAD+, followed by the addition of derivatizing 
agent 234. The presence of the derivatized ketone product 260 was detected by LC-MS 
alongside derivatized ketone standard 260. From the chromatograms shown in figure 4.27, the 
presence of the peak corresponding to the correct mass of derivatized product 260, with the 
same retention time as the derivatized ketone standard 260, but not presence in the boiled 
enzyme control reaction, indicates that VbxM is catalyzing the oxidation at the C-3 position. 
 
                     
 
 
Figure 4.27 The extracted ion chromatograms and HRMS corresponding to the VbxM 
catalyzed oxidation of alcohol 257. 
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4.3 Conclusions 
4.3.1 DHCCA Biosynthesis as Determined in vitro 
 
From the in vitro experiments conducted in this study, DHCCA biosynthesis is predicted to 
proceed via the pathway shown in scheme 4.17. CoA transferase domain, VbxP, catalyzes the 
generation of shikimate CoA 223, before VbxN catalyzes enoyl reduction to afford the reduced 
product 224. VbxP can then use reduced product 224 as a CoA donor in order to generate 
another molecule of shikimate CoA 223, and generating THCCA intermediate 167 in the 
process. VbxM then catalyzes the oxidation of THCCA 167 to afford ketone 228, before 
dehydration catalyzed by VbxL generates unsaturated ketone intermediate 229. VbxK then 
catalyzes enoyl reduction to produce ketone 233 before VbxM catalyzes the final reduction 
yielding DHCCA 48.  
 
    
 
Scheme 4.17 The DHCCA biosynthetic pathway as determined using in vitro assays. 
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of VbxP), enacyloxin IIa production was abolished. This is in agreement with the new pathway 
as shikimate CoA223 cannot be generated, which is essential for the following reduction step, 
and so DHCCA biosynthesis cannot proceed. When bamb_5914 was deleted (gene encoding the 
homologue of VbxN), enacyloxin IIa production was also abolished, which is again in 
agreement with the pathway, as the key reduction step can no longer proceed. When bamb_5912 
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was deleted (gene encoding the homologue of VbxL), enacyloxin analogue 172 harboring the 
THCCA unit was produced. This is again consistent with the pathway, as the dehydration of 
ketone 228 can no longer proceed, and the oxidation step catalyzed by VbxM to form ketone 
228 from THCCA 167 is reversible. This explains the incorporation of the THCCA 167, which 
has already been shown to be a substrate for the condensation domain (section 3.2.1.5). 
 
The deletion of bamb_5913 (gene encoding the homologue of VbxM) resulted in a small 
amount of analogue 172 but mostly wild-type levels of enacyloxin IIa production. The small 
amount of analogue 172 can be explained based on the pathway as if the VbxM-catalyzed 
oxidation of THCCA 167 cannot take place, THCCA 167 would be incorporated. The presence 
of mostly enacyloxin IIa suggests that there may be another enzyme complimenting the role of 
VbxM, which is not an unreasonable explanation as quinate dehydrogenase enzymes are present 
in primary metabolic pathways. Finally the deletion of bamb_5918 (gene encoding the 
homologue of VbxK), also resulted in a small amount of analogue 172 but mostly wild-type 
levels of enacyloxin IIa production. Again, the small amount of analogue 172 can be explained 
based on the pathway, as if the VbxK-catalyzed reduction of unsaturated ketone intermediate 
229 cannot proceed, the reversibility of the preceding steps can result in the incorporation of 
THCCA 167. The presence of enacyloxin IIa again suggests that another enzyme (possibly from 
primary metabolism) may be complimenting the role of VbxK.  
 
An alternative explanation is that the step catalyzed by VbxK can proceed via an alternative 
route, whereby only VbxM is required (scheme 4.18) as suggested by Coggins and co-
workers.226 This involves the tautomerization of unsaturated ketone 229 to diketone 230, which 
can then be reduced by VbxM. The resulting keto-alcohol 231 can then further tautomerize to 
ketone 232 which can be reduced to DHCCA 48. 
 
                                      
 
Scheme 4.18 An alternative pathway where VbxK is no longer required. 
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A preliminary assay was attempted in order to investigate this alternative pathway, whereby 
ketone 228 was incubated with VbxL, as well as VbxM, NAD+ and NADH and the production 
of DHCCA 47 monitored by LC-MS (scheme 4.19). However the DHCCA product 47 could not 
be detected, so it remains unclear whether this is a true alternative pathway. 
 
 
 
Scheme 4.19 The preliminary assay used to investigate the alternative pathway along 
with the proposed sequence of steps. 
 
4.3.3 Future Work 
 
Despite the reconstitution of the DHCCA biosynthetic pathway in vitro, most of the enzymes 
involved have only been characterized at a functional level. With the exception of VbxP (CoA 
transferase, section 4.2.2.1), the mechanistic details of the enzyme-catalyzed steps of the 
pathway requires further investigation. One way in which this can be achieved is by protein 
crystallography. The FMN-dependent enone reductase VbxK (section 4.2.2.5) was crystallized 
(figure 4.28), and a 2.3 Å data set was collected. However, solving of the structure by molecular 
replacement is currently ongoing. 
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Figure 4.28 The crystals obtained for FMN-dependent enone reductase, VbxK. 
 
4.3.4 Summary 
 
Here, the biosynthesis of the DHCCA unit of enacyloxin, which has been shown to be key to the 
activity of the molecule, has been fully reconstituted in vitro. This led to the discovery of a 
promiscuous CoA transferase domain, which has the potential to be utilized as a biocatalyst for 
the generation of CoAs. The pathway utilizes the transient formation of a CoA thioester 
(shikimate CoA 223) in order to facilitate the otherwise chemically unfavorable reduction of an 
enoyl acid, as well as the formation of a transient ketone (ketone 228) in order to facilitate the 
otherwise chemically unfavorable elimination of a hydroxyl group. The pathway proceeds via a 
significantly different route to what was initially predicted, which reinforces the value of 
investigating biosynthetic pathways using in vitro biochemistry. 
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5. Conclusions 
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5.1 Elucidation of Biosynthetic Pathways 	
5.1.1 Diene-Forming DH Domains 
 
The first aim of this project was to investigate the role of a DH domain in the installation of an 
E,Z-diene motif in the macrolide antibiotic, gladiolin 29. The DH domain is embedded in 
module 13 of the gladiolin PKS, which has a type B split module architecture (scheme 5.1). 
Type B split modules are a common feature of trans-AT PKSs, and are proposed to install diene 
motifs in a number of polyketide natural products, yet the mechanism by which the diene is 
formed by a single module had not previously been characterized.94 
 
         
 
Scheme 5.1 The type B split module present in the gladiolin 29 PKS thought to be 
responsible for the installation of the (E,Z)-diene motif (red). 
 
Using an intact protein MS-based assay with chemically synthesized polyketide intermediate 
mimics loaded onto the overproduced DH-ACP didomain of module 13, the DH domain was 
shown to dehydrate a (3R,5S)-3,5-dihydroxyacyl thioester to form an (E,Z)-diene. This is the 
first biochemical evidence of a DH domain catalyzing more than a single dehydration. Using 
sequence alignments, an additional histidine residue in the active site of the DH domain was 
identified, which was shown to be involved in the vinylogous dehydration of a (2E,5S)-5-
hydroxy-2-enoyl thioester intermediate to form the E,Z-diene. The mechanism of DH catalyzed 
diene formation is proposed to proceed via firstly the canonical syn-elimination of the (3R)-
configured hydroxyl group to install the (2E)-configured alkene. The additional histidine residue 
then catalyzes the vinylogous dehydration of the (5S)-configured hydroxyl group in order to 
generate the E,Z-diene (scheme 5.2). The substrate tolerance of the domain was also 
investigated, and the DH was shown to also be capable of the dehydration of a (3R,5R)-3,5-
dihydroxyacyl thioester substrate, which was thought to result in an (E,E)-diene. 
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Scheme 5.2 The proposed mechanism of double dehydration catalyzed by the GbnD5 DH 
domain. 	
To confirm if diene-forming DH domains are present in other systems, the sequence of the 
GbnD5 DH domain was aligned with the sequences of other known DH domains, and a 
phylogenetic tree was generated (Dr. Matt Jenner, appendix 8.1). The phylogenetic analysis 
identified several other diene-forming DH domains (figure 5.1). The domains appear to occur 
mostly within type B dehydrating bimodules, but some occur as part of conventional modules 
(such as in chivosazol biosynthesis) as well as in cis-AT PKS systems (such as in thuggacin 
biosynthesis). There is also an example where the DH domain is predicted to install an (E,E)-
configured diene (tartrolon), consistent with what was observed for the GbnD5 DH domain 
when provided with a (3R,5R)-3,5-dihydroxyacyl thioester. From the biochemical investigation 
of the GbnD5 DH domain, not only has a better understanding of gladiolin biosynthesis been 
obtained, but due to the conserved nature of these DH domains, the biosynthetic pathways of 
many other diene-containing polyketides can now be better understood. 
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Figure 5.1 Examples of diene-forming DH domains identified in other PKS systems. 
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The E,Z-diene motif of gladiolin 29 is also present in the closely related polyketide antibiotic 
etnangien 261 (figure 5.2). Both molecules are very similar in structure and act by binding to 
RNA polymerase.230 The E,Z-diene motif may be required in order for the macrolide ring to 
bind to its target in the correct conformation.  
 
                        
 
Figure 5.2 The structures of gladiolin 29 and etnangien 261. 
 
The discovery and mechanistic understanding of diene-forming DH domains provides scope for 
the introduction of E,Z- or E,E-dienes into polyketide scaffolds via genetic engineering 
approaches. This could conceivably be achieved via the in vivo mutagenesis of a canonical DH 
domain, embedded within a module that processes an appropriate 3,5-dihydroxyacyl 
intermediate, to a diene-forming DH domain, resulting in the formation of the corresponding 
diene (scheme 5.3). This approach results in minimal disruption to the PKS assembly line, 
however is dependent on the ability of the downstream KS domain to accept the resulting 
dienoyl thioester as a substrate for further elongation of the chain and continued polyketide 
assembly. 
 
   
 
Scheme 5.3 The engineering of a diene-forming DH domain into a canonical cis-AT PKS 
module. DHA = canonical alkene-forming DH domain, DHD  = diene-forming DH domain. 
OH O
O
OH
OHOH
OH
OH OH
O
OMe
gladiolin 29
OH O
O
OH
OHOH
OH
OMe
etnangien 261
OH
OH
O
KS
MX
AT
ACP
S
KRB
DHA
O
ACP
S
O
MX-1
R
HO
R
HO
MX+1
KS KS
MX
AT
ACP
S
KRB
DHD
O
ACP
S
O
MX-1
R
HO
MX+1
KS
R
DH
Mutagenesis
	 146	
There is also scope for diene-forming DH domains to be developed into in vitro biocatalysts. 
E,Z-Dienes are often generated synthetically using organometallic coupling reactions, which can 
involve the use of expensive metal catalysts as well as harsh reaction conditions.231 These 
reaction conditions are typically avoided when it comes to industrial scale synthesis, so the 
development of a biocatalyst capable of E,Z-diene production would be beneficial. The diene-
forming DH domain in this study has not yet been shown to process small molecule substrates, 
and so may need to be optimized via directed evolution, a technique that has been used 
successfully for the generation of many robust biocatalysts.232 
 
5.1.2 DHCCA Biosynthesis 
 
The shikimate-derived DHCCA unit of enacyloxin IIa 30 is key to the biological activity of the 
antibiotic (section 3.1.2.3). When the enacyloxin IIa gene cluster was reported in 2011, DHCCA 
48 was proposed to be biosynthesized from shikimate 47 using five enzymes (encoded by 
bamb_5912, 5913, 5914, 5916 and 5918) and an initial pathway was postulated (scheme 5.4).104 
Given the importance of the DHCCA unit to the activity of enacyloxin IIa 30, the predicted 
pathway was investigated using both in vivo gene deletions and in vitro biochemical assays. 
 
 
			
Scheme 5.4 The proposed pathway for the biosynthesis of DHCCA 48.1 04 	
From the results of in vivo gene deletions and initial in vitro assays, it was clear that the initially 
proposed pathway was incorrect. After the BLAST analysis of the five enzymes involved, it 
became apparent that several of the enzymes had different roles to what was initially predicted. 
A new pathway was proposed based on these new roles, which was confirmed using in vitro 
assays (scheme 5.5) and was more consistent with the in vivo results. The pathway utilizes the 
transient formation of a CoA thioester in order to facilitate the otherwise chemically 
unfavorable enoyl reduction of shikimic acid 47, as well as the formation of a transient ketone 
in order to facilitate the otherwise chemically unfavorable elimination of a hydroxyl group 
(from THCCA 167). The pathway proceeds via a significantly different route to the initially 
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predicted pathway, reinforcing the value of investigating biosynthetic pathways using in vitro 
biochemistry. 
 
					 	
 
Scheme 5.5 The DHCCA biosynthetic pathway as determined using in vitro assays. 
 
The discovery and characterization of the enzymes from the DHCCA biosynthetic pathway 
leads to the potential of new biocatalysts. Both enoyl reductase enzymes, VbxN and VbxK, 
catalyze reactions resulting in the installation of stereocenters, which can be challenging to 
install synthetically. Asymmetric synthesis often involves the use of expensive chiral metal 
complexes as catalysts, such as Noyori’s ruthenium-based reduction catalyst, which was used in 
section 2.2.1.1 during the asymmetric synthesis of chiral pantetheines.233 As well as being 
expensive, asymmetric reduction catalysts also often require high-pressure hydrogen 
atmospheres typically avoided during industrial scale synthesis, meaning alternative methods of 
installing stereocenters are of great value.234 The enone-reductase, VbxK is a member of the old 
yellow enzyme (OYE) family, a group of flavin-dependant reductase enzymes, which have 
already been extensively developed into robust biocatalysts for the stereoselective trans 
hydrogenation of conjugated C=C double bonds (scheme 5.6).235 
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Scheme 5.6 The stereospecific enoyl reduction catalyzed by OYEs along with some 
representative substrates.  
 
Another enzyme from the DHCCA biosynthetic pathway, VbxP, also has the potential to be 
developed into a useful biocatalyst. VbxP is a CoA transferase responsible for the generation of 
shikimate CoA 223 in the pathway (scheme 5.5), but was also shown to be capable of 
generating a range of other CoA thioesters when supplied with the appropriate acid substrate 
(section 4.2.2.1). CoA thioesters are often used during the in vitro investigation of biosynthetic 
mechanism, but can often be challenging to synthesize due to their high functionality and 
polarity, and only a limited range are commercially available. Another approach is to synthesize 
the corresponding acyl-pantetheine and use the enzymatic loading cassette utilized in section 
2.4.1, however pantetheine substrates are often also challenging to synthesize depending on the 
required acyl group. VbxP may provide an alternative to these routes, eliminating the need for 
challenging chemical synthesis. Since the discovery and characterization of VbxP, the enzyme 
has been used to generate a required CoA substrate, succinamide-CoA 262, which was then 
successfully loaded onto an apo-ACP domain in situ for a biochemical assay, demonstrating the 
applicability of VbxP (scheme 5.7). 
 
                   
 
Scheme 5.7 The in situ generation of succinamide-CoA 262 via VbxP and loading of an 
apo-ACP domain. 
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Overall, the investigation of biosynthetic mechanism in both the gladiolin 29 and enacyloxin IIa 
30 biosynthetic pathways has provided valuable insights into how key motifs are installed in 
both of these polyketide antibiotics as well as other polyketide natural products. The greater 
understanding of these pathways provides more scope for the engineering of antibiotic 
analogues and has lead to the discovery of potential biocatalysts. 
 
5.2 Engineering Antibiotic Analogues 	
 
The long-term goal of this study was to establish a greater understanding of biosynthetic 
pathways to facilitate the engineering of improved antibiotic analogues. This concept is 
exemplified with the strategies used in order to generate enacyloxin IIa analogues as they rely 
on a thorough understanding of the enacyloxin IIa biosynthetic pathway. The in vitro 
characterization of the unusual chain release mechanism and substrate tolerance of the 
enacyloxin condensation domain (Bamb_5915), led to the design and implementation of a 
strategy for the generation of analogues harbouring alternative DHCCA units (green, figure 
5.3). This strategy consisted of the deletion of several of the DHCCA biosynthesis genes 
(bamb_5912-14) and feeding of simple DHCCA analogues, which had been accepted by the 
condensation domain in vitro (Dr. Joleen Masschelein). This strategy was then expanded to 
include the incorporation of a range of chemically synthesized DHCCA analogues, which 
resulted in the production of an enacyloxin analogue (187, figure 5.3) harbouring an unsaturated 
DHCCA derivative 51 which had increased potency relative to enacyloxin IIa 30.  
 
In addition to the chain release mechanism, the tailoring enzymes involved in enacyloxin IIa 
biosynthesis were also targeted for the engineering of analogues. The tailoring enzymes were 
deleted individually as well as in combination with each other in order to generate an array of 
enacyloxin analogues harbouring changes in the polyol region (blue, figure 5.3). This resulted in 
the production of a more potent enacyloxin analogue lacking the carbamoyl and keto tailoring 
groups (45, figure 5.3). As well as deleting the tailoring enzymes, the ability of the two 
halogenase enzymes (Bamb_5928 and 5931) to catalyse bromination as well as chlorination was 
used to generate bromide analogues, two of which (196 and 199, figure 5.3) were again more 
potent than enacyloxin IIa 30. In an attempt to rationally design an analogue with even greater 
potency, a mutant was generated harbouring both changes in the polyol region and the 
unsaturated DHCCA derivative 51, which had resulted in more potent analogues (45 and 187), 
however the resulting analogue (204) did not display the desired increase in potency. 
 
	 150	
                        
 
Figure 5.3 Engineered enacyloxin analogues with increased potency. 
 
From the crystal structure of enacyloxin IIa 30 bound to its target, EF-Tu (figure 3.27, section 
3.3.2), there appears to be key polar contacts between residues of EF-Tu and functional groups 
in both the polyol and DHCCA regions of enacyloxin IIa.110 One of the aims of generating the 
library of enacyloxin analogues was to examine the affect on activity of altering the structure of 
enacyloxin IIa in both the polyol and DHCCA regions of the molecule. The SAR data generated 
could then potentially be used as a basis for the rational engineering of more potent analogues. 
From the SAR data, it was difficult to correlate the changes in activity observed to the key polar 
contacts identified from the crystal structure. This suggests that data other than MIC assays, 
such as in vitro EF-Tu binding assays or testing in animal infection models, may be required in 
order to form a more reliable basis for the engineering of analogues. However it is clear that the 
removal of many of the tailoring groups, as well as replacing the DHCCA unit with a linear 
analogue, results in reduced potency. 
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Five analogues were still generated which were more potent than enacyloxin IIa, and could be 
used as a platform for the engineering of analogues harboring more complex changes. The 
platform could potentially be used to combat the inherent stability problems associated with 
enacyloxin IIa. The light-induced isomerization believed to be promoted by the methyl group of 
the polyene region has been addressed via the generation of an MT domain-inactive mutant 
(figure 5.4). However the resulting des-methyl analogue 205 loses potency relative to 
enacyloxin IIa (MIC 2 µg/mL). The combination of the MT domain-inactive mutant with some 
of the structural features identified in this study as being key to lowering MIC may result in des-
methyl analogues which retain potent activity (figure 5.4). 
 
                               
                              
Figure 5.4 The des-methyl enacyloxin IIa analogue 205 and potential des-methyl 
enacyloxin analogues (206-208) that may retain potency. 
 
The other potential stability problem associated with enacyloxin IIa, is the labile ester linkage 
between the DHCCA unit and the linear acyl chain. This was addressed via the incorporation of 
a simplified amine DHCCA derivative (140), however the resulting amide enacyloxin analogue 
149 again displayed reduced potency (section 3.1.2.3). The platform of potent analogues 
established in this study could again be used in order to generate amide analogues which may 
retain activity (figure 5.5). 
 
ΔMT (205) MIC = 4 µg/mL
O
OH2N
O
Cl
OH O OH Cl O
OH
CO2H
OH
O
OH2N
O
Cl
OH O OH Cl O
OH
CO2H
XX
OH
O
OH
Cl
OH OH Cl O
OH
CO2H
XX
OH
OH
O
OH2N
O
Br
OH O OH Br O
OH
CO2H
XX
OH
206	
207	
208	
	 152	
                                
 
Figure 5.5 The simplified amide analogue (149) and potential amide enacyloxin 
analogues (209-211),  which are more likely to retain potency. 
 
In addition to the improved analogues generated in this study, vibroxin 151 (figure 5.6) may 
also be considered as a platform for the generation of potent derivatives. Vibroxin 151 is more 
potent than enacyloxin IIa 30. However, it is produced by a genetically intractable Vibrio 
rhizosphaerae strain. The heterologous expression of the vibroxin 151 gene cluster would 
facilitate the engineering of improved vibroxin analogues, and allow the introduction of the 
MIC-lowering features identified in this study (figure 5.6). 
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Figure 5.6 The structure of vibroxin 151 and the structures of potential improved 
vibroxin analogues (262 and 263) 
 
Overall, several enacyloxin IIa analogues have been generated in this study, which display 
greater potency than enacyloxin IIa itself. These analogues were generated using multiple 
strategies, which were designed based upon a thorough understanding of the enacyloxin IIa 
biosynthetic pathway. This reaffirms the importance of the role that the elucidation of 
biosynthetic pathways has to play in the production of improved antibiotics, which are urgently 
required for the treatment of rapidly emerging, life-threatening MDR pathogens. 
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6. Experimental 
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6.1 Instruments and Equipment 		
All media was autoclaved was at at 121 oC and 1 bar for 10 min. Sterile filtering was 
conducted using Minisart syringe filters (Sartorius). Liquid and solid cultures were incubated 
using New Brunswick Scientific Innova shakers or Thermo Scientific Heraeus static 
incubators respectively. Centrifugations were conducted using Eppendorf models 5415D, 
5424, 5804R and 5810R, or a Thermo Scientific Sorvall RC 6 Plus equipped with an SS34 or 
SLA3000 rotor. Burkholderia and Acinetobacter strains were handled in a category 2 
laboratory equipped with a Bassaire laminar flow hood. Optical densities were measured using 
a Thermo Scientific BioMate 3 spectrophotometer. Electroporations were conducted with a 
BioRad Gene Pulserâ II (200 W, 25 µF, 1.7 kV) in combination with a BioRad Pulse 
Controller Plus. DNA and protein concentrations were determined using a Thermo Scientific 
NanoDrop Lite spectrophotometer. PCR was conducted using an Eppendorf Mastercycler 
Gradient. Agarose gel electrophoresis was performed using a BioRad tank in combination with 
either a PowerPac Basic or a PowerPac 300. Visualisation of agarose gels was conducted with 
a UVP BioDoc-It Imaging System 2UV Transilluminator. Cell lysis was conducted using a 
Constant Systems Ltd TS-Series Cabinet cell disruptor (One-Shot mode, 20 KPSI). Proteins 
were analysed by SDS-PAGE gel electrophoresis using a BioRad Mini-PROTEAN Tetra cell. 
UV-Vis readings of solutions in 3 mm path length sub-micro quartz cuvettes (Starna 
scientific) were attained using a Varian Cary 50 Bio UV-Visible Spectrophotometer (single 
wavelength) or a Perkin Elmer Lambda 3S UV/Vis Spectrophotometer (multiple 
wavelengths). 
 
Room temperature (RT) refers to ambient temperature (20-22 °C), 5 oC refers to a cold water 
bath and 0 °C refers to an ice slush bath. Heated experiments were conducted using 
thermostatically controlled oil baths. All commercially available solvents and chemicals were 
used without any further purification. Anhydrous solvents were obtained by distillation under 
argon using calcium hydride as drying reagent and stored over 4 Å molecular sieves. Solvents 
were evaporated using a BUCHI Rotavapor R-200 or R-210 connected to a BUCHI Vacuum 
Pump V-700. NMR spectra were recorded on Bruker Advance AV-300, HD-400 and HD-
500 MHz spectrometers at RT. Chemical shifts are reported in parts per million (ppm) 
referenced from CDCl3 (δH: 7.26 ppm and δC: 77.2 ppm) or MeOD (δH: 3.31 ppm and δC: 
49.0 ppm). Coupling constants (J) are rounded to the nearest 0.5 Hertz (Hz). Multiplicities are 
given as multiplet (m), singlet (s), doublet (d), triplet (t), quartet (q), quintet (quin.), sextet 
(sext.), septet (sept.), octet (oct.) and nonet (non.). Cquart donates a quaternary carbon. 1H and 
13C assignments were established on the basis of COSY, 13C-DEPT, HMQC and HMBC 
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correlations. Infra-red (IR, nmax) spectra were recorded using either a Perkin Elmer Spectrum 
100 FT-IR spectrometer or an Alpha Bruker Platunium ATR single reflection diamond ATR 
module. Optical rotations were measured using an Optical Activity Ltd AA-1000 millidegree 
auto-ranging polarimeter (589 nm). Specific rotations are given in units of 10-1 deg cm2 g-1. 
Melting points were recorded on a Stuart scientific melting point apparatus and are 
uncorrected. Silica column chromatography was performed on 40-60 Å silica gel (Sigma 
Aldrich). Thin layer chromatography (TLC) was carried out aluminum sheets coated with 0.2 
mm silica gel (Fisher Scientific) F254. Visualisation was effected by UV light (254 nm) or by 
potassium permanganate solution followed by heating. Low resolution mass spectra (LRMS) 
were recorded using an Agilent 6130B single Quad (ESI). High resolution mass spectra 
(HRMS) were obtained were obtained by either Dr Lijiang Song or Mr Philip Aston using a 
Bruker micro-TOF ESI spectrometer. 
 
Small molecules were analyzed using a Dionex UltiMate 3000 UHPLC connected to a Zorbax 
Eclipse Plus column (C18, 100 × 2.1 mm, 1.8 mm) coupled to a Bruker maXis impact mass 
spectrometer. Mobile phases consisted of water (A) and acetonitrile (B), each supplemented 
with 0.1% formic acid. The column was eluted with a linear gradient of 5 - 100% B over 
35 min, employing a flow rate of 0.2 mL/min. The mass spectrometer was operated in positive 
ion mode with a scan range of 50-3000 m/z. Source conditions were: end plate offset at 
−500 V; capillary at −4500 V; nebulizer gas (N2) at 1.6 bar; dry gas (N2) at 8 L min−1; dry 
temperature at 180 °C. Ion transfer conditions were: ion funnel RF at 200 Vpp; multiple RF at 
200 Vpp; quadrupole low mass at 55 m/z; collision energy at 5.0 eV; collision RF at 600 Vpp; 
ion cooler RF at 50–350 Vpp; transfer time at 121 ms; pre-pulse storage time at 1 ms. 
Calibration was performed with 1 mM sodium formate through a loop injection of 20 µL at the 
start of each run.  
 
UHPLC-ESI-Q-TOF-MS analyses of intact proteins were conducted using a Dionex UltiMate 
3000 RS UHPLC connected to an ACE 3 C4-300 reverse phase column (Advanced 
Chromatography Technologies, Aberdeen, UK; 100 × 2.1 mm, 5 µM, 30 oC) coupled to a 
Bruker maXis II mass spectrometer. Proteins were eluted with a linear gradient of 5 - 100% 
MeCN containing 0.1% formic acid over 30 min. The mass spectrometer was operated in 
positive ion mode with a scan range of 200–3000 m/z. Source conditions were: end plate 
offset at −500 V; capillary at −4500 V; nebulizer gas (N2) at 1.8 bar; dry gas (N2) at 
9.0 Lmin−1; dry temperature at 200 °C. Ion transfer conditions were: ion funnel RF at 
400 Vpp; multiple RF at 200 Vpp; quadrupole low mass at 200 m/z; collision energy at 8.0 
eV; collision RF at 2000 Vpp; transfer time at 110.0 µs; pre-pulse storage time at 10.0 µs. 
	 157	
Preparative HPLC was conducted using an Agilent 1260 instrument equipped with a Zorbax 
SB-C18 column (21.2 x 100 mm, 5 µm), monitoring absorbance at 360 nm. Mobile phases 
consisted of H2O and MeOH, with the H2O supplemented with 0.1% formic acid. A gradient 
of 30% MeOH to 100% MeOH over 40 minutes was employed at a flow rate of 10 mL/min. 
 
6.2 Materials 
 
6.2.1 General 
 
Bacto casamino acids, Bacto yeast extract and Bacto agar were purchased from Becton 
Dickinson Microbiology. Luria-Bertani (LB) broth powder and Mueller-Hinton (MH) broth 
powder were purchased from Sigma Aldrich. GelRed Nucleic Acid Gel Stain and Instant Blue 
were purchased from Cambridge Bioscience (UK) and Expedeon (UK) respectively. All 
chemical reagents and solvents were purchased from Sigma Aldrich (USA), Thermo Fisher 
Scientific (UK), Fisher Scientific (UK), Alfa Aesar (USA) or VWR (UK). 
 
6.2.2 Growth and Production Media 
 
Luria-Bertani medium (LB): LB broth powder was dissolved in deionised H2O (25 g/L) and 
was sterilized by autoclaving. LB agar was prepared using the same procedure with Bacto agar 
(15 g/L) added prior to sterilization. 
 
Basal salts medium (BSM): K2HPO4.3H2O (4.3 g/L), NaH2PO4 (1.0 g/L), NH4Cl (2.0 g/L), 
MgSO4.7H2O (0.2 g/L), FeSO4.7H2O (0.01 g/L), MnSO4.H2O (0.003 g/L), ZnSO4.H2O 
(0.003 g/L), CoSO4.7H2O (0.001 g/L), nitriloacetic acid (0.1 g/L), Bacto yeast extract 
(0.5 g/L), Bacto casamino acids (0.5 g/L) and glycerol (4.0 g/L) were dissolved in deionised 
H2O and the pH adjusted to 7.2. Bacto agar (15 g/L) was then added prior to sterilization.236 
 
M9 minimal medium: Na2HPO4 (6.0 g/L), KH2PO4 (3.0 g/L), NaCl (0.5 g/L), NH4Cl 
(1.0 g/L), sucrose (10.0 g/L), MgSO4 (0.1 g/L) and CaCl2 (0.01 g/L) were dissolved in 
deionised H2O and the pH adjusted to 7.4. Bacto agar (15 g/L) was then added prior to 
sterilization. 
 
Mueller-Hinton medium (MH): MH broth powder was dissolved in deionised H2O (22 g/L) 
and was sterilized by autoclaving. 
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6.2.3 Buffers 
 
Tris/Borate/EDTA (TBE) buffer (10x): Tris-HCl (890 mM), boric acid (890 mM) and 
EDTA (20 mM) were dissolved in deionised H2O. The solution was diluted to 1 x before use. 
 
Loading Buffer: NaCl (100 mM), Tris base (20 mM) and imidazole (20 mM) were dissolved 
in deionised H2O and the pH was adjusted to 8.0, before the solution was sterile filtered. 
 
Elution Buffers: NaCl (100 mM), Tris base (20 mM) and imidazole (50-300 mM) were 
dissolved in deionised H2O and the pH was adjusted to 8.0, before the solution was sterile 
filtered. 
 
Storage Buffer: NaCl (100 mM) and Tris base (20 mM) were dissolved in deionised H2O and 
the pH was adjusted to 7.4, before the solution was sterile filtered. 10 % glycerol was added 
before flash freezing. 
 
SDS-PAGE sample buffer (5 ×): SDS (10 % w/v), 2-mercaptoethanol (10 mM), glycerol 
(20 % w/v), Tris base (0.2 M) and bromophenol blue (0.05 %, w/v) was dissolved in deionised 
H2O and the pH adjusted to 6.8. The solution was diluted to 1 × with protein sample when 
used. 
 
SDS-PAGE running buffer (10 ×): Tris base (250 mM), glycine (2 M) and SDS (1 % w/v) 
were dissolved in deionised H2O and the pH adjusted to 8.0. The solution was diluted to 1 × 
with protein sample when used. 
 
Chemically competent cell preparation buffer I (CCCI): Potassium acetate (30 mM) and 
CaCl2 (80 mM) were dissolved in deionised H2O and the pH adjusted to 5.8 before 
sterilization. 
 
Chemically competent cell preparation buffer II (CCCII): Potassium acetate (30 mM), 
CaCl2 (80 mM) and glycerol (15 % w/v) were dissolved in deionised H2O and the pH adjusted 
to 5.8 before sterilization. 
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6.2.4 Kits 
 
GeneJET Gel Extraction Kit, GeneJET PCR Purification kit, MagJET Genomic DNA Kit, 
GeneJET Plasmid Miniprep Kit and ChampionTM pET151 Directional TOPO® Expression Kit 
were all purchased from Thermo Fisher Scientific (UK). Restriction enzymes, corresponding 
buffers and OneTaq Hot Start quick-load polymerase master mix were also purchased from the 
same supplier. T4 DNA ligase, Q5® Site-Directed Mutagenesis Kit and Q5® Hot Start High-
Fidelity Master Mix were obtained from New England Biolabs (USA).  
 
6.2.5 Antibiotics 	
Table 6.1: Antibiotics used within this project. 
Antibiotic Working conc. Solvent Supplier Strain to be applied 
Ampicillin 100 µg/mL H2O Melford (UK) E.coli carrying 
recombinant pET151 
Kanamycin 50 µg/mL H2O Melford (UK) E.coli carrying 
recombinant pET28a(+) 
Trimethoprim 50 µg/mL DMSO Sigma Aldrich (UK) E.coli carrying 
recombinant pGPI-SceI 
 150 µg/mL DMSO Sigma Aldrich (UK) Burkholderia carrying 
recombinant pGPI-SceI  
Tetracycline 20 µg/mL 70 % EtOH Sigma Aldrich (UK) E.coli carrying pDAI-SceI 
 200 µg/mL 70 % EtOH Sigma Aldrich (UK) Burkholderia carrying 
pDAI-SceI 
Gentamicin 50 µg/mL H2O Sigma Aldrich (UK) Burkholderia carrying 
recombinant pGPI-SceI, 
Burkholderia carrying 
pDAI-SceI 
 
6.2.6 Bacterial Strains 	
Table 6.2: Bacterial strains used within this project. 
Strain Use Supplier 
Escherichia coli   
E.coli TOP10 Host for general cloning and plasmid  
storage 
Thermo Fisher Scientific 
(UK) 
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E.coli BL21 StarTM 
(DE3) 
High level recombinant protein 
expression 
Thermo Fisher Scientific 
(UK) 
E.coli C43(DE3) High level recombinant protein 
expression 
Challis lab stock 
E.coli SY327 Donor strain for conjugation between 
E.coli and Burkholderia 
Challis lab stock 
E.coli HB101/ 
Burkholderia 
Helper strain for conjugation between 
 
Challis lab stock 
B.ambifaria  
BCC0203 
Enacyloxin producing strain Mahenthiralingam/ 
Challis lab stock 
Acinetobacter   
A.baumannii 
ATCC17978 
Strain used for determining MIC of  
Enacyloxin derivatives 
Mahenthiralingam/ 
Challis lab stock 
A.baumannii 
DSM25645 
Strain used for determining MIC of  
Enacyloxin derivatives 
Mahenthiralingam/ 
Challis lab stock 
Vibrio   
V.rhizosphaerae  
DSM18581 
Genomic DNA extracted for the cloning 
of enzymes from the vibroxin cluster 
Challis lab stock 
 
6.2.7 Vectors 	
Table 6.3: Vectors used within this project 
Vector Use Resistance Supplier 
pET151- TOPO® 
 
Recombinant protein expression 
in E.coli (N-terminal His tag) 
Ampicillin Thermo Fisher  
Scientific (UK) 
pET28a (+) Recombinant protein expression 
in E.coli (N-terminal His tag) 
Kanamycin Novagen 
pGPI-SceI Gene deletion in Burkholderia Trimethoprim Mahenthiralingam/ 
Challis lab stock 
pDAI-SceI Gene deletion in Burkholderia Tetracycline Mahenthiralingam/ 
Challis lab stock 
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6.3 General DNA Manipulation 	
6.3.1 Genomic DNA Isolation 	
Genomic DNA for PCR was extracted using the MagJET Genomic DNA Kit. The DNA 
concentration was measured using a NanoDropTM Lite spectrophotometer. 	
6.3.2 Isolation of Plasmid DNA 	
Plasmid DNA was isolated from an E.coli overnight culture (5 mL) using the GeneJET 
Plasmid Miniprep kit. The concentration of the purified plasmid DNA was measured using a 
NanoDropTM Lite spectrophotometer.	
 
6.3.3 Polymerase Chain Reaction (PCR) 	
Q5® Hot Start High-Fidelity DNA polymerase was used for the amplification of DNA 
fragments for cloning and OneTaq® Hot Start DNA polymerase was used for colony PCR 
screening. Typical reaction conditions are shown in table 6.4. 
	
Table 6.4: Typical PCR reaction components 
Reaction composition for PCR with Q5®  
Hot Start High-Fidelity DNA polymerase 
Reaction composition for PCR with   
OneTaq® Hot Start DNA polymerase 
Component Volume / µL Component Volume / µL 
Template DNA (purified DNA) 0.5 Template DNA (culture) 1 
Q5® Hot Start High-Fidelity 
Master Mix (2x) 
12.5 OneTaq® Hot Start  
Quick-Load Master Mix (2x) 
12.5 
Forward primer (10 µM) 1.5 Forward primer (10 µM) 1.5 
Reverse primer (10 µM) 1.5 Reverse primer (10 µM) 1.5 
DMSO* 0-2 DMSO* 0-2 
Nuclease-free water up to 25 Nuclease-free water up to 25 
*Increased volumes (between 0-2 µL) of DMSO were often used depending on GC content 
 
Typical thermocycling conditions for routine PCR reactions are shown in table 6.5. 
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Table 6.5: Typical thermocycling conditions for routine PCR reactions 
Step  Temperature / oC Duration 
Initial Denaturation  98 1 min* 
Denaturation  98  30 s 
Annealing 30 cycles 58-70** 30 s 
Extension  72 30 s/kb*** 
Final Extension  72 10 min 
Hold  4  
*Initial denaturation step was extended to 10 min for colony PCR 
**Annealing temperatures were approximately 5 oC below the melting temperature of the 
primers used 
***When OneTaq® Hot Start DNA polymerase was used the extension time was extended to 1 
min/kb 
 
6.3.4 Agarose Gel Electrophoresis 	
To 1 × TBE buffer solution (100 mL) was added agarose (0.7 g) and the mixture heated until 
the agarose had fully dissolved. The solution was then allowed to cool to RT before GelRed 
(0.5 µL) was added. The solution was then poured into the appropriate mould and the 
appropriate comb was added. Once set, the gel was placed into a gel tank filled with 1 × TBE 
buffer and the DNA samples were loaded, each containing 1 × DNA loading dye, along with 
the appropriate DNA size marker (Thermo Scientific GeneRuler 1 kb or FastRuler Middle 
Range). The gel was then electrophoresed at 120 V for 40-60 min depending on the size of the 
DNA fragments. 
 
6.3.5 Fragment DNA Purification 	
Following agarose gel electrophoresis, the DNA fragments were visualised using a UV-
transilluminator and the desired fragments were purified using the GeneJET PCR Purification 
kit. If required, the fragments were excised and purified from the gel using a GeneJET Gel 
Extraction kit. The concentration of the resulting purified DNA fragment was determined 
using a NanoDropTM Lite spectrophotometer.  	
 
 	
	 163	
6.3.6 Restriction Digests and Ligations 	
6.3.6.1 Restriction digests for analysis of recombinant vectors 	
To the recombinant vector (3 µL) was added the appropriate restriction enzyme(s) (1-3 µL), 
the appropraiate 10x buffer(s) (2 µL) and H2O (up to 20 µL). The buffer was chosen according 
to supplier recommendation (single digests) or using the Thermo Scientific DoubleDigest 
Calculator (double digests). The reactions were then incubated at 37 oC for 90 min, followed 
by 65 oC for 5 min in order to inactivate the enzymes. The resulting fragments were then 
analyzed by agarose gel electrophoresis. 
 
6.3.6.2 Restriction digests and subsequent ligation into pET28a(+) 	
To the appropriate purified PCR product (48 µL) were added the appropriate restriction 
enzymes (1-3 µL), the appropriate 10x buffer(s) (6 µL) and H2O (up to 60 µL). The reactions 
were then incubated at 37 oC for 90 min, followed by 65 oC for 5 min in order to inactivate the 
enzymes. The resulting digested DNA was then purified using the GeneJET PCR Purification 
kit. 
 
At the same time, to the empty pET28a vector (48 µL) was added the appropriate restriction 
enzyme(s) (1-3 µL), the appropriate 10x buffer(s) (6 µL) and H2O (up to 60 µL). The reaction 
was then incubated at 37 oC for 90 min, before the addition of shrimp alkaline phosphatase 
(rSAP) (2 µL) and the mixture was incubated at 37 oC for a further 30 min. The mixture was 
then heated to 65 oC for 5 min in order to inactivate the enzymes and the resulting digested 
DNA was purified using the GeneJET PCR Purification kit. 
 
The purified digested DNA fragment and the digested linearized vector were ligated using T4 
DNA ligase. To the linearized vector (50 ng) was added the insert (150 ng) followed by the 
10x T4 DNA ligase buffer (4 µL), T4 DNA ligase (1.5 µL) and H2O (up to 20 µL). The 
reaction was incubated at 15 oC overnight before transformation into E.coli TOP10 chemically 
competent cells.    
 
6.3.6.3 TOPO® Cloning  	
TOPO cloning into pET151 was conducted using ChampionTM pET151 Directional TOPO®  
Expression Kit. A four nucleotide CACC- overhang was included at the 5’ end of the forward 
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primer in order to allow directional cloning of the insert into the pET151 vector. Q5® Hot Start 
High-Fidelity DNA polymerase was used to amplify the insert from template DNA. 
 
To the purified fragment DNA (0.5-4 µL, 2 : 1 ratio of insert : vector) was added salt solution 
(1 µL), TOPO® vector (1 µL) and H2O (to 6 µL). The reaction was mixed gently and 
incubated at RT for 1 h before being transformed into E.coli TOP10 chemically competent 
cells. 	
6.3.6.4 Restriction digests and subsequent ligation into pGPI 
 
To the appropriate purified PCR products (48 µL) were added the appropriate restriction 
enzymes (1-3 µL), the appropriate 10 × buffer(s) (6 µL) and H2O (up to 60 µL). The reactions 
were then incubated at 37 oC for 90 min, followed by 65 oC for 5 min in order to inactivate the 
enzymes. The resulting digested DNA was then purified using the GeneJET PCR Purification 
kit. 
 
At the same time, to the empty pGPI vector (48 µL) was added the appropriate restriction 
enzyme(s) (1-3 µL), the appropriate 10x buffer(s) (6 µL) and H2O (up to 60 µL). The reaction 
was then incubated at 37 oC for 90 min, before the addition of shrimp alkaline phosphatase 
(rSAP) (2 µL) and the mixture was incubated at 37 oC for a further 30 min. The mixture was 
then heated to 65 oC for 5 min in order to inactivate the enzymes and the resulting digested 
DNA was purified using the GeneJET PCR Purification kit. 
 
The purified digested DNA fragments and the digested linearized vector were ligated using T4 
DNA ligase. To the linearized vector (50 ng) was added both inserts (2 x 150 ng) followed by 
the 10 × T4 DNA ligase buffer (4 µl), T4 DNA ligase (1.5 µL) and H2O (up to 20 µL). The 
reaction was incubated at 15 oC overnight. 
 
The DNA was then purified by the addition of 3 M sodium acetate (2 µL) followed by 95 % 
EtOH (50 µL) and the reaction was left at -20 oC for 5 min. The mixture was then centrifuged 
(13000 rpm) at 4 oC for 20 min. The supernatant was carefully removed and the pellet washed 
with 70 % EtOH and dried. The purified DNA was then dissolved in H2O (10 µL) before 
transformation into E.coli SY327 electrocompetent cells.    
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6.3.7 Transformation and Electroporation 	
6.3.7.1 Preparation of competent cells 	
Chemically competent E.coli Bl21(DE3), C43(DE3) and TOP10 were required during this 
project. A single colony of the required E.coli strain was picked and grown overnight in LB 
(5 mL) with shaking (180 rpm). From the overnight culture 0.5 mL was taken and diluted with 
LB (50 mL). The resulting culture was shaken (180 rpm) at 37 oC in a 250 mL flask for around 
3.5 h until an OD600 of 0.4-0.6 was reached. The culture was then cooled on ice and the cells 
harvested by centrifuging for 10 min at 4000 rpm at 4 oC. The supernatant was discarded and 
the cell pellet was resuspended in CCCI buffer (30 mL) and kept on ice for 1 h. Cells were 
then harvested by centrifuging for 10 min at 4000 rpm at 4 oC and the supernatant discarded. 
The cell pellet was washed with CCCI (30 mL) again and resuspended in CCCII (1.5 mL) 
before being divided into 50 µl aliquots, flash frozen and stored at -80 oC. 
 
Electrocompetent E.coli SY327 cells were also required during this project. Electrocompetent 
cells were prepared using the same procedure but with the use of sterile 10 % glycerol solution 
in place of CCC1 and CCC2. 
6.3.7.2 Transformation of chemically competent E.coli cells 	
To an aliquot of thawed chemically competent cells (50 µL) was added plasmid DNA (0.5-2 
µL) or ligation mixture (2-8 µL) and the components gently mixed. The mixture was left on 
ice for 30 min before being heat shocked at 42 oC for 60 s and then cooled on ice for 1 min. 
LB (250 µL) was then added and the mixture was shaken (180 rpm) horizontally at 37 oC for 
1 h. Different volumes of the transformation mixture were then spread onto pre-warmed LB 
agar plates supplemented with the appropriate antibiotic and the plates incubated at 37 oC 
overnight. 
 
6.3.7.3 Transformation of electrocompetent E.coli cells 
 	
To an aliquot of thawed electrocompetent cells (50 µL) was added plasmid DNA (0.5-2 µL) or 
ligation mixture (2-8 µL) and the components gently mixed. The mixture was left on ice for 
5 min before being transferred to a pre-cooled 1 mm gap electroporation cuvette (Bio-Rad). 
The electroporation was conducted with a BioRad Gene Pulserâ II (200 W, 25 µF, 1.7 kV) in 
combination with a BioRad Pulse Controller Plus. Immediately after the electroporation LB 
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(950 µL) was then added and the mixture was shaken (180 rpm) horizontally at 37 oC for 1 h. 
Different volumes of the transformation mixture were then spread onto pre-warmed LB agar 
plates supplemented with the appropriate antibiotic and the plates incubated at 37 oC 
overnight. 	
6.4 Genetic Manipulation of Burkholderia 	
6.4.1 Gene Deletions in Burkholderia 
 
In-frame deletions of genes from Burkholderia ambifaria BCC0203 were introduced via a 
double homologous recombination strategy using the suicide plasmid pGPI and the SceI 
expression plasmid pDAI.202 Firstly, the sequences of regions (500-1000 bp) flanking the gene 
targeted for deletion were amplified from B. ambifaria BCC0203 genomic DNA using Q5® 
Hot Start High-Fidelity DNA polymerase. Restriction sites were introduced at the 5’-end of 
the primers to allow for directional cloning of the PCR products into the pGPI vector. 
Constructs were introduced into E. coli SY327 by electroporation and transformants were 
selected on LB agar plates supplemented with trimethoprim (50 µg/mL). Plasmids were 
purified from trimethoprim-resistant colonies using the GeneJET Plasmid Miniprep kit and 
correct assembly of the construct was confirmed by Sanger sequencing (GATC Biotech). 
Validated constructs were introduced into B. ambifaria BCC0203 via triparental mating using 
E. coli SY327 (pGPI) and E. coli HB101 (pRK2013) as the donor and helper strain, 
respectively. and transconjugants were selected using trimethoprim (200 µg/ml) and 
gentamicin (50 µg/ml). Single B. ambifaria mutants were selected and correct integration of 
the mutagenesis plasmids into the genome was confirmed by colony PCR. Next, the pDAI 
plasmid was introduced into the B. ambifaria single crossover mutants by triparental mating 
using E. coli SY327 (pDAI) and E. coli HB101 (pRK2013) as the donor and helper strain, 
respectively. Transconjugants were selected on LB agar plates containing tetracycline 
(200  g/ml) and gentamicin (50 µg/ml). Single B. ambifaria mutants were selected and 
correct gene deletion was confirmed by colony PCR. The mutant strain was then grown on M9 
minimal media in order to remove the pDAI plasmid which was confirmed by the loss of 
tetracycline resistance. In order to generate multi-gene deletion strains the same procedure was 
employed using the appropriate mutant strain in place of the wild-type B. ambifaria BCC0203 
strain. The constructs generated for gene deletions in Burkholderia along with the associated 
primers are shown in table 6.6. 
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Table 6.6: The constructs generated for gene deletions in Burkholderia along with associated primers 
Construct (use) Primer 
pGPI-D5932-5’3’ (deletion of   
PQQ-dependant dehydrogenase 
(5932)) 
5’F: GGCTCTAGACGAGGTGATAGGACGAGGCATC 
5’R: GTCAAGCTTACGCTGCTCGAACTGCCAATG 
3’F: GCCAAGCTTGACGCCGAACAGGGCAAG 
3’R: GCCGAATTCGTTGCTGGTGATCCCGATCGT 
pGPI-D5928-5’3’ (deletion of   
Flavin-dependant halogenase 
(5928)) 
5’F: GACTCTAGAGCGTGCAGTCGGCATCGA 
5’R: GTCAAGCTTGGAACCGGCCTGAGAGGAAC 
3’F: CAGAAGCTTCCGAGCTTGGGCAACTGC 
3’R: TGCGAATTCGGGCGATTGCGGATGAAACC 
pGPI-D5930-31-5’3’ (deletion of 
carbamoyl transferase (5930)  
and non-heme iron-dependent 
halogenase (5931))  
5’F: AGCTCTAGACGGATCGGAACACCTACT 
5’R: GCGAAGCTTTACGAGGCGGATACGTC 
3’F: GGCAAGCTTCCGCGTCATCTTCGTGTAC 
3’R: CAGGAATTCGACCGCCGCAGCTTCTTCAT 
pGPI-D5927-32-5’3’ (deletion of 
all five tailoring enzymes: 5927, 
5928, 5930, 5931 and 5932) 
5’F: GCATCTAGACGAAATCGGCACGGATCT 
5’R: GCAAAGCTTATTACCGATTGGGGCACG 
3’F: GCCAAGCTTGACGCCGAACAGGGCAAG 
3’R: GCCGAATTCGTTGCTGGTGATCCCGATCGT 
pGPI-D5912-5’3’ (deletion of   
dehydratase involved in  
DHCCA biosynthesis 
(5912)) 
5’F: CGCTCTAGACGATGCTCGGCCTGCTCATCTGA 
5’R: CACAAGCTTGGCGGCGGCAGATCGAGT 
3’F: CACAAGCTTGACGGTGCGCTCATGACG 
3’R: CTCGAATTCTGCTCGGGTGCGTCGATG 
pGPI-D5913-5’3’ (deletion of   
dehydrogenase involved in  
DHCCA biosynthesis 
(5913)) 
5’F: CGGTCTAGACGAACTCGAATTCATGGC 
5’R: AGCAAGCTTGAGCGGCGTAACGAACGA 
3’F: GAGAAGCTTTTCGAGCTGTTCACCG 
3’R:	AGAGAATTCCAAGGCCTTCAAGGACG 
pGPI-D5914-5’3’ (deletion of   
enoyl reductase involved in  
DHCCA biosynthesis 
(5914)) 
5’F: CGCTCTAGACTACTCGAACTCGGGGCAAC 
5’R: CTGAAGCTTGATCCGGCCGTTCATCTCG 
3’F: GATAAGCTTGCGACGGTGCTGAGTATGGCT 
3’R: CATGAATTCGCCTGCAGACCTCGCTCTTC 
pGPI-D5916-5’3’ (deletion of   
CoA transferase involved in  
DHCCA biosynthesis 
(5916)) 
5’F: CACTCTAGACGGCCGTCCTCTTCATGGA 
5’R: CACAAGCTTGCCAGCACAATCGCGAGA 
3’F: CCGAAGCTTGGCTTGACATGTCGATCTCCA 
3’R: CACGAATTCGAGAACCTCGCGCTGATCTG 
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pGPI-D5918-5’3’ (deletion of   
enone reductase involved in  
DHCCA biosynthesis 
(5918)) 
5’F: CGCTCTAGACAGATCAGCGCGAGGTTCTC 
5’R: TACAAGCTTGATGCCGACCTGGTGCTG 
3’F: CGCAAGCTTCGGGGAGAACAGTGACATGA 
3’R: GTGGAATTCCCGAGATCGTGGTGCTGT 	
6.4.2 Agarose Gels Confirming Gene Deletions 	
Colony PCR was used to confirm the presence of the gene deletions. Shown in figure 6.1 are 
agarose gels confirming the gene deletions along with the appropriate positive (pGPI 
construct) and negative (B. ambifaria BCC0203 wild-type) controls. 
 
 
 
 
Figure 6.1 Agarose gels confirming the gene deletions in B.ambifaria BCC0203 (d.c. : 
double crossover, fragment sizes are shown in base pairs) 
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6.5 Burkholderia Metobolite Production and Analysis 	
6.5.1 Small-scale Metabolite Production 
 
In order to investigate the effect of the gene deletions on enacyloxin biosynthesis, B. ambifaria 
BCC0203 deletion mutants were grown overnight in LB (5 mL). The cells were harvested and 
resuspended in NaCl (0.9 %) solution, before being spread on a single plate of solid basal salts 
medium (BSM, section 6.2.2). Following incubation for 3 days at 30 oC in the dark, the cells 
were removed, the agar cut into small cubes and extracted with EtOAc (10 mL). The resulting 
extract was concentrated in vacuo, resuspended in MeOH and subjected to UHPLC-ESI-Q-
TOF-MS analysis (see section 6.1), UV absorbance was monitored at 360 nm.  
 
6.5.2 Production and Purification of Enacyloxin Derivatives 
 
For the production of enacyloxin derivatives, the small-scale culture was scaled up to 750 mL 
BSM. Following incubation for 3 days, the cells were scraped off and the agar was extracted 
twice using EtOAc (2 x 500 mL).  The combined extracts were concentrated in vacuo and the 
resulting residue was re-dissolved in MeOH for purification by preparative HPLC (see section 
6.1). Enacyloxin derivative-containing fractions were pooled, concentrated in vacuo, and 
subsequently lyophilized. To avoid photo-induced isomerization of the compounds, exposure 
to light was minimized throughout the entire purification process. 
 
Bromide derivatives were generated using the same procedure, however the ammonium 
chloride in the BSM minimal media was replaced with two equivalents of ammonium 
bromide. For the mutasynthetic production of enacyloxin derivatives, B. ambifaria BCC0203 
wildtype or the relevant mutant strain was grown on BSM supplemented with 10 mM of the 
appropriate DHCCA analogue.  
 
6.5.3 Characterization of Enacyloxin Analogues 
 
Structure elucidation of the enacyloxin derivatives was achieved using a combination of 
UHPLC-ESI-Q-TOF-MS and 1- and 2-D NMR experiments. For NMR analysis, purified 
enacyloxin derivatives were dissolved in CD3OD and 1H, 13C, COSY, HSQC and HMBC 
spectra were recorded on a Bruker Avance 500MHz spectrometer equipped with a DCH 
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cryoprobe at 25 °C. Assignments of enacyloxin analogues produced in section 3.2 are shown 
below in tables 6.7-6.27. 
15-hydroxy-enacyloxin IIa (43) (CD3OD), 1H 500 MHz, 13C 125 MHz. 
 
 
 
Table 6.7: 1H and 13C assignments for enacyloxin analogue 43 
Position 1H (ppm) 13C (ppm) 
1’-COOH  179.5 
1’ 2.55 (br. t, J 11.5) 38.8 
2’ 1.74/2.20-2.14 (br. t, J 8.0/m) 32.4 
3’ 5.22-5.18 (m) 73.1 
4’ 3.74-3.70 (m) 70.5 
5’ 1.85-1.77 (2H) (m) 26.3 
6’ 1.61-1.52/2.07-2.01 (m/m) 27.6 
1  168.5 
2 6.02 (d, J 15.0) 121.3 
3 7.43 (dd, J 15.0, 11.0) 146.8 
4 6.52 (dd, J 15.0, 11.5)  127.8 
5 6.76 (d, J 15.0) 146.6 
6  137.2 
6-Me 1.96 (s) 12.7 
7 6.45-6.40 (m) 137.1 
8 6.76-6.72 (m) 131.7 
9 6.76-6.72 (m) 131.3 
10 6.45-6.40 (m) 127.1 
11  142.0 
12 2.87 (dq, J 9.5, 6.5) 47.4 
12-Me 1.13 (d, J 6.5) 16.2 
13 3.97-3.93 (m) 72.2 
14 3.36 (d, J 8.0) 74.1 
15 3.90 (ddd, J 10.1, 8.0, 2.0) 69.6 
16 2.20/1.48 (ddd, J 14.5, 10.5, 
1.8/ddd, J 14.0, 10.0, 2.0) 
40.3 
17 4.24 (dt, J 10.0, 2.5) 67.6 
18 3.97-93 (m) 72.2 
19 5.29 (t, J 7.5) 75.7 
19-carbamate  158.7 
20 5.57 (ddt, J 15.5, 7.5, 1.5) 126.1 
21 5.89 (dt, J 15.5, 6.5) 139.0 
22 2.10 (qdd, J 7.5, 6.5, 1.5) 26.3 
23 1.01 (t, J 7.5) 13.6 
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11-deschloro-enacyloxin IIa (152) (CD3OD), 1H 500 MHz, 13C 125 MHz. 
 
 
Table 6.8: 1H and 13C assignments for enacyloxin analogue 152 
Position 1H (ppm) 13C (ppm) 
1’-COOH  179.4 
1’ 2.54 (br. t, J 11.0) 39.7 
2’ 1.72/2.19-2.13 (br. t, J 
12.0/m) 
32.7 
3’ 5.22-5.18 (m) 73.3 
4’ 3.75-3.69 (m) 70.7 
5’ 1.84-1.77 (2H) (m) 29.6 
6’ 1.60-51/2.05-1.99 (m/m) 27.9 
1  168.7 
2 5.99 (d, J 15.5) 120.9 
3 7.42 (dd, J 15.0, 11.0) 147.0 
4 6.48 (dd, J 15.0, 11.0)  128.6 
5 6.73 (d, J 15.0) 146.9 
6  135.7 
6-Me 1.94 (s) 12.6 
7 6.35 (d, J 11.0) 137.6 
8 6.41 (dd, J 15.0, 10.5) 137.4 
9  6.48 (dd, J 15.0, 11.5) 126.4 
10 6.29 (dd, J 15.0, 11.0) 132.8 
11 5.86 (dd, J 15.0, 8.5) 140.2 
12 2.60 (tq, J 8.5, 7.5) 41.4 
12-Me 1.10 (d, J 7.0) 17.3 
13 3.73 (dd, J 8.5, 2.5) 76.7 
14 4.22 (d, J 2.5) 79.4 
15  211.7 
16 3.02/2.83 (dd, J 17.0, 8.0/dd, 
J 17.0, 5.0) 
44.7 
17 4.49 (ddd, J 7.5, 4.5, 2.5) 66.7 
18 4.02 (dd, J 8.0, 2.5) 68.0 
19 5.26 (t, J 8.0) 75.5 
19-carbamate  158.6 
20 5.54 (ddt, J 15.5, 7.5, 1.5) 126.1 
21 5.89 (dt, J 15.5, 6.5) 139.2 
22 2.09 (qdd, J 7.5, 6.5, 1.5) 26.3 
23 1.01 (t, J 7.5) 13.6 
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15-hydroxy-decarbamoyl-enacyloxin IIa (45) (CD3OD), 1H 500 MHz, 13C 125 MHz. 
 
 
 
Table 6.9: 1H and 13C assignments for enacyloxin analogue 45 
Position 1H (ppm) 13C (ppm) 
1’-COOH  179.1 
1’ 2.55 (tt, J 11.0, 3.5) 38.6 
2’ 1.74/2.19-2.14 (ddd, J 14.0, 
11.5, 2.0/m) 
32.3 
3’ 5.22-5.18 (m) 73.1 
4’ 3.74-3.70 (m) 71.1 
5’ 1.85-1.77 (2H) (m) 29.4 
6’ 1.61-52/2.07-2.01 (m/m) 27.5 
1  168.5 
2 6.02 (d, J 15.0) 121.2 
3 7.43 (dd, J 15.0, 11.0) 146.9 
4 6.52 (dd, J 15.0, 11.0)  127.4 
5 6.76 (d, J 15.0) 147.0 
6  137.2 
6-Me 1.96 (s) 12.7 
7 6.44-6.40 (m) 137.0 
8 6.75-6.72 (m) 131.7 
9 6.75-6.72 (m) 131.2 
10 6.44-6.40 (m) 127.1 
11  142.0 
12 2.87 (dq, J 9.5, 6.5) 47.5 
12-Me 1.13 (d, J 6.5) 16.1 
13 3.96 (d, J 9.5) 72.2 
14 3.37 (d, J 8.0) 74.1 
15 3.91 (ddd, J 10.0, 8.0, 2.0) 69.5 
16 2.21/1.47 (ddd, J 14.0, 10.0, 
2.0/ddd, J 14.0, 10.0, 2.5) 
40.4 
17 4.45 (dt, J 10.0, 2.5) 67.7 
18 3.75 (dd, J 7.5, 2.0) 70.5 
19 4.27 (t, J 7.5) 74.4 
20 5.59 (ddt, J 15.5, 7.0, 1.5) 126.5 
21 5.82 (dtd, J 15.5, 6.5, 0.5) 136.6 
22 2.10 (qdd, J 7.5, 6.5, 1.0) 26.3 
23 1.02 (t, J 7.5) 13.8 
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18-deschloro-decarbamoyl-enacyloxin IIa (153) (CD3OD), 1H 500 MHz, 13C 125 MHz. 
 
 
 
Table 6.10: 1H and 13C assignments for enacyloxin analogue 153 
Position 1H (ppm) 13C (ppm) 
1’-COOH  179.8 
1’ 2.54 (tt, J 11.5, 3.5) 39.9 
2’ 1.73/2.20-2.13 (ddd, J 14.0, 
11.5, 2.0/m) 
32.4 
3’ 5.22-5.18 (m) 73.2 
4’ 3.73 (ddd, J 9.5, 5.5, 3.0) 70.6 
5’ 1.85-1.77 (2H) (m) 29.5 
6’ 1.56/2.07-2.00 (dtd, J 13.0, 
11.0, 6.0/m) 
27.7 
1  168.5 
2 6.02 (d, J 15.0) 121.4 
3 7.43 (dd, J 15.0, 11.0) 146.8 
4 6.53 (dd, J 15.0, 11.0)  127.2 
5 6.79-6.71 (m) 146.6 
6  137.4 
6-Me 1.96 (s) 12.5 
7 6.41 (d, J 10.0) 136.9 
8 6.79-6.71 (m) 131.5 
9  6.79-6.71 (m) 131.5 
10 6.43 (d, J 10.0) 128.4 
11  140.7 
12 2.94 (dq, J 9.5, 6.5) 47.5 
12-Me 1.18 (d, J 7.0) 16.2 
13 4.06 (dd, J 9.5, 1.5) 74.1 
14 4.23 (d, J 1.5) 78.9 
15  212.1 
16 2.87/2.76 (dd, J 16.5, 7.5/dd, 
J 16.5, 5.0) 
46.6 
17 4.58 (tt, J 7.0, 5.5) 66.5 
18 2.79-2.82 (2H) (m) 47.6 
19  201.3 
20 6.14 (dt, J 16.0, 1.5) 130.8 
21 7.01 (dt, J 16.0, 6.5) 151.8 
22 2.28 (qdd, J 7.5, 6.5, 1.5) 26.6 
23 1.09 (t, J 7.5) 12.6 
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15-hydroxy-18-deschloro-decarbamoyl-enacyloxin IIa (154) (CD3OD), 1H 500 MHz, 13C 
125 MHz. 
 
 
 
Table 6.11: 1H and 13C assignments for enacyloxin analogue 154 
Position 1H (ppm) 13C (ppm) 
1’-COOH  179.3 
1’ 2.58-2.51 (m) 38.7 
2’ 1.74/2.19-2.14 (ddd, J 14.5, 
12.0, 2.5/m) 
32.3 
3’ 5.20 (dt, J 4.5, 2.5) 73.1 
4’ 3.73 (ddd, J 9.5, 5.5, 3.0) 70.5 
5’ 1.84-1.78 (2H) (m) 29.4 
6’ 1.59-52/2.08-2.01 (m/m) 27.5 
1  168.6 
2 6.02 (d, J 15.0) 121.2 
3 7.43 (dd, J 15.0, 11.0) 146.7 
4 6.53 (dd, J 15.0, 11.0)  127.8 
5 6.76 (d, J 15.0) 146.9 
6  137.2 
6-Me 1.96 (s) 12.6 
7 6.44-6.40 (m) 137.1 
8 6.75-6.72 (m) 131.7 
9 6.75-6.72 (m) 131.2 
10 6.44-6.40 (m) 127.1 
11  142.0 
12 2.87 (dq, J 9.5, 6.5) 47.4 
12-Me 1.12 (d, J 6.5) 16.2 
13 3.96 (d, J 10.0) 72.2 
14 3.37 (d, J 8.0) 74.1 
15 3.92 (ddd, J 10.5, 8.0, 2.5) 69.8 
16 2.90/1.52 (ddd, J 14.5, 10.0, 
2.5/ddd, 14.5, 10.0, 3.0) 
42.6 
17 4.15-4.09 (m) 66.3 
18 1.62 (dd, J 7.5, 6.5) 46.5 
19 4.28 (q, J 6.5) 70.3 
20 5.49 (ddt, J 15.5, 6.5, 1.5) 133.5 
21 5.71 (dtd, J 15.5, 6.5, 1.0) 133.4 
22 2.08-2.01 (m) 26.3 
23 1.00 (t, J 7.5) 13.9 
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11-deschloro-14-deshydroxy-15-hydroxy-18-deschloro-decarbamoylenacyloxin IIa (155) 
(CD3OD), 1H 500 MHz, 13C 125 MHz. 
 
 
 
Table 6.12: 1H and 13C assignments for enacyloxin analogue 155 
Position 1H (ppm) 13C (ppm) 
1’-COOH  179.6 
1’ 2.52 (tt, J 11.5, 3.5) 39.4 
2’ 1.73/2.19-2.13 (ddd, J 14.0, 
12.0, 2.0/m) 
32.7 
3’ 5.20 (dt, J 4.5, 2.5) 73.2 
4’ 3.72 (ddd, J 9.5, 6.0, 3.0) 70.7 
5’ 1.84-1.77 (2H) (m) 29.5 
6’ 1.59-51/2.08-1.96 (m/m) 27.9 
1  168.7 
2 6.00 (d, J 15.0) 120.8 
3 7.42 (dd, J 15.0, 11.0) 146.9 
4 6.48 (dd, J 15.0, 11.0)  126.4 
5 6.73 (d, J 15.0) 147.0 
6  135.6 
6-Me 1.94 (s) 12.5 
7 6.34 (d, J 11.5) 137.4 
8 6.57 (dd, J 14.5, 11.5) 128.5 
9 6.40 (dd, J 14.5, 10.5) 137.6 
10 6.25 (dd, J 15.0, 10.5) 132.6 
11 5.83 (dd, J 15.0, 8.5) 139.7 
12 2.34-2.27 (m) 45.0 
12-Me 1.08 (d, J 7.0) 16.9 
13 3.79 (dt, J 9.0, 4.0) 72.7 
14 1.48 (td, J 8.5, 3.5) 43.4 
15 4.09-4.03 (m) 66.4 
16 1.53 (dd, J 6.0, 4.0) 46.6 
17 4.09-4.03 (m) 66.3 
18 1.57 (t, J 6.5) 46.3 
19 4.25 (q, J 6.5) 70.3 
20 5.48 (ddt, J 15.5, 6.5, 1.5) 133.3 
21 5.69 (dtd, J 15.5, 6.5, 0.5) 133.6 
22 2.08-2.01 (m) 26.2 
23 1.00 (t, J 7.5) 14.0 
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3’-epi-enacyloxin IIa (166) (CD3OD), 1H 500 MHz, 13C 125 MHz. 
 
 
 
Table 6.13: 1H and 13C assignments for enacyloxin analogue 166 
Position 1H (ppm) 13C (ppm) 
1’-COOH  179.4 
1’ 2.45 (br. t, J 11.5) 42.5 
2’ 1.54-1.42 (2H) (m) 33.8 
3’ 4.68 (ddd, J 11.0, 9.0, 4.5) 74.1 
4’ 3.58 (td, J 10.0, 4.5) 72.5 
5’ 2.28-2.22/1.54-1.42 (m/m) 33.1 
6’ 2.02-1.98/1.54-1.42 (m/m) 28.1 
1  168.6 
2 5.98 (d, J 15.5) 121.3 
3 7.41 (dd, J 15.0, 11.0) 146.6 
4 6.52 (dd, J 15.0, 11.5)  128.4 
5 6.78-6.70 (1H) (m) 146.8 
6  137.4 
6-Me 1.95 (s) 12.6 
7 6.45-6.39 (1H) (m) 136.9 
8 6.78-6.70 (1H) (m) 131.6 
9 6.78-6.70 (1H) (m) 131.5 
10 6.45-6.39 (1H) (m) 127.2 
11  140.7 
12 2.94 (dq, J 9.5, 7.0) 47.6 
12-Me 1.19 (d, J 6.5) 16.2 
13 4.06-4.02 (1H) (m) 77.7 
14 4.23 (d, J 1.5) 78.9 
15  211.4 
16 3.04/2.83 (dd, J 17.0, 8.0/dd, 
J 17.0, 5.0) 
44.5 
17 4.51 (ddd, J 7.5, 4.5, 2.5) 66.8 
18 4.06-4.02 (1H) (m) 67.9 
19 5.27 (t, J 8.0) 75.5 
19-carbamate  158.6 
20 5.55 (ddt, J 15.5, 7.5, 1.5) 126.2 
21 5.89 (dt, J 15.5, 6.5) 139.2 
22 2.13-2.06 (m) 26.3 
23 1.01 (t, J 7.5) 13.6 
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5’-hydroxy-enacyloxin IIa (167) (CD3OD), 1H 500 MHz, 13C 125 MHz. 
 
 
 
Table 6.14: 1H and 13C assignments for enacyloxin analogue 167 
Position 1H (ppm) 13C (ppm) 
1’-COOH  178.5 
1’ 2.68-2.64 (m) 38.8 
2’ 1.72-1.67/2.11-2.06 (m/m) 32.9 
3’ 5.30 (q, J 3.0) 73.7 
4’ 3.45 (dd, J 9.5, 3.0) 74.4 
5’ 3.82 (ddd, J 11.5, 9.5, 5.0) 69.9 
6’ 1.51-1.46/2.25-2.21 (m/m) 35.7 
1  168.4 
2 6.00 (d, J 15.0) 121.2 
3 7.40 (dd, J 15.0, 11.0) 147.0 
4 6.52 (dd, J 15.0, 11.0)  127.4 
5 6.74 (d, J 15.0) 146.6 
6  137.5 
6-Me 1.95 (br, s) 12.6 
7 6.41 (br. d, J 10.0) 137.5 
8 6.75 (dd, J 15.0, 10.0) 132.2 
9 6.72 (dd, J 15.0, 10.0) 131.5 
10 6.43 (d, J 10.0) 128.4 
11  140.7 
12 2.93 (dq, J 9.5, 6.5) 47.6 
12-Me 1.19 (d, J 6.5) 16.3 
13 4.04 (br. d, J 9.5) 74.2 
14 4.22 (d, J 1.5) 79.0 
15  211.5 
16 2.82/3.03 (dd, J 17.0, 4.5/dd, 
J 17.0, 8.0) 
44.6 
17 4.52-4.47 (m) 66.8 
18 4.07-4.00 (m) 68.0 
19 5.26 (dd, J 8.0, 7.5) 75.9 
19-carbamate  158.7 
20 5.54 (ddt, J 15.5, 7.5, 1.5) 126.2 
21 5.88 (dt, J 15.0, 6.5) 139.2 
22 2.09 (qdd, J 8.0, 6.5, 1.5) 26.4 
23 1.01 (t, J 7.5) 13.7 
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cyclopentyl-enacyloxin IIa (177) (CD3OD), 1H 500 MHz, 13C 125 MHz. 
  
 
 
Table 6.15: 1H and 13C assignments for enacyloxin analogue 177 
Position 1H (ppm) 13C (ppm) 
1’-COOH  180.8 
1’ 2.25 (dt, J 13.0, 6.0) 40.2 
2’ 2.14-2.01 (2H) (m) 35.8 
3’ 5.13-5.08 (m) 74.1 
4’ 4.30 (q, J 5.0) 73.2 
5’ 2.14-2.01 (m/m) 33.0 
1  168.5 
2 6.00 (d, J 15.0) 121.1 
3 7.43 (dd, J 15.0, 11.0) 146.6 
4 6.52 (dd, J 15.0, 11.5)  128.4 
5 6.79-6.70 (1H) (m) 146.9 
6  137.4 
6-Me 1.95 (s) 12.6 
7 6.45-6.39 (1H) (m) 137.0 
8 6.79-6.70 (1H) (m) 131.6 
9 6.79-6.70 (1H) (m) 131.6 
10 6.45-6.39 (1H) (m) 127.2 
11  140.7 
12 2.94 (dq, J 9.5, 7.0) 47.5 
12-Me 1.19 (d, J 6.5) 16.2 
13 4.06-4.02 (1H) (m) 77.4 
14 4.24 (d, J 1.5) 78.9 
15  211.5 
16 3.05/2.83 (dd, J 17.0, 8.0/dd, 
J 17.0, 4.5) 
44.5 
17 4.51 (ddd, J 7.5, 4.5, 2.5) 66.8 
18 4.07-4.03 (1H) (m) 67.9 
19 5.27 (t, J 7.5) 75.5 
19-carbamate  158.6 
20 5.55 (ddt, J 15.5, 7.5, 1.5) 126.2 
21 5.89 (dt, J 15.0, 6.5) 139.2 
22 2.14-2.05 (m) 26.3 
23 1.01 (t, J 7.5) 13.6 
 
Identical spectra was obtained for epi-cyclopentyl-enacyloxin IIa (178). 
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1’,6’-dehydro-enacyloxin IIa (187) (CD3OD), 1H 500 MHz, 13C 125 MHz. 
 
 
Table 6.16: 1H and 13C assignments for enacyloxin analogue 187 
Position 1H (ppm) 13C (ppm) 
1’-COOH  171.2 
1’  130.1 
2’ 2.74-2.55 (2H) (m) 32.6 
3’ 5.15-5.09 (m) 72.8 
4’ 4.08-4.02 (m) 66.9 
5’ 2.74-2.55 (2H) (m) 28.6 
6’ 6.88 (br. s) 136.9 
1  168.5 
2 5.99 (d, J 16.0) 121.0 
3 7.42 (dd, J 15.0, 11.0) 146.6 
4 6.51 (dd, J 15.0, 11.5)  128.3 
5 6.77-6.67 (1H) (m) 146.9 
6  137.3 
6-Me 1.95 (s) 12.6 
7 6.45-6.48 (1H) (m) 136.9 
8 6.77-6.67 (1H) (m) 131.5 
9  6.77-6.67 (1H) (m) 131.5 
10 6.45-6.48 (1H) (m) 127.0 
11  140.6 
12 2.93 (dq, J 9.5, 6.5) 47.4 
12-Me 1.18 (d, J 6.0) 16.2 
13 4.08-4.02 (m) 74.0 
14 4.23 (br. s) 78.8 
15  211.4 
16 3.04/2.83 (dd, J 17.0, 8.0, 
2.1/dd, J 17.5, 4.5) 
44.4 
17 4.53-4.48 (m) 66.7 
18 4.05 (dd, J 4.5, 1.5) 67.8 
19 5.27 (t, J 7.5) 75.4 
20 5.55 (dd, J 15.5, 7.5) 126.0 
21 5.89 (dt, J 15.0, 6.5) 139.1 
22 2.09 (dt, J 14.0, 7.0) 26.2 
23 1.02 (t, J 7.5) 13.5 
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1’,6’-dehydro-15-hydroxy-decarbamoylenacyloxin IIa (204) (CD3OD), 1H 500 MHz, 13C 
125 MHz. 
 
 
 
Table 6.17: 1H and 13C assignments for enacyloxin analogue 204 
Position 1H (ppm) 13C (ppm) 
1’-COOH  170.4 
1’  129.1 
2’ 2.65-2.53 (2H) (m) 32.6 
3’ 5.14-5.10 (m) 72.9 
4’ 4.07-4.03 (m) 66.9 
5’ 2.49-2.42 (1H) (m), 2.65-
2.53 (1H) (m) 
28.6 
6’ 6.88 (br. s) 137.1 
1  168.6 
2 5.98 (d, J 15.0) 121.1 
3 7.42 (dd, J 15.0, 11.0) 146.7 
4 6.51 (dd, J 15.5, 11.5)  127.8 
5 6.77-6.71 (1H) (m) 147.0 
6  137.2 
6-Me 1.95 (s) 12.6 
7 6.45-6.40 (1H) (m) 137.1 
8 6.77-6.71 (1H) (m) 131.8 
9  6.77-6.71 (1H) (m) 131.2 
10 6.45-6.40 (1H) (m) 127.1 
11  142.1 
12 2.87 (dq, J 9.5, 6.5) 47.5 
12-Me 1.12 (d, J 6.5) 16.1 
13 3.96 (dd, J 9.5, 0.5) 72.2 
14 3.36 (dd, J 8.0, 0.5) 74.1 
15 3.90 (ddd,  J 10.0, 8.0, 2.0) 69.5 
16 2.21/1.46 (ddd, J 14.0, 10.0, 
2.1/ddd, J 14.0, 10.0, 2.5) 
40.4 
17 4.44 (dt, J 10.0, 2.5) 67.7 
18 3.74 (dd, J 7.5, 2.0) 70.1 
19 4.27 (t, 7.5) 74.4 
20 5.58 (ddt, J 15.5, 7.0, 1.5) 130.1 
21 5.81 (dtd, J 15.5, 6.5, 0.5) 136.6 
22 2.13-2.06 (m) 26.4 
23 1.02 (t, J 7.5) 13.8 
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11-bromo-18-deschloroenacyloxin IIa (194) (CD3OD), 1H 500 MHz, 13C 125 MHz. 
 
 
 
Table 6.18: 1H and 13C assignments for enacyloxin analogue 194 
Position 1H (ppm) 13C (ppm) 
1’-COOH  179.4 
1’ 2.58-2.47 (m) 39.1 
2’ 1.75-1.71/2.19-2.13 (m/m) 32.6 
3’ 5.22-5.19 (m) 73.3 
4’ 3.73 (ddd, J 8.5, 6.0, 3.0) 70.7 
5’ 1.84-1.79 (m) 29.5 
6’ 1.57-1.50/2.03-2.00 (m/m) 27.8 
1  168.6 
2 6.03 (d, J 15.5) 121.5 
3 7.43 (dd, J 15.0, 11.5) 146.8 
4 6.55 (dd, J 15.0, 11.0) 127.4 
5 6.76 (d, J 15.0) 146.6 
6  137.7 
6-Me 1.95 (s) 12.7 
7 6.41 (d, J 12.0) 136.8 
8 6.82 (dd, J 13.6, 11.0) 132.2 
9 6.70-6.63 (m) 133.7 
10 6.35 (d, J 11.5) 136.6 
11  136.1 
12 2.89-2.84 (m) 49.6 
12-Me 1.17 (d, J 7.0) 17.3 
13 4.05 (dd, J 10.0, 1.5) 74.6 
14 4.23 (d, J 1.5) 78.9 
15 
 
212.0 
16 2.83/2.66  
(dd, J 16.5, 8.5/dd, J 16.5, 
4.0) 
47.2 
17 4.20 (tt, J 8.5, 3.5) 65.2 
18 1.80/1.65 (ddd, J 14.0, 10.0/ 
ddd, J 14.0, 9.5, 3.5) 
43.8 
19 5.23 (ddd, J 10.0, 7.0, 3.5) 73.0 
19-carbamate 
 
159.7 
20 5.45 (ddt, J 15.5, 7.5, 1.5) 129.3 
21 5.78 (dt, J 15.5, 6.5) 135.8 
22 
23  
2.05 (dq, J 7.5, 1.0) 
0.99 (t, J 7.5) 
26.2 
13.7 
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11-bromo-enacyloxin IIa (195) (CD3OD), 1H 500 MHz, 13C 125 MHz. 
 
 
 
Table 6.19: 1H and 13C assignments for enacyloxin analogue 195 
Position 1H (ppm) 13C (ppm) 
1’-COOH  179.5 
1’ 2.58-2.48 (m) 39.0 
2’ 1.76-1.70/2.19-2.14  
(m/m) 
32.5 
3’ 5.23-5.18 (m) 73.2 
4’ 3.76-3.70 (m) 70.6 
5’ 1.84-1.79 (m) 29.5 
6’ 1.62-1.50/2.06-2.01 (m/m) 27.7 
1  168.6 
2 6.03 (d, J 15.5) 121.4 
3 7.43 (dd, J 15.0, 11.0) 146.8 
4 6.55 (dd, J 15.0, 11.0) 127.4 
5 6.76 (d, J 15.0) 146.6 
6  137.7 
6-Me 1.96 (s) 12.7 
7 6.41 (d, J 11.5) 136.8 
8 6.82 (dd, J 13.5, 11,5) 132.3 
9 6.70-6.65 (m) 133.7 
10 6.34 (d, J 11.5) 136.6 
11  136.0 
12 2.90-2.84 (m) 47.7 
12-Me 1.17 (d, J 6.5) 17.3 
13 4.04 (dd, J 8.0, 2.0) 74.7 
14 4.24 (d, J 1.5) 78.9 
15 
 
211.5 
16 2.84/3.04  
(dd, J 17.0, 4.0/dd, J 17.0, 
8.5)  
44.6 
17 4.51 (ddd, J 7.0, 4.5, 2.5) 66.8 
18 4.07-4.05 (m) 67.9 
19 5.27 (t, J 8.0) 75.5 
19-carbamate 
 
158.6 
20 5.55 (ddt, J 15.0, 7.5, 1.5) 126.2 
21 5.90 (dt, J 15.5, 6.5) 139.3 
22 
23  
2.13-2.06 (m) 
1.02 (t, J 7.5) 
26.3 
13.6 
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11,18-dibromo-enacyloxin IIa (196) (CD3OD), 1H 500 MHz, 13C 125 MHz. 
 
 
 
Table 6.20: 1H and 13C assignments for enacyloxin analogue 196 
Position 1H (ppm) 13C (ppm) 
1’-COOH  179.5 
1’ 2.58-2.47 (m) 39.0 
2’ 1.76-1.70/2.19-2.13 (m/m) 32.5 
3’ 5.23-5.18 (m) 73.2 
4’ 3.73 (ddd, J 8.5, 6.0, 3.0) 70.6 
5’ 1.85-1.78 (m) 29.5 
6’ 1.61-1.51/2.04-2.00 (m/m) 27.7 
1  168.5 
2 6.03 (d, J 15.0) 121.5 
3 7.43 (dd, J 15.0, 11.0) 146.8 
4 6.55 (dd, J 15.0, 11.0) 127.4 
5 6.76 (d, J 15.0) 146.6 
6  137.7 
6-Me 1.96 (s) 12.7 
7 6.41 (d, J 11.5) 136.8 
8 6.82 (dd, J 13.5, 11.5) 132.3 
9 6.63 (dd, J 13.5, 11.5) 133.7 
10 6.35 (d, J 11.5) 136.6 
11  136.0 
12 2.90-2.86 (m) 49.6 
12-Me 1.17, (d, J 7.0) 17.3 
13 4.04 (dd, J 10.0, 1.5) 74.7 
14 4.23 (d, J 1.5) 78.9 
15 
 
211.4 
16 2.84/3.04 (dd, J 14.0, 4.5/dd 
J 17.0, 8.0) 
45.9 
17 4.40-4.36 (m) 66.5 
18 4.17 (dd, J 8.0, 2.5) 62.7 
19 5.31 (t, J 8.0) 75.7 
19-carbamate 
 
158.6 
20 5.55 (ddt, J 15.5, 7.5, 1.5) 126.9 
21 5.89 (dt, J 15.5, 6.5) 139.2 
22 
23  
2.10 (dq, J 7.5, 1.0) 
1.02 (t, J 7.5) 
26.3 
13.6 
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11-bromo-15-hydroxy-18-deschloro-decarbamoylenacyloxin IIa (197) (CD3OD), 1H 500 
MHz, 13C 125 MHz. 
 
 
 
Table 6.21: 1H and 13C assignments for enacyloxin analogue 197 
Position 1H (ppm) 13C (ppm) 
1’-COOH  179.4 
1’ 2.59-2.48 (m) 38.8 
2’ 1.76-1.70/2.20-2.13 (m/m) 32.4 
3’ 5.22-5.18 (m) 73.1 
4’ 3.75-3.70 (m) 70.5 
5’ 1.84-1.79 (m) 29.5 
6’ 1.63-1.57/2.03-2.00 (m/m) 27.6 
1  168.5 
2 6.03 (d, J 15.0) 121.4 
3 7.43 (dd, J 15.0, 11.0) 146.8 
4 6.54 (dd, J 15.0, 11.0) 127.2 
5 6.76 (d, J 15.0) 146.6 
6  137.5 
6-Me 1.96 (s) 12.7 
7 6.41 (d, J 11.5) 137.0 
8 6.81 (dd, J 14.0, 11.5) 131.9 
9 6.72-6.63 (m) 133.6 
10 6.35 (d, J 11.5) 136.7 
11  137.5 
12 2.80 (dq, J 10.0, 6.5) 49.6 
12-Me 1.11 (d, J 6.5) 17.2 
13 3.95 (d, J 9.5) 72.8 
14 3.36 (d, J 8.0) 74.0 
15 3.93-3.89 (m) 69.9 
16 1.52/1.90 (ddd, J 14.0, 10.0, 
2.5/ddd, J 14.0, 10.0, 2.5) 
42.7 
17 4.12 (tt, J 10.0, 3.0) 66.3 
18 1.57-1.66 (m) 46.5 
19 4.28 (dt, J 6.5, 6.0) 70.3 
20 5.50 (ddt, J 15.5, 7.0, 1.5) 133.4 
21 5.71 (dt, J 15.5, 6.5)  134.0 
22 2.06 (dq, J 7.5, 1.0) 26.3 
23 1.01 (t, J 7.5) 14.0 
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11-bromo-15-hydroxy-decarbamoylenacyloxin IIa (198) (CD3OD), 1H 500 MHz, 13C 125 
MHz. 
 
 
 
Table 6.22: 1H and 13C assignments for enacyloxin analogue 198 
Position 1H (ppm) 13C (ppm) 
1’-COOH  179.4 
1’ 2.59-2.47 (m) 38.9 
2’ 1.76-1.70/2.19-2.16 (m/m) 32.5 
3’ 5.22-5.18 (m) 73.2 
4’ 3.74-3.70 (m) 70.6 
5’ 1.85-1.79 (m) 29.5 
6’ 1.61-1.54/2.05-2.01 (m/m) 27.7 
1  168.5 
2 6.03 (d, J 15.0) 121.4 
3 7.43 (dd, J 15.0, 11.0) 146.8 
4 6.55 (dd, J 15.0, 11.5) 127.3 
5 6.76 (d, J 15.0) 146.6 
6  137.5 
6-Me 1.96 (s) 12.7 
7 6.42 (d, J 11.5) 137.0 
8 6.81 (dd, J 14.5, 11.5) 131.9 
9 6.73-6.65 (m) 134.0 
10 6.35 (d, J 11.5) 136.7 
11  137.4 
12 2.80 (dq, J 9.5, 6.5) 49.6 
12-Me 1.11 (d, J 6.5) 17.2 
13 3.95 (d, J 9.5) 72.9 
14 3.36 (d, J 8.5) 74.1 
15 3.93-3.88 (m) 69.6 
16 1.46/2.24-2.20 (ddd, J 14.0, 
10.0, 2.5/m) 
40.5 
17 4.27 (t, J 7.5) 74.4 
18 3.74 (dd, J 7.5, 2.5) 71.1 
19 4.47-4.43 (m) 67.8 
20 5.59 (ddt, J 15.5, 7.0, 1.5) 130.6 
21 5.82 (dt, J 15.5, 6.5)  136.6 
22 2.10 (dq, J 7.5, 1.5) 26.4 
23 1.03 (t, J 7.5) 13.8 
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11,18-dibromo-15-hydroxy-decarbamoylenacyloxin IIa (199) (CD3OD), 1H 500 MHz, 13C 
125 MHz. 
 
 
 
Table 6.23: 1H and 13C assignments for enacyloxin analogue 199 
Position 1H (ppm) 13C (ppm) 
1’-COOH  179.4 
1’ 2.61-2.48 (m) 38.8 
2’ 1.76-1.69/2.17-2.14 (m/m) 32.4 
3’ 5.24-5.18 (m) 73.2 
4’ 3.73 (ddd, J 8.5, 6.0, 3.0) 70.6 
5’ 1.85-1.78 (m) 29.5 
6’ 1.62-1.52/2.06-2.01 (m/m) 27.6 
1  168.5 
2 6.03 (d, J 15.5) 121.4 
3 7.43 (dd, J 15.0, 11.0) 146.8 
4 6.55 (dd, J 15.0, 11.0) 127.3 
5 6.76 (d, J 15.0) 146.6 
6  137.5 
6-Me 1.96 (s) 12.7 
7 6.42 (d, J 11.5) 137.0 
8 6.81 (dd, J 14.5, 11.5) 131.9 
9 6.65-6.72 (m) 134.0 
10 6.35 (d, J 11.5) 136.7 
11  137.3 
12 2.80 (dq, J 9.5, 6.5) 49.6 
12-Me 1.11 (d, J 6.5) 17.2 
13 3.95 (d, J 9.5) 72.9 
14 3.36 (d, J 8.0) 74.1 
15 3.90-3.88 (m) 69.5 
16 1.46/2.21 (ddd, J 14.0, 10.0, 
2.5/ddd, J 14.0, 10.0, 2.5) 
41.8 
17 4.35-4.29 (m) 67.6 
18 3.92 (dd, J 7.5, 2.5) 66.7 
19 4.35-4.29 (m) 74.7 
20 5.59 (ddt, J 15.5, 7.0, 1.5) 130.7 
21 5.81 (dt, J 15.5, 6.5) 136.6 
22 2.10 (dq, J 7.5, 1.5) 26.3 
23 1.03 (t, J 7.5) 13.8 
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11-bromo-18-deschloro-decarbamoylenacyloxin IIa (200) (CD3OD), 1H 500 MHz, 13C 125 
MHz. 
 
 
 
Table 6.24: 1H and 13C assignments for enacyloxin analogue 200 
Position 1H (ppm) 13C (ppm) 
1’-COOH  179.4 
1’ 2.58-2.46 (m) 38.9 
2’ 1.79-1.69/2.19-2.13 (m/m) 32.8 
3’ 5.23-5.18 (m) 73.4 
4’ 3.72 (ddd, J 8.5, 6.0, 3.0) 70.8 
5’ 1.83-1.78 (m) 29.6 
6’ 1.63-1.49/2.06-1.99 (m/m) 26.6 
1  168.6 
2 6.03 (d, J 15.5) 121.5 
3 7.43 (dd, J 15.0, 11.0) 146.7 
4 6.55 (dd, J 15.0, 11.0) 127.4 
5 6.76 (d, J 15.0) 146.5 
6  137.7 
6-Me 1.96 (s) 12.6 
7 6.41 (d, J 11.5) 136.8 
8 6.82 (dd, J 14.0, 11.5) 132.2 
9 6.65-6.62 (m) 133.7 
10 6.35 (d, J 11.5) 136.6 
11  136.0 
12 2.81-2.79 (m) 46.6 
12-Me 1.17 (d, J 6.5) 17.3 
13 4.05 (dd, J 10.0, 2.0) 74.7 
14 4.23 (d, J 1.5) 78.9 
15 
 
212.1 
16 2.87 (dd, J 16.5, 7.0) 47.6 
17 2.82-2.79 (m) 47.5 
18 4.61-4.55 (m) 65.5 
19 
 
201.3 
20 6.14 (dt, J 16.0, 1.5) 130.8 
21 7.01 (dt, J 160, 6.5) 151.8 
22 2.28 (dq, J 7.5, 1.5) 26.6 
23 1.10 (t, J 7.5) 12.7 
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11,18-dibromo-decarbamoylenacyloxin IIa (201) (CD3OD), 1H 500 MHz, 13C 125 MHz. 
 
 
 
Table 6.25: 1H and 13C assignments for enacyloxin analogue 201 
Position 1H (ppm) 13C (ppm) 
1’-COOH  179.4 
1’ 2.58-2.49 (m) 38.9 
2’ 1.77-1.69/2.20-2.16 (m, m) 32.5 
3’ 5.22-5.18 (m) 73.2 
4’ 3.73 (ddd, J 8.5, 6.0, 3.0) 70.6 
5’ 1.85-1.78 (m) 29.5 
6’ 1.61-1.52/2.06-2.00 (m/m) 27.7 
1  168.5 
2 6.03 (d, J 15.0) 121.4 
3 7.43 (dd, J 15.0, 11.0) 146.8 
4 6.55 (dd, J 15.0, 11.0) 127.3 
5 6.76 (d, J 15.0) 146.6 
6  137.6 
6-Me 1.95 (s) 12.7 
7 6.41 (d, J 11.5) 136.9 
8 6.81 (dd, J 14.2, 11.5) 132.1 
9 6.71-6.64 (m) 133.8 
10 6.35 (d, J 11.5) 136.6) 
11  137.3 
12 2.82 (dq, J 9.5, 6.5) 49.6 
12-Me 1.10 (d, J 6.5) 17.1 
13 4.16 (d, J 9.5) 73.3 
14 3.45 (d, J 1.0) 73.4 
15 
 
100.5 
16 2.44/1.54 (dd, J 13.0, 5.0, dd, 
J 13.0, 1.5) 
43.0 
17 3.49 (t, J 10.0) 61.5 
18 4.08-4.01 (m) 70.9 
19 4.46 (dd, J 10.0, 7.0) 74.9 
20 5.54 (ddt, J 15.5, 7.0, 1.5) 128.0 
21 5.83 (dt, J 15.5, 6.5) 137.8 
22 2.10 (dq, J 7.5, 1.5) 26.4 
23 1.02 (t, J 7.5) 13.8 
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11-bromo-14-deshydroxydecarbamoylenacyloxin IIa (202) (CD3OD), 1H 500 MHz, 13C 
125 MHz. 
 
 
Table 6.26: 1H and 13C assignments for enacyloxin analogue 202 
Position 1H (ppm) 13C (ppm) 
1’-COOH  179.4 
1’ 2.55-2.46 (m) 38.9 
2’ 1.76-1.69/2.19-2.14 (m/m) 32.6 
3’ 5.23-5.18 (m) 73.3 
4’ 3.73 (ddd, J 8.5, 6.0, 3.0) 70.8 
5’ 1.83-1.79 (m) 29.6 
6’ 1.64-1.47/2.06-1.99 (m/m) 26.3 
1  168.5 
2 6.03 (d, J 15.5) 121.5 
3 7.43 (dd, J 15.0 11.0) 146.7 
4 6.55 (dd, J 15.0, 11.0) 127.4 
5 6.76 (d, J 15.0) 146.5 
6  137.8 
6-Me 1.96 (s) 12.7 
7 6.41 (d, J 11.5) 136.8 
8 6.83 (dd, J 14.0, 11.5) 132.4 
9 6.65-6.60 (m) 133.7 
10 6.35 (d, J 11.5) 136.5 
11  134.6 
12 2.70-2.58 (m) 51.8 
12-Me 1.13 (d, J 7.0) 16.5 
13 4.24 (td, J 8.0, 3.5) 70.7 
14 2.70-2.58 (m) 49.1 
15 
 
209.6 
16 2.90/2.78 (dd, J 17.0, 8.0/dd, 
J 17.0, 5.0) 
50.5 
17 4.48-4.44 (m) 66.6 
18 3.99 (dd, J 8.0, 2.5) 67.8 
19 5.26 (t, J 8.0) 75.5 
19-carbamate 
 
158.6 
20 5.54 (ddt, J 15.5, 7.5, 1.5) 126.2 
21 5.89 (dt, J 15.5, 6.5) 139.2 
22 
23  
2.10 (dq, J 7.5, 1.0) 
1.01 (t, J 7.5) 
26.3 
13.6 
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11,18-dibromo-14-deshydroxydecarbamoylenacyloxin IIa (203) (CD3OD), 1H 500 MHz, 
13C 125 MHz. 
 
 
 
Table 6.27: 1H and 13C assignments for enacyloxin analogue 203 
Position 1H (ppm) 13C (ppm) 
1’-COOH  179.3 
1’ 2.58-2.49 38.8 
2’ 1.77-1.69/2.20-2.13 (m/m) 32.4 
3’ 5.24-5.17 (m) 73.1 
4’ 3.73 (ddd, J 8.5, 6.0, 3.0) 70.7 
5’ 1.85-1.78 (m) 29.5 
6’ 1.62-1.51/2.07-2.00 (m/m) 27.6 
1  168.5 
2 6.03 (d, J 15.0) 121.5 
3 7.43 (dd, J 15.0,11.0) 146.9 
4 6.55 (dd, J 15.0, 11.0) 127.4 
5 6.76 (d, J 15.0) 146.6 
6  137.8 
6-Me 1.96 (s) 12.7 
7 6.41 (d, J 11.5) 136.8 
8 6.83 (dd, J 13.5, 11.5) 132.4 
9 6.68-6.61 (m) 133.8 
10 6.35 (d, J 11.5) 136.5 
11  134.7 
12 2.71-2.58 (m) 51.8 
12-Me 1.13 (d, J 7.0) 16.5 
13 4.24 (td, J 8.0, 3.5) 70.5 
14 2.71-2.58 (m) 49.0 
15 
 
209.5 
16 2.90/2.78 (dd, J 17.0, 8.0/dd, 
J 17.0, 4.5) 
50.4 
17 4.31-4.35 (m) 66.3 
18 4.12 (dd, J 8.0, 2.5) 62.6 
19 5.30 (t, J 8.0) 75.7 
19-carbamate 
 
158.6 
20 5.54 (ddt, J 15.5, 7.5, 1.5) 126.9 
21 5.89 (dt, J 15.5, 6.5) 139.2 
22 
23  
2.10 (dq, J 7.5, 1.0) 
1.01 (t, J 7.5) 
26.3 
13.6 
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6.5.4 Minimum Inhibitory Concentration (MIC) Assays 
 
MIC values were determined using the broth microdilution method according to the official 
CLSI guidelines. Briefly, Acinetobacter baumannii test strains (ATCC17978 and DSM25645) 
were grown overnight in MH broth at 37 ºC. In a 96-well microtiter plate, 50 µL of serial 
twofold dilutions of an enacyloxin derivative in MH broth were mixed with 50 µL of bacterial 
suspension, diluted to a concentration of 106 cell-forming units (CFU)/ml in MH broth. The 
desired inoculum density was achieved using a 0.5 McFarland turbidity standard. Following 
incubation for 18 h at 37°C, MICs were defined as the lowest concentrations that visibly 
inhibited bacterial growth. All MIC determinations were performed in triplicate.  
 
6.6 Recombinant Protein Overproduction and Purification 	
6.6.1 Recombinant Protein Expression Constructs 	
The constructs used for recombinant protein overproduction in E.coli are shown in tables 6.28 
and 6.29 along with the primers used for cloning and the cell line employed for 
overproduction. All DNA inserts were either amplified form the genomic DNA of 
Burkholderia ambifaria BCC0203, Burkholderia gladioli BCC0238 or Vibrio rhizosphaerae. 
Correct assembly of each construct was confirmed by Sanger sequencing (GATC Biotech). 
Constructs GbnD5-DH-ACP and GbnD5-ACP were generated by Dr. Matt Jenner. 
 
Table 6.28: The primers used to generate constructs (Dr. Matt Jenner) for recombinant protein 
overproduction in E.coli in order to investigate the functionality of the diene synthase and VbxP 
(Sections 2.1.4/4.2.2.1). 
Construct Cell Line Primer 
GbnD5-DH-ACP BL21(DE3) 
 
F: CACCATGACTCATCGCCATGCA 
R: TCATGCAGCCACCGATTCGCT 
GbnD5-ACP BL21(DE3) 
 
F: CACCGTGGCGGCCGGGTACGA 
R: TCATGCAGCCACCGATTCGCT 
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Table 6.29: The primers used to generate constructs for recombinant protein overproduction in E.coli in 
order to investigate DHCCA biosynthesis (Section 4.2). 
Construct Cell Line Primer 
pET-151-5914  BL21(DE3) 
C43(DE3) 
F: CACCATGAAAGCCATACTCAGCACC 
R: CTCAGACCAGCGCCTCGT 
pET-151-5916  BL21(DE3) 
C43(DE3) 
F: CACCATGTCAAGCCAAGCACAGT 
R: CTCACAGGCTTGCCGCTT 
pET-151-VbxP  C43(DE3) F: CACCCTAAAACAACCGCCCCCTCTA 
R: TCAGTTAGTTTCATCTTTAAGGGGGACTTG 
pET-151-VbxK C43(DE3) F: CACCTCGCTTTTTTCATCATTTGAACTTGG 
R: TCTAAGTGGCAGACGACCAAG 
pET-151-VbxN BL21(DE3) 
C43(DE3) 
F: CACCAGAGCTTTACTAAGTAAAACAACGGGA 
R: CCTAAAGGGCATCGATTGAGTGTTTTA 
pET-151-VbxL BL21(DE3) 
 
F: CACCAATTTATCAAATATACCGAGTTTGGCA 
R: TTAAAGACATAGACTTTCCTCTACCCGA  
pET-151-VbxM BL21(DE3) 
 
F: CACCTCTTTAAATGATTTGCAAGTTCCTG 
R: GACGCATCAGTTAAGTATTCTATGC 
pET-28a-VbxN BL21(DE3) 
 
F: GAGCATATGAGAGCTTTACTAAGTAAAACAACGG 
R: ATAGTCCACGGCATCGATTGAGTGTTTTAAT 
 
6.6.2 Site-Directed Mutagenesis 	
Site-directed mutagenesis was conducted using the Q5® Site-Directed Mutagenesis Kit. 
Mutant plasmids were first amplified from the wild-type construct using Q5® hot start high 
fidelity polymerase and the resulting linear plasmid was purified using the GeneJET PCR 
Purification kit. The PCR product (1 µl) was then incubated with the kinase, ligase and DpnI 
(KLD) mix (1 µL) along with the KLD buffer (5 µL) and H2O (3 µL). The reaction was left at 
RT for 5 min before transformation (E.coli TOP10). Mutagenesis constructs, primers used for 
cloning and the cell line employed for overproduction are shown in table 6.30. The GbnD5-
DH-ACP (H158Y) construct was generated by Dr. Matt Jenner. 
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Table 6.30: The constructs generated for site-directed mutagenesis (codon change underlined). 
Construct Cell Line Primer 
pET-151-VbxP 
(D171S) 
BL21(DE3) 
 
F: GCCTGTCGCTTCTATGTATGCG 
R: ATTCTCATCAGTGGTGGC 
GbnD5-DH-ACP 
(H158Y) 
BL21(DE3) 
 
F: CGGCGTGGTATATGGCCCGTTCATGC 
R: AGCTCGCGCACGCCGCGA 
 
6.6.3 Recombinant Protein Overproduction 	
Sterile LB supplemented with the appropriate antibiotic (10 mL) was inoculated with single 
transformants of E.coli BL21(DE3) or C43(DE3) and the culture was shaken (180 rpm) at 
37 oC overnight. The following day, sterile LB (1 L) was inoculated with the overnight culture 
(10 mL) and shaken (180 rpm) at 37 oC until OD600 0.6-0.8 was reached. The culture was then 
cooled to 4 oC before the addition of sterile isopropyl-b-thiogalactopyranoside (IPTG) (0.5 mL 
of 1 M stock) was added (0.5 mM in final culture). The culture was then shaken (180 rpm) at 
15 oC overnight in order to induce protein overproduction. 
 
6.6.4 Recombinant Protein Purification 	
Cells were harvested by centrifugation (4000 rpm, 4 oC, 30 min), resuspended in loading 
buffer (10 mL/L of culture) and kept on ice. Cells were then lysed using a cell disrupter before 
centrifugation (17000 rpm, 4 oC, 45 min). The supernatant was then passed through a 0.45 µm 
syringe filter (GE Healthcare) and loaded onto a 1 mL HiTrapTM HP chelating column 
(GE Healthcare) pre-charged with NiSO4 solution (100 mM, 5 mL) and equilibrated with 
loading buffer (5 mL). The loaded column was then washed with loading buffer (15 mL) in 
order to remove any non-specific binding proteins. The protein was then eluted using elution 
buffers containing 50 mM (5 mL), 100 mM (5 mL), 200 mM (3 mL) and 300 mM (3 mL) 
imidazole (see section 6.2.3 for composition of buffers). Fractions containing the 
overproduced protein (as determined by SDS-PAGE analysis, see section 6.6.5) were collected 
and concentrated (4000 rpm, 4 oC) using a Viva-spin concentrator (GE Healthcare) with a 10 
kDa molecular weight cut-off filter. Once concentrated to 1 mL, the protein was exchanged 
into storage buffer (2 × 15 mL) and concentrated again before a desired concentration was 
attained (as determined by nanodrop). Glycerol (25 % of final solution) was then added, the 
protein was aliquoted, flash frozen in liquid N2 and stored at -80 oC. 
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6.6.5 SDS-PAGE Gel Electrophoresis 	
SDS-PAGE gel electrophoresis was used in order to determine the size and the purity of 
overproduced proteins. 10 % acrylamide SDS-PAGE gels were used in this project (for 20-80 
kDa proteins) and were prepared as detailed in table 6.31.		
Table 6.31: The reagents and volumes used for the preparation of 10 % acrylamide SDS-PAGE gels 
Resolving gel Stacking gel 
Reagent Volume (mL) Reagent Volume (mL) 
H2O 3.8 H2O 1.4 
30 % acrylamide mix 3.4 30 % acrylamide mix 0.33 
1.5 M Tris-HCl (pH 8.8) 2.5 1.5 M Tris-HCl (pH 6.8) 0.25 
10 % SDS 0.1 10 % SDS 0.02 
10 % ammonium persulfate 0.1 10 % ammonium persulfate 0.02 
TEMED 0.005 TEMED 0.002 	
Protein samples containing 1 x SDS-PAGE loading dye (10 µL) were then loaded along with a 
protein moleculer weight ladder (Thermo Scientific PageRuler) (6 µL). The gel was 
electrophoresed at 200 V for 40-60 min. Gels were then stained with InstantBlue and destained 
with H2O and EtOH in order to visualise the proteins. 
6.7 In vitro Biochemical Assays 	
All concentrations shown in this section are concentrations in the final reaction volume unless 
specified otherwise. 
6.7.1 Pantetheine Substrate Loading and Dehydration Assay 	
GbnD5 DH-ACP and GbnD5 DH-ACP(H158Y) didomains were cloned and overproduced by 
Dr. Matt Jenner. Constructs for the loading enzymes (Sfp, CoaA, CoaD and CoaE) were taken 
from the lab of Dr. Manuela Tosin.  
 
Typically, loading reactions were carried out using DH-ACP or DH-ACP(H158Y) didomain 
(200 µM) in storage buffer (final volume 50 µL). The loading reaction was initiated by 
addition of Sfp (2 µM), CoaA (1 µM), CoaD (1 µM), CoaE (1 µM), MgCl2 (10 mM), ATP (10 
mM) and pantetheine substrate (500 µM), and the reaction was incubated at RT for 3 h. The 
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reaction was diluted to 20 µM with deionised H2O prior to UHPLC-ESI-Q-TOF-MS analysis 
(see section 6.1).135 All assays were conducted in triplicate. 
 
6.7.2 Condensation Assay with AHCCA 	
5915 condensation domain and 5919 PCP domain were cloned and overproduced by Dr. 
Joleen Masschelein.  
 
apo-PCP Domain (Bamb_5919) (200 µM) was incubated with MgCl2 (12.5 mM), Sfp (10 µM) 
and acetyl-CoA (0.5 mM) in storage buffer (final volume 200 µL) at 30 °C for 45 min. Excess 
acetyl-CoA was then removed using Amicon Ultra centrifugal filters with a 5 kDa MWCO 
membrane (Millipore). Conversion of the protein to the acetylated holo-form was verified by 
UHPLC-ESI-Q-TOF-MS analysis (see Section 6.1). The loaded PCP domain (200 µM) was 
then incubated with the Bamb_5915 condensation domain (20 µM) and AHCCA 192 (1 mM), 
in storage buffer (final volume 100 µL). The condensation domain was omitted from negative 
control reactions. Following incubation for 1 h at 30 °C, the reaction was quenched via the 
addition of MeOH (200 µL). Precipitates were removed by centrifugation (13000 g, 10 min) 
and the supernatants were analysed by UHPLC-ESI-Q-TOF-MS (see section 6.1).93 All assays 
were conducted in triplicate. 	
6.7.3 CoA Transferase Assay with VbxP 
 
To a solution of carboxylic acid (1 mM or 10 mM) and VbxP or VbxP (D171S) (50 µM) in 
storage buffer (final volume 100 µL) was added acetyl CoA (1 mM) and the reaction incubated 
at RT for 16 h. Boiled VbxP was used for negative control reactions. The reaction was 
quenched via the addition of MeOH (200 µL). Precipitates were removed by centrifugation 
(13000 g, 10 min) and the supernatants were analysed by UHPLC-ESI-Q-TOF-MS (see 
section 6.1). All assays were conducted in triplicate. 
  
6.7.4 Intact Analysis of VbxP 	
To a solution of VbxP (50 µM) in storage buffer (final volume 100 µL) was added acetyl CoA 
(1 mM) and the reaction incubated at RT. UHPLC-ESI-QTOF-MS analysis was then 
conducted at various time points (see section 6.1).   
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6.7.5 ACP Loading using VbxP 
 
To a solution of carboxylic acid (10 mM) and VbxP (50 µM) in storage buffer (final volume 
100 µL) was added acetyl CoA (1 mM) and the reaction incubated at RT overnight. The Acyl 
CoA generated in situ (50 µL) was then added to GbnD5 ACP domain (200 µM) in storage 
buffer (50 µL) before the addition of Sfp (2 µM), the resulting solution was incubated at RT 
for 1 h before UHPLC-ESI-Q-TOF-MS analysis (see section 6.1).   
 
6.7.6 Enoyl Reductase Assays with VbxN 	
To a solution of shikimic acid (1 mM) and VbxP (50 µM) in storage buffer (final volume 
85 µL) was added acetyl CoA (1 mM) and the reaction incubated at RT for 1 h. VbxN (50 µM) 
and NADPH (1 mM) was then added and the reaction incubated at RT for 16 h.  Boiled VbxN 
was used for negative control reactions. The reaction was quenched via the addition of MeOH 
(200 µL). Precipitates were removed by centrifugation (13000 g, 10 min) and the supernatants 
were analysed by UHPLC-ESI-Q-TOF-MS (see section 6.1). All assays were conducted in 
triplicate. 
 
For the attempted enoyl reduction of free carboxylic acids (Section 4.2.2) the reaction was set 
up as follows: To a solution of carboxylic acid (1 mM) and VbxN (50 µM) in storage buffer 
(final volume 85 µL) was added NADPH (1 mM) and the reaction incubated at RT for 16 h.  
Boiled VbxN was used for negative control reactions. The reaction was quenched via the 
addition of MeOH (200 µL). Precipitates were removed by centrifugation (13000 g, 10 min) 
and the supernatants were analysed by UHPLC-ESI-Q-TOF-MS (see section 6.1). 	
6.7.7 Dehydrogenation Assays with VbxM 	
To a solution of alcohol (1 mM) and VbxM (50 µM) in storage buffer (final volume 100 µL) 
was added NADP+ (1 mM) and the reaction incubated at RT for 16 h. Boiled VbxM was used 
for negative control reactions. The reaction was quenched via the addition of MeOH (200 µL) 
followed by the addition of O-((perfluorophenyl)methyl)hydroxylamine 234 (30 µL of 100 
mg/mL solution) and the solution left at RT for 1 h. Precipitates were removed by 
centrifugation (13000 g, 10 min) and the supernatants were analysed by UHPLC-ESI-Q-TOF-
MS (see section 6.1). All assays were conducted in triplicate. 
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6.7.8 Dehydration Assays with VbxL 	
To a solution of alcohol (1 mM) in storage buffer (final volume 100 µL) was added and VbxL 
(50 µM) and the reaction incubated at RT for 16 h. Boiled VbxL was used for negative control 
reactions. The reaction was quenched via the addition of MeOH (200 µL) and when required 
was followed by the addition of O-((perfluorophenyl)methyl)hydroxylamine 234 (30 µL of 
100 mg/mL solution) and the solution left at RT for 1 h. Precipitates were removed by 
centrifugation (13000 g, 10 min) and the supernatants were analysed by UHPLC-ESI-QTOF-
MS (see section 6.1). All assays were conducted in triplicate. 
 
6.7.9 Enoyl Reduction Assays with VbxK 
 
To a solution of unsaturated ketone (1 mM) and VbxK (50 µL) in storage buffer (final volume 
100 µL) was added and NADPH or NADH (1 mM) and the reaction incubated at RT for 16 h. 
Boiled VbxK was used for negative control reactions. The reaction was quenched via the 
addition of MeOH (200 µL) and when required was followed by the addition of O-
((perfluorophenyl)methyl)hydroxylamine 234 (30 µL of 100 mg/mL solution) and the solution 
left at RT for 1 h. Precipitates were removed by centrifugation (13000 g, 10 min) and the 
supernatants were analysed by UHPLC-ESI-QTOF-MS (see section 6.1). All assays were 
conducted in triplicate. 
 
For coupled assays, the unsaturated ketone was generated in situ using VbxL, the reaction was 
conducted as follows: To a solution of (1S,3R,4S)-3,4-dihydroxy-5-oxocyclohexane-1-
carboxylic acid 228 (1 mM) in storage buffer (final volume 100 µL) was added and VbxL 
(50 µM) and the reaction incubated at RT for 1 h. VbxK (50 µM) was then added followed by 
NADPH or NADH (1 mM) and the reaction incubated at RT for 16 h. Boiled VbxK and boiled 
VbxL were used for separate negative control reactions. The reaction was quenched via the 
addition of MeOH (200 µL) followed by the addition of O-
((perfluorophenyl)methyl)hydroxylamine (30 µL of 100 mg/mL solution) and the solution left 
at RT for 1 h. Precipitates were removed by centrifugation (13000 g, 10 min) and the 
supernatants were analysed by UHPLC-ESI-Q-TOF-MS (see section 6.1). The assay was 
conducted in triplicate. 
 
For the attempted enoyl reduction of free carboxylic acids (Section 4.2.2) the reaction was set 
up as follows the reaction was set up as follows: To a solution of carboxylic acid (1 mM) and 
VbxK (50 µM) in storage buffer (final volume 85 µL) was added NADPH (1 mM) and the 
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reaction incubated at RT for 16 h.  Boiled VbxK was used for negative control reactions. The 
reaction was quenched via the addition of MeOH (200 µL). Precipitates were removed by 
centrifugation (13000 g, 10 min) and the supernatants were analysed by UHPLC-ESI-Q-TOF-
MS (see Section 6.1). 
 
6.8 Homology Modelling and Bioinformatic Analysis 	
6.8.1 Homology Modelling of GbnD5 DH Domain 	
Homology model of GbnD5 DH domain generated by Dr. Matt Jenner. 		
Homology modelling of GbnD5 DH domain (figure 2.9) (using entry 5KKU from the PDB as 
a template) was conducted using the I-TASSER server, and further refinement of the model 
was achieved using the MolProbity server.237–239 
 
6.8.2 Phylogenetic Analysis of DH Domains 	
Generation of sequence alignment (figure 2.8) and phylogenetic tree (appendix 8.1) carried out 
by Dr. Matt Jenner. 
 
Sequences of DH domains were collected from MIBiG. Multiple sequence alignment of DH 
domains was achieved using ClustalX. Phylogenetic tree was generated using the sequence 
alignment and FigTree.240,241 
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6.9 Chemical Synthesis of Substrates 	
6.9.1 Diene Synthase Substrates 	
(R)-3-(2,2,5,5-tetramethyl-1,3-dioxane-4-carboxamido)propanoic acid (264) 
 
 
 
Procedure taken from Gaudelli et al.152 To a 500 mL round-bottomed flask, equipped with a 
magnetic stir bar, D-pantothenic acid hemicalcium salt (5.0 g, 21.0 mmol, 1.0 equiv.), p-
toluenesulfonic acid monohydrate (4.80 g, 25.2 mmol, 1.2 equiv.), and 3.0 Å molecular sieves 
(5.0 g) were suspended in acetone (250 mL). The flask was capped, and the suspension was 
stirred at RT for 12 h. The slurry was filtered through Celite® and washed with acetone (3 × 
100 mL), and the filtrate was concentrated to a viscous oil. The oil was dissolved in EtOAc 
(200 mL), washed with brine (2 × 100 mL), dried (MgSO4) and concentrated in vacuo. The 
product was recrystallized from boiling EtOAc to afford the product as white crystals (4.68 g, 
83 %, 17.4 mmol).  
dH (500 MHz; CDCl3) 7.02 (1H, br. t, J 6.0, NH), 4.10 (1H, s, CH), 3.69 (1H, d, J 11.5, 
CH2OC(CH3)2), 3.60 (1H, dq, J 12.5 and 6 NHCH2), 3.50 (1H, dq, J 12.5 and 6 NHCH2), 3.28 
(1H, d, J 11.5, CH2OC(CH3)2), 2.63 (2H, t, J 6.5, CH2CO2H), 1.46 (3H, s, OC(CH3)2), 1.43 
(3H, s, OC(CH3)2), 1.04 (3H, s, CH2C(CH3)2), 0.98 (3H, s, CH2C(CH3)2); dC (125 MHz, 
CDCl3) 176.4 (CO2H), 170.4 (CONH), 99.4 (OC(CH3)2), 77.4 (CH), 71.7 (CH2OC(CH3)2), 
34.3 (CH2NH), 34.1 (CH2CO2H), 33.3 (CH2C(CH3)2), 29.7 (OC(CH3)2), 22.4 (CH2C(CH3)2), 
19.1 (CH2C(CH3)2), 19.0 (OC(CH3)2); HRMS (ESI) cald. for C12H20NO5 (M - H+) requires 
258.1347, found 258.1348. Spectroscopic data consistent with that previously reported in the 
literature.152 
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O
H
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(R)-N-(3-((2-mercaptoethyl)amino)-3-oxopropyl)-2,2,5,5-tetramethyl-1,3-dioxane-4-
carboxamide (61) 
 
 
Procedure taken from Gaudelli et al.152. To a 250 mL round-bottomed flask equipped with a 
magnetic stir bar, (R)-3-(2,2,5,5-tetramethyl-1,3-dioxane-4-carboxamido)propanoic acid 264 
(4.18 g, 16.1 mmol, 1.1 equiv.) was dissolved in dry THF (100 mL), and treated with 1′,1′-
carbonyldiimidazole (2.61 g, 16.1 mmol, 1.1 equiv.) and stirred for 1 h at RT. To this solution 
was added cysteamine hydrochloride (1.13 g, 14.6 mmol, 1.0 equiv.) and stirred at RT for 
12 h. The THF was concentrated in vacuo, and CH2Cl2 (100 mL) was added. The organic 
solution was washed with saturated NH4Cl (1 × 50 mL), brine (1 × 50 mL), dried (MgSO4) 
and concentrated to afford colourless oil. The crude mixture was purified by silica 
chromatography (EtOAc) to afford the product product as a white solid (3.61 g, 78 %, 11.4 
mmol).  
dH (500 MHz; CDCl3) 7.00 (1H, br. t, J 6.0, NH), 6.32 (1H, br. t, J 6.0, NHCH2CH2SH), 4.07 
(1H, s, CH), 3.67 (1H, d, J 11.5, CH2OC(CH3)2), 3.58 (1H, dq, J 13.5 and 6.0, NHCH2), 3.52 
(1H, dq, J 13.5 and 6.0, NHCH2), 3.46 (1H, dq, J 13.0 and 6.5, CH2CH2SH), 3.39 (1H, dq, J 
13.0 and 6.5, CH2CH2SH), 3.27 (1H, d, J 11.5, CH2OC(CH3)2), 2.65 (2H, dtd, J 8.5, 6.5 and 
2.0, CH2SH), 2.46 (2H, td, J 6.0 and 1.5, CH2CONH), 1.45 (3H, s, OC(CH3)2), 1.41 (3H, s, 
OC(CH3)2), 1.36 (1H, t, J 8.5, SH), 1.03 (3H, s, CH2C(CH3)2), 0.96 (3H, s, CH2C(CH3)2); dC 
(125 MHz, CDCl3) 171.3 (CH2CONH), 170.5 (CHCONH), 99.4 (OC(CH3)2), 77.4 (CH), 71.7 
(CH2OC(CH3)2), 42.7 (CH2CH2SH), 36.4 (CH2CONH), 35.1 (CH2NH), 33.2 (CH2C(CH3)2), 
29.8 (OC(CH3)2), 24.8 (CH2SH), 22.4 (CH2C(CH3)2), 19.2 (CH2C(CH3)2), 19.0 (OC(CH3)2);  
HRMS (ESI) cald. for C14H26N2NaO4S (M + Na+) requires 341.1505, found 341.1507. 
Spectroscopic data consistent with that previously reported in the literature.152 
 
Methyl 3-oxooctanoate (56) 
 
 
 
Procedure modified from Riva et al.242 To a solution of hexanoic acid (1.0 g, 8.5 mmol, 
1.0 equiv.), Meldrum’s acid (1.2 g, 8.5 mmol, 1.0 equiv.) and DMAP (1.28 g, 10.5 mmol, 
1.24 equiv.) in dry THF (100 mL), was added EDC.HCl (1.8 g, 9.4 mmol, 1.1 equiv.) at 0 oC 
H
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H
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under an Argon atmosphere. The reaction was stirred at RT for 16 hours. The reaction was 
then concentrated in vacuo, the residue dissolved in CH2Cl2  (50 mL), washed with 1 M HCl 
(50 mL), brine (50 mL), dried (MgSO4) and concentrated in vacuo to give the Meldrum’s 
adduct as a yellow oil (1.9 g). The oil was then dissolved in MeOH and heated to reflux for 
16 hours. The reaction was then concentrated in vacuo and subjected to column 
chromatography (1 : 4 diethyl ether : petroleum ether) to afford the product as a yellow oil 
(keto:enol = 15:1, 1.26 g, 86 %, 7.31 mmol). 
dH (500 MHz; CDCl3) 3.73 (3H, s, COOCH3), 3.44 (2H, s, CH2CO2Me), 2.52 (2H, t, J 7.5, 
CH2CO), 1.59 (2H, quin., J 7.5, CH2CH2CO), 1.35-1.23 (4H, m, CH3CH2CH2), 0.88 (3H, t, J 
7.0, CH2CH3); dC (125 MHz, CDCl3) 203.0 (CH2COCH2), 167.8 (COOCH3), 52.5 (COOCH3), 
49.1 (COCH2CO), 43.2 (CH2CO), 31.3 (CH2CH2CO), 23.3 (CH3CH2CH2), 22.5 (CH3CH2) 
14.0 (CH3); HRMS (ESI) cald. for C9H16NaO3 (M + Na+) requires 195.0997, found 195.0993. 
Spectroscopic data consistent with that previously reported in the literature.243 
 
Methyl (R)-3-hydroxyoctanoate (57) 
 
 
 
The following procedure was modified from Ratovelomanana-Vidal et al.150 To a solution of 
[(R)-Ru(OAc)2(BINAP)] (14.5 mg, 0.02 mmol, 0.01 equiv.) and 1 M HCl in MeOH (20 µL, 
20 µmol, 0.01 equiv.) in MeOH (2 mL) was added methyl 3-oxooctanoate 56 (300 mg, 
1.70 mmol, 1.0 equiv.) in a 10 mL test tube containing a magnetic stirring bar. The reaction 
was heated to 60 oC at 50 bar hydrogen pressure using hydrogenation apparatus for 16 h. The 
mixture was then filtered through Celite® and concentrated in vacuo to afford the product as a 
yellow oil (> 95 % e.e. as confirmed by derivatization to the Mosher’s ester, 272 mg, 90 %, 
1.5 mmol, [α]$%&  (c 1.0, CHCl3): -19.4).  
dH (500 MHz; CDCl3) 4.05-3.95 (1H, m, CHOH), 3.71 (3H, s, COOCH3), 2.84 (1H, d, J 4.0, 
OH), 2.52 (1H, dd, J 16.5 and 3.5 CH2CO2Me), 2.41 (1H, dd, J 16.5 and 9.0, CH2CO2Me), 
1.56-1.22 (8H, m, CH3CH2CH2CH2CH2), 0.89 (3H, d, J 7.0, CH2CH3); dC (125 MHz, CDCl3) 
173.7 (COOCH3), 68.2 (CHOH), 51.9 (COOCH3), 42.2 (CH2CO2Me), 36.6 (CHCH2), 31.8 
(CHCH2CH2), 25.3 (CHCH2CH2CH2), 22.7 (CH2CH3), 14.1 (CH2CH3); HRMS (ESI) cald. for 
C9H18NaO3 (M + Na+) requires 197.1148, found 197.1150. Spectroscopic data consistent with 
that previously reported in the literature.244 
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(R)-3-Hydroxyoctanoic acid (62) 
 
 
 
To a solution of methyl (R)-3-hydroxyoctanoate 57 (250 mg, 1.4 mmol, 1.0 equiv.) in a 2 : 1 
mixture of THF (4 mL) and water (2 mL), was added LiOH (56 mg, 2.9 mmol, 2.0 equiv.) and 
the reaction stirred for 16 h. THF was removed in vacuo and the resulting solution acidified to 
pH 2.0 using 1 M HCl. The mixture was then extracted with CH2Cl2 (3 × 10 mL), the 
combined organics washed with brine (20 mL), dried (MgSO4) and concentrated in vacuo to 
afford the product as a colourless oil (178 mg, 81 %).  
δH (500 MHz; CDCl3) 4.03 (1H, dddd, J 9.0, 7.5, 4.5 and 3.0, CHOH), 2.57 (1H, dd, J 16.5 
and 3.0, CH2CO2H), 2.47 (1H, dd, J 16.5 and 9.0, CH2CO2H), 1.59-1.24 (8H, m, 
CH3CH2CH2CH2CH2), 0.89 (3H, t, J 7.0, CH2CH3); δC (125 MHz, CDCl3) 177.9 (COOH), 
68.2 (CHOH), 41.2 (CH2CO2H), 36.6 (CHCH2), 31.8 (CHCH2CH2), 25.3 (CHCH2CH2CH2), 
22.7 (CH2CH3), 14.2 (CH2CH3); HRMS (ESI) cald. for C8H15O3 [M – H]- requires 159.1027, 
found 159.1028. Spectroscopic data consistent with that previously reported in the literature.245 
 
S-(2-(3-((R)-2,2,5,5-tetramethyl-1,3-dioxane-4-carboxamido)propanamido) ethyl)(R)-3-
hydroxyoctanethioate (63) 
 
 
 
To a solution of (R)-3-hydroxyoctanoic acid 62 (100 mg, 0.63 mmol, 1.1 equiv.) in CH2Cl2 
(10 mL) was added CDI (102 mg, 0.63 mmol, 1.1 equiv.) and the reaction was stirred at RT 
for 1 h. (R)-N-(3-((2-mercaptoethyl)amino)-3-oxopropyl)-2,2,5,5-tetramethyl-1,3-dioxane-4-
carboxamide 61 (180 mg, 0.57 mmol, 1.0 equiv.) was then added and the reaction stirred at RT 
for 16 h. 1 M HCl (5 mL) was then added and the mixture was extracted with CH2Cl2 (3 x 5 
mL), the combined organics were then washed with saturated NaHCO3 (10 mL), brine (10 
mL), dried (MgSO4) and concentrated in vacuo to give a yellow oil which was purified by 
silica chromatography (19 : 1 CH2Cl2 : MeOH) to afford the product as a colourless oil 
(196 mg, 75 %, 0.43 mmol). 
nmax/cm-1 (neat) 3417 (OH), 2931 (NH), 1656, 1529 (C=O), 1160 (C-O); dH (500 MHz; 
CDCl3) 6.99 (1H, br. t, J 6.0, NH), 6.38 (1H, br. s, NHCH2CH2S), 4.12-4.06 (1H, m, CHOH), 
OOH
OH
S
OOH H
N
O
H
N
O
OO
	 203	
4.07 (1H, s, CHCONH), 3.67 (1H, d J 11.5, CH2OC(CH3)2), 3.59-3.33 (5H, m, NHCH2, 
CH2CH2S, OH), 3.27 (1H, d J 11.5, CH2OC(CH3)2), 3.12 (1H, ddd, J 14.0, 7.0 and 5.5, CH2S), 
2.98 (1H, ddd, J 14.0, 6.5 and 5.5, CH2S), 2.72 (1H, dd, J 15.0 and 4.0, CH2COS), 2.68 (1H, 
dd, J 15.0 and 8.5, CH2COS), 2.41 (2H, td J 6.5 and 1.5, CH2CONH), 1.55-1.40 (3H, m, 
CHOHCH2CH2), 1.46 (3H, s, OC(CH3)2), 1.42 (3H, s, OC(CH3)2), 1.37-1.23 (5H, m, 
CH2CH2CH2CH3), 1.03 (3H, s, CH2C(CH3)2), 0.95 (3H, s, CH2C(CH3)2), 0.88 (3H, t, J 7.0, 
CH2CH3); dC (125 MHz, CDCl3) 199.4 (COS), 171.3 (CH2CONH), 170.7 (CHCONH), 99.3 
(OC(CH3)2), 77.3 (CH), 71.6 (CH2OC(CH3)2), 69.0 (CHOH), 51.4 (CH2COS), 39.3 
(CH2CH2S), 37.2 (CH2CHOH), 36.4 (CH2CONH), 35.4 (CH2NH), 33.1 (CH2C(CH3)2), 31.9 
(CHOHCH2CH2), 29.6 ((OC(CH3)2), 28.8 (CH2S), 25.3 (CH3CH2CH2), 22.7 (CH3CH2), 22.3 
(CH2C(CH3)2), 19.0 (CH2C(CH3)2), 18.9 (OC(CH3)2), 14.2 (CH2CH3); HRMS (ESI) cald. for 
C22H40N2NaO6S (M + Na+) requires 483.2499, found 483.2500; [α]$%' (c 0.2, CHCl3): +17.5. 
 
S-(2-(3-((R)-2,4-dihydroxy-3,3-dimethylbutanamido)propanamido)ethyl)(R)-3-
hydroxyoctanethioate (53) 
 
 
 
S-(2-(3-((R)-2,2,5,5-tetramethyl-1,3-dioxane-4-carboxamido)propanamido)ethyl) (R)-3-
hydroxyoctanethioate 63 (100 mg, 0.22 mmol, 1.0 equiv.) was stirred in AcOH : H2O (2 : 1, 
3 mL), for 16 h at RT. The reaction was then concentrated in vacuo and purified using silica 
chromatography (17 : 3 CH2Cl2 : MeOH) to afford the product as a colourless oil (76 mg, 
83 %, 0.18 mmol). 
nmax/cm-1 (neat) 3405 (OH), 2871 (NH), 1642, 1529 (C=O), 1076 (C-O); dH (500 MHz; 
CD3OD) 4.05-3.99 (1H, m, CHOH), 3.89 (1H, s, CH), 3.53-3.32 (6H, m, NHCH2, CH2CH2S, 
CH2CHOH), 3.02 (2H, t, J 6.5, CH2S), 2.71 (1H, dd, J 15.0 and 5.0, CH2COS), 2.68 (1H, dd, J 
15.0 and 7.5, CH2COS), 2.41 (2H, t, J 6.5, CH2CONH), 1.50-1.25 (8H, m, 
CH3CH2CH2CH2CH2), 0.92 (6H, s, CH2C(CH3)2), 0.91 (3H, t, J 7.5, CH2CH3); dC (125 MHz, 
CD3OD) 198.9 (COS), 176.0 (CHCONH), 173.9 (CH2CONH), 77.3 (CH), 70.3 (CH2OH), 
69.6 (CHOH), 52.6 (CH2COS), 40.3 (CH2C(CH3)2), 40.0 (CH2CH2S), 38.1 (CH2CONH), 36.4 
(CH2OH), 36.3 (CH2NH), 32.8 (CH3CH2CH2CH2), 29.3 (CH2S), 26.3 (CH3CH2CH2), 23.6 
(CH3CH2), 21.3 (CH2C(CH3)2), 20.9 (CH2C(CH3)2), 14.4 (CH3CH2);  HRMS (ESI) cald. for 
C19H36N2NaO6S (M + Na+) requires 443.2186, found 443.2189; [α]$%' (c 0.1, CHCl3): +16.5. 
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Methyl (S)-3-hydroxyoctanoate (265) 
 
 
 
Methyl (S)-3-hydroxyoctanoate 265 was synthesized using the same procedure as for the 
synthesis of methyl (R)-3-hydroxyoctanoate 57 using methyl 3-oxooctanoate 56 (300 mg, 1.70 
mmol, 1.0 equiv.) and [(S)-Ru(OAc)2(BINAP)] (14.5 mg, 0.02 mmol, 0.01 equiv.) to afford 
the product as a yellow oil (268 mg, 88 %, 1.56 mmol, >95 % e.e. as confirmed by 
derivatization to the Mosher’s ester, [α]$%& (c 1.0, CHCl3): +20.5). Spectroscopic data was 
identical to that of methyl (R)-3-hydroxyoctanoate 57 and consistent with that previously 
reported in the literature.246 
 
(S)-3-Hydroxyoctanoic acid (266) 
 
 
 
(S)-3-hydroxyoctanoic acid 266 was synthesized using the same procedure as for the synthesis 
of (R)-3-hydroxyoctanoic acid 62 using methyl (S)-3-hydroxyoctanoate 265 (220 mg, 
1.26 mmol, 1.0 equiv.) to give the product as a colourless oil (139 mg, 69 %, 0.87 mmol). 
Spectroscopic data was identical to that of (R)-3-hydroxyoctanoic acid and consistent with that 
previously reported in the literature.247   
 
S-(2-(3-((R)-2,2,5,5-tetramethyl-1,3-dioxane-4-carboxamido)propan-amido) ethyl) (S)-3-
hydroxyoctanethioate (267) 
 
 
 
S-(2-(3-((R)-2,2,5,5-tetramethyl-1,3-dioxane-4-carboxamido)propanamido)ethyl) (S)-3-
hydroxyoctanethioate 267 was synthesized using the same procedure as for the synthesis of S-
(2-(3-((R)-2,2,5,5-tetramethyl-1,3-dioxane-4-carboxamido) propanamido)ethyl) (R)-3-
hydroxyoctanethioate 63 using (S)-3-hydroxyoctanoic acid 266 (100 mg, 0.63 mmol, 
1.1 equiv.) to give the product as a colourless oil (202 mg, 77 %, 0.44 mmol). 
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nmax/cm-1 (neat) 3324 (OH), 2930 (NH), 1666, 1542 (C=O), 1159 (C-O); dH (500 MHz; 
CDCl3) 6.99 (1H, br. t, J 6.5, NH), 6.38 (1H, br. t, J 5.5, NHCH2CH2S), 4.11-4.05 (1H, m, 
CHOH), 4.06 (1H, s, CHCONH), 3.67 (1H, d J 11.5, CH2OC(CH3)2), 3.59-3.39 (5H, m, 
NHCH2, CH2CH2S, OH), 3.27 (1H, d, J 11.5, CH2OC(CH3)2), 3.09 (1H, dt, J 14.0 and 6.0, 
CH2S), 3.00 (1H, dt, J 14.0 and 6.0, CH2S), 2.72 (1H, dd, J 15.0 and 3.5, CH2COS), 2.67 (1H, 
dd, J 15.0 and 9.0, CH2COS), 2.40 (2H, td, J 7.0 and 2.5, CH2CONH), 1.55-1.39 (3H, m, 
CHOHCH2CH2), 1.45 (3H, s, OC(CH3)2), 1.41 (3H, s, OC(CH3)2), 1.37-1.21 (5H, m, 
CH2CH2CH2CH3), 1.02 (3H, s, CH2C(CH3)2), 0.96 (3H, s, CH2C(CH3)2), 0.88 (3H, t, J 7.0, 
CH2CH3); dC (125 MHz, CDCl3) 199.4 (COS), 171.3 (CH2CONH), 170.7 (CHCONH), 99.3 
(OC(CH3)2), 77.3 (CH), 71.5 (CH2OC(CH3)2), 69.2 (CHOH), 51.4 (CH2COS), 39.4 
(CH2CH2S), 37.3 (CH2CHOH), 36.5 (CH2CONH), 35.3 (CH2NH), 33.1 (CH2C(CH3)2), 31.9 
(CHOHCH2CH2), 29.6 ((OC(CH3)2), 28.8 (CH2S), 25.3 (CH3CH2CH2), 22.7 (CH3CH2), 22.3 
(CH2C(CH3)2), 19.0 (CH2C(CH3)2), 18.8 (OC(CH3)2), 14.2 (CH2CH3); HRMS (ESI) cald. for 
C22H40N2NaO6S (M + Na+) requires 483.2499, found 483.2498; [α]$%' (c 0.075, CHCl3): +34. 
 
S-(2-(3-((R)-2,4-dihydroxy-3,3-dimethylbutanamido)propanamido)ethyl) (S)-3-
hydroxyoctanethioate (54) 
 
 
 
S-(2-(3-((R)-2,4-dihydroxy-3,3-dimethylbutanamido)propanamido)ethyl) (S)-3-
hydroxyoctanethioate 54 was synthesized using the same procedure as for the synthesis of S-
(2-(3-((R)-2,4-dihydroxy-3,3-dimethylbutanamido)propanamido)ethyl) (R)-3-
hydroxyoctanethioate 53 using S-(2-(3-((R)-2,2,5,5-tetramethyl-1,3-dioxane-4-
carboxamido)propanamido)ethyl) (S)-3-hydroxyoctanethioate 267 (100 mg, 0.22 mmol, 
1.0 equiv.) to give the product as a colourless oil (78 mg, 85 %, 0.19 mmol). 
nmax/cm-1 (neat) 3293 (OH), 2870 (NH), 1642, 1529 (C=O), 1076 (C-O); dH (500 MHz; 
CD3OD) 4.05-3.99 (1H, m, CHOH), 3.89 (1H, s, CH), 3.53-3.32 (6H, m, NHCH2, CH2CH2S, 
CH2CHOH), 3.02 (2H, t, J 6.5, CH2S), 2.71 (1H, dd, J 15.0 and 5.0, CH2COS), 2.68 (1H, dd, J 
15.0 and 7.5, CH2COS), 2.41 (2H, t, J 6.5, CH2CONH), 1.49-1.26 (8H, m, 
CH3CH2CH2CH2CH2), 0.92 (6H, s, CH2C(CH3)2), 0.91 (3H, t, J 7.5, CH2CH3); dC (125 MHz, 
CD3OD) 198.9 (COS), 176.0 (CHCONH), 173.9 (CH2CONH), 77.3 (CH), 70.4 (CH2OH), 
69.6 (CHOH), 52.6 (CH2COS), 40.4 (CH2C(CH3)2), 40.0 (CH2CH2S), 38.1 (CH2CONH), 36.4 
(CH2OH), 36.3 (CH2NH), 32.9 (CH3CH2CH2CH2), 29.3 (CH2S), 26.3 (CH3CH2CH2), 23.7 
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(CH3CH2), 21.3 (CH2C(CH3)2), 20.9 (CH2C(CH3)2), 14.4 (CH3CH2);  HRMS (ESI) cald. for 
C22H40N2NaO6S (M + Na+) requires 483.2499, found 483.2500; [α]$%' (c 0.15, CHCl3): +10.3. 
 
Methyl (R)-3-(((S)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoyl) oxy)octanoate (268) 
 
 
 
To a solution of methyl (R)-3-hydroxyoctanoate 57 (10 mg, 0.06 mmol, 1.0 equiv.), (S)-3,3,3-
trifluoro-2-methoxy-2-phenylpropanoic acid (28 mg, 0.12 mmol, 2.0 equiv.) and DMAP (15 
mg, 0.12 mmol, 2.0 equiv.) in CH2Cl2 (5 mL), was added EDC.HCl (19 mg, 0.12 mmol, 2.0 
equiv.) at 0 oC. The reaction was stirred at RT for 17 h, and was quenched by the addition of 2 
M HCl. The mixture was extracted with CH2Cl2 (3 × 10 mL), washed with brine (10 mL), 
dried (MgSO4), filtered and concentrated in vacuo. The resulting was purified by silica 
chromatography (EtOAc) to afford the product as a colourless oil (13 mg, 56 %, 0.03 mmol). 
dH (500 MHz; CDCl3) 7.54-7.50 (2H, m, ArH), 7.41-7.37 (3H, m, ArH), 5.48 (1H, tt, J 7.5 and 
5.5 CHOCH2), 3.59 (3H, s, COOCH3), 3.52 (3H, s, OCH3), 2.65 (1H, dd, J 16.0 and 8.0 
CH2CO2Me), 2.58 (1H, dd, J 16.0 and 5.0, CH2CO2Me), 1.79-1.62 (2H, m, CH2CHO), 1.38-
1.21 (6H, m, CH3CH2CH2CH2), 0.88 (3H, t, J 6.5, CH2CH3); dC (125 MHz, CDCl3) 170.5 
(COOCH3), 166.0 (COOCH), 132.3 (ArCquart), 129.7 (ArC), 128.5 (ArC), 127.6 (ArC), 124.6 
(CF3), 122.3 (COCH3), 73.6 (CHOCO), 55.5 (OCH3) 51.9 (COOCH3), 38.6 (CH2CO2Me), 
33.8 (CHOCH2), 31.5 (CHCH2CH2), 24.8 (CHCH2CH2CH2), 22.6 (CH2CH3), 14.1 (CH2CH3); 
HRMS (ESI) cald. for C19H25F3NaO5 (M + Na+) requires 413.1552, found 413.1543. 
 
Methyl (S)-3-(((S)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoyl)oxy)octanoate (269) 
 
 
 
Methyl (S)-3-(((S)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoyl)oxy)octanoate 269 was 
synthesized using the same procedure as for the synthesis of methyl (R)-3-(((S)-3,3,3-trifluoro-
2-methoxy-2-phenylpropanoyl)oxy)octanoate 268 using methyl (S)-3-hydroxyoctanoate 265 
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(10 mg, 0.06 mmol, 1.0 equiv.) to give the product as a colourless oil (11 mg, 47 %, 0.03 
mmol). 
dH (500 MHz; CDCl3) 7.55-7.51 (2H, m, ArH), 7.41-7.37 (3H, m, ArH), 5.48 (1H, tt, J 7.5 and 
5.0 CHOCH2), 3.66 (3H, s, COOCH3), 3.55 (3H, s, OCH3), 2.70 (1H, dd, J 16.0 and 8.5 
CH2CO2Me), 2.61 (1H, dd, J 16.0 and 5.0, CH2CO2Me), 1.70-1.52 (2H, m, CH2CHO), 1.34-
1.12 (6H, m, CH3CH2CH2CH2), 0.86 (3H, t, J 7.0, CH2CH3); dC (125 MHz, CDCl3) 170.7 
(COOCH3), 166.1 (COOCH), 132.4 (ArCquart), 129.7 (ArC), 128.4 (ArC), 127.5 (ArC), 124.6 
(CF3), 122.3 (COCH3), 73.5 (CHOCO), 55.6 (OCH3) 52.1 (COOCH3), 38.7 (CH2CO2Me), 
33.7 (CHOCH2), 31.5 (CHCH2CH2), 24.4 (CHCH2CH2CH2), 22.5 (CH2CH3), 14.0 (CH2CH3); 
HRMS (ESI) cald. for C19H25F3NaO5 (M + Na+) requires 413.1552, found 413.1550. 
 
(R)-S-(2-(3-(2,2,5,5-tetramethyl-1,3-dioxane-4-carboxamido)propanamido) ethyl) (E)-
hex-2-enethioate (69) (made by Dr. Doug Roberts) 
 
 
 
Procedure modified from Roberts et al.73 To a solution of hex-2-enoic acid (76 mg, 0.67 
mmol, 1.3 equiv.), (R)-N-(3-((2-mercaptoethyl)amino)-3-oxopropyl)-2,2,5,5-tetramethyl-1,3-
dioxane-4-carboxamide 61 (235 mg, 0.74 mmol, 1.4 equiv.) and DMAP (18 mg, 0.16 mmol, 
0.3 equiv.) in CH2Cl2 (5 mL), was added EDC.HCl (141 mg, 0.75 mmol, 1.4 equiv.) at 0 oC. 
The reaction was stirred at RT for 17 h, and was quenched by the addition of 2 M HCl. The 
mixture was extracted with CH2Cl2 (3 × 10 mL), washed with brine (10 mL), dried (MgSO4), 
filtered and concentrated in vacuo. The resulting was purified by silica chromatography 
(EtOAc) to afford the product as a colourless oil (167 mg, 61 %, 0.33 mmol). 
nmax/cm-1 (neat) 2914 (NH), 1618 (C=O), 1520 (C=O), 1159 (C-O); dH (300 MHz; CDCl3) 
7.01 (1H, br. t, J 6.0, NH), 6.92 (1H, dt, J 15.5 and 7.0, CHCHCOS), 6.18-6.07 (2H, m, 
NHCH2CH2S, CHCOS), 4.07 (1H, s, CH), 3.67 (1H, d, J 12.0, CH2OC(CH3)2), 3.62-3.40 (4H, 
m, NHCH2, CH2CH2S), 3.27 (1H, d, J 12.0, CH2OC(CH3)2), 3.07 (2H, t, J 6.0, CH2S), 2.40 
(2H, t, J 6.0, CH2CONH), 2.17 (2H, q, J 7.0, CH3CH2CH2), 1.50-1.44 (2H, m, CH3CH2), 1.44 
(3H, s, OC(CH3)2), 1.40 (3H, s, OC(CH3)2), 1.03 (3H, s, CH2C(CH3)2), 0.97-0.89 (6H, m, 
CH2CH3, CH2C(CH3)2); dC (75 MHz, CDCl3) 190.1 (COS), 171.6 (CH2CONH), 170.1 
(CHCONH), 146.7 (CHCHCOS), 128.5 (CHCOS), 99.2 (OC(CH3)2), 77.2 (CH), 71.5 
(CH2OC(CH3)2), 39.8 (CH2CH2S), 36.0 (CH2CONH), 34.8 (CH2NH), 34.2 (CH2S), 33.0 
(CH2C(CH3)2), 29.5 (OC(CH3)2), 22.2 (CH2C(CH3)2), 21.2 (CH3CH2CH2), 21.1 (CH3CH2), 
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19.0 (CH2C(CH3)2), 18.8 (OC(CH3)2), 13.6 (CH3CH2);  HRMS (ESI) cald. for C20H34N2NaO5S 
(M + Na+) requires 437.2086, found 437.2088; [α]$%' (c 0.2, CHCl3): +6.5. 
 
(R)-S-(2-(3-(2,4-dihydroxy-3,3-dimethylbutanamido)propanamido)ethyl)(E)-hex-2-
enethioate (64) (made by Dr. Doug Roberts) 
 
 
 
Procedure modified from Roberts et al.73 To a solution of (R)-S-(2-(3-(2,2,5,5-tetramethyl-1,3-
dioxane-4-carboxamido)propanamido)ethyl) (E)-hex-2-enethioate 69 (167 mg, 0.40 mmol, 1.0 
equiv.) in MeOH (2 mL) was added Dowex 50w resin (85 mg) and the reaction stirred at RT 
for two days. The reaction mixture was then filtered and concentrated in vacuo to afford the 
product as a colourless oil (91 mg, 60 %, 0.24 mmol). 
nmax/cm-1 (neat) 3301 (OH), 2946 (NH), 1642, 1530 (C=O), 1099 (C-O); dH (400 MHz; 
CDCl3) 7.59 (1H, br. t, J 6.5, NH), 7.06 (1H, br. s, NHCH2CH2S), 6.89 (1H, dt, J 15.5 and 6.5, 
CHCHCOS), 6.08 (1H, dt, J 15.5 and 1.5, CHCOS), 3.98 (1H, s, CH), 3.56-3.35 (6H, m, 
NHCH2, CH2CH2S, CH2CHOH), 3.06-3.00 (2H, m, CH2S), 2.45 (2H, t, J 6.0, CH2CONH), 
2.15 (2H, qd, J 7.0 and 1.5, CH3CH2CH2), 1.51-1.42 (2H, m, CH3CH2), 0.94-0.87 (9H, m, 
CH2CH3, CH2C(CH3)2); dC (100 MHz, CDCl3) 190.5 (COS), 174.2 (CHCONH),  172.0 
(CH2CONH), 146.8 (CHCHCOS), 128.5 (CHCOS), 77.1 (CH), 70.6 (CH2OH), 39.7 
(CH2CH2S), 39.4 (CH2CONH), 35.8 (CH2NH), 35.5 (CH2S), 34.3 (CH3CH2CH2), 28.1 
(CH2C(CH3)2), 23.1 (CH3CH2), 20.7 (CH2C(CH3)2), 13.7 (CH3CH2);  HRMS (ESI) cald. for 
C17H30N2NaO5S (M + Na+) requires 397.1768, found 397.1770; [α]$%' (c 0.2, CHCl3): +8.3. 
 
(R)-S-(2-(3-(2,2,5,5-tetramethyl-1,3-dioxane-4-carboxamido)propanamido) ethyl) hex-2-
ynethioate (70) 
 
 
To a solution of hex-2-ynoic acid (0.12 mL, 0.75 mmol, 1.0 equiv.), (R)-N-(3-((2-
mercaptoethyl)amino)-3-oxopropyl)-2,2,5,5-tetramethyl-1,3-dioxane-4-carboxamide 61 
(255 mg, 0.80 mmol, 1.1 equiv.) and DMAP (21 mg, 0.23 mmol, 0.2 equiv.) in CH2Cl2 
(10 mL), was added EDC.HCl (156 mg, 0.80 mmol, 1.1 equiv.) at 0 oC. The reaction was 
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stirred at RT for 16 h, and was quenched by the addition of 1 M HCl. The mixture was 
extracted with CH2Cl2 (3 × 10 mL), washed with saturated NaHCO3 solution (10 mL), dried 
(MgSO4), filtered and concentrated in vacuo to give a viscous oil which was purified by silica 
chromatography (EtOAc) to give the product as a colourless oil (305 mg, 99 %, 0.75 mmol). 
nmax/cm-1 (neat) 3309 (OH), 2939 (NH), 1649 (C=O), 1529 (C=O), 1158 (C-O); dH (500 MHz; 
CDCl3) 7.01 (1H, br. t, J 6.0, NH), 6.20 (1H, br. s, NHCH2CH2S), 4.07 (1H, s, CH), 3.67 (1H, 
d, J 11.5, CH2OC(CH3)2), 3.61-3.39 (4H, m, NHCH2, CH2CH2S), 3.27 (1H, d, J 11.5, 
CH2OC(CH3)2), 3.09 (2H, t, J 6.5, CH2S), 2.43 (2H, t, J 6.0, CH2CONH), 2.37 (2H, t, J 7.0, 
CH3CH2CH2), 1.62 (2H, sext., J 7.5, CH3CH2), 1.46 (3H, s, OC(CH3)2), 1.42 (3H, s, 
OC(CH3)2), 1.03 (3H, s, CH2C(CH3)2), 1.02 (3H, t, J 7.5, CH2CH3), 0.96 (3H, s, CH2C(CH3)2); 
dC (125 MHz, CDCl3) 176.4 (COS), 171.4 (CH2CONH), 170.3 (CHCONH), 99.2 (OC(CH3)2), 
96.7 (CCCOS), 78.9 (CCCOS), 77.3 (CH), 71.6 (CH2OC(CH3)2), 42.6 (CH2CH2S), 36.1 
(CH2CONH), 34.9 (CH2NH), 33.1 (CH2C(CH3)2), 29.6 (OC(CH3)2), 29.5 (CH2S), 22.3 
(CH2C(CH3)2), 21.2 (CH3CH2CH2), 21.1 (CH3CH2), 19.0 (CH2C(CH3)2), 18.8 (OC(CH3)2), 
13.6 (CH3CH2);  HRMS (ESI) cald. for C20H32N2NaO5S (M + Na+) requires 435.1924, found 
435.1926; [α]$%' (c 0.3, CHCl3): +4.8. 
 
(R)-S-(2-(3-(2,4-dihydroxy-3,3-dimethylbutanamido)propanamido)ethyl) hex-2-
ynethioate (68) 
 
 
 
(R)-S-(2-(3-(2,2,5,5-tetramethyl-1,3-dioxane-4-carboxamido)propanamido)ethyl) hex-2-
ynethioate 70 (300 mg, 0.73 mmol, 1.0 equiv.) was stirred in AcOH (4 mL) and water (2 mL) 
for 16 h and RT. The mixture was then concentrated in vacuo and purified using silica 
chromatography (1 : 10 MeOH : EtOAc) to give the product as a colourless oil (216 mg, 80 %, 
0.58 mmol). 
nmax/cm-1 (neat) 3299 (OH), 2964 (NH), 1643 (C=O), 1533 (COS), 1037 (C-O); dH (500 MHz; 
CD3OD) 3.89 (1H, s, CH), 3.61-3.39 (6H, m, NHCH2, CH2CH2S, CH2CHOH), 3.09 (2H, t, J 
6.5, CH2S), 2.42 (2H, t, J 7.0, CH3CH2CH2), 2.41 (2H, t, J 6.5, CH2CONH), 1.62 (2H, sext., J 
7.5, CH3CH2), 1.03 (3H, t, J 7.5, CH2CH3), 0.92 (6H, s, CH2C(CH3)2); dC (125 MHz, CD3OD) 
177.2 (COS), 176.1 (CHCONH), 174.0 (CH2CONH), 96.9 (CCCOS), 79.6 (CCCOS), 77.3 
(CH), 70.4 (CH2OH), 40.4 (CH2C(CH3)2), 39.8 (CH2CH2S), 36.4 (CH2CONH), 36.3 (CH2NH), 
30.1 (CH2S), 22.2 (CH3CH2CH2), 21.4 (CH3CH2), 21.2 (CH2C(CH3)2), 19.0 (CH2C(CH3)2), 
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13.7 (CH3CH2);  HRMS (ESI) cald. for C17H28N2NaO5S (M + Na+) requires 395.1611, found 
395.1615; [α]$%' (c 0.4, CHCl3): +15.4. 
 
(R)-S-(2-(3-(2,4-dihydroxy-3,3-dimethylbutanamido)propanamido)ethyl) (Z)-hex-2-
enethioate (65) 
 
 
Procedure modified from Alhamadsheh et al.248 A mixture of Lindlar catalyst (10 mg, 5 wt% 
of Pd on CaCO3, poisoned with Pb) and quinoline (5.0 µL, 0.05 mmol, 0.1 equiv.) in 
anhydrous ethanol (5 ml) was stirred at RT for 20 min. A solution of (R)-S-(2-(3-(2,4-
dihydroxy-3,3-dimethylbutanamido)propanamido)ethyl) hex-2-ynethioate 68 (200 mg, 
0.51 mmol, 1.0 equiv.) in ethanol (5 ml) was added and the mixture was stirred for an 
additional 20 min at RT. The reaction mixture was placed under hydrogen atmosphere 
(balloon) and stirred for additional 4 hr. After analysis via mass spectrometry, the reaction 
appeared to have not yet reached completion. More catalyst was added (10 mg), and this 
process was repeated until the reaction was complete (8 days, 100 mg total catalyst). The 
catalyst was removed by filtration through Celite® and the filtrate was concentrated in vacuo 
to afford a yellow oil which was purified by silica chromatography (1 : 10 MeOH : EtOAc) to 
afford the product as a colourless oil (168 mg, 88 % 0.45 mmol, 95 : 5, Z : E). 
nmax/cm-1 (neat) 3287 (OH), 2951 (NH), 1640 (C=O), 1539 (COS), 1070 (C-O); dH (500 MHz; 
CD3OD) 6.14-6.06 (2H, m, CHCHCOS, CHCHCOS), 3.89 (1H, s, CH), 3.53-3.33 (6H, m, 
NHCH2, CH2CH2S, CH2CHOH), 3.05 (2H, t, J 7.0, CH2S), 2.59 (2H, q, J 7.0, CH3CH2CH2), 
2.41 (2H, t, J 6.5, CH2CONH), 1.48 (2H, sext., J 7.5, CH3CH2), 0.94 (3H, t, J 7.5, CH2CH3), 
0.92 (6H, s, CH2C(CH3)2); dC (125 MHz, CD3OD) 190.4 (COS), 176.1 (CHCONH), 173.9 
(CH2CONH), 148.5 (CHCHCOS), 127.2 (CHCHCOS), 77.3 (CH), 70.3 (CH2OH), 40.4 
(CH2C(CH3)2), 40.2 (CH2CH2S), 36.4 (CH2CONH), 36.3 (CH2NH), 32.9 (CH2S), 29.1 
(CH3CH2CH2), 23.3 (CH3CH2), 21.3 (CH2C(CH3)2), 20.9 (CH2C(CH3)2), 14.1 (CH3CH2);  
HRMS (ESI) cald. for C17H30N2NaO5S (M + Na+) requires 397.1768, found 397.1767; [α]$%' (c 
0.1, CHCl3): +7. 
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Methyl (S)-3-((tert-butyldimethylsilyl)oxy)butanoate (79) 
 
 
 
Procedure taken from Sugimoto et al.249 Under an Argon atmosphere, TBSCl (3.35 g, 
22.2 mmol, 1.05 equiv.) was added to a solution of methyl (S)-3-hydroxybutanoate (2.50 g, 
21.2 mmol, 1.00 equiv.), imidazole (2.16 g, 31.8 mmol, 1.50 equiv.) and DMAP (1.30 g, 
10.6 mmol, 0.50 equiv.) in DMF (60 mL) at 0 oC, and the mixture was stirred for 3 hours at 
RT. The reaction mixture was then diluted with Et2O, successively washed with HCl solution 
(10 %, 50 mL), saturated NaHCO3 (50 mL), dried (MgSO4) and concentrated in vacuo to 
afford the product as a colourless oil (4.72 g, 96 %, 20.3 mmol). 
dH (500 MHz; CDCl3) 4.27 (1H, dqd, J 7.5, 6 and 5.5, CH), 3.66 (3H, s, OCH3), 2.48 (1H, dd, 
J 14.5 and 7.5, CH2), 2.37 (1H, dd, J 14.5 and 5.5, CH2), 1.19 (3H, d, J 6.0, CH3), 0.86 (9H, s, 
C(CH3)3), 0.06 (3H, s, SiCH3), 0.04 (3H, s, SiCH3); dC (125 MHz, CDCl3) 172.4 (CO2Me), 
66.1 (CH), 51.7 (OCH3), 45.1 (CH2), 26.0 (C(CH3)3), 24.2 (CH3), 18.2 (C(CH3)3), -4.2 
(SiCH3), -4.8 (SiCH3)3; HRMS (ESI) cald. for C11H24NaO3Si (M + Na+) requires 255.1387, 
found 255.1387. Spectroscopic data consistent with that previously reported in the literature.249 
 
(S)-3-((tert-butyldimethylsilyl)oxy)butanal (74) 
 
 
 
Procedure modified from Fernandes et al.250 To a stirred solution of methyl (S)-3-((tert-
butyldimethylsilyl)oxy)butanoate 79 (1.23 g, 5.00 mmol, 1.0 equiv.) in CH2Cl2 (50 mL) was 
added a 1 M solution DIBAL-H in hexane (5.50 mL, 5.50 mmol, 1.1 equiv.) dropwise at -
78 oC under an argon atmosphere. After being stirred for 30 minutes at this temperature, 
MeOH (10 mL) was added, and the reaction was warmed to RT. A saturated solution of 
sodium potassium tartrate was then added (50 mL), and the mixture stirred until clear 
separation was observed. The organic layer was removed, and the aqueous layer further 
extracted with CH2Cl2 (2 × 50 mL), the combined organics were washed with brine (50 mL), 
dried (MgSO4) and concentrated in vacuo. The resulting oil was then purified by silica 
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chromatography (3:100 Et2O : Petroleum ether) to afford the product as a colourless oil (891 
mg, 82 %, 4.5 mmol).  
dH (500 MHz; CDCl3) 9.79 (1H, dd, J 3.0 and 2.0, CHO), 4.35 (1H, dqd, J 7.0, 6.0 and 5.0, 
CH), 2.55 (1H, ddd, J 15.5, 7.0 and 3.0, CH2), 2.46 (1H, dd, J 15.5, 5.0 and 2.0, CH2), 1.23 
(3H, d, J 6.0, CH3), 0.87 (9H, s, C(CH3)3), 0.07 (3H, s, SiCH3), 0.06 (3H, s, SiCH3); dC (125 
MHz, CDCl3) 202.6 (CHO), 64.9 (CH), 53.4 (CH2), 26.1 (C(CH3)3), 24.6 (CH3), 18.3 
(C(CH3)3), -4.0 (SiCH3), -4.6 (SiCH3)3; HRMS (ESI) cald. for C11H26NaO3Si (M + MeOH + 
Na+) requires 257.1543, found 257.1543. Spectroscopic data consistent with that previously 
reported in the literature.250  
 
(3R,5S)-1-((S)-4-benzyl-2-thioxothiazolidin-3-yl)-5-((tert-butyldimethylsilyl) oxy)-3-
hydroxyhexan-1-one and (3S,5S)-1-((S)-4-benzyl-2-thioxothiazolidin-3-yl)-5-((tert-
butyldimethylsilyl)oxy)-3-hydroxyhexan-1-one (76 and 77) 
 
 
 
Procedure taken from Gao et al.251 To a solution of (S)-1-(4-benzyl-2-thioxothiazolidin-3-
yl)ethan-1-one 75 (600 mg, 2.39 mmol, 1.00 equiv.) in dry CH2Cl2 (20 mL) under an Ar 
atmosphere was added a 1 M solution of TiCl4 in CH2Cl2 (2.55 mL, 2.51 mmol, 1.05 equiv.) 
dropwise at 0 oC. The orange suspension was allowed to stir for 15 minutes at the same 
temperature before diisopropylethylamine (0.46 mL, 2.63 mmol, 1.10 equiv.) was added 
dropwise, the resulting purple solution was allowed to stir for a further 40 min at 0 oC. 1-
Methyl-2-pyrrolidinone (0.46 mL, 4.78 mmol, 2.00 equiv.) was then added at the same 
temperature and the reaction stirred for an additional 10 min before a solution of (S)-3-((tert-
butyldimethylsilyl)oxy)butanal 74 (965 mg, 4.78 mmol, 2.00 equiv.) in dry CH2Cl2 (5 mL) was 
added. The reaction was left to stir for 2 h at 0 oC before the addition of saturated NH4Cl 
(10 mL), the organic layer was separated and the aqueous layer extracted with CH2Cl2 (2 × 20 
mL). The combined organics were dried (MgSO4), filtered and concentrated in vacuo to give the 
crude product, which was purified by silica chromatography (1 : 9 EtOAc : Petroleum ether) to 
give (3R,5S)-1-((S)-4-benzyl-2-thioxothiazolidin-3-yl)-5-((tert-butyldimethylsilyl)oxy)-3-
hydroxyhexan-1-one 77 (196 mg, 18 %, 0.43 mmol) and (3S,5S)-1-((S)-4-benzyl-2-
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thioxothiazolidin-3-yl)-5-((tert-butyldimethylsilyl)oxy)-3-hydroxyhexan-1-one 76 (326 mg, 30 
%, 0.7 mmol) as yellow oils respectively.  
(3R,5S)-1-((S)-4-benzyl-2-thioxothiazolidin-3-yl)-5-((tert-butyldimethylsilyl)oxy)-3-
hydroxyhexan-1-one 77: dH (500 MHz; CDCl3) 7.36-7.27 (5H, m, ArH), 5.41 (1H, ddd, J 10.5, 
7.0 and 4.0, CHN), 4.38 (1H, tt, J 9.5 and 3.0, CHOH), 4.18 (1H, quin.d, J 6.5 and 3.5, CHOSi), 
3.59 (1H, br. s, OH), 3.48 (1H, dd, J 17.5 and 9.0, CH2CON), 3.39 (1H, dd, J 11.5 and 7.5, 
CH2S), 3.36 (1H, dd, J 17.5 and 3.5, CH2CON), 3.23 (1H, dd, J 13.0 and 4.0, CH2Ar), 3.04 (1H, 
dd, J 13.0 and 10.5, CH2Ar), 2.89 (1H, d, J 11.5, CH2S), 1.68 (1H, ddd, J 14.0, 10.0 and 3.0, 
CHCH2CHOH), 1.53 (1H, ddd, J 14.0, 7.5 and 2.5, CHCH2CHOH), 1.21 (3H, d, J 6.5, CH3CH), 
0.89 (9H, s, C(CH3)3), 0.10 (3H, s, SiCH3), 0.09 (3H, s, SiCH3); dC (125 MHz, CDCl3) 201.5 
(CS2), 173.3 (CON), 136.6 (ArCquat), 129.6 (ArC), 129.1 (ArC), 127.4 (ArC), 68.5 (CHN), 66.4 
(CHOSi), 65.3 (CHOH), 46.4 (CH2CON), 45.0 (CHCH2CHOH), 37.0 (CH2Ar), 32.1 (CH2S), 
26.1 (C(CH3)3), 23.8 (CHCH3), 18.2 (C(CH3)3), -4.3 (SiCH3), -4.7 (SiCH3); HRMS (ESI) cald. 
for C22H36NO3S2Si (M + H+) requires 454.1900, found 454.1905. 
 
(3S,5S)-1-((S)-4-benzyl-2-thioxothiazolidin-3-yl)-5-((tert-butyldimethylsilyl)oxy)-3-
hydroxyhexan-1-one 76: dH (500 MHz; CDCl3) 7.36-7.25 (5H, m, ArH), 5.40 (1H, ddd, J 11.0, 
7.0 and 4.0, CHN), 4.36 (1H, tt, J 8.5 and 3.5, CHOH), 4.12 (1H, dqd., J 8.5, 6.0 and 4.5, 
CHOSi), 3.52 (1H, br. s, OH), 3.50 (1H, dd, J 17.5 and 3.5, CH2CON), 3.39 (1H, dd, J 11.5 and 
7.0, CH2S), 3.28 (1H, dd, J 17.5 and 8.5, CH2CON), 3.23 (1H, dd, J 13.5 and 4.0, CH2Ar), 3.04 
(1H, dd, J 13.5 and 10.5, CH2Ar), 2.88 (1H, d, J 11.5, CH2S), 1.73 (1H, dt, J 14.0 and 9.0, 
CHCH2CHOH), 1.62 (1H, dt, J 14.0 and 4.0, CHCH2CHOH), 1.21 (3H, d, J 6.5, CH3CH), 0.89 
(9H, s, C(CH3)3), 0.12 (3H, s, SiCH3), 0.10 (3H, s, SiCH3); dC (125 MHz, CDCl3) 201.5 (CS2), 
172.6 (CON), 136.7 (ArCquat), 129.6 (ArC), 129.1 (ArC), 127.4 (ArC), 68.8  (CHOSi), 68.6 
(CHN), 67.2 (CHOH), 46.3 (CH2CON), 45.6 (CHCH2CHOH), 36.9 (CH2Ar), 32.2 (CH2S), 26.0 
(C(CH3)3), 24.4 (CHCH3), 18.1 (C(CH3)3), -3.8 (SiCH3), -4.6 (SiCH3); HRMS (ESI) cald. for 
C22H35NNaO3S2Si (M + Na+) requires 476.1720, found 476.1724. Spectroscopic data for both 
compounds was consistent with that previously reported in the literature.251 The relative 
stereochemistry of each aldol product was further confirmed by comparison of diagnostic proton 
shifts to those described previously in the literature.154 
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S-(2-(3-((R)-2,2,5,5-tetramethyl-1,3-dioxane-4-carboxamido)propanamido) ethyl) (3R,5S)-
5-((tert-butyldimethylsilyl)oxy)-3-hydroxyhexanethioate (80) 
 
 
 
Procedure modified from Gao et al.251 To a stirred solution of (3R,5S)-1-((S)-4-benzyl-2-
thioxothiazolidin-3-yl)-5-((tert-butyldimethylsilyl)oxy)-3-hydroxyhexan-1-one 77 (150 mg, 
0.33 mmol, 1.0 equiv.) in acetonitrile (5 mL), was added K2CO3 (63 mg, 0.33 mmol, 1.0 equiv.) 
and (R)-N-(3-((2-mercaptoethyl)amino)-3-oxopropyl)-2,2,5,5-tetramethyl-1,3-dioxane-4-
carboxamide 61 (106 mg, 0.33 mmol, 1.0 equiv.). The mixture was stirred at RT for 1 h before 
being quenched by the addition of saturated NH4Cl solution (1 mL). The acetonitrile was then 
removed in vacuo and the resulting solution extracted with EtOAc (3 × 10 mL) The combined 
organics were washed with brine, dried (MgSO4), filtered and concentrated in vacuo to give a 
crude oil which was purified by silica chromatography (1 : 10 MeOH : CH2Cl2) to give the 
product as a colourless oil (128 mg, 70 %, 0.23 mmol). 
nmax/cm-1 (neat) 3323 (OH), 2956 (NH), 1656 (C=O), 1530 (C=O), 1099 (C-O); dH (500 MHz; 
CDCl3) 7.02 (1H, br. t, J 6.0, CHCONH), 6.32 (1H, br. s, NHCH2CH2S), 4.43-4.38 (1H, m, 
CHOH), 4.17 (1H, quin.d, J 6.0 and 3.5, CHOSi),  4.06 (1H, s, CHCONH), 3.83 (1H, br. s, 
OH), 3.67 (1H, d, J 11.5, CH2OC(CH3)2),  3.60-3.35 (4H, m, NHCH2, CH2CH2S), 3.27 (1H, d, J 
11.5, CH2OC(CH3)2), 3.05 (1H, dt, J 14.0 and 6.5, CH2S), 3.01 (1H, dt, J 14.0 and 6.5, CH2S), 
2.75 (1H, dd, J 15.0 and 8.5, CH2COS), 2.65 (1H, dd, J 15.0 and 4.0, CH2COS) 2.40 (2H, t, J 
6.5, CH2CONH), 1.65 (1H, ddd, J 14.0, 9.5 and 4.0, CH2CHOSi), 1.50 (1H, ddd, J 14.0, 6.5 and 
2.5, CH2CHOSi), 1.45 (3H, s, OC(CH3)2), 1.41 (3H, s, OC(CH3)2), 1.21 (3H, d, J 6.0, CHCH3), 
1.02 (3H, s, CH2C(CH3)2), 0.96 (3H, s, CH2C(CH3)2), 0.88 (9H, s, C(CH3)3), 0.08 (3H, s, 
SiCH3), 0.07 (3H, s, SiCH3); dC (125 MHz, CDCl3) 198.5 (CO2S), 171.4 (CH2CONH), 170.4 
(CHCONH), 99.3 (OC(CH3)2), 77.3 (CH), 71.6 (CH2OC(CH3)2), 70.0 (CHOSi), 66.0 (CHOH), 
51.9 (CH2COS), 44.4 (CH2CHOSi), 39.4 (CH2CH2S), 36.2 (CH2CONH), 35.0 (CH2NH), 33.1 
(CH2C(CH3)2), 29.6 (OC(CH3)2), 28.9 (CH2S), 26.0 (C(CH3)3), 23.3 (CHCH3), 22.3 
(CH2C(CH3)2), 19.1 (CH2C(CH3)2), 18.9 (OC(CH3)2), 18.1 (C(CH3)3), -4.3 (SiCH3), -4.8 
(SiCH3); HRMS (ESI) cald. for C26H50N2NaO7SSi (M + Na+) requires 585.3000, found 
585.3004; [α]$%' (c 0.3, CHCl3): +40. 
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S-(2-(3-((R)-2,2,5,5-tetramethyl-1,3-dioxane-4-carboxamido)propanamido)ethyl) (3S,5S)-
5-((tert-butyldimethylsilyl)oxy)-3-hydroxyhexanethioate (270) 
 
 
 
S-(2-(3-((R)-2,2,5,5-tetramethyl-1,3-dioxane-4-carboxamido)propanamido)ethyl) (3S,5S)-5-
((tert-butyldimethylsilyl)oxy)-3-hydroxyhexanethioate 270 was synthesized using the same 
procedure as that used for the synthesis of S-(2-(3-((R)-2,2,5,5-tetramethyl-1,3-dioxane-4-
carboxamido)propanamido)ethyl) (3R,5S)-5-((tert-butyldimethylsilyl)oxy)-3-
hydroxyhexanethioate 80 using (3S,5S)-1-((S)-4-benzyl-2-thioxothiazolidin-3-yl)-5-((tert-
butyldimethylsilyl)oxy)-3-hydroxyhexan-1-one 76 (200 mg, 0.44 mmol), to afford the product 
as a colourless oil (179 mg, 78 %, 0.38 mmol). 
nmax/cm-1 (neat) 3320 (OH), 2953 (NH), 1655 (C=O), 1529 (C=O), 1098 (C=O); dH (500 MHz; 
CDCl3) 7.01 (1H, br. t, J 6.0, CHCONH), 6.20 (1H, br. t, J 6.0, NHCH2CH2S), 4.25 (1H, tt, J 
8.0 and 4.0, CHOH), 4.11-4.04 (2H, m, CHOSi, CHCONH), 3.86 (1H, br. s, OH), 3.67 (1H, d, J 
11.5, CH2OC(CH3)2),  3.60-3.41 (4H, m, NHCH2, CH2CH2S), 3.28 (1H, d, J 11.5, 
CH2OC(CH3)2), 3.07 (1H, dt, J 14.0 and 6.0, CH2S), 3.02 (1H, dt, J 14.0 and 6.0), CH2S), 2.75 
(1H, dd, J 15.0 and 8.0, CH2COS), 2.68 (1H, dd, J 15.0 and 4.5, CH2COS) 2.42 (1H, dt, J 15.0 
and 6.5, CH2CONH), 2.39 (1H, dt, J 15.0 and 6.5, CH2CONH), 1.67 (1H, dt, J 14 and 9, 
CH2CHOSi), 1.58 (1H, dt, J 14.0 and 4.0, CH2CHOSi), 1.46 (3H, s, OC(CH3)2), 1.42 (3H, s, 
OC(CH3)2), 1.18 (3H, d, J 6.0, CHCH3), 1.04 (3H, s, CH2C(CH3)2), 0.97 (3H, s, CH2C(CH3)2), 
0.89 (9H, s, C(CH3)3), 0.11 (3H, s, SiCH3), 0.10 (3H, s, SiCH3); dC (125 MHz, CDCl3) 198.4 
(CO2S), 171.3 (CH2CONH), 170.4 (CHCONH), 99.3 (OC(CH3)2), 77.3 (CH), 71.6 
(CH2OC(CH3)2), 69.0 (CHOSi), 68.2 (CHOH), 51.6 (CH2COS), 45.6 (CH2CHOSi), 39.5 
(CH2CH2S), 36.2 (CH2CONH), 35.1 (CH2NH), 33.1 (CH2C(CH3)2), 29.7 (OC(CH3)2), 28.9 
(CH2S), 26.0 (C(CH3)3), 24.5 (CHCH3), 22.4 (CH2C(CH3)2), 19.1 (CH2C(CH3)2), 18.9 
(OC(CH3)2), 18.1 (C(CH3)3), -3.8 (SiCH3), -4.6 (SiCH3); HRMS (ESI) cald. for 
C26H50N2NaO7SSi (M + Na+) requires 585.3000, found 585.3004; [α]$%' (c 0.1, CHCl3): +64. 
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(2-(3-((R)-2,4-dihydroxy-3,3-dimethylbutanamido)propanamido)ethyl) (3R,5S)-3,5-
dihydroxyhexanethioate (71) 
 
 
 
S-(2-(3-((R)-2,2,5,5-tetramethyl-1,3-dioxane-4-carboxamido)propanamido)ethyl) (3R,5S)-5-
((tert-butyldimethylsilyl)oxy)-3-hydroxyhexanethioate 80 (100 mg, 0.18 mmol, 1.0 equiv.) was 
stirred in a 2:1 ratio of AcOH/H2O (3 mL) at RT for 16 h. The reaction was then concentrated in 
vacuo and purified by silica chromatography (15 : 85 MeOH : CH2Cl2) to afford the desired 
product as a colourless oil (51 mg, 70 %, 0.13 mmol). 
nmax/cm-1 (neat) 3380 (OH), 2960 (NH), 1654 (C=O), 1528 (C=O); dH (500 MHz; CD3OD) 4.28 
(1H, quin., J 6.5, CH2CHOHCH2), 3.97 (1H, sext., J 6.0, CH3CHOH),  3.89 (1H, s, CHCONH), 
3.54-3.30 (6H, m, NHCH2, CH2CH2S, CH2OH), 3.02 (2H, t, J 6.5, CH2S), 2.74 (1H, dd, J 15.0 
and 7.5, CH2COS), 2.71 (1H, dd, J 15.0 and 6.0, CH2COS) 2.41 (2H, t, J 7.0, CH2CONH), 1.53 
(2H, dd, J 7.0 and 5.5, CH3CH2CHOH), 1.18 (3H, d, J 6.5, CHCH3), 0.92 (6H, s, C(CH3)2); 
dC (125 MHz, CD3OD) 198.7 (CO2S), 176.1 (CH2CONH), 174.0 (CHCONH), 77.3 
(CHOHC(CH3)2), 70.4 (CH2OH), 66.9 (CH2CHOHCH2), 65.1 (CH3CHOH), 53.1 (CH2COS), 
46.8 (CHOHCH2CHOH), 40.4 (CH2C(CH3)2), 40.0 (CH2CH2S), 36.4 (CH2CONH), 36.3 
(CH2NH), 29.3 (CH2S), 24.3 (CHCH3), 21.3 (CH2C(CH3)2), 20.9 (CH2C(CH3)2); HRMS (ESI) 
cald. for C17H32N2NaO7S (M + Na+) requires 431.1822, found 431.1824; [α]$%' (c 0.3, CHCl3): 
+8.2. 
 
S-(2-(3-((R)-2,4-dihydroxy-3,3-dimethylbutanamido)propanamido)ethyl) (3S,5S)-3,5-
dihydroxyhexanethioate (78) 
 
 
 
S-(2-(3-((R)-2,4-dihydroxy-3,3-dimethylbutanamido)propanamido)ethyl) (3S,5S)-3,5-
dihydroxyhexanethioate 78 was synthesized using the same procedure as that used for the 
synthesis of (2-(3-((R)-2,4-dihydroxy-3,3-dimethylbutanamido)propanamido) ethyl) (3R,5S)-
3,5-dihydroxyhexanethioate 71 using S-(2-(3-((R)-2,2,5,5-tetramethyl-1,3-dioxane-4-
carboxamido)propanamido)ethyl) (3S,5S)-5-((tert-butyldimethylsilyl) oxy)-3-
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hydroxyhexanethioate 270 (100 mg, 0.18 mmol), to afford the product as a colourless oil (70 
mg, 96 %, 0.17 mmol). 
nmax/cm-1 (neat) 3326 (OH), 2966 (NH), 1647 (C=O), 1560 (C=O); dH (500 MHz; CD3OD) 4.21 
(1H, tt, J 8.5 and 5.5, CH2CHOHCH2), 3.93 (1H, dquin., J 7.5 and 6.0, CH3CHOH),  3.89 (1H, 
s, CHCONH), 3.53-3.33 (6H, m, NHCH2, CH2CH2S, CH2OH), 3.04 (1H, dt, J 13.5 and 6.5, 
CH2S), 3.01 (1H, dt, J 13.5 and 6.5, CH2S), 2.76 (1H, dd, J 15.0 and 5.0, CH2COS), 2.72 (1H, 
dd, J 15.0 and 7.5, CH2COS) 2.41 (2H, t, J 7.0, CH2CONH), 1.66 (1H, dt, J 14.0 and 8.0, 
CHOHCH2CHOH), 1.55 (1H, dt, J 14.0 and 5.0, CHOHCH2CHOH), 1.18 (3H, d, J 6.0, 
CHCH3), 0.92 (6H, s, C(CH3)2); dC (125 MHz, CD3OD) 198.7 (CO2S), 176.1 (CH2CONH), 
174.0 (CHCONH), 77.3 (CHOHC(CH3)2), 70.3 (CH2OH), 68.2 (CH2CHOHCH2), 66.8 
(CH3CHOH), 52.6 (CH2COS), 46.3 (CHOHCH2CHOH), 40.4 (CH2C(CH3)2), 40.0 (CH2CH2S), 
36.4 (CH2CONH), 36.3 (CH2NH), 29.3 (CH2S), 23.5 (CHCH3), 21.3 (CH2C(CH3)2), 20.9 
(CH2C(CH3)2); HRMS (ESI) cald. for C17H32N2NaO7S (M + Na+) requires 431.1822, found 
431.1821; [α]$%' (c 0.35, CHCl3): +17.7. 
 
Methyl (R)-3-((tert-butyldimethylsilyl)oxy)butanoate (271) 
 
 
 
Methyl (R)-3-((tert-butyldimethylsilyl)oxy)butanoate 271 was synthesized using the same 
procedure as that used for the synthesis of Methyl (S)-3-((tert-
butyldimethylsilyl)oxy)butanoate 79  using (R)-3-hydroxybutanoate (2.50 g, 21.2 mmol). The 
product was observed as a colourless oil (4.01 g, 82 %, 17.3 mmol). Spectroscopic data was 
identical to that of Methyl (S)-3-((tert-butyldimethylsilyl)oxy)butanoate 79 and consistent 
with that previously reported in the literature.252 
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(R)-3-((tert-butyldimethylsilyl)oxy)butanal (93) 
 
 
 
(R)-3-((tert-butyldimethylsilyl)oxy)butanal 93 was synthesized using the same procedure as 
that used for the synthesis of (S)-3-((tert-butyldimethylsilyl)oxy)butanal 74 using methyl (R)-
3-((tert-butyldimethylsilyl)oxy)butanoate 271 (1.84 g, 7.5 mmol). The product was observed 
as a colourless oil (1.32 g, 82 %, 6.15 mmol). Spectroscopic data was identical to that of (S)-3-
((tert-butyldimethylsilyl)oxy)butanal 74 and consistent with that previously reported in the 
literature.253 
 
(3R,5R)-1-((S)-4-benzyl-2-thioxothiazolidin-3-yl)-5-((tert-butyldimethylsilyl)oxy)-3-
hydroxyhexan-1-one and (3S,5R)-1-((S)-4-benzyl-2-thioxothiazolidin-3-yl)-5-((tert-
butyldimethylsilyl)oxy)-3-hydroxyhexan-1-one (95 and 94) 
 
 
 
(3R,5R)-1-((S)-4-benzyl-2-thioxothiazolidin-3-yl)-5-((tert-butyldimethylsilyl)oxy)-3-hydroxy 
hexan-1-one 95 and (3S,5R)-1-((S)-4-benzyl-2-thioxothiazolidin-3-yl)-5-((tert-
butyldimethylsilyl)oxy)-3-hydroxyhexan-1-one 94 were synthesized using the same procedure 
as that used for the synthesis of (3R,5S)-1-((S)-4-benzyl-2-thioxothiazolidin-3-yl)-5-((tert-
butyldimethylsilyl)oxy)-3-hydroxyhexan-1-one 77 and (3S,5S)-1-((S)-4-benzyl-2-
thioxothiazolidin-3-yl)-5-((tert-butyldimethylsilyl)oxy)-3-hydroxyhexan-1-one 76, using (R)-3-
((tert-butyldimethylsilyl)oxy)butanal 93 (900 mg, 4.4 mmol) to afford the products (3R,5R)-1-
((S)-4-benzyl-2-thioxothiazolidin-3-yl)-5-((tert-butyldimethylsilyl)oxy)-3-hydroxyhexan-1-one 
95 (488 mg, 27 %, 1.2 mmol) and (3S,5R)-1-((S)-4-benzyl-2-thioxothiazolidin-3-yl)-5-((tert-
butyldimethylsilyl)oxy)-3-hydroxyhexan-1-one 94 (436 mg, 24 %, 1.05 mmol). 
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(3R,5R)-1-((S)-4-benzyl-2-thioxothiazolidin-3-yl)-5-((tert-butyldimethylsilyl)oxy)-3-hydroxy 
hexan-1-one 95: nmax/cm-1 (neat) 3498 (OH), 2955 (ArH), 1689 (C=O); dH (500 MHz; CDCl3) 
7.37-7.27 (5H, m, ArH), 5.38 (1H, ddd, J 11.0, 7.5 and 4.0, CHN), 4.26 (1H, dddd, J 9.5, 6.5, 
6.0 and 4.0, CHOH), 4.10 (1H, dquin., J 8.5 and 6.0, CHOSi), 3.63 (1H, br. d, J 2.5, OH), 3.47 
(1H, dd, J 17.5 and 7.0, CH2CON), 3.43 (1H, dd, J 17.5 and 5.5, CH2CON), 3.38 (1H, dd, J 
11.5 and 7.5, CH2S), 3.24 (1H, dd, J 13.5 and 3.5, CH2Ar), 3.04 (1H, dd, J 13.5 and 10.5, 
CH2Ar), 2.89 (1H, d, J 11.5, CH2S), 1.74 (1H, dt, J 14.0 and 8.5, CHCH2CHOH), 1.61 (1H, 
ddd, J 14.0, 4.5 and 3.5, CHCH2CHOH), 1.19 (3H, d, J 6.0, CH3CH), 0.89 (9H, s, C(CH3)3), 
0.10 (3H, s, SiCH3), 0.07 (3H, s, SiCH3); dC (125 MHz, CDCl3) 201.6 (CS2), 173.2 (CON), 
136.8 (ArCquat), 129.8 (ArC), 129.3 (ArC), 127.6 (ArC), 68.8  (CHN), 68.6 (CHOSi), 67.2 
(CHOH), 46.1 (CH2CON), 45.8 (CHCH2CHOH), 37.1 (CH2Ar), 32.3 (CH2S), 26.2 (C(CH3)3), 
24.4 (CHCH3), 18.3 (C(CH3)3), -3.7 (SiCH3), -4.6 (SiCH3); HRMS (ESI) cald. for 
C22H35NNaO3S2Si (M + Na+) requires 476.1720, found 476.1723; [α]$%' (c 0.15, CHCl3): +101. 
 
(3S,5R)-1-((S)-4-benzyl-2-thioxothiazolidin-3-yl)-5-((tert-butyldimethylsilyl)oxy)-3-
hydroxyhexan-1-one 94: nmax/cm-1 (neat) 3501 (OH), 2954 (ArH), 1689 (C=O); dH (500 MHz; 
CDCl3) 7.36-7.25 (5H, m, ArH), 5.39 (1H, ddd, J 11.0, 7.0 and 4.0, CHN), 4.54 (1H, tt, J 10.0 
and 2.5, CHOH), 4.21 (1H, quin.d, J 6.5 and 3.5, CHOSi), 3.63 (1H, br. s, OH), 3.42 (1H, dd, J 
17.5 and 3.0, CH2CON), 3.39 (1H, dd, J 11.5 and 7.0, CH2S), 3.30 (1H, dd, J 17.5 and 9.0, 
CH2CON), 3.25 (1H, dd, J 13.0 and 3.5, CH2Ar), 3.04 (1H, dd, J 13.0 and 10.5, CH2Ar), 2.88 
(1H, d, J 11.5, CH2S), 1.73 (1H, ddd, J 14.0, 10.0 and 3.5, CHCH2CHOH), 1.57 (1H, ddd, J 
14.0, 6.5 and 2.0, CHCH2CHOH), 1.25 (3H, d, J 6.5, CH3CH), 0.89 (9H, s, C(CH3)3), 0.11 (3H, 
s, SiCH3), 0.09 (3H, s, SiCH3); dC (125 MHz, CDCl3) 201.4 (CS2), 172.6 (CON), 136.6 
(ArCquat), 129.6 (ArC), 129.0 (ArC), 127.3 (ArC), 68.7 (CHN), 67.0 (CHOSi), 64.9 (CHOH), 
46.7 (CH2CON), 44.2 (CHCH2CHOH), 36.8 (CH2Ar), 32.2 (CH2S), 26.0 (C(CH3)3), 23.3 
(CHCH3), 18.1 (C(CH3)3), -4.3 (SiCH3), -4.8 (SiCH3); HRMS (ESI) cald. for C22H35NNaO3S2Si 
(M + Na+) requires 476.1720, found 476.1722; [α]$%' (c 0.1, CHCl3): +110.5. 
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S-(2-(3-((R)-2,2,5,5-tetramethyl-1,3-dioxane-4-carboxamido)propanamido)ethyl) (3R,5R)-
5-((tert-butyldimethylsilyl)oxy)-3-hydroxyhexanethioate (97) 
 
 
 
S-(2-(3-((R)-2,2,5,5-tetramethyl-1,3-dioxane-4-carboxamido)propanamido)ethyl) (3R,5R)-5-
((tert-butyldimethylsilyl)oxy)-3-hydroxyhexanethioate 97 was synthesized using the same 
procedure as that used for the synthesis of S-(2-(3-((R)-2,2,5,5-tetramethyl-1,3-dioxane-4-
carboxamido)propanamido)ethyl) (3R,5S)-5-((tert-butyldimethylsilyl)oxy)-3-
hydroxyhexanethioate 80 using (3R,5R)-1-((S)-4-benzyl-2-thioxothiazolidin-3-yl)-5-((tert-
butyldimethylsilyl)oxy)-3-hydroxyhexan-1-one 95 (310 mg, 0.68 mmol), to afford the product 
as a colourless oil (243 mg, 64 %, 0.43 mmol). 
nmax/cm-1 (neat) 3310 (OH), 2953 (NH), 1655 (C=O), 1527 (C=O); dH (500 MHz; CDCl3) 7.02 
(1H, br. t, J 6.0, CHCONH), 6.19 (1H, br. t, J 6.0, NHCH2CH2S), 4.28 (1H, tt, J 8.5 and 3.5, 
CHOH), 4.12-4.04 (2H, m, CHOSi, CHCONH), 3.68 (1H, d J 11.5, CH2OC(CH3)2),  3.60-3.40 
(4H, m, NHCH2, CH2CH2S), 3.28 (1H, d J 11.5, CH2OC(CH3)2), 3.07 (1H, dt, J 14.0 and 6.0, 
CH2S), 3.02 (1H, dt, J 14.0 and 6.0), CH2S), 2.75 (1H, dd, J 15.0 and 8.5, CH2COS), 2.67 (1H, 
dd, J 15.0 and 4.0, CH2COS) 2.42 (1H, dt, J 15.0 and 6.5, CH2CONH), 2.40 (1H, dt, J 15.0 and 
6.5, CH2CONH), 1.67 (1H, dt, J 14.0 and 8.5, CH2CHOSi), 1.57 (1H, dt, J 14.0 and 3.5, 
CH2CHOSi), 1.46 (3H, s, OC(CH3)2), 1.42 (3H, s, OC(CH3)2), 1.18 (3H, d, J 6.0, CHCH3), 1.04 
(3H, s, CH2C(CH3)2), 0.97 (3H, s, CH2C(CH3)2), 0.89 (9H, s, C(CH3)3), 0.11 (3H, s, SiCH3), 
0.10 (3H, s, SiCH3); dC (125 MHz, CDCl3) 198.5 (CO2S), 171.3 (CH2CONH), 170.3 
(CHCONH), 99.3 (OC(CH3)2), 77.4 (CH), 71.5 (CH2OC(CH3)2), 69.0 (CHOSi), 68.2 (CHOH), 
51.6 (CH2COS), 45.7 (CH2CHOSi), 39.4 (CH2CH2S), 36.2 (CH2CONH), 35.0 (CH2NH), 33.1 
(CH2C(CH3)2), 29.8 (OC(CH3)2), 28.9 (CH2S), 26.0 (C(CH3)3), 24.5 (CHCH3), 22.4 
(CH2C(CH3)2), 19.1 (CH2C(CH3)2), 18.9 (OC(CH3)2), 18.1 (C(CH3)3), -3.8 (SiCH3), -4.6 
(SiCH3); HRMS (ESI) cald. for C26H50N2NaO7SSi (M + Na+) requires 585.3000, found 
585.3003; [α]$%' (c 0.1, CHCl3): +45.5. 
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S-(2-(3-((R)-2,2,5,5-tetramethyl-1,3-dioxane-4-carboxamido)propanamido)ethyl) (3S,5R)-
5-((tert-butyldimethylsilyl)oxy)-3-hydroxyhexanethioate (96) 
 
 
 
S-(2-(3-((R)-2,2,5,5-tetramethyl-1,3-dioxane-4-carboxamido)propanamido)ethyl) (3S,5R)-5-
((tert-butyldimethylsilyl)oxy)-3-hydroxyhexanethioate 96 was synthesized using the same 
procedure as that used for the synthesis of S-(2-(3-((R)-2,2,5,5-tetramethyl-1,3-dioxane-4-
carboxamido)propanamido)ethyl) (3R,5S)-5-((tert-butyldimethylsilyl)oxy)-3-
hydroxyhexanethioate 80 using (3S,5R)-1-((S)-4-benzyl-2-thioxothiazolidin-3-yl)-5-((tert-
butyldimethylsilyl)oxy)-3-hydroxyhexan-1-one 94 (185 mg, 0.41 mmol), to afford the product 
as a colourless oil (158 mg, 69 %, 0.28 mmol). 
nmax/cm-1 (neat) 3310 (OH), 2954 (NH), 1655 (C=O), 1529 (C=O); dH (500 MHz; CDCl3) 7.02 
(1H, br. t, J 6.5, CHCONH), 6.33 (1H, br. t, J 6.0, NHCH2CH2S), 4.40 (1H, dddd, J 10.0, 8.5, 
4.5 and 2.5 CHOH), 4.17 (1H, quin.d, J 6.5 and 3.5, CHOSi),  4.06 (1H, s, CHCONH), 3.81 
(1H, br. s, OH), 3.67 (1H, d, J 11.5, CH2OC(CH3)2),  3.60-3.35 (4H, m, NHCH2, CH2CH2S), 
3.26 (1H, d J 11.5, CH2OC(CH3)2), 3.05 (1H, dt, J 14.0 and 6.0, CH2S), 3.01 (1H, dt, J 14.0 and 
6.5, CH2S), 2.74 (1H, dd, J 15.0 and 8.5, CH2COS), 2.66 (1H, dd, J 15.0 and 4.0, CH2COS), 
2.42 (1H, dt, J 15.0 and 5.5, CH2CONH), 2.38 (1H, dt, J 15.0 and 6.0, CH2CONH), 1.65 (1H, 
ddd, J 14.0, 10.0 and 3.5, CH2CHOSi), 1.51 (1H, ddd, J 14.0, 6.5 and 2.5, CH2CHOSi), 1.45 
(3H, s, OC(CH3)2), 1.41 (3H, s, OC(CH3)2), 1.20 (3H, d, J 6.5, CHCH3), 1.02 (3H, s, 
CH2C(CH3)2), 0.95 (3H, s, CH2C(CH3)2), 0.88 (9H, s, C(CH3)3), 0.08 (3H, s, SiCH3), 0.07 (3H, 
s, SiCH3); dC (125 MHz, CDCl3) 198.5 (CO2S), 171.4 (CH2CONH), 170.4 (CHCONH), 99.3 
(OC(CH3)2), 77.3 (CH), 71.6 (CH2OC(CH3)2), 66.9 (CHOSi), 66.0 (CHOH), 52.0 (CH2COS), 
44.5 (CH2CHOSi), 39.4 (CH2CH2S), 36.2 (CH2CONH), 35.1 (CH2NH), 33.1 (CH2C(CH3)2), 
29.6 (OC(CH3)2), 28.9 (CH2S), 26.0 (C(CH3)3), 23.3 (CHCH3), 22.3 (CH2C(CH3)2), 19.1 
(CH2C(CH3)2), 18.9 (OC(CH3)2), 18.1 (C(CH3)3), -4.3 (SiCH3), -4.8 (SiCH3); HRMS (ESI) cald. 
for C26H50N2NaO7SSi (M + Na+) requires 585.3000, found 585.3007; [α]$%' (c 0.15, CHCl3): 
+27.7. 
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S-(2-(3-((R)-2,4-dihydroxy-3,3-dimethylbutanamido)propanamido)ethyl) (3R,5R)-3,5-
dihydroxyhexanethioate (92) 
 
 
 
S-(2-(3-((R)-2,4-dihydroxy-3,3-dimethylbutanamido)propanamido)ethyl) (3R,5R)-3,5-
dihydroxyhexanethioate 92 was synthesized using the same procedure as that used for the 
synthesis of (2-(3-((R)-2,4-dihydroxy-3,3-dimethylbutanamido)propanamido) ethyl) (3R,5S)-
3,5-dihydroxyhexanethioate 71 using S-(2-(3-((R)-2,2,5,5-tetramethyl-1,3-dioxane-4-
carboxamido)propanamido)ethyl) (3R,5R)-5-((tert-butyldimethylsilyl) oxy)-3-
hydroxyhexanethioate 97 (100 mg, 0.18 mmol), to afford the product as a colourless oil (61 mg, 
83 %, 0.15 mmol). 
nmax/cm-1 (neat) 3344 (OH), 2960 (NH), 1647 (C=O), 1560 (C=O); dH (500 MHz; CD3OD) 4.21 
(1H, tt, J 8.5 and 5.0, CH2CHOHCH2), 3.93 (1H, dquin., J 8.0 and 6.0, CH3CHOH), 3.89 (1H, s, 
CHCONH), 3.53-3.32 (6H, m, NHCH2, CH2CH2S, CH2OH), 3.02 (2H, t, J 6.5, CH2S), 2.76 
(1H, dd, J 15.0 and 5.0, CH2COS), 2.72 (1H, dd, J 15.0 and 7.5, CH2COS), 2.41 (2H, t, J 6.5, 
CH2CONH), 1.66 (1H, dt, J 14.0 and 8.0, CH3CH2CHOH), 1.55 (1H, dt, J 14.0 and 5.0, 
CH3CH2CHOH), 1.18 (3H, d, J 6.0, CHCH3), 0.92 (6H, s, C(CH3)2); dC (125 MHz, CD3OD) 
198.7 (CO2S), 176.1 (CH2CONH), 174.0 (CHCONH), 77.3 (CHOHC(CH3)2), 70.3 (CH2OH), 
68.2 (CH2CHOHCH2), 66.8 (CH3CHOH), 52.6 (CH2COS), 46.3 (CHOHCH2CHOH), 40.4 
(CH2C(CH3)2), 40.0 (CH2CH2S), 36.4 (CH2CONH), 36.3 (CH2NH), 29.3 (CH2S), 23.6 
(CHCH3), 21.3 (CH2C(CH3)2), 20.9 (CH2C(CH3)2); HRMS (ESI) cald. for C17H32N2NaO7S (M + 
Na+) requires 431.1822, found 431.1822; [α]$%' (c 0.45, CHCl3): +3.9. 
 
S-(2-(3-((R)-2,4-dihydroxy-3,3-dimethylbutanamido)propanamido)ethyl) (3S,5R)-3,5-
dihydroxyhexanethioate (91) 
 
 
 
S-(2-(3-((R)-2,4-dihydroxy-3,3-dimethylbutanamido)propanamido)ethyl) (3S,5R)-3,5-
dihydroxyhexanethioate 91 was synthesized using the same procedure as that used for the 
synthesis of (2-(3-((R)-2,4-dihydroxy-3,3-dimethylbutanamido)propanamido) ethyl) (3R,5S)-
3,5-dihydroxyhexanethioate 71 using S-(2-(3-((R)-2,2,5,5-tetramethyl-1,3-dioxane-4-
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carboxamido)propanamido)ethyl)(3S,5R)-5-((tert-butyldimethylsilyl) oxy)-3-
hydroxyhexanethioate 96 (100 mg, 0.18 mmol), to afford the product as a colourless oil (54 mg, 
74 %, 0.13 mmol). 
nmax/cm-1 (neat) 3328 (OH), 2964 (NH), 1648 (C=O), 1543 (C=O); dH (500 MHz; CD3OD) 4.28 
(1H, quintet, J 6.5, CH2CHOHCH2), 3.97 (1H, sextet, J 6.0, CH3CHOH),  3.89 (1H, s, 
CHCONH), 3.53-3.32 (6H, m, NHCH2, CH2CH2S, CH2OH), 3.02 (2H, t, J 6.5, CH2S), 2.74 
(1H, dd, J 15.0 and 7.5, CH2COS), 2.71 (1H, dd, J 15.0 and 5.5, CH2COS) 2.41 (2H, t, J 7.0, 
CH2CONH), 1.53 (2H, dd, J 6.5 and 5.5, CH3CH2CHOH), 1.18 (3H, d, J 6.5, CHCH3), 0.92 
(6H, s, C(CH3)2); dC (125 MHz, CD3OD) 198.6 (CO2S), 176.1 (CH2CONH), 173.9 (CHCONH), 
77.3 (CHOHC(CH3)2), 70.3 (CH2OH), 66.8 (CH2CHOHCH2), 65.1 (CH3CHOH), 53.1 
(CH2COS), 46.8 (CHOHCH2CHOH), 40.4 (CH2C(CH3)2), 40.0 (CH2CH2S), 36.4 (CH2CONH), 
36.3 (CH2NH), 29.3 (CH2S), 24.3 (CHCH3), 21.3 (CH2C(CH3)2), 20.9 (CH2C(CH3)2); HRMS 
(ESI) cald. for C17H32N2NaO7S (M + Na+) requires 431.1822, found 431.1822; [α]$%' (c 0.5, 
CHCl3): +5.3. 
 
tert-butyl (2E,4Z)-hexa-2,4-dienoate (85) 
 
 
 
Procedure modified from Davies et al..155 To a stirred solution of tert-butyl acrylate (16.9 g, 
18.9 mL, 132 mmol, 2.0 equiv.), cis-bromopropene (8.0 g, 5.6 mL, 66 mmol, 1.0 equiv.), 
K2CO3 (22.8 g, 165 mmol, 2.5 equiv.), triphenylphosphine (1.73 g, 6.6 mmol, 0.1 equiv.) and 
Bu4NHSO4 (22.4 g, 66 mmol, 1.0 equiv.) in MeCN/H2O (10 : 1, 100 mL) under an Ar 
atmposhphere was added palladium acetate (739 mg, 3.3 mmol, 0.05 equiv.). The mixture was 
heated to 50 °C for 48 h, then allowed to cool to RT and filtered through Celite®, eluting with 
ether (250 mL). The resulting organic solution was washed with H2O (150 mL) then brine 
(150 mL), dried (MgSO4), filtered and concentrated in vacuo. The crude material was purified 
by silica chromatography (1 : 200 Et2O : petroleum ether) to afford the products as a colourless 
oil (2.70 g, 24 %, 16 mmol). 
dH (500 MHz; CDCl3) 7.55 (1H, ddd, J 15.0, 11.5 and 0.5, CHCHCO), 6.15-6.09 (1H, m, 
CH3CHCH), 5.88 (1H, dqt, J 11.0, 7.0 and 1.0, CH3CH), 5.80 (1H, d, J 15.5, CHCO), 1.87 (3H, 
dd, J 7.0 and 1.5, CH3CH), 1.50 (9H, s, C(CH3)3); dC (125 MHz, CDCl3) 166.9 (CO), 138.3 
(CHCHCO), 135.2 (CH3CH), 127.6 (CH3CHCH), 123.1 (CHCO), 80.4 (C(CH3)3), 28.3 
(C(CH3)3), 14.1 (CH3CH); HRMS (ESI) cald. for C10H16NaO2 (M + Na+) requires 191.1048, 
found 191.1050. Spectroscopic data consistent with that previously reported in the literature.155 
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(2E,4Z)-hexa-2,4-dienoic acid (82) 
 
 
 
Procedure modified from Davies et al..155 To a stirred solution of (2E,4Z )-tert-butyl hex-2,4-
dienoate 85 (2.50 g, 14.9 mmol, 1.0 equiv.) in CH2Cl2 (25 mL) at 0 °C was added TFA (25 mL) 
dropwise. The mixture was stirred for 30 min at RT and the volatile material removed in vacuo. 
Purification via silica chromatography (3 : 1 EtO : petroleum ether) afforded the product as a 
yellow oil (1.53 g, 92 %, 13.7 mmol, 94 : 6 dr). 
dH (500 MHz; CDCl3) 7.74 (1H, ddd, J 15.0, 12.0 and 0.5, CHCHCO), 6.22-6.16 (1H, m, 
CH3CHCH), 6.00 (1H, dqt, J 11.0, 7.0 and 0.5, CH3CH), 5.80 (1H, d, J 15.0, CHCO), 1.91 (3H, 
dd, J 7.0 and 1.5, CH3CH); dC (125 MHz, CDCl3) 172.8 (CO), 141.7 (CHCHCO), 137.4 
(CH3CH), 127.4 (CH3CHCH), 120.2 (CHCO), 14.3 (CH3CH). Spectroscopic data consistent 
with that previously reported in the literature.155 
 
S-(2-(3-((R)-2,4-dihydroxy-3,3-dimethylbutanamido)propanamido)ethyl) (2E,4Z)-hexa-2,4-
dienethioate (72) 
 
 
 
To a stirred solution of (2E,4Z )-hex-2,4-dienoic acid 82 (50 mg, 0.45 mmol, 1.0 equiv.) in 
CH2Cl2 (5 mL) was added oxalyl chloride (40 µL, 0.45 mmol, 1.0 equiv.) drop-wise, followed 
by 2 drops of DMF. The reaction was stirred for 2 h after which time the reaction was added 
drop-wise to a pre-stirred mixture of (R)-2,4-dihydroxy-N-(3-((2-mercaptoethyl)amino)-3-
oxopropyl)-3,3-dimethylbutanamide 84 (125 mg, 0.45 mmol, 1.0 equiv.) and TEA (0.06 mL, 
0.45 mmol, 1.0 equiv.) in dry THF (1 mL). The reaction was then stirred at RT for 1 h under 
an inert atmosphere before being concentrated in vacuo. The resulting orange oil was purified 
by silica chromatography (1 : 10 MeOH ; EtOAc) to afford the product as a yellow oil (23 mg, 
14 %, 0.06 mmol 4 : 1 E,Z : E,E). 
nmax/cm-1 (neat) 3355 (OH), 2976 (NH), 2921 (C=C-H), 1636, 1543 (C=O); dH (500 MHz; 
CD3OD) 7.61 (1H, dd, J 15.0 and 11.5, CHCHCOS), 6.17 (1H, t, J 11.0, CH3CHCH), 6.15 
(1H, d, J 15.0, CHCOS), 6.07 (1H, dq, J 11.0 and 7.0 CH3CH), 3.89 (1H, s, CHCONH), 3.53-
3.33 (6H, m, NHCH2, CH2CH2S, CH2OH), 3.10 (2H, t, J 7.0, CH2S), 2.41 (2H, t, J 6.5, 
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CH2CONH), 1.90 (3H, dd, J 7.0 and 1.5, CHCH3), 0.92 (6H, s, C(CH3)2); dC (125 MHz, 
CD3OD) 191.3 (CO2S), 176.1 (CH2CONH), 173.9 (CHCONH), 138.9 (CHCHCOS), 136.5 
(CH3CH), 128.8 (CH3CHCH), 128.3 (CHCOS), 77.3 (CH), 70.4 (CH2OH), 40.4 
(CH2C(CH3)2), 40.2 (CH2CH2S), 36.4 (CH2CONH), 36.3 (CH2NH), 29.1 (CH2S), 21.3 
(CH2C(CH3)2), 20.9 (CH2C(CH3)2), 14.2 (CHCH3); HRMS (ESI) cald. for C17H28N2NaO5S (M 
+ Na+) requires 395.1611, found 395.1613; [α]$%& (c 0.3, CHCl3): +28.9. 
 
Methyl (S,E)-5-((tert-butyldimethylsilyl)oxy)hex-2-enoate (88) 
 
 
 
Procedure modified from Ohta et al.254 To a solution of (S)-3-((tert-
butyldimethylsilyl)oxy)butanal 74 (610 mg, 3.0 mmol, 1.0 equiv.) in dry toluene (25 mL) was 
added methoxycarbonylmethylenetriphenylphosphorane (1.10 g, 3.3 mmol, 1.1 equiv.) and the 
mixture heated to reflux for 16 hours. The precipitate was removed by filtration and the filtrate 
concentrated in vacuo to afford a colourless oil, which was purified by silica chromatography 
(3:10 Et2O:Petroleum ether) to afford the desired product as a colourless oil (723 mg, 94 %, 
2.82 mmol).  
dH (500 MHz; CDCl3) 6.96 (1H, dt, J 15.5 and 7.5, CH2CHCH), 5.84 (1H, dt, J 15.5 and 1.5, 
CH2CHCH), 4.35 (1H, sext., J 6.0, CH), 3.72 (3H, s, OCH3), 2.37-2.27 (2H, m, CH2), 1.15 
(3H, d, J 6.0, CH3), 0.88 (9H, s, C(CH3)3), 0.04 (3H, s, SiCH3), 0.04 (3H, s, SiCH3); dC (125 
MHz, CDCl3) 167.3 (COOCH3), 146.7 (CH2CHCH), 123.2 (CH2CHCH), 68.0 (CH), 51.8 
(OCH3), 42.8 (CH2), 26.2 (C(CH3)3), 24.1 (CH3), 18.5 (C(CH3)3), -4.2 (SiCH3), -4.4 (SiCH3)3; 
HRMS (ESI) cald. for C13H26NaO3Si (M + Na+) requires 281.1543, found 281.1543. 
Spectroscopic data consistent with that previously reported in the literature.254 
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(S,E)-5-((tert-butyldimethylsilyl)oxy)hex-2-enoic acid (89) 
 
 
 
To a solution of methyl (S,E)-5-((tert-butyldimethylsilyl)oxy)hex-2-enoate 88 (510 mg, 
2.0 mmol, 1.0 equiv.) in a 5:3 mixture of THF (10 mL) and water (6 mL), was added LiOH 
(80 mg, 4.0 mmol, 2.0 equiv.) and the reaction stirred for 16 hours. THF was removed in 
vacuo and the resulting solution acidified to pH 2.0 using 1 M HCl. The mixture was then 
extracted with CH2Cl2 (3 x 10 mL), the combined organics washed with brine (10 mL), dried 
(MgSO4) and concentrated in vacuo to afford the product as a colourless oil (391 mg, 81 %, 
1.62 mmol).  
dH (500 MHz; CDCl3) 7.07 (1H, dt, J 15.5 and 7.5, CH2CHCH), 5.84 (1H, dt, J 15.5 and 1.5, 
CH2CHCH), 3.94 (1H, sext., J 6.0, CH), 2.40-2.30 (2H, m, CH2), 1.17 (3H, d, J 6.0, CH3), 
0.88 (9H, s, C(CH3)3), 0.05 (3H, s, SiCH3), 0.04 (3H, s, SiCH3); dC (125 MHz, CDCl3) 171.4 
(COOH), 149.4 (CH2CHCH), 122.8 (CH2CHCH), 67.9 (CH), 42.9 (CH2), 26.2 (C(CH3)3), 24.2 
(CH3), 18.5 (C(CH3)3), -4.2 (SiCH3), -4.4 (SiCH3)3; HRMS (ESI) cald. for C12H23O3Si (M - 
H+) requires 243.1422, found 243.1420. Spectroscopic data consistent with that previously 
reported in the literature.254 
 
S-(2-(3-((R)-2,2,5,5-tetramethyl-1,3-dioxane-4-carboxamido)propanamido) ethyl) (S,E)-
5-((tert-butyldimethylsilyl)oxy)hex-2-enethioate (90) 
 
 
 
To a solution of (S,E)-5-((tert-butyldimethylsilyl)oxy)hex-2-enoic acid 89 (60 mg, 0.25 mmol, 
1.3 equiv.), (R)-N-(3-((2-mercaptoethyl)amino)-3-oxopropyl)-2,2,5,5-tetramethyl-1,3-dioxane-
4-carboxamide 61 (85 mg, 0.27 mmol, 1.4 equiv.) and DMAP (7 mg, 0.06 mmol, 0.3 equiv.) in 
CH2Cl2 (4 mL) was added EDC.HCl (52 mg, 0.27 mmol, 1.4 equiv.) at 0 oC, and the mixture 
allowed to stir at RT for 16 hours. The mixture was then diluted with CH2Cl2 (10 mL), washed 
with 1 M HCl (10 mL), saturated NaHCO3 solution (10 mL), dried (MgSO4) and concentrated in 
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vacuo to give a colourless oil which was purified by silica chromatography (1:99 
MeOH:CH2Cl2) to afford the desired product as a colourless oil (108 mg, 80 %, 0.15 mmol). 
nmax/cm-1 (neat) 3304 (NH), 2953 (C=C-H), 1664 (C=O), 1525 (C=O); dH (500 MHz; CDCl3) 
7.03 (1H, br. t, J 5.5, NH), 6.92 (1H, dt, J 15.5 and 7.5, CHCHCOS), 6.14 (1H, br. s, 
NHCH2CH2S), 6.13 (1H, dt, J 15.5 and 1.5, CHCHCOS), 4.07 (1H, s, CHCONH), 3.93 (1H, 
sext., J 6.0, CHOSi), 3.68 (1H, d J 11.5, CH2OC(CH3)2),  3.61-3.39 (4H, m, NHCH2, 
CH2CH2S), 3.27 (1H, d J 11.5, CH2OC(CH3)2), 3.08 (2H, t, J 6.5, CH2S), 2.42 (2H, t, J 6.5, 
CH2CONH), 2.32 (2H, td, J 6.5 and 0.5, CH2CHOSi), 1.46 (3H, s, OC(CH3)2), 1.41 (3H, s, 
OC(CH3)2), 1.16 (3H, d, J 6.0, CHCH3), 1.03 (3H, s, CH2C(CH3)2), 0.97 (3H, s, CH2C(CH3)2), 
0.88 (9H, s, C(CH3)3), 0.05 (3H, s, SiCH3), 0.04 (3H, s, SiCH3); dC (125 MHz, CDCl3) 190.3 
(CO2S), 171.6 (CH2CONH), 170.5 (CHCONH), 144.0 (CHCHCOS), 130.5 (CHCHCOS), 99.5 
(OC(CH3)2), 77.5 (CH), 71.9 (CH2OC(CH3)2), 67.9 (CHOSi), 42.8 (CH2CHOSi), 40.1 
(CH2CH2S), 36.3 (CH2CONH), 35.1 (CH2NH), 33.4 (CH2C(CH3)2), 29.9 (OC(CH3)2), 28.6 
(CH2S), 26.2 (C(CH3)3), 24.3 (CHCH3), 22.5 (CH2C(CH3)2), 19.3 (CH2C(CH3)2), 19.1 
(OC(CH3)2), 18.4 (C(CH3)3), -4.1 (SiCH3), -4.4 (SiCH3); HRMS (ESI) cald. for 
C26H48N2NaO6SSi (M + Na+) requires 567.2895, found 567.2901; [α]$%' (c 0.2, CHCl3): +37.5. 
 
S-(2-(3-((R)-2,4-dihydroxy-3,3-dimethylbutanamido)propanamido)ethyl) (S,E)-5-
hydroxyhex-2-enethioate (86) 
 
 
 
S-(2-(3-((R)-2,2,5,5-tetramethyl-1,3-dioxane-4-carboxamido)propanamido)ethyl) (S,E)-5-((tert-
butyldimethylsilyl)oxy)hex-2-enethioate 90 (100 mg, 0.18 mmol, 1.0 equiv.) was stirred in a 2:1 
ratio of AcOH/H2O (3 mL) at RT for 16 h. The reaction was then concentrated in vacuo and 
purified by silica chromatography (1 : 9 MeOH : CH2Cl2) to afford the desired product as a 
colourless oil (63 mg, 88 %, 0.16 mmol). 
nmax/cm-1 (neat) 3310 (OH), 2967 (C=C-H), 1644 (C=O), 1534 (C=O); dH (500 MHz; CD3OD) 
6.96 (1H, dt, J 15.5 and 7.5, CHCHCOS), 6.23 (1H, dt, J 15.5 and 1.5, CHCHCOS), 3.91 (1H, 
sextet, J 6.5, CHOH), 3.91 (1H, s, CHCONH), 3.55-3.32 (6H, m, CH2OH, NHCH2, CH2CH2S), 
3.09 (2H, t, J 6.5, CH2S), 2.43 (2H, t, J 6.5, CH2CONH), 2.38-2.34 (2H, m, CH2CHOH), 1.16 
(3H, d, J 6.0, CHCH3), 1.03 (3H, s, CH2C(CH3)2), 0.94 (6H, s, CH2C(CH3)2); dC (125 MHz, 
CDCl3) 191.3 (CO2S), 176.4 (CHCONH), 174.2 (CH2CONH),  144.3 (CHCHCOS), 131.6 
(CHCHCOS), 77.6 (CHONH), 70.6 (CH2OC(CH3)2), 67.8 (CHOH), 42.9 (CH2CHOH), 40.7 
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(CH2C(CH3)2),  40.5 (CH2CH2S), 36.7 (CH2NH), 36.6 (CH2CONH), 29.2 (CH2S), 23.7 
(CHCH3), 21.6 (CH2C(CH3)2), 21.2 (CH2C(CH3)2); HRMS (ESI) cald. for C17H30N2NaO6S (M + 
Na+) requires 413.1717, found 413.1717; [α]$%' (c 0.2, CHCl3): +8.5. 
 
Methyl (R,E)-5-((tert-butyldimethylsilyl)oxy)hex-2-enoate (101) 
 
 
 
Methyl (R,E)-5-((tert-butyldimethylsilyl)oxy)hex-2-enoate 101 was synthesized using the 
same procedure as that used for the synthesis of methyl (S,E)-5-((tert-
butyldimethylsilyl)oxy)hex-2-enoate 88 using (R)-3-((tert-butyldimethylsilyl)oxy)butanal 93 
(1.22 g, 5.98 mmol) to afford the desired product as a colourless oil (1.32 g, 86 %, 5.14 
mmol). Spectroscopic data was identical to that of methyl (S,E)-5-((tert-
butyldimethylsilyl)oxy)hex-2-enoate 88  and consistent with that previously reported in the 
literature.254 
 
(R,E)-5-((tert-butyldimethylsilyl)oxy)hex-2-enoic acid (102) 
 
 
 
(R,E)-5-((tert-butyldimethylsilyl)oxy)hex-2-enoic acid 102 was synthesized using the same 
procedure as that used for the synthesis of (S,E)-5-((tert-butyldimethylsilyl)oxy)hex-2-enoic 
acid 89 using methyl (R,E)-5-((tert-butyldimethylsilyl)oxy)hex-2-enoate 101 (170 mg, 
0.66 mmol) to afford the product as a colourless oil (88 mg, 55 %, 0.36 mmol). Spectroscopic 
data was identical to that of (S,E)-5-((tert-butyldimethylsilyl)oxy)hex-2-enoic acid 89 and 
consistent with that previously reported in the literature.254 
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S-(2-(3-((R)-2,2,5,5-tetramethyl-1,3-dioxane-4-carboxamido)propanamido) ethyl) (R,E)-
5-((tert-butyldimethylsilyl)oxy)hex-2-enethioate (103) 
 
 
 
S-(2-(3-((R)-2,2,5,5-tetramethyl-1,3-dioxane-4-carboxamido)propanamido)ethyl) (R,E)-5-((tert-
butyldimethylsilyl)oxy)hex-2-enethioate 103 was synthesized using the same procedure as that 
used for the synthesis of S-(2-(3-((R)-2,2,5,5-tetramethyl-1,3-dioxane-4-
carboxamido)propanamido)ethyl)(S,E)-5-((tert-butyldimethylsilyl)oxy) hex-2-enethioate 90 
using (R,E)-5-((tert-butyldimethylsilyl)oxy)hex-2-enoic acid 102 (180 mg, 0.74 mmol), to 
afford the product as a colourless oil (296 mg, 73 %, 0.54 mmol). 
nmax/cm-1 (neat) 3339 (NH), 2953 (C=C-H), 1660 (C=O); dH (500 MHz; CDCl3) 7.03 (1H, br. t, 
J 5.5, NH), 6.94 (1H, dt, J 15.5 and 7.5, CHCHCOS), 6.14 (1H, br. s, NHCH2CH2S), 6.12 (1H, 
dt, J 15.5 and 1.5, CHCHCOS), 4.07 (1H, s, CHCONH), 3.93 (1H, sext., J 6.0, CHOSi), 3.68 
(1H, d, J 11.5, CH2OC(CH3)2),  3.60-3.39 (4H, m, NHCH2, CH2CH2S), 3.29 (1H, d, J 11.5, 
CH2OC(CH3)2), 3.08 (2H, t, J 6.5, CH2S), 2.40 (2H, t, J 6.5, CH2CONH), 2.32 (2H, td, J 6.5 and 
0.5, CH2CHOSi), 1.46 (3H, s, OC(CH3)2), 1.41 (3H, s, OC(CH3)2), 1.16 (3H, d, J 6.0, CHCH3), 
1.03 (3H, s, CH2C(CH3)2), 0.97 (3H, s, CH2C(CH3)2), 0.88 (9H, s, C(CH3)3), 0.04 (3H, s, 
SiCH3), 0.04 (3H, s, SiCH3); dC (125 MHz, CDCl3) 190.2 (CO2S), 171.6 (CH2CONH), 170.4 
(CHCONH), 144.0 (CHCHCOS), 130.5 (CHCHCOS), 99.5 (OC(CH3)2), 77.4 (CH), 71.9 
(CH2OC(CH3)2), 67.9 (CHOSi), 42.8 (CH2CHOSi), 40.0 (CH2CH2S), 36.3 (CH2CONH), 35.1 
(CH2NH), 33.6 (CH2C(CH3)2), 29.9 (OC(CH3)2), 28.6 (CH2S), 26.2 (C(CH3)3), 24.3 (CHCH3), 
22.5 (CH2C(CH3)2), 19.2 (CH2C(CH3)2), 19.1 (OC(CH3)2), 18.4 (C(CH3)3), -4.1 (SiCH3), -4.3 
(SiCH3); HRMS (ESI) cald. for C26H48N2NaO6SSi (M + Na+) requires 567.2895, found 
567.2896; [α]$%' (c 0.2, CHCl3): +17.5. 
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S-(2-(3-((R)-2,4-dihydroxy-3,3-dimethylbutanamido)propanamido)ethyl) (R,E)-5-
hydroxyhex-2-enethioate (98) 
 
 
 
S-(2-(3-((R)-2,4-dihydroxy-3,3-dimethylbutanamido)propanamido)ethyl) (R,E)-5-hydroxyhex-
2-enethioate 98 was synthesized using the same procedure as that used for the synthesis of S-(2-
(3-((R)-2,4-dihydroxy-3,3- dimethylbutanamido)propanamido) ethyl)(S,E)-5-hydroxyhex-2-
enethioate 86 using S-(2-(3-((R)-2,2,5,5-tetramethyl-1,3-dioxane-4-
carboxamido)propanamido)ethyl) (R,E)-5-((tert-butyldimethylsilyl)oxy) hex-2-enethioate 103 
(100 mg, 0.18 mmol), to afford the product as a colourless oil (60 mg, 84 %, 0.15 mmol). 
nmax/cm-1 (neat) 3327 (OH), 2966 (C=C-H), 1655 (C=O), 1561 (C=O); dH (500 MHz; CD3OD) 
6.96 (1H, dt, J 15.5 and 7.5, CHCHCOS), 6.23 (1H, dt, J 15.5 and 1.5, CHCHCOS), 3.89 (1H, 
sext., J 6.5, CHOH), 3.91 (1H, s, CHCONH), 3.53-3.33 (6H, m, CH2OH, NHCH2, CH2CH2S), 
3.07 (2H, t, J 6.5, CH2S), 2.41 (2H, t, J 6.5, CH2CONH), 2.36-2.32 (2H, m, CH2CHOH), 1.18 
(3H, d, J 6.5, CHCH3), 1.03 (3H, s, CH2C(CH3)2), 0.92 (6H, s, CH2C(CH3)2); dC (125 MHz, 
CDCl3) 190.9 (CO2S), 176.1 (CHCONH), 173.9 (CH2CONH),  143.9 (CHCHCOS), 131.3 
(CHCHCOS), 77.3 (CHONH), 70.3 (CH2OC(CH3)2), 67.4 (CHOH), 42.6 (CH2CHOH), 40.4 
(CH2C(CH3)2),  40.1 (CH2CH2S), 36.4 (CH2NH), 36.3 (CH2CONH), 28.9 (CH2S), 23.4 
(CHCH3), 21.3 (CH2C(CH3)2), 20.9 (CH2C(CH3)2); HRMS (ESI) cald. for C17H30N2NaO6S (M + 
Na+) requires 413.1717, found 413.1719; [α]$%' (c 0.55, CHCl3): +12.7. 
 
S-(2-(3-((R)-2,2,5,5-tetramethyl-1,3-dioxane-4-carboxamido)propanamido)ethyl) (2E,4E)-
hexa-2,4-dienethioate (104) 
 
 
 
S-(2-(3-((R)-2,2,5,5-tetramethyl-1,3-dioxane-4-carboxamido)propanamido)ethyl) (2E,4E)-hexa-
2,4-dienethioate 104 was synthesized using the same procedure as that used for the synthesis of 
S-(2-(3-((R)-2,2,5,5-tetramethyl-1,3-dioxane-4-carboxamido)propanamido)ethyl)(S,E)-5-((tert-
butyldimethylsilyl)oxy) hex-2-enethioate 90 using sorbic acid (61 mg, 0.54 mmol, 1.30 equiv.), 
to afford the product as a colourless oil (199 mg, 90 %, 0.49 mmol). 
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nmax/cm-1 (neat) 3328 (NH), 2940 (C=C-H), 1671 (C=O), 1512 (C=O); dH (500 MHz; CDCl3) 
7.19 (1H, dd, J 15.0 and 10.5, CHCHCOS), 7.03 (1H, br. t, J 6.0, NH), 6.24 (1H, dq, J 15.0 and 
7.0, CH3CH), 6.23 (1H, m, NHCH2CH2S), 6.15 (1H, ddd, J 15.0, 11.0 and 1.0, CH3CHCH), 
6.06 (1H, d, J 15.0, CHCOS), 4.06 (1H, s, CHCONH), 3.67 (1H, d, J 11.5, CH2OC(CH3)2), 
3.60-3.40 (4H, m, NHCH2, CH2CH2S), 3.26 (1H, d, J 11.5, CH2OC(CH3)2), 3.08 (2H, t, J 6.5, 
CH2S), 2.41 (2H, t, J 6.5, CH2CONH), 1.87 (3H, d, J 7.0, CHCH3), 1.45 (3H, s, OC(CH3)2), 
1.41 (3H, s, OC(CH3)2), 1.02 (3H, s, CH2C(CH3)2), 0.96 (3H, s, CH2C(CH3)2); dC (125 MHz, 
CDCl3) 190.3 (CO2S), 171.4 (CH2CONH), 170.2 (CHCONH), 142.1 (CH3CH), 142.0 
(CHCHCOS), 129.7 (CH3CHCH), 125.8 (CHCHCOS), 99.2 (OC(CH3)2), 77.3 (CH), 71.6 
(CH2OC(CH3)2), 40.0 (CH2CH2S), 36.1 (CH2CONH), 34.9 (CH2NH), 33.1 (CH2C(CH3)2), 29.7 
(OC(CH3)2), 28.5 (CH2S), 22.3 (CH2C(CH3)2), 19.1 (OC(CH3)2),  18.9 (CH2C(CH3)2), 14.1 
(CHCH3); HRMS (ESI) cald. for C20H32N2NaO5S (M + Na+) requires 435.1924, found 
435.1923; [α]$%& (c 0.1, CHCl3): +21.2. 
 
 
S-(2-(3-((R)-2,4-dihydroxy-3,3-dimethylbutanamido)propanamido)ethyl) (2E,4E) -hexa-
2,4-dienethioate (99) 
 
 
 
S-(2-(3-((R)-2,4-dihydroxy-3,3-dimethylbutanamido)propanamido)ethyl) (2E,4E)-hexa-2,4-
dienethioate 99 was synthesized using the same procedure as that used for the synthesis of S-(2-
(3-((R)-2,4-dihydroxy-3,3- dimethylbutanamido)propanamido) ethyl)(S,E)-5-hydroxyhex-2-
enethioate 86 using S-(2-(3-((R)-2,2,5,5-tetramethyl-1,3-dioxane-4-
carboxamido)propanamido)ethyl) (2E,4E)-hexa-2,4-dienethioate 104 (180 mg, 0.45 mmol) to 
afford the product as a colourless oil (42 mg, 25 %, 0.11 mmol). 
nmax/cm-1 (neat) 3340 (OH), 2969 (NH), 2940 (C=C-H), 1651 (C=O), 1540 (C=O); dH (500 
MHz; CD3OD) 7.21 (1H, dd, J 15.0 and 10.0, CHCHCOS), 6.30 (1H, dq, J 15.0 and 6.5, 
CH3CH), 6.24 (1H, dd, J 15.0 and 10.0, CH3CHCH), 6.15 (1H, d, J 15.0, CHCOS), 3.89 (1H, s, 
CHCONH), 3.53-3.33 (6H, m, NHCH2, CH2CH2S, CH2OH), 3.08 (2H, t, J 7.0, CH2S), 2.41 
(2H, t, J 6.5, CH2CONH), 1.87 (3H, d, J 6.0, CHCH3), 0.92 (6H, s, C(CH3)2); dC (125 MHz, 
CD3OD) 191.2 (CO2S), 176.1 (CH2CONH), 173.9 (CHCONH), 142.8 (CH3CH), 142.8 
(CHCHCOS), 130.8 (CH3CHCH), 126.9 (CHCHCOS), 77.3 (CH), 70.3 (CH2OH), 40.4 
(CH2C(CH3)2), 40.2 (CH2CH2S), 36.4 (CH2CONH), 36.3 (CH2NH), 29.0 (CH2S), 21.3 
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(CH2C(CH3)2), 20.9 (CH2C(CH3)2), 14.2 (CHCH3); HRMS (ESI) cald. for C17H28N2NaO5S (M + 
Na+) requires 395.1611, found 395.1605; [α]$%& (c 0.5, CHCl3): +40.4. 
 
 
6.9.2 Synthesis of DHCCA analogues 	
(S)-4-Benzyl-3-(hex-5-enoyl)oxazolidin-2-one (272) 
 
 
 
The following procedure was modified from Steele et al.255 To a solution of 5-hexenoic acid 
158 (3.50 ml, 29.6 mmol, 1.05 equiv.) and triethylamine (10.8 mL, 77.4 mmol, 2.75 equiv.) in 
anhydrous THF (150 mL) at -10°C was added pivaloyl chloride (3.64 mL, 29.6 mmol, 1.05 
equiv.) dropwise, the mixture was then stirred at this temperature for 1 h. LiCl (1.37 g, 32.4 
mmol, 1.10 equiv.) and (S)-4-(phenylmethyl)-2-oxazolidinone (5.00 g, 28.2 mmol, 1.00 
equiv.) were then quickly added in one portion, and reaction was allowed to warm to RT and 
stirred for 16 h. The reaction was quenched with saturated NH4Cl (50 mL) and extracted with 
EtOAc (3 × 50mL). The combined organics were then washed with saturated NaHCO3 (50 
mL), brine (50 mL), dried (MgSO4), concentrated in vacuo and purified by silica 
chromatography (1:5 EtOAc:Petroleum ether) to afford the product as a colourless oil (7.03 g, 
91%, 25.7 mmol). 
dH (500 MHz; CDCl3) 7.35-7.31 (2H, m, ArH), 7.30-7.27 (1H, m, ArH), 7.23-7.19 (2H, m, 
ArH), 5.82 (1H, ddt, J 17.0, 10.0 and 6.5, CH2CHCH2), 5.06 (1H, dq, J 17.0 and 1.5, 
CH2CHCH2), 5.00 (1H, d, J 10.0, CH2CHCH2), 4.67 (1H, ddt, J 9.5, 7.5 and 3.0, CHCH2Ph), 
4.20 (1H, dd, J 9.0 and 7.5, CH2Ph), 4.16 (1H, dd, J 9.0 and 3.0, CH2Ph), 3.30 (1H, dd, J 13.0 
and 3.0, OCH2CH), 2.98 (1H, ddd, J 17.0, 8.0 and 6.5, CH2CHCH2), 2.91 (1H, ddd, J 17.0, 8.0 
and 7.0, CH2CHCH2), 2.77 (1H, dd, J 13.5 and 9.5, OCH2CH), 2.16 (2H, q, J 7.0, COCH2), 
1.87-1.75 (2H, m, COCH2CH2); dC (125 MHz, CDCl3) 173.3 (CON), 153.6 (NCOO), 137.9 
(CH2CHCH2), 135.4 (ArCquart), 129.5 (ArC), 129.1 (ArC), 127.5 (ArC), 115.5 (CH2CHCH2), 
66.3 (CH2Ph), 55.3 (CHCH2Ph), 38.0 (OCH2CH), 35.0 (CH2CHCH2), 33.1 (COCH2), 23.5 
(COCH2CH2); HRMS (ESI) cald. for C16H19NNaO3 (M + Na+) requires 296.1257, found 
296.1259. Spectroscopic data consistent with that previously reported in the literature.255 
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(R)-4-Benzyl-3-(hex-5-enoyl)oxazolidin-2-one (164) 
 
 
 
(R)-4-benzyl-3-(hex-5-enoyl)oxazolidin-2-one 164 was synthesized using the same procedure 
as for the synthesis of (S)-4-benzyl-3-(hex-5-enoyl)oxazolidin-2-one 272 using (R)-4-
(phenylmethyl)-2-oxazolidinone to afford the product as a colourless oil (7.18 g, 93 %, 26.2 
mmol). Spectroscopic data was identical to that of (S)-4-benzyl-3-(hex-5-enoyl)oxazolidin-2-
one 272 and consistent with that previously reported in the literature.255 
 
(S)-3-((R)-2-Allylhex-5-enoyl)-4-benzyloxazolidin-2-one (273) 
 
 
 
To a stirred solution of (S)-4-benzyl-3-(hex-5-enoyl)oxazolidin-2-one 272 (7.0 g, 25.6 mmol, 
1.0 equiv.) in THF (100 mL), under an atmosphere of argon at -78 °C, was added LiHMDS 
(30.7 mL, 1 M in THF, 30.7 mmol, 1.2 equiv.) and the resulting mixture stirred at -78 °C for 
30 min. Allyl bromide (4.53 mL, 51.2 mmol, 2.0 equiv.) was added dropwise, the reaction 
mixture allowed to warm to RT and stirred for 22 h. Saturated aqueous NH4Cl (50 mL) was 
added and extracted with CH2Cl2 (3 × 50 mL). The organic extracts were combined, washed 
with brine (20 mL) and dried (MgSO4). Solvent was removed in vacuo and the crude product 
purified by silica chromatography (1:9 EtOAc:Petroleum ether) to afford the product as a 
colourless oil (6.25 g, 78 %). 
nmax/cm-1 (neat) 3075 (ArCH), 1774 (NH), 1773 (CO), 1693 (CO); dH (500 MHz; CDCl3) 
7.35-7.31 (2H, m, ArH), 7.29-7.27 (1H, m, ArH), 7.24-7.21 (2H, m, ArH), 5.83 (1H, ddt, J 
17.0, 10.0 and 7.0, CHCH2CHCH2), 5.78 (1H, ddt, J 17.0, 10.0 and 6.5, CHCH2CH2CHCH2), 
5.09 (1H, dq, J 17.0 and 1.5, CHCH2CHCH2), 5.05 (1H, d, J 10.0, CHCH2CHCH2), 5.00 (1H, 
O
N O
O
O
N O
O
	 234	
dq, J 17.0 and 1.5, CHCH2CH2CHCH2), 4.95 (1H, d, J 10.0, CHCH2CH2CHCH2), 4.68 (1H, 
ddt, J 10.0, 7.0 and 3.5, CHCH2Ph), 4.17 (1H, d, J 9.0, CH2Ph), 4.14 (1H, dd, J 9.0 and 3.5, 
CH2Ph), 3.94 (1H, tt, J 7.5 and 5.5, CHCO), 3.30 (1H, dd, J 13.0 and 3.0, OCH2CH), 2.66 
(1H, dd, J 13.5 and 10.0, OCH2CH), 2.48 (1H, dt, J 14.0 and 7.5, CHCH2CHCH2), 2.33 (1H, 
dt, J 13.5 and 6.5, CHCH2CHCH2), 2.08 (2H, q, J 7.5, CHCH2CH2CHCH2) 1.87 (1H, dq, J 
14.0 and 8.0, CHCH2CH2CHCH2), 1.61 (1H, dtd, J 13.5, 7.5 and 5.5, CHCH2CH2CHCH2); dC 
(125 MHz, CDCl3) 176.0 (CON), 153.3 (NCOO), 138.2 (CHCH2CH2CHCH2), 135.5 
(ArCquart), 135.2 (CHCH2CHCH2), 129.6 (ArC), 129.1 (ArC), 127.5 (ArC), 117.5 
(CHCH2CHCH2), 115.1 (CHCH2CH2CHCH2), 66.1 (CH2Ph), 55.6 (CHCH2Ph), 41.9 (COCH), 
38.2 (OCH2CH), 37.0 (CHCH2CHCH2), 31.7 (CHCH2CH2CHCH2), 30.7 
(CHCH2CH2CHCH2); HRMS (ESI) cald. for C19H23NNaO3 (M + Na+) requires 336.1576, 
found 336.1573; [α]$%( (c 0.7, MeOH): +41.3.  
  
(R)-3-((S)-2-Allylhex-5-enoyl)-4-benzyloxazolidin-2-one (160) 
 
 
 
(R)-3-((S)-2-Allylhex-5-enoyl)-4-benzyloxazolidin-2-one 160 was synthesized using the same 
procedure as for the synthesis of (S)-3-((R)-2-allylhex-5-enoyl)-4-benzyloxazolidin-2-one 273 
using (R)-4-benzyl-3-(hex-5-enoyl)oxazolidin-2-one 164 to afford the product as a colourless 
oil (5.77 g, 72 %, 16.5 mmol). Spectroscopic data was identical to that of (S)-3-((R)-2-
Allylhex-5-enoyl)-4-benzyloxazolidin-2-one 273. 
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(S)-4-Benzyl-3-((R)-cyclohex-3-ene-1-carbonyl)oxazolidin-2-one (274) 
 
 
 
The following procedure was modified from Fu et al.256 To a sparged solution of (S)-3-((R)-2-
allylhex-5-enoyl)-4-benzyloxazolidin-2-one 273 (6.0 g, 19.2 mmol, 1.0 equiv.) in anhydrous 
CH2Cl2 (50 mL), under an argon atmosphere was added Grubbs CatalystTM 2nd Generation 
(85 mg, 0.10 mmol, 0.005 equiv.). The reaction was then heated to reflux for 5 h before being 
concentrated in vacuo and purified by silica chromatography (1:9 EtOAc:Petroleum ether) to 
afford the product as a white solid (5.20 g, 95 %, 18.2 mmol). 
dH (500 MHz; CDCl3) 7.36-7.31 (2H, m, ArH), 7.29-7.27 (1H, m, ArH), 7.22-7.19 (2H, m, 
ArH), 5.75-5.69 (2H, m, CHCH2CHCH), 4.68 (1H, ddt, J 9.5, 7.5 and 3.0, CHCH2Ph), 4.21 
(1H, t, J 9.0, CH2Ph), 4.17 (1H, dd, J 9.0 and 3.0, CH2Ph), 3.75 (1H, dddd, J 11.5, 9.5, 6.5 and 
2.5, CHCO), 3.28 (1H, dd, J 13.5 and 3.0, OCH2CH), 2.78 (1H, dd, J 13.5 and 9.5, OCH2CH), 
2.36-2.27 (2H, m, CHCH2CH), 2.21-2.10 (2H, m, CHCH2CH2CH), 1.97-1.91 (1H, m, 
CHCH2CH2CH), 1.72 (1H, qd, J 11.5 and 7.0, CHCH2CH2CH); dC (125 MHz, CDCl3) 176.5 
(CON), 153.2 (NCOO), 135.4 (ArCquart), 129.5 (ArC), 129.0 (ArC), 127.5 (ArC), 126.8 
(CHCH2CHCH), 125.2 (CHCH2CHCH), 66.2 (CH2Ph), 55.5 (CHCH2Ph), 38.6 (COCH), 38.0 
(OCH2CH), 27.6 (CHCH2CHCH), 25.5 (CHCH2CH2CHCH), 24.8 (CHCH2CH2CHCH); 
HRMS (ESI) cald. for C17H19NNaO3 (M + Na+) requires 308.1257, found 308.1260. 
Spectroscopic data consistent with that previously reported in the literature.257 
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(R)-4-Benzyl-3-((S)-cyclohex-3-ene-1-carbonyl)oxazolidin-2-one (162) 
 
 
 
(R)-4-Benzyl-3-((S)-cyclohex-3-ene-1-carbonyl)oxazolidin-2-one 162 was synthesized using 
the same procedure as for the synthesis of (S)-4-benzyl-3-((R)-cyclohex-3-ene-1-
carbonyl)oxazolidin-2-one 274 using (R)-3-((S)-2-allylhex-5-enoyl)-4-benzyloxazolidin-2-one 
160 to afford the product as a white solid (4.93 g, 90 %, 17.3 mmol). Spectroscopic data was 
identical to that of (S)-4-benzyl-3-((R)-cyclohex-3-ene-1-carbonyl)oxazolidin-2-one 274 and 
consistent with that previously reported in the literature.257 
 
(R)-Cyclohex-3-ene-1-carboxylic acid (168) 
 
 
 
The following procedure was modified from Miyashita et al.257 To a stirred solution of (S)-4-
benzyl-3-((R)-cyclohex-3-ene-1-carbonyl)oxazolidin-2-one 274 (5.0 g, 16.9 mmol, 1.0 equiv.) 
in THF-water (4:1, 50 mL) were added 30% H2O2 solution (8.27 mL, 84.5 mmol, 5.0 equiv.) 
and LiOH (1.69 g, 84.5 mmol, 5.0 equiv.) at 0 °C, and the reaction was stirred at RT for 5 h. 
At 0 °C, Na2SO3 (10.0 g) was added to the reaction mixture, which was then stirred at RT for 
15 min. After evaporation of THF under reduced pressure, the resulting aqueous solution was 
washed with CH2Cl2, acidified to pH 1 with conc. HCl, and extracted with ether. The ethereal 
layer was washed with saturated NaCl solution, dried (MgSO4), and concentrated in vacuo to 
afford the product as a colourless oil (1.55 g, 73 %, 12.3 mmol). 
dH (500 MHz; CDCl3) 5.72-5.65 (2H, m, CHCH), 2.61 (1H, dddd, J 11.5, 9.0, 6.5 and 3.0, 
CHCO2H), 2.32-2.22 (2H, m, CHCH2CH), 2.19-2.01 (3H, m, CHCH2CH2), 1.76-1.68 (1H, m, 
CHCH2CH2CH); dC (125 MHz, CDCl3) 182.5 (CO2H), 126.9 (CHCH2CHCH), 125.1 
(CHCH2CHCH), 39.2 (CHCO2H), 27.3 (CHCH2CHCH), 25.0 (CHCH2CH2CHCH), 24.4 
(CHCH2CH2CHCH); HRMS (ESI) cald. for C7H10NaO2 (M + Na+) requires 149.0587, found 
149.0588. Spectroscopic data consistent with that previously reported in the literature.258 
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(S)-Cyclohex-3-ene-1-carboxylic acid (161) 
 
 
 
(S)-Cyclohex-3-ene-1-carboxylic acid 161 was synthesized using the same procedure as for 
the synthesis of (R)-cyclohex-3-ene-1-carboxylic acid 168 using (R)-4-benzyl-3-((S)-cyclohex-
3-ene-1-carbonyl)oxazolidin-2-one 162 to afford the product as a colourless oil (1.57 g, 74 %, 
12.5 mmol). Spectroscopic data was identical to that of (R)-cyclohex-3-ene-1-carboxylic acid 
168 and consistent with that previously reported in the literature.258 
 
(1R,4R,5R)-4-Iodo-6-oxabicyclo[3.2.1]octan-7-one (169) 
 
 
 
The following procedure was modified from Schwizer et al.259 To a stirred solution of (R)-
cyclohex-3-ene-1-carboxylic acid 168 (1.50 g, 11.9 mmol, 1.0 equiv.) in H2O (50 mL) was 
added NaHCO3 (3.0 g, 35.7 mmol, 3.0 equiv.), followed by a solution of KI (11.8 g, 
71.4 mmol, 6.0 equiv.) and iodine (3.31 g, 13.1 mmol, 1.1 equiv.) in H2O (30 mL). The 
reaction was stirred at RT for 24 h and then extracted with CH2Cl2 (3 × 50 mL). The combined 
organic layers were washed with a saturated solution of Na2S2O3 (50 mL). The aqueous layer 
was extracted with CH2Cl2 (2 × 50 mL). The combined organic layers were dried (MgSO4), 
filtered and concentrated in vacuo to afford the product as an off-white solid (2.87 g, 96 %, 
11.4 mmol). 
dH (500 MHz; CDCl3) 4.82 (1H, t, J 5.0, CHICHO), 4.51 (1H, t, J 5.0, CHI), 2.80 (1H, d, J 
12.5, CHICH2CHO), 2.67 (1H, br. t, J 4.5, CHCOO), 2.49-2.42 (1H, m, CHICH2), 2.39 (1H, 
dd, J 13.0 and 6.0, CHICH2CHO), 2.12 (1H, dd, J 16.5 and 5.0, CHICH2), 1.90 (1H, tdd, J 
13.5, 5.5 and 2.0, CHICH2CH2), 1.82 (1H, dt, J 13.0 and 5.5, CHICH2CH2); dC (125 MHz, 
CDCl3) 178.0 (CO2), 80.4 (CHO), 38.8 (CHCO2), 34.7 (CH2CHOCHI), 29.9 (CHICH2), 23.9 
(CHI), 23.3 (CHICH2CH2); HRMS (ESI) cald. for C7H9INaO2 (M + Na+) requires 274.9539, 
found 274.9539. Spectroscopic data was identical to that previously reported in the 
literature.259 
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(1S,4S,5S)-4-Iodo-6-oxabicyclo[3.2.1]octan-7-one (188) 
 
 
 
(1S,4S,5S)-4-Iodo-6-oxabicyclo[3.2.1]octan-7-one 188 was synthesized using the same 
procedure as for the synthesis of (1R,4R,5R)-4-iodo-6-oxabicyclo[3.2.1]octan-7-one 169 using 
(S)-cyclohex-3-ene-1-carboxylic acid  161 to afford the product as a colourless oil (2.75 g, 92 
%, 1.1 mmol). Spectroscopic data was identical to that of (1R,4R,5R)-4-Iodo-6-
oxabicyclo[3.2.1]octan-7-one 169 and consistent with that previously reported in the 
literature.260 
 
(1R,5R)-6-Oxabicyclo[3.2.1]oct-3-en-7-one (170) 
 
 
 
The following procedure was modified from Schwizer et al.259 To a stirred solution of 
(1R,4R,5R)-4-iodo-6-oxabicyclo[3.2.1]octan-7-one 169 (1.0 g, 4.0 mmol, 1.0 equiv.) in dry 
THF (50 mL) was added DBU (0.9 mL, 6.0 mmol, 1.5 equiv.) under argon and the mixture 
was refluxed for 20 h. The reaction mixture was cooled to RT, diluted with Et2O (50 mL) and 
washed with HCl solution (50 mL, 0.5 M) and brine (50 mL). The aqueous layers were further 
extracted with Et2O (3 × 20 mL). The combined organic layers were dried (MgSO4), filtered 
and concentrated in vacuo. The crude product was purified by silica chromatography (1:3 
EtOAc:Petroleum ether) to afford the product as a yellowish oil (383 mg, 94 %, 3.76 mmol). 
dH (500 MHz; CDCl3) 6.26-6.21 (1H, m, CHCHCHO), 5.85 (1H, dt, J 9.5 and 3.0, 
CHCHCHO), 4.76 (1H, t, J 5.5, CHCHCHO), 2.92 (1H, t, J 5.5, CHCO2), 2.55-2.22 (3H, m, 
CHCH2CHO, CHCH2CO2), 2.09 (1H, d, J 11.0, CHCH2CHO); dC (125 MHz, CDCl3) 179.5 
(CO2), 130.4 (CHCHCHO), 129.5 (CHCHCHO), 73.4 (CHCHCHO), 38.2 (CHCO2), 34.6 
(CHOCH2CHCO2), 29.3 (CH2); HRMS (ESI) cald. for C7H9O2 (M + H+) requires 125.0603, 
found 125.0597. Spectroscopic data was identical to that previously reported in the 
literature.259 
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(1R,3R,4R,5R)-3,4-Dihydroxy-6-oxabicyclo[3.2.1]octan-7-one (171) 
 
 
 
The following procedure was modified from Ueda et al.205 To a stirred solution of NMO 
(361 mg, 3.09 mmol, 1.05 equiv.) in H2O (5 mL) and acetone (2 mL) were added 
K2[OsO2(OH)4] (33.0 mg, 88.0 µmol, 0.03 equiv.) and a solution of (1R,5R)-6-
oxabicyclo[3.2.1]oct-3-en-7-one 170 (300 mg, 2.94 mmol, 1.00 equiv.) in acetone (5 mL). The 
resulting mixture was stirred at RT for 6 h, and then quenched with saturated aqueous 
NaHSO3 (10 mL). The resulting mixture was extracted with EtOAc (3 × 20 mL). The 
combined organic extracts were washed with brine (20 mL), dried (MgSO4), filtered, and 
concentrated in vacuo. The residue was purified by silica chromatography on silica gel 
(EtOAc) to afford the product as a brown solid (367 mg 79 %, 2.32 mmol, m.p. 160-162 oC). 
dH (500 MHz; CDCl3) 4.86 (1H, t, J 5.0, CH2CHOHCHOH), 4.19 (1H, t, J 4.5, 
CH2CHOHCHOH), 3.96 (1H, dq, J 10.5 and 5.5, CHOCHOCHO), 2.72 (1H, br. s, 
CH2CHOHCHOH), 2.62 (1H, t, J 5.0, CHCO2), 2.37 (1H, d, J 12.0, CH2CHCO2), 2.23-2.15 
(3H, m, CH2CHOH, CH2CHOH), 1.67 (1H, ddd, J 12.5, 11.5 and 2.0); dC (125 MHz, CDCl3) 
177.9 (CO2), 79.2 (CH2CHOHCHOH), 67.1 (CH2CHOHCHOH), 66.2 (CHOCHOCHO), 36.1 
(CHCO2), 31.3 (CH2CHCO2), 30.6 CHOHCH2); HRMS (ESI) cald. for C7H10NaO4 (M + Na+) 
requires 181.0477, found 181.0476. Spectroscopic data was identical to that previously 
reported in the literature.205 
 
(1R,3R,4R,5R)-3,4,5-Trihydroxycyclohexane-1-carboxylic acid (167) 
 
 
 
To a solution of (1R,3R,4R,5R)-3,4-dihydroxy-6-oxabicyclo[3.2.1]octan-7-one 171 (350 mg, 
2.21 mmol, 1.0 equiv.) in a 5:3 mixture of THF (5 mL) and water (3 mL), was added LiOH 
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(88 mg, 4.42 mmol, 2.0 equiv.) and the reaction stirred for 16 h. The reaction was then 
acidified to pH 2.0 using 1 M HCl before being concentrated in vacuo to afford the product as 
a white solid (381 mg, 98 %, 2.17 mmol, m.p. 133-135 oC). 
nmax/cm-1 (neat) 3261 (OH), 1701 (CO); dH (500 MHz; CD3OD) 4.06 (1H, q, J 3.5, 
CHOHCHOHCHOH), 3.75 (1H, ddd, J 11.0, 9.5 and 4.5, CHOHCHOHCHOH), 3.27 (1H, dd, 
J 9.0 and 3.0, CHOHCHOHCHOH), 2.82 (1H, tt, J 12.5 and 3.5, CHCO2H), 2.16-2.19 (1H, m, 
CH2CHCO2HCH2), 2.03 (1H, dq, J 14.0 and 3.5, CH2CHCO2HCH2), 1.61 (1H, ddd, J 14.5, 
12.5 and 2.0, CH2CHCO2HCH2), 1.41 (1H, q, J 12.5, CH2CHCO2HCH2); dC (125 MHz, 
CD3OD) 177.2 (CO2H), 77.3 (CHOHCHOHCHOH), 70.4 (CHOHCHOHCHOH), 70.1 
(CHOHCHOHCHOH), 37.2 (CHCO2), 36.3 (CH2CHCO2CH2), 34.9 (CH2CHCO2CH2); 
HRMS (ESI) cald. for C7H12NaO5 (M + Na+) requires 199.0582, found 199.0581; [α]$%' (c 1.0, 
H2O): -61.2. 
 
(1S,4S,5S)-4-Hydroxy-6-oxabicyclo[3.2.1]octan-7-one (163) 
 
 
 
The following procedure was modified from Corey et al.261 To a stirred solution of (S)-
cyclohex-3-ene-1-carboxylic acid 161 (500 mg, 3.97 mmol, 1.0 equiv.) in CHCl3 (20 mL) was 
added m-CPBA (751 mg, 4.37 mmol, 1.1 equiv.) and the reaction mixture was stirred at 0 oC 
for 4 h. Triethyl amine (2.78 mL, 19.9 mmol, 5.00 equiv.) was added and the resulting 
reaction mixture was heated to 65 °C for a further 4 h. The mixture was diluted with CHCl3 
(50 mL), washed with 1 M HCl (50 mL), brine (50 mL), dried (MgSO4) and concentrated 
in vacuo. The resulting residue was purified by silica chromatography (1 : 1 EtOAc : 
Petroleum ether) to afford the product as a white solid (242 g, 43 %, 1.71 mmol, m.p. 165-166 
oC). 
nmax/cm-1 (neat) 3424 (OH), 1741 (CO), 1160 (C-O); dH (500 MHz; CDCl3) 4.66 (1H, t, J 5.5, 
CHCH2CHCO2), 4.19 (1H, t, J 4.5, CHOH), 2.61 (1H, t, J 5.0, CHCO2), 2.39 (1H, d, J 12.0, 
CHCH2CHCO2), 2.21 (1H, dt, J 11.5 and 5.5, CHCH2CHCO2), 2.00-1.76 (4H, m, 
CHCH2CH2); dC (125 MHz, CDCl3) 178.8 (CO2), 79.1 (CHCH2CHCO2) 65.3 (CHOH), 38.5 
(CHCO2), 36.1 (CHCO2), 31.3 (CHCH2CHCO2), 27.5 (CH2CH2CHOH), 22.8 
(CH2CH2CHOH); HRMS (ESI) cald. for C7H11O3 (M + H+) requires 143.0708, found 
143.0704; [α]$%' (c 0.5, CHCl3): -21.1. 
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(1S,3S,4S)-3,4-Dihydroxycyclohexane-1-carboxylic acid (157) 
 
 
 
(1S,3S,4S)-3,4-Dihydroxycyclohexane-1-carboxylic acid 157 was synthesized using the same 
procedure as for the synthesis of (1R,3R,4R,5R)-3,4,5-trihydroxycyclohexane-1-carboxylic 
acid 167 using (1R,4R,5R)-4-hydroxy-6-oxabicyclo[3.2.1]octan-7-one 163 (200 mg, 1.41 
mmol) to afford the product as a viscous oil (236 mg, 92 %, 1.3 mmol). 
nmax/cm-1 (neat) 3192 (OH), 2936 (CO2H), 1700 (CO), 1061 (C-O); dH (500 MHz; D2O) 3.45-
3.25 (2H, m, CHOH, CHOH), 2.25 (1H, tt, J 12.5 and 3.5, CHCO2H), 2.09 (1H, dq, J 12.0 and 
2.0, CHCOHCH2CHCO2H), 2.00-1.95 (1H, m, CHOHCH2CH2), 1.88-1.82 (1H, m, 
CHOHCH2CH2), 1.41-1.27 (3H, m, CHCOHCH2CHCO2H, CHOHCH2CH2, CHOHCH2CH2); 
dC (125 MHz, D2O) 184.8 (CO2H), 75.0 (CHOHCH2CH2), 74.6 (CHOH), 45.5 (CHCO2H), 
36.7 (CHOHCH2CHCO2), 32.2 (CH2CH2CHCO2H), 28.3 (CH2CH2CHCO2H); HRMS (ESI) 
cald. for C7H12NaO4 (M + H+) requires 183.0633, found 183.0630; [α]$%( (c 0.15, MeOH): 
22.5. 
 
Methyl (3aR,5r,6aS)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxole-5-carboxylate 
(175) and methyl (3aR,5s,6aS)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxole-5-
carboxylate (176) 
 
 
 
The following procedure was modified from Semak et al.218 To a stirred solution of NMO 
(487 mg, 4.17 mmol, 1.05 equiv.) in H2O (5 mL) and acetone (2 mL) were added 
K2[OsO2(OH)4] (45 mg, 119 µmol, 0.03 equiv.) and a solution of methyl cyclopent-3-ene-1-
carboxylate 174 (500 mg, 3.97 mmol, 1.00 equiv.) in acetone (5 mL). The resulting mixture 
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was stirred at RT temperature for 6 h, and then quenched with saturated aqueous NaHSO3 
(10 mL). The resulting mixture was extracted with EtOAc (3 × 20 mL). The combined organic 
extracts were washed with brine (20 mL), dried (MgSO4), filtered, and concentrated in vacuo. 
The crude mixture was then re-suspended in CH2Cl2 (20 mL) before the addition of 2,2-
dimethoxypropane (2 mL) and a catalytic amount of TsOH. The resulting mixture was stirred 
for a further 2 h before being concentrated in vacuo. The crude mixture was then purified by 
silica chromatography (1:5 EtOAc:Petroleum ether) to afford methyl (3aR,5r,6aS)-2,2-
dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxole-5-carboxylate 175 (270 mg, 34 %, 1.35 
mmol) and methyl (3aR,5s,6aS)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxole-5-
carboxylate 176 (421 mg, 53 %, 2.1 mmol) as colourless oils. 
Methyl (3aR,5r,6aS)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxole-5-carboxylate 175: 
dH (500 MHz; CDCl3) 4.69-4.67 (2H, m, CHO), 3.68 (3H, s, CO2CH3) 3.03 (1H, tt, J 12.0 and 
6.0, CHCO2CH3), 2.13 (1H, dd, J 14.0 and 6.0, CHCH2), 1.72 (1H, td, J 14.0 and 3.5, 
CHCH2), 1.44 (3H, s, C(CH3)2), 1.28 (3H, s, C(CH3)2); dC (125 MHz, CDCl3) 175.5 
(CO2CH3), 109.1 (C(CH3)2), 80.1 (CH2CHO), 51.9 (OCH3), 40.7 (CHCO2), 37.1 (CH2CHO), 
26.2 (C(CH3)2), 23.9 (C(CH3)2); HRMS (ESI) cald. for C10H16NaO4 (M + Na+) requires 
223.0946, found 223.0947. Spectroscopic data was identical to that previously reported in the 
literature.206 
 
Methyl (3aR,5s,6aS)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxole-5-carboxylate 176: 
dH (500 MHz; CDCl3) 4.64-4.61 (2H, m, CHO), 3.66 (3H, s, CO2CH3) 2.80 (1H, tt, J 8.0 and 
3.0, CHCO2CH3), 2.47 (1H, dd, J 14.5 and 3.0, CHCH2), 1.86 (1H, ddd, J 13.5, 6.5 and 4.0, 
CHCH2), 1.37 (3H, s, C(CH3)2), 1.26 (3H, s, C(CH3)2); dC (125 MHz, CDCl3) 174.5 
(CO2CH3), 110.5 (C(CH3)2), 80.6 (CH2CHO), 51.9 (OCH3), 42.5 (CHCO2), 35.1 (CH2CHO), 
26.1 (C(CH3)2), 24.2 (C(CH3)2); HRMS (ESI) cald. for C10H16NaO4 (M + Na+) requires 
223.0946, found 223.0946. Spectroscopic data was identical to that previously reported in the 
literature.206 
 
(1s,3R,4S)-3,4-Dihydroxycyclopentane-1-carboxylic acid (173) 
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To a solution of acetonide 176 (328 mg, 1.64 mmol, 1.0 equiv.) in MeOH (10 mL) was added 
TsOH (35 mg, 0.20 mmol, 0.12 equiv.) and the reaction was stirred at RT for 1 h. The mixture 
was then concentrated in vacuo and partitioned between EtOAc (20 mL) and saturated 
NaHCO3 (20 mL). The layers were separated and the aqueous phase further extracted with 
EtOAc (2 × 20 mL), the combined organics were then washed with brine, dried (MgSO4), 
filtered and concentrated in vacuo to afford the crude diol as a viscous oil. The diol was then 
dissolved in THF (10 mL) and H2O (5 mL), and LiOH was added (40 mg, 2.0 mmol, 1.20 
equiv.). The reaction was then stirred at RT for 16 h, acidified (1 M HCl, 5 mL) and 
concentrated in vacuo to afford the product as a viscous oil (162 mg, 78 %, 1.29 mmol). 
nmax/cm-1 (neat) 3347 (OH), 1652 (C=O), 1025 (C-O); dH (500 MHz, MeOD) 4.09-4.02 (2H, 
br. m, CHOH), 3.06 (1H, tt, J 9.5 and 3, CHCOOH), 2.09-1.88 (4H, m, CH2); dC (125 MHz, 
MeOD) 183.2 (CO2H), 73.2 (CHOH), 40.1 (CHCOOH), 35.1 (CH2); HRMS (ESI) cald. for 
C6H10NaO4 (M + Na+) requires 169.0477, found 169.0475.  
 
(3aR,4R,7S,8aR)-7-Hydroxy-2,2-dimethyltetrahydro-4,7-methano [1,3]dioxolo[4,5-
c]oxepin-6(4H)-one (181) 
 
 
 
The following procedure was modified from Wang et al.262 To a stirred solution of D-(-)-
quinic acid (10.0 g, 52.0 mmol, 1.0 equiv.) in acetone (150 mL), was added 2,2-
dimethoxypropane (19.2 mL, 156 mmol, 3.0 equiv.) and TsOH (95 mg, 0.50 mmol, 
0.01 equiv.), the reaction was heated to reflux for 4 h. The reaction mixture was then 
concentrated in vacuo and re-suspended in EtOAc (150 mL), before being washed with sat. 
NaHCO3 solution (50 mL), brine (50 mL), dried (MgSO4) and concentrated in vacuo to afford 
the product as a white solid (10.5 g, 94 %, 48.9 mmol). 
dH (500 MHz; CDCl3) 4.72 (1H, dd, J 6.0 and 2.5, CHOCO), 4.50 (1H, td, J 7.5 and 3.0, 
CH2CHCH), 4.30 (1H, d, J 6.5, CH2CHCH), 2.74 (1H, br. s, OH), 2.65 (1H, d, J 12.0, 
CCH2COCO), 2.36 (1H, ddd, J 14.5, 7.5 and 2.0, CH2), 2.30 (1H, dd, J 12.0 and 6.5, 
CCH2COCO), 2.18 (1H, dd, J 14.5 and 3.0, CH2), 1.52 (3H, s, CH3), 1.33 (3H, s, CH3); dC 
(125 MHz, CDCl3) 178.9 (CO2), 109.9 (C(CH3)2), 76.0 (CHOCO), 72.3 (CH2CHCH), 71.7 
(CH2CHCH), 71.6 (CCO2). 38.4 (CH2), 34.4 (CH2COCO), 27.1 (CH3), 24.2 (CH3); HRMS 
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(ESI) cald. for C10H14NaO5 (M + Na+) requires 237.0739, found 237.0731. Spectroscopic data 
was identical to that previously reported in the literature.262 
 
Methyl (3aR,5R,7R,7aS)-5,7-dihydroxy-2,2-dimethylhexahydrobenzo[d][1,3] dioxole-5-
carboxylate (182) 
 
 
 
The following procedure was modified from Wang et al.262 To a stirred solution of 
(3aR,4R,7S,8aR)-7-hydroxy-2,2-dimethyltetrahydro-4,7-methano [1,3]dioxolo[4,5-c]oxepin-
6(4H)-one 181 (10.2 g, 47.7 mmol, 1.0 equiv.) in MeOH (250 mL), was added NaOMe (2.57 
g. 47.7 mmol, 1.0 equiv.) and the reaction was stirred at RT for 4 h. The reaction was 
quenched via the addition of AcOH (2.0 mL) before being concentrated in vacuo. The 
resulting residue was re-suspended in EtOAc (100 mL), before being washed with water (50 
mL), brine (50 mL), dried (MgSO4) and concentrated in vacuo. The resulting residue was 
purified by silica chromatography (EtOAc) to afford the product as a colourless oil (9.86 g, 84 
%, 40 mmol) 
dH (500 MHz; CDCl3) 4.49-4.46 (1H, m, CHOH), 4.16-4.06 (1H, m, CHOHCHCH), 3.98 (1H, 
t, J 6.0, CHOHCHCH), 3.81 (3H, s, OCH3), 3.35 (1H, br. s, OH), 2.44 (1H, br. s, OH), 2.30-
2.22 (2H, m, CH2CHOH), 2.10-2.05 (1H, m, CH2), 1.88 (1H, ddd, J 13.5, 10.5 and 3.0, CH2), 
1.54 (3H, s, CH3), 1.37 (3H, s, CH3); dC (125 MHz, CDCl3) 175.8 (CO2), 109.4 (C(CH3)2), 
79.9 (CHOHCHCH), 74.0 (CCO2), 73.5 (CHOH), 68.3 (CHOHCHCH), 53.3 (OCH3), 39.1 
(CH2), 34.9 (CH2CHOH), 28.3 (CH3), 25.8 (CH3); HRMS (ESI) cald. for C11H18NaO6 (M + 
Na+) requires 269.1001, found 269.0999. Spectroscopic data was identical to that previously 
reported in the literature.262 
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Methyl (3aR,7aR)-2,2-dimethyl-7-oxo-3a,4,7,7a-tetrahydrobenzo[d][1,3]dioxole-5-
carboxylate (183) 
 
 
 
The following procedure was modified from Wang et al.262  To a stirred solution of methyl 
(3aR,5R,7R,7aS)-5,7-dihydroxy-2,2-dimethylhexahydrobenzo[d][1,3]dioxole-5-carboxylate 
182 (9.50 g, 38.6 mmol, 1.0 equiv.), 3.0 Å molecular sieves (20.0 g) and anhydrous pyridine 
(9.38 mL, 116 mmol, 3.0 equiv.) in anhydrous CH2Cl2 (100 mL) was added PCC (33.2 g, 
154 mmol, 4.0 equiv.) and the reaction stirred at RT for 16 h. The reaction mixture was then 
filtered through Celite®, the filtrate washed with brine (50 mL), dried (MgSO4) and 
concentrated in vacuo. The crude residue was then purified by silica chromatography (1:1 
EtOAc:Petroleum ether) to afford the product as a yellow solid (4.45 g, 51 %, 19.7 mmol). 
dH (500 MHz; CDCl3) 6.85 (1H, d, J 2.5, CCHCO), 4.70 (1H, td, J 5.0 and 1.5, CHCHCO), 
4.31 (1H, d, J 5.0, CHCHCO), 3.87 (3H, s, OCH3), 3.22 (1H, d, J 20.5, CH2), 2.88 (1H, ddd, J 
20.0, 5.0 and 3.0, CH2), 1.41 (3H, s, CH3), 1.33 (3H, s, CH3); dC (125 MHz, CDCl3) 197.6 
(CO), 166.3 (CO2Me), 144.4 (CCO2Me), 131.4 (CHCCO2Me), 109.7 (C(CH3)2), 75.3 
(CHCHCO), 72.7 (CHCHCO), 53.1 (OCH3), 27.5 (CH3), 26.8 (CH2), 26.0 (CH3); HRMS 
(ESI) cald. for C11H14NaO5 (M + Na+) requires 249.0739, found 249.0735 Spectroscopic data 
was identical to that previously reported in the literature.262 
 
Methyl (3aR,7aS)-7-hydroxy-2,2-dimethyl-3a,4,7,7a-tetrahydrobenzo[d][1,3]dioxole-5-
carboxylate (184) 
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The following procedure was modified from Wang et al.262  To a stirred solution of methyl 
(3aR,7aR)-2,2-dimethyl-7-oxo-3a,4,7,7a-tetrahydrobenzo[d][1,3]dioxole-5-carboxylate 183 
(4.00 g, 17.7 mmol, 1.0 equiv.) in MeOH (50 mL) at 0 oC was added NaBH4 (737 mg, 
19.4 mmol, 1.1 equiv.) and the reaction mixture was stirred at this temperature for 30 min. The 
reaction was quenched with saturated NH4Cl solution (5 mL) and the MeOH was removed 
in vacuo. The resulting mixture was re-dissolved in CH2Cl2 (50 mL), washed with brine (50 
mL), dried (MgSO4) and concentrated in vacuo to afford the product as a colourless oil (3.87 
g, 96 %, 17 mmol).  
dH (500 MHz; CDCl3) 6.94 (1H, s, CHCCO2Me), 4.64 (1H, ddd, J 7.5, 3.5 and 2.5, 
CHCHCHOH), 4.57 (1H, dd, J 6.0 and 4.5, CHCHCHOH), 4.07 (1H, br. s, CHOH), 3.77 (3H, 
s, OCH3), 3.04 (1H, dd, J 16.5 and 2.0, CH2), 2.65 (1H, br. s, OH), 1.95 (1H, dq, J 16.5 and 
3.0, CH2), 1.33 (3H, s, CH3), 1.32 (3H, s, CH3); dC (125 MHz, CDCl3) 166.3 (CO2Me), 142.6 
(CCO2Me), 128.5 (CHCCO2Me), 109.2 (C(CH3)2), 76.2 (CHCHCHOH), 72.6 (CHCHCHOH), 
68.1 (CHOH), 52.1 (OCH3), 26.6 (CH2), 26.0 (CH3), 24.5 (CH3); HRMS (ESI) cald. for 
C11H16NaO5 (M + Na+) requires 251.0895, found 251.0890. Spectroscopic data was identical 
to that previously reported in the literature.262 
 
Methyl (3aR,7aR)-2,2-dimethyl-7-((methylsulfonyl)oxy)-3a,4,7,7a-tetrahydrobenzo 
[d][1,3]dioxole-5-carboxylate (186) 
 
 
 
To a stirred solution of methyl (3aR,7aS)-7-hydroxy-2,2-dimethyl-3a,4,7,7a-
tetrahydrobenzo[d][1,3]dioxole-5-carboxylate 184 (3.70 g, 16.2 mmol, 1.0 equiv.) in CH2Cl2 
(100 mL) was added Et3N (22.55 mL, 162 mmol, 10.0 equiv.) and methanesulfonyl chloride 
(6.3 mL, 81.1 mmol, 5.0 equiv.) at 0 oC and the mixture was stirred overnight at RT. The 
reaction was quenched with 1 M HCl (20 mL) and the mixture extracted with CH2Cl2 (3 × 50 
mL), the combined organics were then washed with brine, dried (MgSO4), filtered and 
concentrated in vacuo to afford the crude product as an orange solid. The crude product was 
purified by silica chromatography (2 : 1 EtOAc : Petroleum ether) to afford the product as a 
white solid (4.11 g, 83 %, 13.4 mmol,  m.p. 88-90 oC). 
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nmax/cm-1 (neat) 1701 (C=O), 1351 (S=O), 1063 (C-O); dH (500 MHz, CDCl3) 6.95 (1H, br. s, 
CHCHOS), 5.06 (1H, br. s, CHOS), 4.75-4.71 (1H, m, CH2CHOCHO), 4.67-4.63 (1H, m, 
CH2CHO), 3.78 (3H, s, OCH3), 3.17 (3H, s SCH3), 3.07 (1H, d, J 16.5, CH2), 2.00 (1H, d, J 
16.5, CH2), 1.34 (3H, s, CCH3), 1.32 (3H, s, CCH3); dC (125 MHz, CDCl3) 165.5 (CO2Me), 
136.2 (CHCOS), 130.8 (CCOOMe), 109.9 (C(CH3)2), 75.7 (CHOS), 75.4 (CH2CHOCHO), 
72.5 (CH2CHO), 52.4 (COOCH3), 39.2 (SCH3), 27.2 (CH2), 25.8 (CH3), 24.4 (CH3); HRMS 
(ESI) cald. for C12H18NaO7S (M + Na+) requires 329.0671, found 329.0672. 
 
Methyl (3aR,7aS)-2,2-dimethyl-3a,4,7,7a-tetrahydrobenzo[d][1,3]dioxole-5-carboxylate 
(185) 
 
 
 
To a stirred solution of Pd2(dba)3.CHCl3 (600 mg, 0.60 mmol, 0.18 equiv.), tributylphosphine 
(150 µl. 0.60 mmol, 0.18 equiv.) and methyl (3aR,7aR)-2,2-dimethyl-7-((methylsulfonyl)oxy)-
3a,4,7,7a-tetrahydrobenzo[d][1,3]dioxole-5-carboxylate 186 (3.30 g, 11.0 mmol, 1.0 equiv.) in 
dioxane (100 mL) under and argon atmosphere was added a suspension of NaBH4 (400 mg, 
11.0 mmol, 1.00 equiv.) in H2O (10 mL) and the reaction was stirred for 2 h at RT. The 
reaction mixture was then diluted with saturated brine (10 mL) and extracted with Et2O (3 
× 50 mL), the combined organics were then washed with brine, dried (MgSO4), filtered and 
concentrated in vacuo to afford the crude product as a black oil. The crude product was 
purified by silica chromatography (1 : 9 EtOAc : Petroleum ether) to afford the product as a 
colourless oil (1.59 g, 68 %, 7.48 mmol).  
nmax/cm-1 (neat) 2985 (C=C-H), 1711 (C=O), 1092 (C-O); dH (500 MHz, CDCl3) 7.02 (1H, dt, 
J 6.0 and 3.0, CHCH2CHO), 4.52 (1H, ddd, J 7.0, 4.0 and 3.0, CH2CHO), 4.48 (1H, ddd, J 
7.0, 5.0 and 2.5, CHCH2CHO), 3.74 (3H, s, OCH3), 2.74 (1H, dd, J 16.5 and 3.0, CH2C), 2.50 
(1H, dd, J 17.0, 6.0 and 2.0, CHCH2), 2.29-2.20 (2H, m, CH2C, CHCH2), 1.29 (3H, s, CCH3), 
1.28 (3H, s, CCH3); dC (125 MHz, CDCl3) 168.4 (CO2Me), 139.5 (CHCH2), 130.7 
(CCOOMe), 108.9 (C(CH3)2), 74.7 (CH2CHO), 74.0 (CHCH2CHO), 52.2 (COOCH3), 30.0 
(CH2C), 28.0 (CHCH2) 26.7 (CH3), 24.6 (CH3); HRMS (ESI) cald. for C11H16NaO4 (M + Na+) 
requires 235.0946, found 235.0949; [α]$%( (c 0.1, MeOH): +33.8. 
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(4S,5R)-4,5-Dihydroxycyclohex-1-ene-1-carboxylic acid (51) 
 
 
 
To a solution of methyl (3aR,7aS)-2,2-dimethyl-3a,4,7,7a-tetrahydrobenzo[d][1,3]dioxole-5-
carboxylate 185 (1.50 g, 7.0 mmol, 1.0 equiv.) in MeOH (50 mL) was added TsOH (170 mg, 
1.0 mmol, 0.14 equiv.) and the reaction was stirred at RT for 1 h. The mixture was then 
concentrated in vacuo and partitioned between EtOAc (50 mL) and saturated NaHCO3 
(50 mL). The layers were separated and the aqueous phase further extracted with EtOAc (2 × 
50 mL), the combined organics were then washed with brine, dried (MgSO4), filtered and 
concentrated in vacuo to afford the crude diol as a viscous oil. The diol was then dissolved in 
THF (50 mL) and H2O (25 mL), and LiOH was added (140 mg, 7.00 mmol, 1.00 equiv.). The 
reaction was then stirred at RT for 16 h, acidified (1 M HCl, 10 mL) and concentrated in vacuo 
to afford the product as a viscous oil (810 mg, 73 %, 5.11 mmol).  
nmax/cm-1 (neat) 3287 (OH), 2927 (C=C-H), 1709 (C=O), 1089 (C-O); dH (500 MHz, MeOD) 
6.87-6.84 (1H, m, CHCH2CHO), 3.92-3.84 (2H, m, CHO), 2.55-2.35 (4H, m, CH2), dC 
(125 MHz, MeOD) 170.25 (CO2H), 137.8 (CHCH2), 128.9 (CCOOH), 69.6 (CH2CHO), 68.5 
(CHCH2CHO), 32.3 (CH2C), 31.0 (CHCH2) 26.7 (CH3); HRMS (ESI) cald. for C7H10NaO4 
(M + Na+) requires 181.0477, found 181.0476. [α]$%( (c 0.5, MeOH): +18. 
 
Ethyl (1S,3S,6R)-7-oxabicyclo[4.1.0]heptane-3-carboxylate (189) 
 
 
 
The following procedure was modified from Wang et al.258 To a solution of (1S,4S,5S)-4-iodo-
6-oxabicyclo[3.2.1]octan-7-one 188 (2.50 g, 1.0 mmol, 1.0 equiv.) in EtOH (50 mL) was 
added 2 M NaOH solution (20 mL) and the reaction was stirred at RT for 4 h. The EtOH was 
HO
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removed in vacuo and the resulting residue was re-dissolved in CH2Cl2 (50 mL), the mixture 
was then washed with brine (50 mL), dried (MgSO4) and concentrated in vacuo. The crude 
residue was then purified by silica chromatography (1 : 3 EtOAc : Petroleum ether) to afford 
the product as a colourless oil (1.41 g 83 %, 0.83 mmol). 
dH (500 MHz; CDCl3) 4.11 (2H, q, J 5.0, CH2CH3), 3.17-3.14 (2H, m, CHCHO), 2.26-2.08 
(4H, m, CHOCH2CH2, CHOCH2CH, CHCO2), 1.77 (1H, dddd, J 15.0, 11.0, 5.5 and 1.5, 
CHOCH2CH2), 1.66-1.53 (2H, m, CH2CHCO2), 1.24 (3H, t, J 7.5, CH3); dC (125 MHz, CDCl3) 
175.0 (CO2), 60.6 (CH2CH3), 51.9 (CHCH2CHO), 50.9 (CHO), 38.2 (CHCO2), 26.4 
(CHCH2CH), 24.3 (CHOCH2), 21.2 (CHCH2), 14.4 (CH3); HRMS (ESI) cald. for C9H14NaO3 
(M + Na+) requires 193.0841, found 193.0836. Spectrascopic data consistent with that 
previously reported in the literature.258 
 
Ethyl (1S,3R,4R)-3-benzamido-4-hydroxycyclohexane-1-carboxylate (190) 
 
 
 
To a solution of ethyl (1S,3S,6R)-7-oxabicyclo[4.1.0]heptane-3-carboxylate 189 in (1.15 g, 
6.76 mmol, 1.0 equiv.) in EtOH (10 mL) was added 28 % aqueous ammonia (20 mL). The 
reaction was stirred at 45 oC overnight and concentrated in vacuo to afford the amino alcohol 
as a yellow oil. The oil was dissolved EtOH (20 mL) and benzoic anhydride (1.68 g, 7.44 
mmol, 1.1 equiv.) was then added in an ice-water bath. After 15 min the reaction was allowed 
to warm to RT and stirred for a further 2 h. The reaction was then concentrated in vacuo, and 
the crude oil purified by silica chromatography (1 : 2 EtOAc : Petroleum ether) to afford the 
product as a white solid (1.75 g, 89 %, 6.0 mmol, m.p. 138-140 oC). 
nmax/cm-1 (neat) 3423 (NH), 3310 (OH), 2944 (ArH), 1720 (C=O), 1627 (C=O), 1025 (C-O); dH 
(500 MHz; CDCl3) 7.76 (2H, d, J 7.5, ArH), 7.51 (1H, t, J 7.0, ArH), 7.43 (2H, t, J 7.5, ArH), 
7.18 (1H, br. d, J 6.5, NH), 4.19 (2H, q, J 7.5, OCH2CH3), 4.12-4.05 (1H, m, CHN), 3.71 (1H, 
br. s, OH), 3.56 (1H, td, J 9.0 and 4.5, CHOH),  2.72 (1H, quin., J 4.0, CHCO2), 2.50-2.44 (1H, 
m, CH2CHN), 2.22-2.14 (1H, m, CH2CHCO2), 1.99-1.91 (1H, m, CH2CHOH), 1.73 (1H, br. s, 
OH), 1.63-1.54 (3H, m, CH2CHN, CH2CHCO2 and CH2CHOH), 1.29 (3H, t, J 7.0, CH3); dC 
(125 MHz, CDCl3) 174.0 (CO2CH2), 169.3 (CON), 134.2 (ArCquart.), 132.0 (ArC), 128.8 (ArC), 
127.2 (ArC), 74.2 (CHO), 60.9 (CH2CH3), 53.1 (CHN), 38.9 (CHCO2), 31.5 (CH2CHN), 30.7 
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(CH2CHOH), 25.0 (CH2CHCO2), 14.4 (CH3); HRMS (ESI) cald. for C16H21NNaO4 (M + Na+) 
requires 314.1363, found 314.1363; [α]$%' (c 0.15, MeOH): +13.3. 
 
Ethyl (3aR,5S,7aS)-2-phenyl-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-5-carboxylate (191) 
 
 
 
To a solution of ethyl (1S,3R,4R)-3-benzamido-4-hydroxycyclohexane-1-carboxylate 190 
(1.5 g, 5.15 mmol, 1.0 equiv.) in CHCl3 (30 mL) was added SOCl2 (1.5 mL, 9.82 mmol, 1.9 
equiv.) dropwise under an inert atmosphere. The reaction was allowed to stir for 1 h at 40 oC, 
before the addition of saturated NaHCO3 (15 mL), the reaction was then stirred for a further 10 
min. The organic layer was then separated and the aqueous layer further extracted with CHCl3 
(2 x 20 mL), the combined organics were dried (MgSO4), filtered and concentrated in vacuo to 
afford the product as a yellow oil (1.21 g, 86 %, 4.4 mmol). 
nmax/cm-1 (neat) 2941 (ArH), 1720 (C=O), 1631 (C=N), 1025 (C-O); dH (500 MHz; CDCl3) 7.94 
(2H, d, J 7.5, ArH), 7.48 (1H, t, J 7.5, ArH), 7.41 (2H, t, J 7.5, ArH), 4.81 (1H, dt., J 9.0 and 
5.5, CHOCN), 4.39 (1H, quin., J 4.5, CHN), 4.13 (2H, qd, J 7.0 and 2.0, OCH2CH3), 2.59 (1H, 
dtd, J 11.5, 7.0 and 5.0, CHCO2), 2.24 (1H, dt, J 14.5 and 4.0, CH2CHN), 2.01-1.92 (2H, m, 
CH2CHN and CH2CHO), 1.88-1.73 (2H, m, CH2CHO and CH2CHCO2), 1.68-1.60 (1H, m, 
CH2CHCO2), 1.24 (3H, t, J 7.0, CH3); dC (125 MHz, CDCl3) 176.0 (CO2CH2), 164.5 (CON), 
131.6 (ArC), 128.5 (ArC), 128.3 (ArC), 128.0 (ArCquart.), 77.7 (CHO), 63.2 (CHN), 60.6 
(CH2CH3), 35.7 (CHCO2), 28.6 (CH2CHN), 25.0 (CH2CHO), 20.9 (CH2CHCO2), 14.3 (CH3); 
HRMS (ESI) cald. for C16H20NO3 (M + H+) requires 274.1438, found 274.1439; [α]$%' (c 0.35, 
MeOH): +28.6. 
 
(1S,3R,4S)-3-amino-4-hydroxycyclohexane-1-carboxylic acid (192) 
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Ethyl (3aR,5S,7aS)-2-phenyl-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-5-carboxylate 191 
(1.20 g, 4.41 mmol, 1.0 equiv.) was dissolved in aqueous HCl (6 M, 50 mL) and heated to 
reflux overnight. The reaction was then concentrated in vacuo, diluted with water and then 
washed with Et2O (5 × 50 mL). The aqueous phase was then concentrated in vacuo to afford 
the product as a white solid (0.65 g, 92 %, 4.05 mmol, m.p. 233-235 oC). 
nmax/cm-1 (neat) 3283 (NH2), 3134 (OH), 2904 (CO2H), 1697 (C=O), 1040 (C-O); dH (500 MHz; 
D2O) 4.06 (1H, dt, J 6.5 and 3.0, CHOH), 3.62 (1H, dt, J 8.0 and 4.0, CHNH2), 2.79 (1H, quin., 
J 6.0 CHCO2H), 2.10-1.91 (3H, m, CHCH2CHNH2, CH2CHCO2H), 1.85-1.67 (3H, m, 
CH2CHCO2H, CH2CHOH); dC (125 MHz, D2O) 178.9 (CO2H), 65.5 (CHOH), 50.2 (CHNH), 
37.1 (CHCO2H), 27.1 (CH2CHOH), 26.3 (CH2CHNH2), 22.0 (CH2CHCO2H);  HRMS (ESI) 
cald. for C7H14NO3 (M + H+) requires 160.0967, found 160.0968; [α]$%' (c 0.18, MeOH): +25.7. 
 
(1S,3R,4S)-3-acetamido-4-hydroxycyclohexane-1-carboxylic acid (193) 
 
 
 
To a solution of (1S,3R,4S)-3-amino-4-hydroxycyclohexane-1-carboxylic acid 192 (100 mg, 
0.63 mmol, 1.0 equiv.) in H2O (2 mL) was added acetic anhydride (75 µL, 0.85 mmol, 
1.4 equiv.) followed by sodium acetate (200 mg, 2.52 mmol, 4.0 equiv.) and the reaction 
stirred at RT for 4 h. The reaction mixture was then acidified using aqueous HCl (2 M, 2 mL), 
and concentrated in vacuo to afford a white tacky solid. The crude was then re-suspended in 
MeOH (10 mL), filtered and concentrated in vacuo to afford the product as a viscous oil 
(92 mg, 73 %, 0.46 mmol).  
nmax/cm-1 (neat) 3136 (OH), 2935 (NH), 1699, 1618 (C=O), 1023 (C-O); dH (500 MHz; D2O) 
5.12 (1H, dt, J 6.0 and 3.0, CHOH), 3.77 (1H, dt, J 9.5 and 3.5, CHNH), 2.82 (1H, quin., J 5.0, 
CHCO2H), 2.19-2.14 (1H, m, CH2CHNH), 2.16 (3H, s, CH3CON), 2.07 (1H, ddd, J 14.0, 10.0 
and 5.0, CH2CHNH),  1.96-1.75 (4H, m, CH2CHCO2H, CH2CHOH); dC (125 MHz, D2O) 177.4 
(CO2H), 171.2 (CONH), 67.7 (CHOH), 46.5 (CHNH), 35.9 (CHCO2H), 24.8 (CH2CHNH), 22.5 
(CH2CHOH), 19.8 (CH2CHCO2H), 18.4 CH3;  HRMS (ESI) cald. for C9H16NO4 (M + H+) 
requires 202.1074, found 202.1075; ); [α]$%' (c 0.3, MeOH): +7.7. 
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6.9.3 Synthesis of Substrates used to Probe DHCCA Biosynthesis 	
Methyl (3aR,7R,7aS)-7-hydroxy-2,2-dimethyl-3a,6,7,7a-tetrahydro benzo[d] [1,3]dioxole-
5-carboxylate (229) 
 
 
 
The following procedure was modified from Chahoua et al.263 To a solution of shikimic acid 
(1.0 g, 5.7 mmol, 1.0 equiv.) in MeOH (50 mL) was added 2 M HCl solution (2 mL) and the 
reaction was heated to reflux for 16 h. The reaction was then concentrated in vacuo to afford 
the crude methyl ester. The ester was then re-dissolved in CH2Cl2 (10 mL) and 2,2-
dimethoxypropane (10 mL) before a catalytic amount of TsOH was added and the reaction 
stirred at RT for 4 h. The reaction was then concentrated in vacuo and the crude residue 
purified by silica chromatography (1 : 2 EtOAc : Petroleum ether) to afford the product as a 
white solid (1.08 g, 83 %, 4.7 mmol). 
dH (500 MHz; CDCl3) 6.92 (1H, br. t, J 2.5, CHCCO2Me), 4.74 (1H, dd, J 6.0 and 4.0, 
CHCHCHOH), 4.08 (1H, t, J 7.0, CHCHCHOH), 3.89 (1H, td, J 8.0 and 5.0, CHOH), 3.77 
(3H, s, OCH3), 2.79 (1H, dd, J 17.5 and 4.5, CH2), 2.24 (1H, ddt, J 17.5, 8.5 and 2.0, CH2), 
2.10 (1H, br. s, OH), 1.44 (3H, s, CH3), 1.40 (3H, s, CH3); dC (125 MHz, CDCl3) 166.7 
(CO2Me), 134.1 (CHCCO2Me), 130.8 (CCO2Me), 109.9 (C(CH3)2), 78.1 (CHCHCHOH), 72.4 
(CHCHCHOH), 69.0 (CHOH), 52.3 (OCH3), 29.6 (CH2), 28.1 (CH3), 25.9 (CH3); HRMS 
(ESI) cald. for C11H16NaO5 (M + Na+) requires 251.0895, found 251.0897. Spectroscopic data 
was identical to that previously reported in the literature.263 
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(3aR,7R,7aS)-7-Hydroxy-2,2-dimethyl-3a,6,7,7a-tetrahydrobenzo [d][1,3]dioxole-5-
carboxylic acid (227) 
 
 
 
To a stirred solution of methyl (3aR,7R,7aS)-7-hydroxy-2,2-dimethyl-3a,6,7,7a-tetrahydro 
benzo[d][1,3]dioxole-5-carboxylate 229 (900 mg, 3.95 mmol, 1.0 equiv.) in THF (20 mL) and 
H2O (10 mL) was added LiOH (158 mg, 7.90 mmol, 2.0 equiv.) and the reaction stirred at RT 
for 16 h. The THF was then removed in vacuo and the mixture acidified using 1 M HCl (5 
mL). The resulting mixture was extracted with Et2O (3 × 20 mL), the combined organics were 
washed with brine (20 mL), dried (MgSO4), filtered and concentrated in vacuo to afford the 
product as a crystalline white solid (668 mg, 79 %, 3.12 mmol). 
dH (500 MHz; CD3OD) 6.82 (1H, br. s, CHCCO2H), 4.76 (1H, dd, J 5.5 and 4.0, 
CHCHCHOH), 4.10 (1H, t, J 6.5, CHCHCHOH), 3.88 (1H, q, J 6.5, CHOH), 2.60 (1H, dd, J 
17.5 and 4.5, CH2), 2.25 (1H, ddt, J 17.5, 7.0 and 1.0, CH2), 1.39 (3H, s, CH3), 1.38 (3H, s, 
CH3); dC (125 MHz, CD3OD) 169.7 (CO2H), 135.3 (CHCCO2H), 131.6 (CCO2H), 110.5 
(C(CH3)2), 78.5 (CHCHCHOH), 73.7 (CHCHCHOH), 69.0 (CHOH), 30.3 (CH2), 28.3 (CH3), 
26.1 (CH3); HRMS (ESI) cald. for C10H14NaO5 (M + Na+) requires 237.0739, found 237.0737. 
Spectroscopic data was identical to that previously reported in the literature.264 
 
S-(2-(3-((R)-2,4-Dihydroxy-3,3-dimethylbutanamido)propanamido)ethyl) (3R,4S,5R)-
3,4,5-trihydroxycyclohex-1-ene-1-carbothioate (228) 
 
 
 
To a stirred solution of (3aR,7R,7aS)-7-Hydroxy-2,2-dimethyl-3a,6,7,7a-tetrahydrobenzo 
[d][1,3]dioxole-5-carboxylic acid 227 (100 mg, 0.47 mmol, 1.3 equiv.), (R)-N-(3-((2-
mercaptoethyl)amino)-3-oxopropyl)-2,2,5,5-tetramethyl-1,3-dioxane-4-carboxamide 61 
(161 mg, 0.51 mmol, 1.4 equiv.) and DMAP (13 mg, 0.11 mmol, 0.3 equiv.) in CH2Cl2 (10 
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mL) was added EDC.HCl (79 mg, 0.51 mmol, 1.4 equiv.) at 0 oC, and the mixture allowed to 
stir at RT for 16 h. The mixture was then diluted with CH2Cl2 (10 mL), washed with 1 M HCl 
(10 mL), saturated NaHCO3 solution (10 mL), dried (MgSO4) and concentrated in vacuo to 
afford the crude acetonide as a yellow oil. The crude product was re-dissolved in AcOH : H2O 
(2 : 1, 3 mL) and stirred for 16 h at RT. The reaction was then concentrated in vacuo and 
purified using silica chromatography (9 : 1 EtOAc : MeOH) to give the product as a colourless 
oil (107 mg, 68 %, 0.25 mmol). 
nmax/cm-1 (neat) 3306 (OH), 2930 (NH), 1720 (COS), 1638 (CON); dH (500 MHz; CD3OD) 
6.80 (1H, br. s, CHCCOS), 4.41 (1H, br. s, CHCHCCOS), 4.01 (1H, dt, J 6.5 and 4.5, 
CH2CHOHCHOH),  3.89 (1H, s, CHCONH), 3.71 (1H, dd, J 7.0 and 4.5, CH2CHOHCHOH), 
3.53-3.33 (6H, m, NHCH2, CH2CH2S, CH2OH), 3.07 (2H, t, J 6.5, CH2S), 2.72 (1H, ddt, J 
18.0, 4.0 and 2.0, CH2CCOS), 2.41 (2H, t, J 7.0, CH2CONH), 2.24 (1H, dd, J 18.0 and 5.0, 
CH2CCOS), 0.91 (6H, s, C(CH3)2); dC (125 MHz, CD3OD) 193.5 (CO2S), 176.1 (CH2CONH), 
174.0 (CHCONH), 137.7 (CCOS), 137.7 (CHCCOS), 77.3 (CHOHC(CH3)2), 72.5 
(CH2CHOHCHOH), 70.3 (CH2OH), 68.4 (CH2CHOHCHOH), 67.3 (CHCHCCOS), 40.4 
(CH2C(CH3)2), 40.0 (CH2CH2S), 36.4 (CH2CONH), 36.3 (CH2NH), 31.0 (CH2CCOS), 29.0 
(CH2S), 21.3 (CH2C(CH3)2), 20.9 (CH2C(CH3)2); HRMS (ESI) cald. for C18H30N2NaO8S (M + 
Na+) requires 457.1621, found 457.1620; [α]$%( (c 0.1, MeOH): +18.8. 
 
2-hydroxycyclohex-2-en-1-one (250) 
 
 
 
The following procedure was modified from Amon et al.265 A magnetically stirred solution of 
dimethyl sulfoxide (300 µL, 4.23 mmol, 3.2 equiv.) in CH2C12 (18 mL) maintained under an 
argon atmosphere at -60 °C was treated in a dropwise fashion with TFAA (540 µL, 
3.82 mmol, 2.9 equiv.). The resulting clear colourless solution was stirred at -60 °C for 10 
min, and then cis-1,2-cyclohexanediol (154 mg, 1.33 mmol, 1.0 equiv.) dissolved in a 
minimum volume of CH2C12/dimethyl sulfoxide was added in a dropwise fashion. The clear 
colourless solution was stirred at -60 °C for 1.5 h. After the dropwise addition of Et3N (1.23 
mL, 8.82 mmol, 6.60 equiv.), the light yellow reaction mixture was stirred for a further 1.5 h 
at -60 °C, warmed to 5 °C, poured into aqueous 2 M HC1 (50 mL), and extracted with CH2C12 
(2 × 30 mL). The combined organic extracts were washed with water (50 mL), dried (MgSO4), 
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filtered and concentrated in vacuo to afford a crude residue, which was purified by silica 
chromatography to afford the product as a white solid (72 mg, 48 %, 0.64 mmol). 
dH (500 MHz, CDCl3) 6.15 (1H, t, J 4.5, CH), 2.54 (2H, t, J 6.0, CH2CO), 2.40 (2H, q, J 5.5, 
CHCH2), 2.01 (2H, quin., J 6.5,  CH2CH2CO); dC (125 MHz, CDCl3) 195.8 (CO), 147.2 
(COH), 118.7 (CH), 36.6 (CH2CO), 24.0 (CH2CH), 23.4 (CH2CH2CO); HRMS (ESI) cald. for 
C6H8NaO2 (M + Na+) requires 135.0422, found 135.0420. Spectrascopic data consistent with 
that previously reported in the literature. 
 
(1S,5S)-6-Oxabicyclo[3.2.1]oct-3-en-7-one (246) 
 
 
 
(1S,5S)-6-Oxabicyclo[3.2.1]oct-3-en-7-one 246 was synthesized using the same procedure as 
for the synthesis of (1R,5R)-6-Oxabicyclo[3.2.1]oct-3-en-7-one 170 using (1S,4S,5S)-4-iodo-
6-oxabicyclo[3.2.1]octan-7-one 188 to afford the product as a colourless oil (371 mg, 91 %, 
3.0 mmol). Spectroscopic data was identical to that of (1R,5R)-6-Oxabicyclo[3.2.1]oct-3-en-7-
one 170 and consistent with that previously reported in the literature.266 
 
Methyl (1S,5S)-5-hydroxycyclohex-3-ene-1-carboxylate (247) 
 
 
 
The following procedure was modified from Trost et al.266 To a stirred solution of (1S,5S)-6-
oxabicyclo[3.2.1]oct-3-en-7-one 246 (300 mg, 2.42 mmol, 1.0 equiv.) in MeOH (10 mL) was 
added NaHCO3 (203 mg, 2.42 mmol, 1.0 equiv.). The reaction was stirred for 16 h at RT 
before being concentrated in vacuo. The resulting residue was partitioned between Et2O 
(20 mL) and H2O (20 mL), the organic layer was collected and washed with brine (20 mL), 
dried (MgSO4), filtered and concentrated in vacuo to afford a crude residue which was 
columned using silica chromatography (Et2O) to afford the product as a colourless oil (298 
mg, 79 %). 
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dH (500 MHz; CDCl3) 6.79-6.73 (2H, m, CHCHCHOH), 4.76 (1H, q, J 6.5, CHCHCHOH), 
3.70 (3H, s, OCH3), 2.72 (1H, dtd, J 10.5, 7.5 and 3.0, CHCO2Me), 2.33-2.23 (3H, m, CH2, 
CHOHCH2CO2Me), 2.07 (1H, d, J 7.5, OH), 1.74 (1H, ddd, J 13.0, 10.5 and 8.0, 
CHOHCH2CO2Me); dC (125 MHz, CDCl3) 175.8 (CO2Me), 130.9 (CHCHCHOH), 127.1 
(CHCHCHOH), 66.1 (CHCHCHOH), 52.1 (OCH3), 37.8 (CHCO2Me), 34.3 (CHOHCH2), 
27.5 (CH2); HRMS (ESI) cald. for C8H13O3 (M + H+) requires 157.0685, found 157.0682. 
Spectrascopic data consistent with that previously reported in the literature.266 
 
Methyl (S)-5-oxocyclohex-3-ene-1-carboxylate (245) 
 
 
 
To a stirred solution of methyl (1S,5S)-5-hydroxycyclohex-3-ene-1-carboxylate 247 (25 mg, 
0.16 mmol, 1.0 equiv.) in CH2Cl2 (10 mL), was added MnO2 (140 mg, 1.6 mmol, 10.0 equiv.) 
and the reaction allowed to stir in the absence of light for 16 h at RT. The reaction was then 
filtered through Celite® and concentrated in vacuo to afford the product as a colourless oil 
(21 mg, 84 %, 0.13 mmol).  
nmax/cm-1 (neat) 1738 (C=O), 1671 (C=O), 1156 (C-O); dH (500 MHz; CDCl3) 6.96 (1H, dt, J 
10.0 and 4.0, CHCHCO), 6.06 (1H, dt, J 10.0 and 2.0, CHCHCO), 3.72 (3H, s, OCH3), 3.09 
(1H, ddt, J 11.0, 9.0 and 5.5, CHCO2Me), 2.74-2.58 (4H, m, COCH2, CHCH2CH); dC (125 
MHz, CDCl3) 197.1 (CO), 173.6 (CO2Me), 147.9 (CHCHCO), 130.0 (CHCHCO), 52.4 
(OCH3), 39.9 (CHCO2Me), 39.8 (COCH2), 28.1 (CHCH2CH); HRMS (ESI) cald. for C8H11O3 
(M + H+) requires 155.0708, found 155.0708; [α]$%( (c 1.0, CHCl3): 76.3. 
 
Methyl (1S,3R)-3-hydroxycyclohexane-1-carboxylate (249) 
 
 
 
To a stirred solution of methyl (1S,5S)-5-hydroxycyclohex-3-ene-1-carboxylate 247 (200 mg, 
1.28 mmol, 1.0 equiv.) in MeOH (10 mL) was added palladium on carbon (10 mg) and the 
reaction placed under a H2 atmosphere and stirred at RT for 16 h. The reaction was then 
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filtered through Celite® and concentrated in vacuo to afford the product as a colourless oil 
(184 mg, 91 %, 1.16 mmol). 
dH (500 MHz; CDCl3) 3.68 (3H, s, OCH3), 3.62 (1H, tt, J 10.0 and 4.0, CHOH), 2.37 (1H, tt, J 
12.0 and 4.0, CHCO2Me), 2.19 (1H, br. d, J 12.5, CHOHCH2CH), 1.95 (1H, br. d, J 12.0, 
CH2CHOH), 1.92-1.81 (2H, m, CH2, CH2CHCO2Me), 1.63 (1H, br. s, OH), 1.42 (1H, q, J 
12.0, CHOHCH2CH), 1.37-1.19 (3H, m, CH2CHOH, CH2, CH2CHCO2Me); dC (125 MHz, 
CDCl3) 175.7 (CO2Me), 69.9 (CHOH), 51.9 (OCH3), 41.8 (CHCO2Me), 37.7 (CHOHCH2CH), 
35.0 (CH2CHOH), 28.1 (CH2CHCO2Me), 23.3 (CH2); HRMS (ESI) cald. for C8H15O3 (M + 
H+) requires 159.1021, found 159.1019. Spectrascopic data consistent with that previously 
reported in the literature.267  
 
Methyl (S)-3-oxocyclohexane-1-carboxylate (248) 
 
 
 
To a stirred solution of methyl (1S,3R)-3-hydroxycyclohexane-1-carboxylate 249 (150 mg, 
0.96 mmol, 1.0 equiv.), in acetone (10 mL) at 0 oC was added 1 mL of a prepared solution of 
Jones’ reagent (CrO3 (800 mg), H2SO4 (3 mL), H2O (3 mL)) and the reaction left to stir at RT 
for 1 h. The reaction was quenched via the addition of isopropanol (3 mL) and the reaction 
was concentrated in vacuo. The resulting residue was partitioned between CH2Cl2 (10 mL) and 
H2O (10 mL), the organic layer was collected, washed with brine (10 mL), dried (MgSO4), 
filtered and concentrated in vacuo to afford the product as a colourless oil (84 mg, 56 %) 
dH (500 MHz; CDCl3) 3.69 (3H, s, OCH3), 2.80 (1H, dtd, J 11.0, 8.0 and 4.0, CHCO2Me), 2.53 
(2H, d, J 8.0, COCH2CHCO2Me), 2.37 (1H, dt, J 15.0 and 5.0, CH2CO), 2.30 (1H, ddd, J 15.0, 
11.0 and 6.0, CH2CO), 2.13-2.01 (2H, m, CH2, CH2CHCO2Me), 1.87-1.67 (2H, m, CH2, 
CH2CHCO2Me); dC (125 MHz, CDCl3) 209.3 (CO), 174.3 (CO2Me), 52.2 (OCH3), 43.2 
(COCH2CH), 43.2 (CHCO2Me), 41.0 (CH2CO), 27.8 (CH2CHCO2Me), 24.5 (CH2); HRMS 
(ESI) cald. for C8H13O3 (M + H+) requires 157.0685, found 157.0683. Spectrascopic data 
consistent with that previously reported in the literature.268 
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(S)-3-Oxocyclohexane-1-carboxylic acid (258) 
 
 
 
To a stirred solution of methyl (S)-3-oxocyclohexane-1-carboxylate 248 (10 mg, 0.06 mmol, 
1.0 equiv.) in THF (2 mL) and H2O (1 mL) was added LiOH (2.0 mg, 0.12 mmol, 2.0 equiv.) 
and the reaction stirred at RT for 16 h. The THF was then removed in vacuo and the mixture 
acidified using 1 M HCl (1 mL). The resulting mixture was extracted with Et2O (3 x 5 mL), 
the combined organics were washed with brine (5 mL), dried (MgSO4), filtered and 
concentrated in vacuo to afford the product as a crystalline white solid (9 mg, 96 %, 0.06 
mmol). 
dH (500 MHz; CD3OD) 2.84 (1H, tt, J 9.5 and 4.5, CHCO2H), 2.58-2.31 (2H, m, 
COCH2CHCO2H), 2.25-2.09 (2H, m, CH2CO), 2.06-1.67 (4H, m, CH2CHCO2H, CH2); dC 
(125 MHz, CD3OD) 208.6 (CO), 179.1 (CO2Me), 43.9 (COCH2CH), 41.3 (CHCO2Me), 36.2 
(CH2CO), 29.5 (CH2CHCO2H), 22.8 (CH2); HRMS (ESI) cald. for C7H10NaO3 (M + Na+) 
requires 165.0528, found 165.0525. Spectrascopic data consistent with that previously 
reported in the literature.268 
 
Methyl (1S,3S)-3-hydroxycyclohexane-1-carboxylate (259) 
 
 
 
To a stirred solution of methyl (S)-3-oxocyclohexane-1-carboxylate 248 (50 mg, 0.32 mmol, 
1.0 equiv.) in THF (5 ml) cooled to -20 °C was added 1 M K-selectride in THF (0.64 ml, 0.64 
mmol, 2.0 equiv.). The reaction was stirred at RT for 1 h before being quenched with saturated 
NH4Cl solution (5 mL) and extracted with diethyl ether (3 × 10 ml). The organic extracts were 
combined, dried (MgSO4) and concentrated in vacuo. The crude material was then stirred in 
1M HCl (10 ml) for 15 min, neutralised with NaHCO3, extracted with diethyl ether (3 × 20 
ml), dried with MgSO4 and concentrated in vacuo. The crude material was purified using silica 
chromatography (1 : 1 Et2O:petroleum ether) to afford the product as a colourless oil (14 mg, 
28 %, 0.09 mmol). 
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dH (500 MHz; CDCl3) 4.08 (1H, quin., J 4.5, CHOH), 3.66 (3H, s, OCH3), 2.78 (1H, tt, J 9.5 
and 4.5, CHCO2Me), 1.92-1.77 (2H, m, CHOHCH2CH, CH2CHOH), 1.74-1.63 (2H, m, 
CHOHCH2CH, CH2CHOH), 1.62-1.26 (4H, m, CH2, CH2CHCO2Me); dC (125 MHz, CDCl3) 
176.4 (CO2Me), 66.3 (CHOH), 51.7 (OCH3), 38.0 (CHCO2Me), 36.7 (CHOHCH2CH), 33.0 
(CH2CHOH), 28.3 (CH2CHCO2Me), 20.0 (CH2); HRMS (ESI) cald. for C8H15O3 (M + H+) 
requires 159.1021, found 159.1018. Spectrascopic data consistent with that previously 
reported in the literature.267 
 
(1S,3S)-3-Hydroxycyclohexane-1-carboxylic acid (257) 
 
 
 
To a stirred solution of methyl (1S,3S)-3-hydroxycyclohexane-1-carboxylate 259 (10 mg, 
0.06 mmol, 1.0 equiv.) in THF (2 mL) and H2O (1 mL) was added LiOH (2.0 mg, 0.12 mmol, 
2.0 equiv.) and the reaction stirred at RT for 16 h. The THF was then removed in vacuo and 
the mixture acidified using 1 M HCl (1 mL). The resulting mixture was extracted with Et2O (3 
× 5 mL), the combined organics were washed with brine (5 mL), dried (MgSO4), filtered and 
concentrated in vacuo to afford the product as a crystalline white solid (9 mg, 96 %, 0.06 
mmol). 
dH (500 MHz; CD3OD) 4.00 (1H, quin., J 3.5, CHOH), 2.78 (1H, tdd, J 9.5, 5.0 and 4.5, 
CHCO2H), 1.81-1.72 (3H, m, CHOHCH2CH, CH2CHOH, CH2CHCO2H), 1.71-1.63 (1H, m, 
CH2), 1.62-1.47 (4H, m, CH2, CH2CHCO2H, CHOHCH2CH, CH2CHOH); dC (125 MHz, 
CD3OD) 185.2 (CO2H), 67.5 (CHOH), 42.3 (CHCO2H), 37.6 (CHOHCH2CH), 33.9 
(CH2CHOH), 30.6 (CH2CHCO2H), 21.4 (CH2); HRMS (ESI) cald. for C7H12NaO3 (M + Na+) 
requires 167.0684, found 167.0681. Spectrascopic data consistent with that previously 
reported in the literature.267 
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Methyl (3aR,5S,7aS)-2,2-dimethylhexahydrobenzo[d][1,3]dioxole-5-carboxylate (222) 
and Methyl (3aS,5S,7aR)-2,2-dimethylhexahydrobenzo[d][1,3]dioxole-5-carboxylate 
(221) 
 
 
 
The following procedure was modified from Semak et al. To a stirred solution of NMO (878 
mg, 7.50 mmol, 1.05 equiv.) in H2O (10 mL) and acetone (4 mL) were added K2[OsO2(OH)4] 
(78 mg, 0.21 mmol, 0.03 equiv.) and a solution of methyl cyclohex-3-ene-1-carboxylate  (1.00 
g, 7.14 mmol, 1.00 equiv.) in acetone (10 mL). The resulting mixture was stirred at RT for 6 h, 
and then quenched with saturated aqueous NaHSO3 (20 mL). The resulting mixture was 
extracted with EtOAc (3 x 20 mL). The combined organic extracts were washed with brine (20 
mL), dried (MgSO4), filtered, and concentrated in vacuo. The resulting mixture was then re-
suspended in CH2Cl2 (20 mL) before the addition of 2,2-dimethoxypropane (4.0 mL) and a 
catalytic amount of TsOH. The resulting mixture was stirred for a further 2 h before being 
concentrated in vacuo. The crude mixture was then purified by silica chromatography (1:5 
EtOAc:Petroleum ether) to afford methyl (3aR,5r,6aS)-2,2-dimethyltetrahydro-4H-
cyclopenta[d][1,3]dioxole-5-carboxylate 222 (596 mg, 39 %, 2.78 mmol) and methyl 
(3aR,5s,6aS)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxole-5-carboxylate 221 (413 
mg, 27 %, 1.92 mmol) as colourless oils. 
Methyl (3aR,5S,7aS)-2,2-dimethylhexahydrobenzo[d][1,3]dioxole-5-carboxylate 222: dH 
(500 MHz; CDCl3) 4.29 (1H, q, J 4.0, CHOCH2CHCO2), 4.10 (1H, dt, J 7.0 and 5.5, 
CHOCHO), 3.67 (3H, s, OCH3), 2.67 (1H, tt, J 9.5 and 4.5, CHCO2), 2.19 (1H, dt, J 15.0 and 
4, CHOCH2CHCO2), 1.95-1.75 (3H, m, CHOCH2CHCO2, CH2CHO, CH2CHCO2), 1.62 (1H, 
dddd, J 14.0, 10.5, 7.5 and 4.0, CH2CHO), 1.49 (3H, s, C(CH3)2), 1.46 (1H, dtd, J 17.0, 10.0, 
3.5, CH2CHCO2), 1.33 (3H, s, C(CH3)2); dC (125 MHz, CDCl3) 176.3 (CO2CH3), 108.2 
(C(CH3)2), 73.2 (CH2CHO), 72.6 (CHCH2CHO), 51.9 (OCH3), 36.6 (CHCO2), 29.4 
(CHCH2CHO), 28.3 (C(CH3)2), 27.2 (CH2CHO), 26.1 (C(CH3)2), 23.7 (CH2CHCO2); HRMS 
(ESI) cald. for C11H18NaO4 (M + Na+) requires 237.1103, found 237.1101. Spectrascopic data 
consistent with that previously reported in the literature.218 
Methyl (3aS,5S,7aR)-2,2-dimethylhexahydrobenzo[d][1,3]dioxole-5-carboxylate 221: dH 
(500 MHz; CDCl3) 4.17-4.14 (1H, m, CHOCHO), 4.07 (1H, dt, J 9.5 and 6.0, 
222 221
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CHOCH2CHCO2), 3.67 (3H, s, OCH3), 2.26-2.20 (1H, m, CHCO2), 2.16 (1H, dt, J 11.0 and 
3.0, CHOCH2), 2.10-2.06 (1H, m, CHOCH2CHCO2), 1.75-1.63 (4H, m, CH2CHO, 
CHOCH2CHCO2, CH2CHCO2), 1.49 (3H, s, C(CH3)2), 1.33 (3H, s, C(CH3)2); dC (125 MHz, 
CDCl3) 175.4 (CO2CH3), 108.4 (C(CH3)2), 73.9 (CH2CHO), 72.5 (CHCH2CHO), 51.9 
(OCH3), 39.6 (CHCO2), 31.7 (CHCH2CHO), 28.5 (C(CH3)2), 26.4 (C(CH3)2),  26.3 
(CH2CHO), 22.8 (CH2CHCO2); HRMS (ESI) cald. for C11H18NaO4 (M + Na+) requires 
237.1103, found 237.1103. Spectrascopic data consistent with that previously reported in the 
literature.218 
 
(1S,3R,4S)-3,4-Dihydroxycyclohexane-1-carboxylic acid (48) 
 
 
 
To a solution of methyl (3aR,5S,7aS)-2,2-dimethylhexahydrobenzo[d][1,3]dioxole-5-
carboxylate 222 (350 mg, 1.64 mmol, 1.0 equiv.) in MeOH (30 mL) was added TsOH (35 mg, 
0.20 mmol, 0.12 equiv.) and the reaction was stirred at RT for 1 h. The mixture was then 
concentrated in vacuo and partitioned between EtOAc (20 mL) and saturated NaHCO3 
solution (20 mL). The layers were separated and the aqueous phase further extracted with 
EtOAc (2 × 20 mL), the combined organics were then washed with brine, dried (MgSO4), 
filtered and concentrated in vacuo to afford the crude diol as a viscous oil. The diol was then 
dissolved in THF (10 mL) and H2O (5 mL), and LiOH was added (40 mg, 1.4 mmol, 
2.0 equiv.). The reaction was then stirred at RT overnight and the THF removed in vacuo. The 
resulting suspension was then acidified (1 M HCl. 10 mL) and extracted with EtOAc (5 × 10 
mL). The combined organics were then washed with brine, dried (MgSO4), filtered and 
concentrated in vacuo to afford the product as a viscous oil (192 mg, 73 %). 
nmax/cm-1 (neat) 3147 (OH), 2935 (CO2H), 1718 (C=O), 1066 (C-O); dH (500 MHz; D2O) 4.05-
4.01 (1H, br. m, CHCH2CHOH), 3.69 (1H, ddd, J 11.0, 4.0 and 3.0, CHOH), 2.55 (1H, tt, J 
12.0 and 3.5, CHCO2H), 2.06-1.99 (1H, m, CHCOHCH2CHCO2H), 1.96-1.90 (1H, m, 
CH2CHCO2H), 1.76-1.60 (3H, m, CHCOHCH2CHCO2H, CH2CHOH), 1.47 (1H, qd, J 12.5 
and 4.0, CH2CHCO2H); dC (125 MHz, D2O) 183.1 (CO2H), 71.2 (CHOH), 69.2 
(CHCH2CHOH), 38.4 (CHCO2H), 33.9 (CHCH2CHOH), 26.3 (CH2CH2CHCO2H), 27.0 
(CH2CHCO2H); HRMS (ESI) cald. for C7H13O4 (M + H+) requires 161.0814, found 161.0813; [α]$%' (c 0.2, MeOH): +12.5.  
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8.1 Phylogenetic Analysis of Diene-Forming DH Domains (Matt Jenner) 		
					  	
Figure 8.1 The phylogenetic analysis of DH domains from trans-AT PKSs. The colored 
clades correspond to the function of the DH domain as follows: alkene-forming DH 
(DHa), blue; diene-forming DH (DHd), red; Enoyl Isomerase (DHi), green; Pyran 
Synthase (DHp), orange. 						
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8.2 HRMS of Brominated Enacyloxin IIa Derivatives 	
																								 	
																								 	
																							 	
Figure 8.2 The HRMS corresponding to brominated enacyloxin IIa derivatives 194-203. 
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8.3 Intact Protein MS of DHCCA Biosynthesis Enzymes 	
	
	
																																				 		
Figure 8.3 The deconvoluted spectra corresponding to the intact MS of the proteins 
involved in DHCCA biosynthesis.  	
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8.4 Intact Protein MS DH-ACP Control 	
 
                       
 
Figure 8.4 The deconvoluted spectra corresponding to the intact MS of DH-ACP control 
(no loaded substrate). 
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8.5 Masses of Species from DH-ACP Assays 		
Substrate 
Substrate-Loaded 
Mass (Theoretical 
Mass) / Da 
Dehydrated Mass(s) 
(Theoretical Mass(s)) 
/ Da 
Rehydrated Mass(s) 
(Theoretical Mass(s)) 
/ Da 
Related 
Figure 
WT GbnD5 DH-ACP 
53 52706.6 (52706.5) 
52687.4 
(52688.5) - Fig. 2.4 
54 52705.3 (52706.5) 
N.D. 
(52688.5) - Fig. 2.4 
64 52658.6 (52660.4) - 
52676.4 
(52678.4) Fig. 2.5 
65 52658.8 (52660.4) - 
N.D. 
(52678.4) Fig. 2.5 
71 52693.6 (52694.5) 
-1 x H2O 
52676.3 
(52676.4) 
-2 x H2O 
52657.8 
(52658.4) 
- Fig. 2.7 
72 52657.2 (52658.4) - 
+1 x H2O 
52674.6 
(52676.4) 
+2 x H2O 
52695.6 
(52694.5) 
Fig. 2.7 
86 52675.1 (52676.4) 
52657.5 
(52658.4) 
52693.6 
(52694.5) Fig. 2.10 
92 52693.6 (52694.5) 
-1 x H2O 
52673.0 
(52676.4) 
-2 x H2O 
52656.5 
(52658.4) 
- Fig. 2.11 
99 52657.2 (52658.4) - 
+1 x H2O 
52675.8 
(52676.4) 
+2 x H2O 
52695.7 
(52694.5) 
Fig. 2.12 
78 52692.9 (52694.5) 
-1 x H2O 
52675.1 
(52676.4) 
-2 x H2O 
52657.9 
(52658.4) 
- Fig. 2.11 
91 52692.9 (52694.5) 
-1 x H2O 
52675.1 
(52676.4) 
-2 x H2O 
52657.2 
(52658.4) 
- Fig. 2.11 
98 52675.1 (52676.4) 
52657.2 
(52658.4) 
52694.3 
(52694.5) Fig. 2.12 
                GbnD5 DH-ACP(H158Y)  
86 52701.2 (52702.4) N.D. 
52719.1 
(52720.4) Fig. 2.10 	
Table 8.1 The masses of the dehydrated species from the DH-ACP assays.  	
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8.6 Putative Functions of the Genes from the Enacyloxin Cluster 	
 
Gene Putative Function 
Bamb_5912 Dehydratase involved in DHCCA biosynthesis 
Bamb_5913 Shikimate dehydrogenase 
Bamb_5914 Enoyl reductase involved in DHCCA biosynthesis 
Bamb_5915 NRPS Condensation domain 
Bamb_5916 CoA Transferase involved in DHCCA biosynthesis 
Bamb_5917 ACP 
Bamb_5918 Enone reductase involved in DHCCA biosynthesis 
Bamb_5919 trans-AT PKS 
Bamb_5920 cis-AT PKS 
Bamb_5921 cis-AT PKS 
Bamb_5922 cis-AT PKS 
Bamb_5923 cis-AT PKS 
Bamb_5924 cis-AT PKS 
Bamb_5925 cis-AT PKS 
Bamb_5926 Type II thioesterase 
Bamb_5927 a-Ketoglutarate and non-heme iron-dependent hydroxylase 
Bamb_5928 Flavin-dependent chlorinase 
Bamb_5929 Hypothetical protein 
Bamb_5930 Carbamoyl transferase 
Bamb_5931 a-Ketoglutarate and non-heme iron-dependent chlorinase 
Bamb_5932 PQQ-Dependent dehydrogenase 
 
Table 8.2 The putative functions of the genes from the enacyloxin gene cluster.  
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8.7 MS Data for CoAs Generated by VbxP 
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Figure 8.5 MS data for the CoAs generated using VbxP.  
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